S1260|The|O
S1260|incidence|O
S1260|of|O
S1260|TEAEs|O
S1260|was|O
S1260|similar|O
S1260|across|O
S1260|the|O
S1260|different|O
S1260|doses|O
S1260|of|O
S1260|GP|O
S1260|MDI|O
S1260|,|O
S1260|ranging|O
S1260|from|O
S1260|22.0|O
S1260|%|O
S1260|of|O
S1260|patients|O
S1260|with|O
S1260|GP|O
S1260|MDI|O
S1260|0.6|O
S1260|μg|O
S1260|to|O
S1260|29.7|O
S1260|%|O
S1260|with|O
S1260|GP|O
S1260|MDI|O
S1260|2.4|O
S1260|μg|O
S1260|,|O
S1260|and|O
S1260|compared|O
S1260|with|O
S1260|24.2|O
S1260|%|O
S1260|and|O
S1260|25.8|O
S1260|%|O
S1260|in|O
S1260|placebo|O
S1260|MDI|O
S1260|and|O
S1260|open-label|B-Blinding_Open_Label
S1260|tiotropium|O
S1260|groups|O
S1260|,|O
S1260|respectively|O
S1260|(|O
S1260|Table|O
S1260|3|O
S1260|)|O
S1260|.|O
S2540|Results|O
S2540|A|O
S2540|total|O
S2540|of|O
S2540|614|B-Sample_Size_Actual_at_Enrollment
S2540|participants|O
S2540|were|O
S2540|randomized|O
S2540|to|O
S2540|treatment|O
S2540|.|O
S3237|Randomisation|O
S3237|occurred|O
S3237|through|O
S3237|the|B-Randomization_Personnel
S3237|Nottingham|I-Randomization_Personnel
S3237|Clinical|I-Randomization_Personnel
S3237|Trials|I-Randomization_Personnel
S3237|Unit|I-Randomization_Personnel
S3237|using|O
S3237|a|B-Randomization_Sequence_Generation_Method
S3237|web|I-Randomization_Sequence_Generation_Method
S3237|based|I-Randomization_Sequence_Generation_Method
S3237|database|I-Randomization_Sequence_Generation_Method
S3237|and|I-Randomization_Sequence_Generation_Method
S3237|randomisation|I-Randomization_Sequence_Generation_Method
S3237|system|I-Randomization_Sequence_Generation_Method
S3237|.|O
S1484|Images|O
S1484|were|O
S1484|read|O
S1484|by|O
S1484|an|O
S1484|experienced|O
S1484|musculoskeletal|B-Blinding_Object_Others
S1484|radiologist|I-Blinding_Object_Others
S1484|,|O
S1484|blind|O
S1484|to|O
S1484|treatment|O
S1484|and|O
S1484|chronologic|O
S1484|sequence|O
S1484|of|O
S1484|images|O
S1484|.|O
S2790|Results|O
S2790|Patient|O
S2790|disposition|O
S2790|,|O
S2790|demographics|O
S2790|,|O
S2790|and|O
S2790|baseline|O
S2790|characteristics|O
S2790|Out|O
S2790|of|O
S2790|796|O
S2790|patients|O
S2790|who|O
S2790|were|O
S2790|screened|O
S2790|,|O
S2790|356|B-Sample_Size_Actual_at_Enrollment
S2790|(|O
S2790|45|O
S2790|%|O
S2790|)|O
S2790|met|O
S2790|the|O
S2790|entry|O
S2790|criteria|O
S2790|and|O
S2790|were|O
S2790|randomly|O
S2790|assigned|O
S2790|to|O
S2790|treatment|O
S2790|groups|O
S2790|(|O
S2790|Figure1|O
S2790|)|O
S2790|.|O
S2110|Considering|O
S2110|a|O
S2110|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S2110|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S2110|dropout|O
S2110|rate|O
S2110|,|O
S2110|randomisation|O
S2110|of|O
S2110|approximately|O
S2110|180|B-Sample_Size_Target
S2110|subjects|O
S2110|(|O
S2110|90|O
S2110|per|O
S2110|group|O
S2110|)|O
S2110|was|O
S2110|required|O
S2110|.|O
S6433|We|O
S6433|excluded|O
S6433|patients|O
S6433|who|O
S6433|had|O
S6433|received|O
S6433|trimethoprim-sulfamethoxazole|O
S6433|or|O
S6433|vancomycin|O
S6433|for|O
S6433|more|O
S6433|than|O
S6433|48|O
S6433|hours|O
S6433|;|O
S6433|patients|O
S6433|with|O
S6433|MRSA|O
S6433|resistant|O
S6433|to|O
S6433|trimethoprim-sulfamethoxazole|O
S6433|or|I-Design_Parallel_Group
S6433|vancomycin|I-Design_Parallel_Group
S6433|;|O
S6433|those|O
S6433|with|O
S6433|highly|O
S6433|suspected|O
S6433|or|O
S6433|confirmed|O
S6433|left|O
S6433|sided|O
S6433|endocarditis|O
S6433|or|O
S6433|meningitis|O
S6433|;|O
S6433|patients|O
S6433|with|O
S6433|chronic|O
S6433|renal|O
S6433|failure|O
S6433|(|O
S6433|creatinine|O
S6433|clearance|O
S6433|<|O
S6433|15|O
S6433|mL/min|O
S6433|)|O
S6433|and|O
S6433|chronic|O
S6433|haemodialysis|O
S6433|(|O
S6433|those|O
S6433|with|O
S6433|severe|O
S6433|acute|O
S6433|renal|O
S6433|failure|O
S6433|,|O
S6433|including|O
S6433|acute|O
S6433|haemodialysis|O
S6433|,|O
S6433|could|O
S6433|be|O
S6433|included|O
S6433|)|O
S6433|;|O
S6433|neutropenic|O
S6433|patients|O
S6433|with|O
S6433|acute|O
S6433|leukaemia|O
S6433|or|O
S6433|bone|O
S6433|marrow|O
S6433|transplantation|O
S6433|;|O
S6433|and|O
S6433|patients|O
S6433|with|O
S6433|known|O
S6433|allergy|O
S6433|to|O
S6433|either|O
S6433|study|O
S6433|drug|O
S6433|,|O
S6433|treatment|O
S6433|with|O
S6433|methotrexate|O
S6433|,|O
S6433|pregnancy|O
S6433|or|O
S6433|lactation|O
S6433|,|O
S6433|previous|O
S6433|enrolment|O
S6433|in|O
S6433|this|O
S6433|study|O
S6433|,|O
S6433|or|O
S6433|concurrent|O
S6433|participation|O
S6433|in|O
S6433|another|O
S6433|trial|O
S6433|.|O
S7730|RESULTS|O
S7730|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S7730|for|O
S7730|the|O
S7730|change|O
S7730|from|O
S7730|baseline|O
S7730|in|O
S7730|HbA1c|O
S7730|16|O
S7730|weeks|O
S7730|after|O
S7730|randomization|O
S7730|(|O
S7730|primary|O
S7730|end|O
S7730|point|O
S7730|)|O
S7730|was|O
S7730|confirmed|O
S7730|for|O
S7730|faster|O
S7730|aspart|O
S7730|versus|O
S7730|IAsp|O
S7730|(|O
S7730|estimated|O
S7730|treatment|O
S7730|difference|O
S7730|[|O
S7730|ETD|O
S7730|]|O
S7730|−0.04|O
S7730|%|O
S7730|[|O
S7730|95|O
S7730|%|O
S7730|CI|O
S7730|−0.11|O
S7730|;|O
S7730|0.03|O
S7730|]|O
S7730|;|O
S7730|−0.39|O
S7730|mmol/mol|O
S7730|[|O
S7730|−1.15|O
S7730|;|O
S7730|0.37|O
S7730|]|O
S7730|;|O
S7730|P|O
S7730|<|O
S7730|0.001|O
S7730|)|O
S7730|.|O
S6292|Statistical|O
S6292|Analysis|O
S6292|Approximately|O
S6292|120|B-Sample_Size_Target
S6292|patients|O
S6292|(|O
S6292|60|O
S6292|per|O
S6292|group|O
S6292|)|O
S6292|were|O
S6292|planned|O
S6292|to|O
S6292|be|O
S6292|enrolled|O
S6292|to|O
S6292|confirm|O
S6292|that|O
S6292|the|O
S6292|responder|O
S6292|rate|O
S6292|based|O
S6292|on|O
S6292|the|O
S6292|elbow|O
S6292|MAS|O
S6292|score|O
S6292|in|O
S6292|the|O
S6292|400|O
S6292|U|O
S6292|group|O
S6292|would|O
S6292|exceed|O
S6292|that|O
S6292|in|O
S6292|the|O
S6292|240|O
S6292|U|O
S6292|group|O
S6292|.|O
S1240|Airway|O
S1240|reversibility|O
S1240|at|O
S1240|baseline|O
S1240|ranged|O
S1240|from|O
S1240|0.272|O
S1240|L|O
S1240|(|O
S1240|open-label|B-Blinding_Open_Label
S1240|tiotropium|O
S1240|)|O
S1240|to|O
S1240|0.206|O
S1240|L|O
S1240|(|O
S1240|GP|O
S1240|MDI|O
S1240|9|O
S1240|μg|O
S1240|[|O
S1240|Table|O
S1240|1|O
S1240|]|O
S1240|)|O
S1240|.|O
S7438|Patients|O
S7438|were|O
S7438|randomized|O
S7438|2:1:2:2|B-Randomization_Ratio
S7438|to|O
S7438|placebo|B-Design_Parallel_Group
S7438|or|I-Design_Parallel_Group
S7438|erenumab|I-Design_Parallel_Group
S7438|28|I-Design_Parallel_Group
S7438|,|I-Design_Parallel_Group
S7438|70|I-Design_Parallel_Group
S7438|,|I-Design_Parallel_Group
S7438|or|I-Design_Parallel_Group
S7438|140|I-Design_Parallel_Group
S7438|mg.|O
S7438|Randomization|O
S7438|was|O
S7438|based|O
S7438|on|O
S7438|a|O
S7438|schedule|O
S7438|generated|O
S7438|by|O
S7438|the|O
S7438|study|B-Randomization_Personnel
S7438|sponsor|I-Randomization_Personnel
S7438|and|O
S7438|was|O
S7438|centrally|O
S7438|executed|O
S7438|using|O
S7438|an|O
S7438|interactive|B-Randomization_Sequence_Generation_Method
S7438|voice|I-Randomization_Sequence_Generation_Method
S7438|response|I-Randomization_Sequence_Generation_Method
S7438|system|I-Randomization_Sequence_Generation_Method
S7438|(|O
S7438|Fig|O
S7438|.|O
S2926|Randomization|O
S2926|and|O
S2926|Treatment|O
S2926|Children|O
S2926|were|O
S2926|enrolled|O
S2926|in|O
S2926|parallel|B-Design_Parallel_Group
S2926|to|O
S2926|2|O
S2926|cohorts|O
S2926|:|O
S2926|1–|O
S2926|<|O
S2926|5|O
S2926|years|O
S2926|old|O
S2926|(|O
S2926|minimum|O
S2926|of|O
S2926|20|O
S2926|children|O
S2926|)|O
S2926|and|O
S2926|5–|O
S2926|<|O
S2926|12|O
S2926|years|O
S2926|old|O
S2926|(|O
S2926|minimum|O
S2926|of|O
S2926|40|O
S2926|children|O
S2926|)|O
S2926|.|O
S304|The|O
S304|sponsor|B-Blinding_Object_Others
S304|(|I-Blinding_Object_Others
S304|Dermira|I-Blinding_Object_Others
S304|,|I-Blinding_Object_Others
S304|Inc|I-Blinding_Object_Others
S304|)|I-Blinding_Object_Others
S304|,|O
S304|investigators|B-Blinding_Object_Investigators
S304|,|O
S304|study|B-Blinding_Object_Care_Providers
S304|site|I-Blinding_Object_Care_Providers
S304|personnel|I-Blinding_Object_Care_Providers
S304|,|O
S304|and|O
S304|patients|B-Blinding_Object_Patients
S304|were|O
S304|blinded|O
S304|to|O
S304|treatment|O
S304|assignments|O
S304|,|O
S304|and|O
S304|blind|O
S304|integrity|O
S304|was|O
S304|maintained|O
S304|throughout|O
S304|the|O
S304|study|O
S304|.|O
S85|Thus|O
S85|,|O
S85|noninferiority|B-Design_Comparative_Intent_NonInferiority
S85|in|O
S85|the|O
S85|rate|O
S85|of|O
S85|fever|O
S85|was|O
S85|demonstrated|O
S85|for|O
S85|the|O
S85|full|O
S85|dose|O
S85|compared|O
S85|with|O
S85|the|O
S85|half|O
S85|dose|O
S85|of|O
S85|IIV4|O
S85|.|O
S5611|Results|O
S5611|Four|B-Sample_Size_Actual_at_Enrollment
S5611|hundred|I-Sample_Size_Actual_at_Enrollment
S5611|forty|I-Sample_Size_Actual_at_Enrollment
S5611|patients|I-Sample_Size_Actual_at_Enrollment
S5611|(|O
S5611|male|O
S5611|:|O
S5611|98|O
S5611|[|O
S5611|22.3|O
S5611|%|O
S5611|]|O
S5611|;|O
S5611|female|O
S5611|:|O
S5611|342|O
S5611|[|O
S5611|77.7|O
S5611|%|O
S5611|]|O
S5611|)|O
S5611|were|O
S5611|randomized|O
S5611|.|O
S5298|Results|O
S5298|A|O
S5298|total|O
S5298|of|O
S5298|1538|B-Sample_Size_Actual_at_Enrollment
S5298|patients|O
S5298|were|O
S5298|enrolled|O
S5298|(|O
S5298|mean|O
S5298|estimated|O
S5298|glomerular|O
S5298|filtration|O
S5298|rate|O
S5298|35.5|O
S5298|mL/min/1.73|O
S5298|m2|O
S5298|)|O
S5298|.|O
S8256|Materials|O
S8256|and|O
S8256|Methods|O
S8256|Study|O
S8256|Design|O
S8256|This|O
S8256|is|O
S8256|a|O
S8256|randomized|O
S8256|,|O
S8256|double-blind|B-Blinding_Double_Blind
S8256|,|O
S8256|placebo-controlled|O
S8256|pilot|O
S8256|study|O
S8256|comparing|O
S8256|WL|O
S8256|plus|O
S8256|AI|O
S8256|vs.|O
S8256|WL|O
S8256|plus|O
S8256|PBO|O
S8256|.|O
S5323|Participants|O
S5323|The|O
S5323|trial|O
S5323|was|O
S5323|conducted|O
S5323|at|O
S5323|143|B-Settings_Multicenter
S5323|sites|I-Settings_Multicenter
S5323|(|O
S5323|hospitals|O
S5323|,|O
S5323|private|O
S5323|clinics|O
S5323|and|O
S5323|clinical|O
S5323|research|O
S5323|centres|O
S5323|)|O
S5323|in|O
S5323|the|O
S5323|USA|B-Settings_Location
S5323|.|O
S6766|Although|O
S6766|59|O
S6766|patients|O
S6766|entered|O
S6766|the|O
S6766|extension|O
S6766|,|O
S6766|only|O
S6766|58|B-Sample_Size_Actual_at_Outcome_Analysis
S6766|received|O
S6766|evolocumab|O
S6766|and|O
S6766|were|O
S6766|included|O
S6766|in|O
S6766|the|O
S6766|open-label|O
S6766|extension|O
S6766|analysis|O
S6766|set|O
S6766|.|O
S7158|Participants|B-Blinding_Object_Patients
S7158|,|O
S7158|care|B-Blinding_Object_Care_Providers
S7158|providers|I-Blinding_Object_Care_Providers
S7158|,|O
S7158|and|O
S7158|investigators|B-Blinding_Object_Investigators
S7158|were|O
S7158|masked|O
S7158|to|O
S7158|group|O
S7158|assignment|O
S7158|.|O
S52|Statistical|O
S52|Analysis|O
S52|The|O
S52|primary|O
S52|objective|O
S52|was|O
S52|assessed|O
S52|by|O
S52|determining|O
S52|if|O
S52|the|O
S52|rate|O
S52|of|O
S52|any|O
S52|fever|O
S52|(|O
S52|temperature|O
S52|≥100.4°F|O
S52|[|O
S52|38.0°C|O
S52|]|O
S52|)|O
S52|within|O
S52|7|O
S52|days|O
S52|after|O
S52|administration|O
S52|of|O
S52|any|O
S52|full|O
S52|dose|O
S52|of|O
S52|IIV4|O
S52|was|O
S52|noninferior|B-Design_Comparative_Intent_NonInferiority
S52|to|O
S52|the|O
S52|rate|O
S52|of|O
S52|fever|O
S52|after|O
S52|administration|O
S52|of|O
S52|any|O
S52|half|O
S52|dose|O
S52|.|O
S5520|Thus|O
S5520|a|O
S5520|study|O
S5520|with|O
S5520|80|B-Sample_Size_Calculation_Power_Value
S5520|%|I-Sample_Size_Calculation_Power_Value
S5520|power|O
S5520|and|O
S5520|95|B-Sample_Size_Calculation_Alpha_Value
S5520|%|I-Sample_Size_Calculation_Alpha_Value
S5520|significance|O
S5520|needed|O
S5520|22|O
S5520|079|O
S5520|child-months|O
S5520|per|O
S5520|group|O
S5520|(|O
S5520|total|O
S5520|of|O
S5520|2454|B-Sample_Size_Required
S5520|children|O
S5520|for|O
S5520|18|O
S5520|months|O
S5520|follow-up|O
S5520|)|O
S5520|.|O
S7027|Randomization|O
S7027|,|O
S7027|Stratification|O
S7027|,|O
S7027|and|O
S7027|Blinding|O
S7027|Eligible|O
S7027|patients|O
S7027|,|O
S7027|stratified|B-Randomization_Type_Stratified
S7027|by|O
S7027|geographic|B-Randomization_Stratified_Criteria
S7027|region|I-Randomization_Stratified_Criteria
S7027|,|I-Randomization_Stratified_Criteria
S7027|age|I-Randomization_Stratified_Criteria
S7027|(|I-Randomization_Stratified_Criteria
S7027|18–64|I-Randomization_Stratified_Criteria
S7027|years|I-Randomization_Stratified_Criteria
S7027|and|I-Randomization_Stratified_Criteria
S7027|≥65|I-Randomization_Stratified_Criteria
S7027|years|I-Randomization_Stratified_Criteria
S7027|)|I-Randomization_Stratified_Criteria
S7027|,|O
S7027|and|O
S7027|underlying|B-Randomization_Stratified_Criteria
S7027|diagnosis|I-Randomization_Stratified_Criteria
S7027|(|I-Randomization_Stratified_Criteria
S7027|trauma|I-Randomization_Stratified_Criteria
S7027|or|I-Randomization_Stratified_Criteria
S7027|nontrauma|I-Randomization_Stratified_Criteria
S7027|)|I-Randomization_Stratified_Criteria
S7027|,|O
S7027|were|O
S7027|randomized|O
S7027|1:1|B-Randomization_Ratio
S7027|to|O
S7027|tedizolid|B-Design_Parallel_Group
S7027|phosphate|I-Design_Parallel_Group
S7027|or|I-Design_Parallel_Group
S7027|linezolid|I-Design_Parallel_Group
S7027|(|O
S7027|Supplementary|O
S7027|Figure|O
S7027|1|O
S7027|)|O
S7027|via|O
S7027|an|B-Randomization_Sequence_Generation_Method
S7027|interactive|I-Randomization_Sequence_Generation_Method
S7027|voice|I-Randomization_Sequence_Generation_Method
S7027|response|I-Randomization_Sequence_Generation_Method
S7027|system|I-Randomization_Sequence_Generation_Method
S7027|.|O
S5212|To|O
S5212|account|O
S5212|for|O
S5212|possible|O
S5212|dropouts|O
S5212|,|O
S5212|we|O
S5212|intended|O
S5212|to|O
S5212|include|O
S5212|134|B-Sample_Size_Target
S5212|patients|I-Sample_Size_Target
S5212|per|I-Sample_Size_Target
S5212|group|I-Sample_Size_Target
S5212|.|O
S6711|Methods|O
S6711|Study|O
S6711|Design|O
S6711|This|O
S6711|double-blind|B-Blinding_Double_Blind
S6711|,|O
S6711|randomized|O
S6711|,|O
S6711|multicenter|B-Settings_Multicenter
S6711|,|O
S6711|phase|B-Design_Phase_3
S6711|3|I-Design_Phase_3
S6711|study|O
S6711|randomized|O
S6711|patients|O
S6711|to|O
S6711|evolocumab|B-Design_Parallel_Group
S6711|or|I-Design_Parallel_Group
S6711|ezetimibe|O
S6711|at|O
S6711|30|B-Settings_Multicenter
S6711|sites|I-Settings_Multicenter
S6711|in|O
S6711|Japan|B-Settings_Location
S6711|.|O
S5018|Participants|B-Blinding_Open_Label
S5018|,|I-Blinding_Open_Label
S5018|treating|I-Blinding_Open_Label
S5018|clinicians|I-Blinding_Open_Label
S5018|,|I-Blinding_Open_Label
S5018|and|I-Blinding_Open_Label
S5018|coordinators|I-Blinding_Open_Label
S5018|were|I-Blinding_Open_Label
S5018|not|I-Blinding_Open_Label
S5018|masked|I-Blinding_Open_Label
S5018|.|O
S6265|At|O
S6265|the|O
S6265|same|O
S6265|time|O
S6265|,|O
S6265|an|O
S6265|additional|B-Design_Parallel_Group
S6265|injection|I-Design_Parallel_Group
S6265|of|I-Design_Parallel_Group
S6265|onabotulinumtoxinA|I-Design_Parallel_Group
S6265|160|I-Design_Parallel_Group
S6265|U|I-Design_Parallel_Group
S6265|(|I-Design_Parallel_Group
S6265|400|I-Design_Parallel_Group
S6265|U|I-Design_Parallel_Group
S6265|group|I-Design_Parallel_Group
S6265|)|I-Design_Parallel_Group
S6265|or|I-Design_Parallel_Group
S6265|placebo|I-Design_Parallel_Group
S6265|(|O
S6265|240|O
S6265|U|O
S6265|group|O
S6265|)|O
S6265|was|O
S6265|given|O
S6265|,|O
S6265|in|O
S6265|3|O
S6265|elbow|O
S6265|flexors|O
S6265|(|O
S6265|biceps|O
S6265|brachii|O
S6265|,|O
S6265|brachialis|O
S6265|,|O
S6265|and|O
S6265|brachioradialis|O
S6265|)|O
S6265|.|O
S1613|Open-label|B-Blinding_Open_Label
S1613|assessments|O
S1613|were|O
S1613|performed|O
S1613|every|O
S1613|12|O
S1613|weeks|O
S1613|to|O
S1613|week|O
S1613|104|O
S1613|(|O
S1613|ClinicalTrials.gov|O
S1613|number|O
S1613|NCT00535782|O
S1613|)|O
S1613|.|O
S1765|MacroGenics|O
S1765|provided|O
S1765|teplizumab|B-Design_Parallel_Group
S1765|and|I-Design_Parallel_Group
S1765|matching|I-Design_Parallel_Group
S1765|placebo|I-Design_Parallel_Group
S1765|but|O
S1765|was|O
S1765|not|O
S1765|involved|O
S1765|in|O
S1765|the|O
S1765|conduct|O
S1765|of|O
S1765|the|O
S1765|trial|O
S1765|or|O
S1765|in|O
S1765|data|O
S1765|analysis|O
S1765|.|O
S3884|The|O
S3884|mean|O
S3884|ARR|O
S3884|was|O
S3884|lower|O
S3884|with|O
S3884|40|O
S3884|mg|O
S3884|ponesimod|B-Design_Parallel_Group
S3884|versus|I-Design_Parallel_Group
S3884|placebo|I-Design_Parallel_Group
S3884|,|O
S3884|with|O
S3884|a|O
S3884|maximum|O
S3884|reduction|O
S3884|of|O
S3884|52|O
S3884|%|O
S3884|(|O
S3884|0.25|O
S3884|vs|O
S3884|0.53|O
S3884|;|O
S3884|p=0.0363|O
S3884|)|O
S3884|.|O
S3877|Oral|O
S3877|ponesimod|O
S3877|in|O
S3877|relapsing–remitting|O
S3877|multiple|O
S3877|sclerosis|O
S3877|:|O
S3877|a|O
S3877|randomised|O
S3877|phase|B-Design_Phase_2
S3877|II|I-Design_Phase_2
S3877|trial|O
S3917|All|O
S3917|ponesimod|B-Allocation_Concealment_Method
S3917|doses|I-Allocation_Concealment_Method
S3917|and|I-Allocation_Concealment_Method
S3917|matching|I-Allocation_Concealment_Method
S3917|placebo|I-Allocation_Concealment_Method
S3917|were|I-Allocation_Concealment_Method
S3917|indistinguishable|I-Allocation_Concealment_Method
S3917|and|I-Allocation_Concealment_Method
S3917|identically|I-Allocation_Concealment_Method
S3917|packaged|I-Allocation_Concealment_Method
S3917|.|O
S6715|Randomization|O
S6715|was|O
S6715|performed|O
S6715|using|O
S6715|an|O
S6715|interactive|B-Randomization_Sequence_Generation_Method
S6715|voice/web|I-Randomization_Sequence_Generation_Method
S6715|response|I-Randomization_Sequence_Generation_Method
S6715|system|I-Randomization_Sequence_Generation_Method
S6715|.|O
S755|We|O
S755|assessed|O
S755|the|O
S755|time|O
S755|in|O
S755|minutes|O
S755|that|O
S755|gabapentin|B-Design_Parallel_Group
S755|or|I-Design_Parallel_Group
S755|placebo|I-Design_Parallel_Group
S755|was|O
S755|administered|O
S755|prior|O
S755|to|O
S755|the|O
S755|different|O
S755|pain|O
S755|assessments|O
S755|.|O
S2361|Patients|O
S2361|and|O
S2361|Methods|O
S2361|This|O
S2361|multinational|B-Settings_Multicenter
S2361|,|O
S2361|double-blind|B-Blinding_Double_Blind
S2361|,|O
S2361|randomized|O
S2361|,|O
S2361|phase|B-Design_Phase_3
S2361|III|I-Design_Phase_3
S2361|study|O
S2361|(|O
S2361|STELLA|O
S2361|)|O
S2361|compared|O
S2361|MB02|B-Design_Parallel_Group
S2361|or|I-Design_Parallel_Group
S2361|EU-bevacizumab|I-Design_Parallel_Group
S2361|(|I-Design_Parallel_Group
S2361|15|I-Design_Parallel_Group
S2361|mg/kg|I-Design_Parallel_Group
S2361|)|I-Design_Parallel_Group
S2361|administered|I-Design_Parallel_Group
S2361|with|I-Design_Parallel_Group
S2361|chemotherapy|I-Design_Parallel_Group
S2361|(|O
S2361|paclitaxel|O
S2361|200|O
S2361|mg/m2|O
S2361|and|O
S2361|carboplatin|O
S2361|AUC6|O
S2361|)|O
S2361|on|O
S2361|Day|O
S2361|1|O
S2361|of|O
S2361|every|O
S2361|3-week|O
S2361|cycle|O
S2361|for|O
S2361|6|O
S2361|cycles|O
S2361|(|O
S2361|Week|O
S2361|18|O
S2361|)|O
S2361|,|O
S2361|followed|O
S2361|by|O
S2361|MB02/EU-bevacizumab|O
S2361|in|O
S2361|blinded|O
S2361|monotherapy|O
S2361|until|O
S2361|disease|O
S2361|progression|O
S2361|,|O
S2361|unacceptable|O
S2361|toxicity|O
S2361|,|O
S2361|death|O
S2361|,|O
S2361|withdrawal|O
S2361|of|O
S2361|consent|O
S2361|or|O
S2361|end|O
S2361|of|O
S2361|study|O
S2361|(|O
S2361|Week|O
S2361|52|O
S2361|)|O
S2361|.|O
S6217|Efficacy|O
S6217|and|O
S6217|Safety|O
S6217|of|O
S6217|OnabotulinumtoxinA|O
S6217|400|O
S6217|Units|O
S6217|in|O
S6217|Patients|O
S6217|with|O
S6217|Post-Stroke|O
S6217|Upper|O
S6217|Limb|O
S6217|Spasticity|O
S6217|:|O
S6217|Final|O
S6217|Report|O
S6217|of|O
S6217|a|O
S6217|Randomized|B-Randomization_Type_Simple
S6217|,|O
S6217|Double-Blind|B-Blinding_Double_Blind
S6217|,|O
S6217|Placebo-Controlled|O
S6217|Trial|O
S6217|with|O
S6217|an|O
S6217|Open-Label|B-Blinding_Open_Label
S6217|Extension|O
S6217|Phase|O
S6988|Methods|O
S6988|In|O
S6988|this|O
S6988|randomized|O
S6988|,|O
S6988|noninferiority|B-Design_Comparative_Intent_NonInferiority
S6988|,|O
S6988|double-blind|B-Blinding_Double_Blind
S6988|,|O
S6988|double-dummy|O
S6988|,|O
S6988|global|O
S6988|phase|B-Design_Phase_3
S6988|3|I-Design_Phase_3
S6988|trial|O
S6988|,|O
S6988|patients|O
S6988|were|O
S6988|randomized|O
S6988|1:1|B-Randomization_Ratio
S6988|to|O
S6988|receive|O
S6988|intravenous|B-Design_Parallel_Group
S6988|tedizolid|I-Design_Parallel_Group
S6988|phosphate|I-Design_Parallel_Group
S6988|200|I-Design_Parallel_Group
S6988|mg|I-Design_Parallel_Group
S6988|once|I-Design_Parallel_Group
S6988|daily|I-Design_Parallel_Group
S6988|for|I-Design_Parallel_Group
S6988|7|I-Design_Parallel_Group
S6988|days|I-Design_Parallel_Group
S6988|or|I-Design_Parallel_Group
S6988|intravenous|I-Design_Parallel_Group
S6988|linezolid|I-Design_Parallel_Group
S6988|600|I-Design_Parallel_Group
S6988|mg|I-Design_Parallel_Group
S6988|every|I-Design_Parallel_Group
S6988|12|I-Design_Parallel_Group
S6988|hours|I-Design_Parallel_Group
S6988|for|I-Design_Parallel_Group
S6988|10|I-Design_Parallel_Group
S6988|days|I-Design_Parallel_Group
S6988|.|O
S7255|Modified-|O
S7255|versus|O
S7255|immediate-release|O
S7255|tofacitinib|O
S7255|in|O
S7255|Japanese|O
S7255|rheumatoid|O
S7255|arthritis|O
S7255|patients|O
S7255|:|O
S7255|a|O
S7255|randomized|B-Randomization_Type_Simple
S7255|,|O
S7255|phase|B-Design_Phase_3
S7255|III|I-Design_Phase_3
S7255|,|O
S7255|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7255|study|O
S7153|Randomisation|O
S7153|and|O
S7153|masking|O
S7153|Study|O
S7153|drug|O
S7153|packs|O
S7153|were|O
S7153|prepared|O
S7153|by|O
S7153|Bilcare|O
S7153|Global|O
S7153|Clinical|O
S7153|Supplies|O
S7153|(|O
S7153|Europe|O
S7153|;|O
S7153|Powys|O
S7153|,|O
S7153|UK|B-Settings_Location
S7153|)|O
S7153|.|O
S2588|Based|O
S2588|on|O
S2588|simulations|O
S2588|,|O
S2588|a|O
S2588|sample|O
S2588|size|O
S2588|of|O
S2588|at|O
S2588|least|O
S2588|600|B-Sample_Size_Required
S2588|participants|O
S2588|(|O
S2588|100|O
S2588|in|O
S2588|each|O
S2588|of|O
S2588|the|O
S2588|6|O
S2588|study|O
S2588|treatment|O
S2588|groups|O
S2588|)|O
S2588|was|O
S2588|used|O
S2588|to|O
S2588|allow|O
S2588|for|O
S2588|adequate|O
S2588|precision|O
S2588|in|O
S2588|estimation|O
S2588|of|O
S2588|the|O
S2588|35|O
S2588|mg|O
S2588|DNX|O
S2588|dose|O
S2588|as|O
S2588|well|O
S2588|as|O
S2588|a|O
S2588|sufficient|O
S2588|proportion|O
S2588|with|O
S2588|90|B-Sample_Size_Calculation_Alpha_Value
S2588|%|I-Sample_Size_Calculation_Alpha_Value
S2588|confidence|O
S2588|interval|O
S2588|(|O
S2588|CI|O
S2588|)|O
S2588|difference|O
S2588|from|O
S2588|placebo|O
S2588|excluding|O
S2588|0|O
S2588|,|O
S2588|and|O
S2588|a|O
S2588|sufficient|O
S2588|proportion|O
S2588|with|O
S2588|90|O
S2588|%|O
S2588|CI|O
S2588|of|O
S2588|dose|O
S2588|estimate|O
S2588|excluding|O
S2588|0|O
S2588|.|O
S730|The|O
S730|Duke|O
S730|Family|O
S730|Planning|O
S730|Clinic|O
S730|is|O
S730|a|O
S730|hospital-affiliated|O
S730|clinic|O
S730|that|O
S730|provides|O
S730|care|O
S730|to|O
S730|both|O
S730|insured|O
S730|and|O
S730|uninsured|O
S730|patients|O
S730|in|O
S730|Durham|B-Settings_Location
S730|,|I-Settings_Location
S730|North|I-Settings_Location
S730|Carolina|I-Settings_Location
S730|.|O
S7261|The|O
S7261|primary|O
S7261|objective|O
S7261|was|O
S7261|to|O
S7261|demonstrate|O
S7261|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7261|of|O
S7261|MR|O
S7261|11|O
S7261|mg|O
S7261|QD|O
S7261|to|O
S7261|IR|O
S7261|5|O
S7261|mg|O
S7261|BID|O
S7261|.|O
S7892|PAST-BP|O
S7892|was|O
S7892|an|O
S7892|individually|O
S7892|randomised|O
S7892|trial|O
S7892|in|O
S7892|which|O
S7892|participants|O
S7892|were|O
S7892|allocated|O
S7892|to|O
S7892|either|O
S7892|an|B-Design_Parallel_Group
S7892|intensive|I-Design_Parallel_Group
S7892|blood|I-Design_Parallel_Group
S7892|pressure|I-Design_Parallel_Group
S7892|target|I-Design_Parallel_Group
S7892|(|I-Design_Parallel_Group
S7892|<|I-Design_Parallel_Group
S7892|130|I-Design_Parallel_Group
S7892|mm|I-Design_Parallel_Group
S7892|Hg|I-Design_Parallel_Group
S7892|or|I-Design_Parallel_Group
S7892|a|I-Design_Parallel_Group
S7892|10|I-Design_Parallel_Group
S7892|mm|I-Design_Parallel_Group
S7892|Hg|I-Design_Parallel_Group
S7892|reduction|I-Design_Parallel_Group
S7892|if|I-Design_Parallel_Group
S7892|baseline|I-Design_Parallel_Group
S7892|pressure|I-Design_Parallel_Group
S7892|was|I-Design_Parallel_Group
S7892|<|I-Design_Parallel_Group
S7892|140|I-Design_Parallel_Group
S7892|mm|I-Design_Parallel_Group
S7892|Hg|I-Design_Parallel_Group
S7892|)|I-Design_Parallel_Group
S7892|or|I-Design_Parallel_Group
S7892|a|I-Design_Parallel_Group
S7892|standard|I-Design_Parallel_Group
S7892|target|I-Design_Parallel_Group
S7892|(|I-Design_Parallel_Group
S7892|<|I-Design_Parallel_Group
S7892|140|I-Design_Parallel_Group
S7892|mm|I-Design_Parallel_Group
S7892|Hg|I-Design_Parallel_Group
S7892|)|I-Design_Parallel_Group
S7892|.|O
S474|Of|O
S474|the|O
S474|nine|O
S474|subjects|O
S474|who|O
S474|were|O
S474|randomised|O
S474|,|O
S474|three|B-Sample_Size_Actual_at_Outcome_Analysis
S474|subjects|O
S474|(|O
S474|33.3|O
S474|%|O
S474|)|O
S474|completed|O
S474|the|O
S474|study|O
S474|.|O
S398|Phase|B-Design_Phase_2
S398|II|I-Design_Phase_2
S398|,|O
S398|randomised|O
S398|,|O
S398|double-blind|B-Blinding_Double_Blind
S398|,|O
S398|multicentre|B-Settings_Multicenter
S398|study|O
S398|evaluating|O
S398|the|O
S398|safety|O
S398|and|O
S398|efficacy|O
S398|of|O
S398|filgotinib|O
S398|and|O
S398|lanraplenib|O
S398|in|O
S398|patients|O
S398|with|O
S398|lupus|O
S398|membranous|O
S398|nephropathy|O
S1609|Patients|O
S1609|were|O
S1609|randomly|O
S1609|assigned|O
S1609|using|O
S1609|an|B-Randomization_Sequence_Generation_Method
S1609|interactive|I-Randomization_Sequence_Generation_Method
S1609|voice|I-Randomization_Sequence_Generation_Method
S1609|response|I-Randomization_Sequence_Generation_Method
S1609|system|I-Randomization_Sequence_Generation_Method
S1609|to|O
S1609|blinded|O
S1609|(|O
S1609|patient|B-Blinding_Object_Patients
S1609|and|O
S1609|treating|B-Blinding_Object_Care_Providers
S1609|clinical|I-Blinding_Object_Care_Providers
S1609|team|I-Blinding_Object_Care_Providers
S1609|)|O
S1609|intravenous|O
S1609|treatment|O
S1609|with|O
S1609|TCZ|B-Design_Parallel_Group
S1609|8|I-Design_Parallel_Group
S1609|mg/kg|I-Design_Parallel_Group
S1609|or|I-Design_Parallel_Group
S1609|placebo|I-Design_Parallel_Group
S1609|in|O
S1609|a|O
S1609|1:1|B-Randomization_Ratio
S1609|ratio|O
S1609|,|O
S1609|both|O
S1609|in|O
S1609|combination|O
S1609|with|O
S1609|oral|O
S1609|MTX|O
S1609|,|O
S1609|every|O
S1609|4|O
S1609|weeks|O
S1609|for|O
S1609|6|O
S1609|months|O
S1609|between|O
S1609|November|O
S1609|2007|O
S1609|and|O
S1609|June|O
S1609|2008|O
S1609|.|O
S2109|A|O
S2109|sample|O
S2109|size|O
S2109|of|O
S2109|162|B-Sample_Size_Required
S2109|subjects|O
S2109|(|O
S2109|81|O
S2109|per|O
S2109|treatment|O
S2109|group|O
S2109|)|O
S2109|provided|O
S2109|≥90|B-Sample_Size_Calculation_Power_Value
S2109|%|I-Sample_Size_Calculation_Power_Value
S2109|power|O
S2109|to|O
S2109|show|O
S2109|PK|O
S2109|equivalence|O
S2109|of|O
S2109|CT‐P17|O
S2109|AI|O
S2109|and|O
S2109|CT‐P17|O
S2109|PFS|O
S2109|,|O
S2109|given|O
S2109|the|O
S2109|primary|O
S2109|endpoint|O
S2109|equivalence|O
S2109|margin|O
S2109|,|O
S2109|expected|O
S2109|geometric|O
S2109|mean|O
S2109|ratio|O
S2109|of|O
S2109|1.0|O
S2109|,|O
S2109|and|O
S2109|coefficient|O
S2109|of|O
S2109|variation|O
S2109|of|O
S2109|45|O
S2109|%|O
S2109|(|O
S2109|assumed|O
S2109|based|O
S2109|on|O
S2109|historical|O
S2109|PK|O
S2109|data|O
S2109|in|O
S2109|healthy|O
S2109|individuals|O
S2109|)|O
S2109|.|O
S2891|Results|O
S2891|:|O
S2891|In|O
S2891|total|O
S2891|,|O
S2891|173|B-Sample_Size_Actual_at_Enrollment
S2891|children|I-Sample_Size_Actual_at_Enrollment
S2891|were|O
S2891|randomized|O
S2891|and|O
S2891|dosed|O
S2891|,|O
S2891|115|O
S2891|to|O
S2891|the|O
S2891|baloxavir|O
S2891|group|O
S2891|and|O
S2891|58|O
S2891|to|O
S2891|the|O
S2891|oseltamivir|O
S2891|group|O
S2891|.|O
S6696|Eligible|O
S6696|patients|O
S6696|were|O
S6696|randomized|O
S6696|at|O
S6696|2:2:1:1|B-Randomization_Ratio
S6696|into|O
S6696|four|O
S6696|groups|O
S6696|:|O
S6696|420|O
S6696|mg|O
S6696|evolocumab|O
S6696|every|O
S6696|4|O
S6696|weeks|O
S6696|(|O
S6696|Q4W|O
S6696|)|O
S6696|+|O
S6696|oral|O
S6696|placebo|O
S6696|daily|O
S6696|,|O
S6696|140|O
S6696|mg|O
S6696|evolocumab|O
S6696|every|O
S6696|2|O
S6696|weeks|O
S6696|(|O
S6696|Q2W|O
S6696|)|O
S6696|+|O
S6696|oral|O
S6696|placebo|O
S6696|daily|O
S6696|,|O
S6696|subcutaneous|O
S6696|(|O
S6696|SC|O
S6696|)|O
S6696|placebo|O
S6696|Q4W|O
S6696|+|O
S6696|10|O
S6696|mg|O
S6696|ezetimibe|O
S6696|daily|O
S6696|,|O
S6696|and|O
S6696|SC|O
S6696|placebo|O
S6696|Q2W|O
S6696|+|O
S6696|10|O
S6696|mg|O
S6696|ezetimibe|O
S6696|daily|O
S6696|.|O
S1430|GO-DACT|O
S1430|:|O
S1430|a|O
S1430|phase|B-Design_Phase_3
S1430|3b|I-Design_Phase_3
S1430|randomised|O
S1430|,|O
S1430|double-blind|B-Blinding_Double_Blind
S1430|,|O
S1430|placebo-controlled|O
S1430|trial|O
S1430|of|O
S1430|GOlimumab|O
S1430|plus|O
S1430|methotrexate|O
S1430|(|O
S1430|MTX|O
S1430|)|O
S1430|versus|O
S1430|placebo|O
S1430|plus|O
S1430|MTX|O
S1430|in|O
S1430|improving|O
S1430|DACTylitis|O
S1430|in|O
S1430|MTX-naive|O
S1430|patients|O
S1430|with|O
S1430|psoriatic|O
S1430|arthritis|O
S8595|Methods|O
S8595|Patients|O
S8595|(|O
S8595|N|O
S8595|=|O
S8595|189|B-Sample_Size_Actual_at_Enrollment
S8595|)|O
S8595|with|O
S8595|atherosclerotic|O
S8595|disease|O
S8595|and|O
S8595|either|O
S8595|type|O
S8595|2|O
S8595|diabetes|O
S8595|mellitus|O
S8595|or|O
S8595|impaired|O
S8595|glucose|O
S8595|tolerance|O
S8595|were|O
S8595|randomized|O
S8595|to|O
S8595|receive|O
S8595|placebo|B-Design_Parallel_Group
S8595|(|I-Design_Parallel_Group
S8595|n|I-Design_Parallel_Group
S8595|=|I-Design_Parallel_Group
S8595|94|I-Design_Parallel_Group
S8595|)|I-Design_Parallel_Group
S8595|or|I-Design_Parallel_Group
S8595|canakinumab|I-Design_Parallel_Group
S8595|150|I-Design_Parallel_Group
S8595|mg|I-Design_Parallel_Group
S8595|monthly|I-Design_Parallel_Group
S8595|(|I-Design_Parallel_Group
S8595|n|I-Design_Parallel_Group
S8595|=|I-Design_Parallel_Group
S8595|95|I-Design_Parallel_Group
S8595|)|I-Design_Parallel_Group
S8595|for|O
S8595|12|O
S8595|months|O
S8595|.|O
S6768|Thus|O
S6768|,|O
S6768|57|B-Sample_Size_Actual_at_Outcome_Analysis
S6768|patients|O
S6768|(|O
S6768|97|O
S6768|%|O
S6768|)|O
S6768|completed|O
S6768|the|O
S6768|extension|O
S6768|.|O
S783|One|O
S783|patient|O
S783|in|O
S783|the|O
S783|gabapentin|O
S783|group|O
S783|did|O
S783|not|O
S783|complete|O
S783|the|O
S783|procedure|O
S783|,|O
S783|for|O
S783|a|O
S783|total|O
S783|of|O
S783|95|B-Sample_Size_Actual_at_Outcome_Analysis
S783|patients|O
S783|who|O
S783|received|O
S783|their|O
S783|allocated|O
S783|intervention|O
S783|.|O
S7893|Patients|O
S7893|were|O
S7893|recruited|O
S7893|from|O
S7893|106|B-Settings_Multicenter
S7893|general|I-Settings_Multicenter
S7893|practices|I-Settings_Multicenter
S7893|(|O
S7893|of|O
S7893|which|O
S7893|99|O
S7893|contributed|O
S7893|at|O
S7893|least|O
S7893|one|O
S7893|patient|O
S7893|)|O
S7893|in|O
S7893|England|B-Settings_Location
S7893|during|O
S7893|2009-11|O
S7893|.|O
S7307|The|O
S7307|study|O
S7307|sample|O
S7307|size|O
S7307|was|O
S7307|determined|O
S7307|based|O
S7307|on|O
S7307|the|O
S7307|following|O
S7307|assumptions|O
S7307|for|O
S7307|treatment|O
S7307|comparisons|O
S7307|:|O
S7307|one-sided|B-Sample_Size_Calculation_Alpha_Value
S7307|type|I-Sample_Size_Calculation_Alpha_Value
S7307|I|I-Sample_Size_Calculation_Alpha_Value
S7307|error|I-Sample_Size_Calculation_Alpha_Value
S7307|of|I-Sample_Size_Calculation_Alpha_Value
S7307|0.025|I-Sample_Size_Calculation_Alpha_Value
S7307|;|O
S7307|patient|O
S7307|assignment|O
S7307|to|O
S7307|treatment|O
S7307|in|O
S7307|a|O
S7307|1:1|B-Randomization_Ratio
S7307|ratio|O
S7307|;|O
S7307|the|O
S7307|true|O
S7307|difference|O
S7307|in|O
S7307|treatment|O
S7307|means|O
S7307|between|O
S7307|the|O
S7307|tofacitinib|O
S7307|formulations|O
S7307|of|O
S7307|zero|O
S7307|;|O
S7307|and|O
S7307|an|O
S7307|s.d|O
S7307|.|O
S877|Methods|O
S877|This|O
S877|was|O
S877|a|O
S877|3|O
S877|week|O
S877|,|O
S877|randomised|O
S877|,|O
S877|stratified|B-Randomization_Type_Stratified
S877|,|O
S877|examiner-blind|B-Blinding_Single_Blind
S877|,|O
S877|two-treatment|O
S877|,|O
S877|parallel-group|B-Design_Parallel_Group
S877|clinical|O
S877|trial|O
S877|performed|O
S877|at|O
S877|a|B-Settings_Single_Center
S877|clinical|I-Settings_Single_Center
S877|study|I-Settings_Single_Center
S877|centre|I-Settings_Single_Center
S877|in|O
S877|Las|B-Settings_Location
S877|Vegas|I-Settings_Location
S877|,|I-Settings_Location
S877|USA|I-Settings_Location
S877|.|O
S8658|To|O
S8658|ensure|O
S8658|120|O
S8658|datasets|O
S8658|with|O
S8658|12-month|O
S8658|follow-up|O
S8658|data|O
S8658|,|O
S8658|it|O
S8658|was|O
S8658|planned|O
S8658|to|O
S8658|randomize|O
S8658|190|B-Sample_Size_Target
S8658|patients|O
S8658|.|O
S1764|An|O
S1764|independent|B-Blinding_Object_Others
S1764|medical|I-Blinding_Object_Others
S1764|monitor|I-Blinding_Object_Others
S1764|(|O
S1764|who|O
S1764|was|O
S1764|unaware|O
S1764|of|O
S1764|the|O
S1764|treatment-group|O
S1764|assignments|O
S1764|)|O
S1764|reviewed|O
S1764|all|O
S1764|accruing|O
S1764|safety|O
S1764|data|O
S1764|.|O
S452|Randomisation|O
S452|was|O
S452|stratified|B-Randomization_Type_Stratified
S452|by|O
S452|prior|B-Randomization_Stratified_Criteria
S452|treatment|I-Randomization_Stratified_Criteria
S452|with|I-Randomization_Stratified_Criteria
S452|cyclophosphamide|I-Randomization_Stratified_Criteria
S452|.|O
S908|Randomisation|O
S908|was|O
S908|undertaken|O
S908|by|O
S908|the|O
S908|Biostatistics|B-Randomization_Personnel
S908|Department|I-Randomization_Personnel
S908|of|I-Randomization_Personnel
S908|the|I-Randomization_Personnel
S908|study|I-Randomization_Personnel
S908|sponsor|I-Randomization_Personnel
S908|using|O
S908|validated|B-Randomization_Sequence_Generation_Method
S908|internal|I-Randomization_Sequence_Generation_Method
S908|software|I-Randomization_Sequence_Generation_Method
S908|.|O
S1063|Including|O
S1063|a|O
S1063|5|B-Sample_Size_Calculation_Dropout_Rate_Value
S1063|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1063|dropout|O
S1063|rate|O
S1063|,|O
S1063|we|O
S1063|estimated|O
S1063|that|O
S1063|100|B-Sample_Size_Required
S1063|patients|O
S1063|,|O
S1063|at|O
S1063|α=0.05|O
S1063|,|O
S1063|would|O
S1063|have|O
S1063|90|B-Sample_Size_Calculation_Power_Value
S1063|%|I-Sample_Size_Calculation_Power_Value
S1063|power|O
S1063|to|O
S1063|detect|O
S1063|the|O
S1063|difference|O
S1063|between|O
S1063|groups|O
S1063|.|O
S5968|With|O
S5968|a|O
S5968|sample|O
S5968|size|O
S5968|of|O
S5968|80|B-Sample_Size_Required
S5968|patients|O
S5968|,|O
S5968|we|O
S5968|had|O
S5968|90|B-Sample_Size_Calculation_Power_Value
S5968|%|I-Sample_Size_Calculation_Power_Value
S5968|power|O
S5968|to|O
S5968|detect|O
S5968|this|O
S5968|40|O
S5968|%|O
S5968|difference|O
S5968|in|O
S5968|AUC|O
S5968|cTnI|O
S5968|with|O
S5968|a|O
S5968|significance|O
S5968|level|O
S5968|of|O
S5968|5|B-Sample_Size_Calculation_Alpha_Value
S5968|%|I-Sample_Size_Calculation_Alpha_Value
S5968|,|O
S5968|using|O
S5968|a|O
S5968|t|O
S5968|test|O
S5968|with|O
S5968|unequal|O
S5968|variances|O
S5968|and|O
S5968|allowing|O
S5968|for|O
S5968|four|B-Sample_Size_Calculation_Dropout_Rate_Value
S5968|dropouts|I-Sample_Size_Calculation_Dropout_Rate_Value
S5968|in|I-Sample_Size_Calculation_Dropout_Rate_Value
S5968|each|I-Sample_Size_Calculation_Dropout_Rate_Value
S5968|arm|I-Sample_Size_Calculation_Dropout_Rate_Value
S5968|.|O
S1625|A|O
S1625|sample|O
S1625|size|O
S1625|of|O
S1625|120|B-Sample_Size_Required
S1625|patients|O
S1625|(|O
S1625|60|O
S1625|per|O
S1625|arm|O
S1625|)|O
S1625|,|O
S1625|calculated|O
S1625|based|O
S1625|on|O
S1625|previous|O
S1625|results|O
S1625|in|O
S1625|patients|O
S1625|with|O
S1625|RA|O
S1625|,|O
S1625|was|O
S1625|expected|O
S1625|to|O
S1625|provide|O
S1625|sufficient|O
S1625|power|O
S1625|to|O
S1625|detect|O
S1625|a|O
S1625|difference|O
S1625|at|O
S1625|week|O
S1625|12|O
S1625|in|O
S1625|PWV|O
S1625|(|O
S1625|−1.14|O
S1625|m/s|O
S1625|)|O
S1625|and|O
S1625|small|O
S1625|LDL|O
S1625|(|O
S1625|−5.51|O
S1625|mg/dL|O
S1625|(|O
S1625|30|O
S1625|%|O
S1625|reduction|O
S1625|)|O
S1625|)|O
S1625|in|O
S1625|patients|O
S1625|treated|O
S1625|with|O
S1625|TCZ|B-Design_Parallel_Group
S1625|compared|I-Design_Parallel_Group
S1625|with|I-Design_Parallel_Group
S1625|placebo|I-Design_Parallel_Group
S1625|.|O
S7309|Based|O
S7309|on|O
S7309|these|O
S7309|assumptions|O
S7309|,|O
S7309|a|O
S7309|total|O
S7309|of|O
S7309|⩾200|O
S7309|patients|O
S7309|(|O
S7309|100|O
S7309|per|O
S7309|treatment|O
S7309|arm|O
S7309|)|O
S7309|were|O
S7309|required|O
S7309|to|O
S7309|demonstrate|O
S7309|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7309|with|O
S7309|a|O
S7309|power|O
S7309|of|O
S7309|90|B-Sample_Size_Calculation_Power_Value
S7309|%|I-Sample_Size_Calculation_Power_Value
S7309|.|O
S1867|Methods|O
S1867|A|O
S1867|randomized|O
S1867|,|O
S1867|open-label|B-Blinding_Open_Label
S1867|trial|O
S1867|was|O
S1867|conducted|O
S1867|at|O
S1867|19|B-Settings_Multicenter
S1867|hospitals/clinics|I-Settings_Multicenter
S1867|in|O
S1867|Argentina|B-Settings_Location
S1867|,|I-Settings_Location
S1867|Brazil|I-Settings_Location
S1867|,|I-Settings_Location
S1867|South|I-Settings_Location
S1867|Africa|I-Settings_Location
S1867|,|I-Settings_Location
S1867|Tanzania|I-Settings_Location
S1867|,|I-Settings_Location
S1867|Thailand|I-Settings_Location
S1867|,|I-Settings_Location
S1867|and|I-Settings_Location
S1867|the|I-Settings_Location
S1867|US|I-Settings_Location
S1867|.|O
S6398|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S6398|was|O
S6398|defined|O
S6398|by|O
S6398|a|O
S6398|difference|O
S6398|of|O
S6398|less|O
S6398|than|O
S6398|15|O
S6398|%|O
S6398|for|O
S6398|treatment|O
S6398|failure|O
S6398|.|O
S5338|The|O
S5338|block|O
S5338|size|O
S5338|was|O
S5338|six|B-Randomization_Block_Size
S5338|.|O
S6855|Study|O
S6855|Design|O
S6855|This|O
S6855|was|O
S6855|a|O
S6855|randomized|O
S6855|,|O
S6855|double-blind|B-Blinding_Double_Blind
S6855|,|O
S6855|multicenter|B-Settings_Multicenter
S6855|,|O
S6855|placebo|O
S6855|,|O
S6855|and|O
S6855|active|O
S6855|comparator-controlled|O
S6855|trial|O
S6855|designed|O
S6855|to|O
S6855|evaluate|O
S6855|the|O
S6855|efficacy|O
S6855|and|O
S6855|safety|O
S6855|of|O
S6855|once-daily|O
S6855|aprocitentan|O
S6855|5|O
S6855|,|O
S6855|10|O
S6855|,|O
S6855|25|O
S6855|,|O
S6855|and|O
S6855|50|O
S6855|mg|O
S6855|in|O
S6855|patients|O
S6855|with|O
S6855|grade|O
S6855|1|O
S6855|to|O
S6855|2|O
S6855|essential|O
S6855|hypertension|O
S6855|.|O
S724|METHODS|O
S724|This|O
S724|was|O
S724|a|O
S724|prospective|O
S724|,|O
S724|randomized|O
S724|,|O
S724|double-blind|B-Blinding_Double_Blind
S724|,|O
S724|placebo-controlled|O
S724|trial|O
S724|approved|O
S724|by|O
S724|the|O
S724|Duke|O
S724|Health|O
S724|Institutional|O
S724|Review|O
S724|Board|O
S724|(|O
S724|Pro00063872|O
S724|)|O
S724|.|O
S5776|A|O
S5776|phase|B-Design_Phase_2
S5776|2|I-Design_Phase_2
S5776|,|O
S5776|randomized|O
S5776|,|O
S5776|double-blind|B-Blinding_Double_Blind
S5776|,|O
S5776|placebo-controlled|O
S5776|trial|O
S5776|of|O
S5776|AMG|O
S5776|301|O
S5776|,|O
S5776|a|O
S5776|pituitary|O
S5776|adenylate|O
S5776|cyclase-activating|O
S5776|polypeptide|O
S5776|PAC1|O
S5776|receptor|O
S5776|monoclonal|O
S5776|antibody|O
S5776|for|O
S5776|migraine|O
S5776|prevention|O
S4832|Methods|O
S4832|Study|O
S4832|Design|O
S4832|and|O
S4832|Participants|O
S4832|We|O
S4832|conducted|O
S4832|a|O
S4832|prospective|O
S4832|,|O
S4832|randomized|O
S4832|,|O
S4832|blinded|B-Blinding_Double_Blind
S4832|clinical|O
S4832|trial|O
S4832|at|O
S4832|CDC-sponsored|B-Settings_Multicenter
S4832|Clinical|I-Settings_Multicenter
S4832|Immunization|I-Settings_Multicenter
S4832|Safety|I-Settings_Multicenter
S4832|Assessment|I-Settings_Multicenter
S4832|(|I-Settings_Multicenter
S4832|CISA|I-Settings_Multicenter
S4832|)|I-Settings_Multicenter
S4832|Project|I-Settings_Multicenter
S4832|centers|I-Settings_Multicenter
S4832|during|O
S4832|the|O
S4832|2017|O
S4832|to|O
S4832|2018|O
S4832|(|O
S4832|Duke|O
S4832|University|O
S4832|Medical|O
S4832|Center|O
S4832|and|O
S4832|Boston|O
S4832|Medical|O
S4832|Center|O
S4832|)|O
S4832|and|O
S4832|2018|O
S4832|to|O
S4832|2019|O
S4832|(|O
S4832|Duke|O
S4832|,|O
S4832|Boston|O
S4832|,|O
S4832|and|O
S4832|Cincinnati|O
S4832|Children|O
S4832|’|O
S4832|s|O
S4832|Hospital|O
S4832|Medical|O
S4832|Center|O
S4832|)|O
S4832|influenza|O
S4832|seasons|O
S4832|.|O
S5939|Patients|O
S5939|were|O
S5939|randomised|O
S5939|(|O
S5939|1:1|B-Randomization_Ratio
S5939|)|O
S5939|to|O
S5939|receive|O
S5939|elafin|B-Design_Parallel_Group
S5939|or|I-Design_Parallel_Group
S5939|matched|I-Design_Parallel_Group
S5939|placebo|I-Design_Parallel_Group
S5939|by|O
S5939|Edinburgh|B-Settings_Location
S5939|Clinical|I-Settings_Location
S5939|Trials|I-Settings_Location
S5939|Unit|I-Settings_Location
S5939|to|O
S5939|ensure|O
S5939|allocation|O
S5939|concealment|O
S5939|.|O
S6401|However|O
S6401|,|O
S6401|trimethoprim-sulfamethoxazole|O
S6401|did|O
S6401|not|O
S6401|meet|O
S6401|the|O
S6401|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S6401|criterion—absolute|O
S6401|difference|O
S6401|10.4|O
S6401|%|O
S6401|(|O
S6401|95|O
S6401|%|O
S6401|confidence|O
S6401|interval|O
S6401|−1.2|O
S6401|%|O
S6401|to|O
S6401|21.5|O
S6401|%|O
S6401|)|O
S6401|.|O
S39|The|O
S39|participant|B-Blinding_Object_Patients
S39|,|O
S39|study|B-Blinding_Object_Others
S39|site|I-Blinding_Object_Others
S39|personnel|I-Blinding_Object_Others
S39|(|O
S39|including|O
S39|investigators|B-Blinding_Object_Investigators
S39|)|O
S39|and|O
S39|sponsor|B-Blinding_Object_Others
S39|’|I-Blinding_Object_Others
S39|s|I-Blinding_Object_Others
S39|clinical|I-Blinding_Object_Others
S39|team|I-Blinding_Object_Others
S39|members|I-Blinding_Object_Others
S39|involved|O
S39|in|O
S39|the|O
S39|study|O
S39|were|O
S39|blinded|O
S39|to|O
S39|the|O
S39|vaccine|O
S39|dose|O
S39|administered|O
S39|,|O
S39|with|O
S39|the|O
S39|exception|O
S39|of|O
S39|unblinded|O
S39|qualified|O
S39|study|O
S39|staff|O
S39|who|O
S39|administered|O
S39|the|O
S39|vaccine|O
S39|.|O
S5328|Interventions|O
S5328|Patients|O
S5328|were|O
S5328|randomized|O
S5328|2:1|B-Randomization_Ratio
S5328|to|O
S5328|either|O
S5328|IIM|B-Design_Parallel_Group
S5328|(|I-Design_Parallel_Group
S5328|Monofer®/Monoferric®|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|Pharmacosmos|I-Design_Parallel_Group
S5328|A/S|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|Holbaek|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|Denmark|I-Design_Parallel_Group
S5328|)|I-Design_Parallel_Group
S5328|administered|I-Design_Parallel_Group
S5328|at|I-Design_Parallel_Group
S5328|baseline|I-Design_Parallel_Group
S5328|as|I-Design_Parallel_Group
S5328|a|I-Design_Parallel_Group
S5328|single|I-Design_Parallel_Group
S5328|dose|I-Design_Parallel_Group
S5328|of|I-Design_Parallel_Group
S5328|1000|I-Design_Parallel_Group
S5328|mg|I-Design_Parallel_Group
S5328|infused|I-Design_Parallel_Group
S5328|over|I-Design_Parallel_Group
S5328|20|I-Design_Parallel_Group
S5328|min|I-Design_Parallel_Group
S5328|or|I-Design_Parallel_Group
S5328|IS|I-Design_Parallel_Group
S5328|(|I-Design_Parallel_Group
S5328|Venofer®|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|American|I-Design_Parallel_Group
S5328|Regent|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|Shirley|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|NY|I-Design_Parallel_Group
S5328|,|I-Design_Parallel_Group
S5328|USA|I-Design_Parallel_Group
S5328|)|I-Design_Parallel_Group
S5328|administered|I-Design_Parallel_Group
S5328|as|I-Design_Parallel_Group
S5328|200|I-Design_Parallel_Group
S5328|mg|I-Design_Parallel_Group
S5328|IV|I-Design_Parallel_Group
S5328|injections|I-Design_Parallel_Group
S5328|repeated|O
S5328|according|O
S5328|to|O
S5328|standard|O
S5328|practice|O
S5328|or|O
S5328|physician|O
S5328|choice|O
S5328|up|O
S5328|to|O
S5328|a|O
S5328|maximum|O
S5328|of|O
S5328|five|O
S5328|times|O
S5328|within|O
S5328|the|O
S5328|first|O
S5328|2|O
S5328|weeks|O
S5328|starting|O
S5328|at|O
S5328|baseline|O
S5328|.|O
S1234|Results|O
S1234|Patient|O
S1234|disposition|O
S1234|and|O
S1234|baseline|O
S1234|characteristics|O
S1234|Overall|O
S1234|,|O
S1234|140|B-Sample_Size_Actual_at_Enrollment
S1234|patients|O
S1234|were|O
S1234|randomly|O
S1234|assigned|O
S1234|to|O
S1234|treatment|O
S1234|groups|O
S1234|,|O
S1234|and|O
S1234|110|B-Sample_Size_Actual_at_Outcome_Analysis
S1234|(|O
S1234|79|O
S1234|%|O
S1234|)|O
S1234|patients|O
S1234|completed|O
S1234|four|O
S1234|treatment|O
S1234|periods|O
S1234|with|O
S1234|120|O
S1234|included|O
S1234|in|O
S1234|the|O
S1234|mITT|O
S1234|population|O
S1234|(|O
S1234|Fig|O
S1234|.|O
S6599|Randomization|O
S6599|was|O
S6599|performed|O
S6599|through|O
S6599|an|O
S6599|interactive|B-Randomization_Sequence_Generation_Method
S6599|voice|I-Randomization_Sequence_Generation_Method
S6599|and|I-Randomization_Sequence_Generation_Method
S6599|web|I-Randomization_Sequence_Generation_Method
S6599|response|I-Randomization_Sequence_Generation_Method
S6599|system|I-Randomization_Sequence_Generation_Method
S6599|(|I-Randomization_Sequence_Generation_Method
S6599|IxRS|I-Randomization_Sequence_Generation_Method
S6599|)|I-Randomization_Sequence_Generation_Method
S6599|and|O
S6599|stratified|B-Randomization_Type_Stratified
S6599|for|O
S6599|baseline|B-Randomization_Stratified_Criteria
S6599|BCVA|I-Randomization_Stratified_Criteria
S6599|(|I-Randomization_Stratified_Criteria
S6599|ETDRS|I-Randomization_Stratified_Criteria
S6599|letter|I-Randomization_Stratified_Criteria
S6599|score|I-Randomization_Stratified_Criteria
S6599|≥55|I-Randomization_Stratified_Criteria
S6599|vs|I-Randomization_Stratified_Criteria
S6599|≤54|I-Randomization_Stratified_Criteria
S6599|)|I-Randomization_Stratified_Criteria
S6599|.|O
S8130|Results|O
S8130|Disposition|O
S8130|and|O
S8130|demographics|O
S8130|Of|O
S8130|124|O
S8130|screened|O
S8130|participants|O
S8130|,|O
S8130|89|B-Sample_Size_Actual_at_Enrollment
S8130|were|O
S8130|randomized|O
S8130|(|O
S8130|placebo|O
S8130|,|O
S8130|n|O
S8130|=|O
S8130|44|O
S8130|;|O
S8130|SHP465|O
S8130|MAS|O
S8130|,|O
S8130|n|O
S8130|=|O
S8130|45|O
S8130|;|O
S8130|Fig|O
S8130|.|O
S7155|We|O
S7155|used|O
S7155|a|B-Randomization_Sequence_Generation_Method
S7155|computer-generated|I-Randomization_Sequence_Generation_Method
S7155|randomisation|I-Randomization_Sequence_Generation_Method
S7155|sequence|I-Randomization_Sequence_Generation_Method
S7155|with|O
S7155|a|O
S7155|block|B-Randomization_Type_Block
S7155|size|O
S7155|of|O
S7155|eight|B-Randomization_Block_Size
S7155|.|O
S1346|Sample|O
S1346|size|O
S1346|and|O
S1346|statistical|O
S1346|analysis|O
S1346|The|O
S1346|primary|O
S1346|objective|O
S1346|was|O
S1346|to|O
S1346|demonstrate|O
S1346|equivalence|B-Design_Comparative_Intent_Equivalence
S1346|of|O
S1346|ACR20|O
S1346|at|O
S1346|week|O
S1346|30|O
S1346|.|O
S1868|Antiretroviralnaïve|O
S1868|pregnant|O
S1868|women|O
S1868|(|O
S1868|20–36|O
S1868|weeks|O
S1868|gestation|O
S1868|)|O
S1868|living|O
S1868|with|O
S1868|HIV|O
S1868|were|O
S1868|assigned|O
S1868|to|O
S1868|antiretroviral|B-Design_Parallel_Group
S1868|regimens|I-Design_Parallel_Group
S1868|containing|I-Design_Parallel_Group
S1868|either|I-Design_Parallel_Group
S1868|RAL|I-Design_Parallel_Group
S1868|(|I-Design_Parallel_Group
S1868|400mg|I-Design_Parallel_Group
S1868|twice|I-Design_Parallel_Group
S1868|daily|I-Design_Parallel_Group
S1868|)|I-Design_Parallel_Group
S1868|or|I-Design_Parallel_Group
S1868|EFV|I-Design_Parallel_Group
S1868|(|I-Design_Parallel_Group
S1868|600|I-Design_Parallel_Group
S1868|mg|I-Design_Parallel_Group
S1868|each|I-Design_Parallel_Group
S1868|night|I-Design_Parallel_Group
S1868|)|I-Design_Parallel_Group
S1868|,|O
S1868|plus|O
S1868|lamivudine|O
S1868|150|O
S1868|mg/zidovudine|O
S1868|300|O
S1868|mg|O
S1868|twice|O
S1868|daily|O
S1868|(|O
S1868|or|O
S1868|approved|O
S1868|alternative|O
S1868|backbone|O
S1868|regimen|O
S1868|)|O
S1868|,|O
S1868|using|O
S1868|a|B-Randomization_Sequence_Generation_Method
S1868|web-based|I-Randomization_Sequence_Generation_Method
S1868|,|I-Randomization_Sequence_Generation_Method
S1868|permuted-block|B-Randomization_Type_Block
S1868|randomization|I-Randomization_Sequence_Generation_Method
S1868|stratified|B-Randomization_Type_Stratified
S1868|by|O
S1868|gestational|B-Randomization_Stratified_Criteria
S1868|age|I-Randomization_Stratified_Criteria
S1868|and|O
S1868|backbone|B-Randomization_Stratified_Criteria
S1868|regimen|I-Randomization_Stratified_Criteria
S1868|.|O
S4369|Patients|O
S4369|were|O
S4369|enrolled|O
S4369|from|O
S4369|one|B-Settings_Multicenter
S4369|center|I-Settings_Multicenter
S4369|in|I-Settings_Multicenter
S4369|Hong|I-Settings_Multicenter
S4369|Kong|I-Settings_Multicenter
S4369|and|I-Settings_Multicenter
S4369|five|I-Settings_Multicenter
S4369|centers|I-Settings_Multicenter
S4369|in|I-Settings_Multicenter
S4369|the|I-Settings_Multicenter
S4369|Republic|I-Settings_Multicenter
S4369|of|I-Settings_Multicenter
S4369|Korea|I-Settings_Multicenter
S4369|.|O
S4068|A|O
S4068|Phase|B-Design_Phase_2
S4068|II|I-Design_Phase_2
S4068|Trial|O
S4068|of|O
S4068|Safety|O
S4068|,|O
S4068|Tolerability|O
S4068|and|O
S4068|Immunogenicity|O
S4068|of|O
S4068|V114|O
S4068|,|O
S4068|a|O
S4068|15-Valent|O
S4068|Pneumococcal|O
S4068|Conjugate|O
S4068|Vaccine|O
S4068|,|O
S4068|Compared|O
S4068|With|O
S4068|13-Valent|O
S4068|Pneumococcal|O
S4068|Conjugate|O
S4068|Vaccine|O
S4068|in|O
S4068|Healthy|O
S4068|Infants|O
S648|In|O
S648|the|O
S648|analysis|O
S648|of|O
S648|the|O
S648|primary|O
S648|outcome|O
S648|performed|O
S648|on|O
S648|all|O
S648|patients|O
S648|who|O
S648|received|O
S648|at|O
S648|least|O
S648|one|O
S648|dose|O
S648|of|O
S648|the|O
S648|interventional|O
S648|treatment|O
S648|(|O
S648|eg|O
S648|,|O
S648|103|B-Sample_Size_Actual_at_Outcome_Analysis
S648|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S648|in|I-Sample_Size_Actual_at_Outcome_Analysis
S648|the|I-Sample_Size_Actual_at_Outcome_Analysis
S648|rhEPO|I-Sample_Size_Actual_at_Outcome_Analysis
S648|arm|I-Sample_Size_Actual_at_Outcome_Analysis
S648|and|I-Sample_Size_Actual_at_Outcome_Analysis
S648|97|I-Sample_Size_Actual_at_Outcome_Analysis
S648|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S648|in|I-Sample_Size_Actual_at_Outcome_Analysis
S648|the|I-Sample_Size_Actual_at_Outcome_Analysis
S648|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S648|arm|I-Sample_Size_Actual_at_Outcome_Analysis
S648|)|O
S648|,|O
S648|the|O
S648|rate|O
S648|of|O
S648|events|O
S648|(|O
S648|death|O
S648|,|O
S648|tracheotomy|O
S648|,|O
S648|>|O
S648|23|O
S648|h|O
S648|NIV|O
S648|)|O
S648|at|O
S648|12-month|O
S648|follow-up|O
S648|did|O
S648|not|O
S648|differ|O
S648|between|O
S648|the|O
S648|treatment|O
S648|groups|O
S648|,|O
S648|even|O
S648|after|O
S648|stratification|O
S648|by|O
S648|disease|O
S648|severity|O
S648|and|O
S648|onset|O
S648|(|O
S648|table|O
S648|2|O
S648|)|O
S648|.|O
S1620|Blinded|O
S1620|assessors|B-Blinding_Object_Outcome_Assessors
S1620|from|O
S1620|all|O
S1620|centres|O
S1620|underwent|O
S1620|training|O
S1620|with|O
S1620|an|O
S1620|expert|O
S1620|assessor|O
S1620|,|O
S1620|and|O
S1620|certification|O
S1620|was|O
S1620|provided|O
S1620|by|O
S1620|AtCor|O
S1620|.|O
S4076|Results|O
S4076|:|O
S4076|Overall|O
S4076|,|O
S4076|1044|O
S4076|of|O
S4076|1051|B-Sample_Size_Actual_at_Enrollment
S4076|randomized|O
S4076|infants|O
S4076|received|O
S4076|≥1|O
S4076|dose|O
S4076|of|O
S4076|vaccine|O
S4076|(|O
S4076|V114|O
S4076|Lot|O
S4076|1|O
S4076|[|O
S4076|n|O
S4076|=|O
S4076|350|O
S4076|]|O
S4076|,|O
S4076|V114|O
S4076|Lot|O
S4076|2|O
S4076|[|O
S4076|n|O
S4076|=|O
S4076|347|O
S4076|]|O
S4076|or|O
S4076|PCV13|O
S4076|[|O
S4076|n|O
S4076|=|O
S4076|347|O
S4076|]|O
S4076|)|O
S4076|.|O
S5442|Effect|O
S5442|on|O
S5442|the|O
S5442|incidence|O
S5442|of|O
S5442|pneumonia|O
S5442|of|O
S5442|vitamin|O
S5442|D|O
S5442|supplementation|O
S5442|by|O
S5442|quarterly|O
S5442|bolus|O
S5442|dose|O
S5442|to|O
S5442|infants|O
S5442|in|O
S5442|Kabul|B-Settings_Location
S5442|:|O
S5442|a|O
S5442|randomised|O
S5442|controlled|O
S5442|superiority|B-Design_Comparative_Intent_Superiority
S5442|trial|O
S4796|Design|O
S4796|,|O
S4796|Setting|O
S4796|,|O
S4796|and|O
S4796|Participants|O
S4796|This|O
S4796|randomized|O
S4796|blinded|O
S4796|clinical|O
S4796|trial|O
S4796|was|O
S4796|a|O
S4796|multicenter|B-Settings_Multicenter
S4796|US|B-Settings_Location
S4796|study|O
S4796|conducted|O
S4796|during|O
S4796|the|O
S4796|2017|O
S4796|to|O
S4796|2018|O
S4796|and|O
S4796|2018|O
S4796|to|O
S4796|2019|O
S4796|influenza|O
S4796|seasons|O
S4796|.|O
S8114|Taking|O
S8114|into|O
S8114|account|O
S8114|an|O
S8114|expected|O
S8114|15|B-Sample_Size_Calculation_Dropout_Rate_Value
S8114|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S8114|dropout|O
S8114|rate|O
S8114|,|O
S8114|60|B-Sample_Size_Target
S8114|participants|O
S8114|were|O
S8114|targeted|O
S8114|for|O
S8114|randomization|O
S8114|.|O
S4984|The|O
S4984|primary|O
S4984|hypotheses|O
S4984|were|O
S4984|that|O
S4984|:|O
S4984|1|O
S4984|)|O
S4984|intravitreal|O
S4984|triamcinolone|O
S4984|acetonide|O
S4984|will|O
S4984|have|O
S4984|superior|B-Design_Comparative_Intent_Superiority
S4984|efficacy|O
S4984|to|O
S4984|periocular|O
S4984|triamcinolone|O
S4984|acetonide|O
S4984|in|O
S4984|the|O
S4984|treatment|O
S4984|of|O
S4984|uveitic|O
S4984|macular|O
S4984|edema|O
S4984|;|O
S4984|2|O
S4984|)|O
S4984|the|O
S4984|intravitreal|O
S4984|dexamethasone|O
S4984|implant|O
S4984|will|O
S4984|have|O
S4984|superior|B-Design_Comparative_Intent_Superiority
S4984|efficacy|O
S4984|to|O
S4984|periocular|O
S4984|triamcinolone|O
S4984|acetonide|O
S4984|in|O
S4984|the|O
S4984|treatment|O
S4984|of|O
S4984|uveitic|O
S4984|macular|O
S4984|edema|O
S4984|;|O
S4984|and|O
S4984|that|O
S4984|3|O
S4984|)|O
S4984|the|O
S4984|intravitreal|O
S4984|dexamethasone|O
S4984|implant|O
S4984|will|O
S4984|be|O
S4984|non-inferior|O
S4984|to|O
S4984|intravitreal|O
S4984|triamcinolone|O
S4984|acetonide|O
S4984|in|O
S4984|the|O
S4984|treatment|O
S4984|of|O
S4984|uveitic|O
S4984|macular|O
S4984|edema|O
S4984|.|O
S4326|This|O
S4326|phase|B-Design_Phase_2
S4326|2|I-Design_Phase_2
S4326|double-blinded|B-Blinding_Double_Blind
S4326|,|O
S4326|randomized|O
S4326|,|O
S4326|placebo-controlled|O
S4326|trial|O
S4326|is|O
S4326|the|O
S4326|first|O
S4326|evaluation|O
S4326|of|O
S4326|the|O
S4326|safety|O
S4326|and|O
S4326|activity|O
S4326|of|O
S4326|an|O
S4326|antisense|O
S4326|oligonucleotide|O
S4326|targeting|O
S4326|HBV|O
S4326|RNA|O
S4326|in|O
S4326|both|O
S4326|treatment-naïve|O
S4326|and|O
S4326|virally|O
S4326|suppressed|O
S4326|individuals|O
S4326|with|O
S4326|chronic|O
S4326|HBV|O
S4326|infection|O
S4326|.|O
S3065|Patients|B-Blinding_Object_Patients
S3065|,|O
S3065|physicians|B-Blinding_Object_Care_Providers
S3065|,|O
S3065|and|O
S3065|investigators|B-Blinding_Object_Investigators
S3065|were|O
S3065|masked|O
S3065|to|O
S3065|treatment|O
S3065|allocation|O
S3065|.|O
S6831|After|O
S6831|a|O
S6831|single-blind|O
S6831|placebo|O
S6831|run-in|O
S6831|period|O
S6831|,|O
S6831|490|B-Sample_Size_Actual_at_Enrollment
S6831|eligible|O
S6831|patients|O
S6831|were|O
S6831|randomized|O
S6831|to|O
S6831|the|O
S6831|double-blind|O
S6831|phase|O
S6831|,|O
S6831|with|O
S6831|409|B-Sample_Size_Actual_at_Outcome_Analysis
S6831|patients|O
S6831|completing|O
S6831|8|O
S6831|weeks|O
S6831|of|O
S6831|therapy|O
S6831|per|O
S6831|protocol|O
S6831|.|O
S7195|Recruitment|O
S7195|was|O
S7195|stopped|O
S7195|after|O
S7195|the|O
S7195|second|O
S7195|interim|O
S7195|analysis|O
S7195|,|O
S7195|when|O
S7195|the|O
S7195|Data|O
S7195|Monitoring|O
S7195|and|O
S7195|Ethics|O
S7195|Committee|O
S7195|reviewed|O
S7195|the|O
S7195|results|O
S7195|for|O
S7195|273|B-Sample_Size_Actual_at_Outcome_Analysis
S7195|patients|O
S7195|in|O
S7195|March|O
S7195|,|O
S7195|2010|O
S7195|.|O
S127|Intranasal|B-Design_Parallel_Group
S127|fentanyl|I-Design_Parallel_Group
S127|spray|I-Design_Parallel_Group
S127|versus|I-Design_Parallel_Group
S127|intravenous|I-Design_Parallel_Group
S127|opioids|I-Design_Parallel_Group
S127|for|O
S127|the|O
S127|treatment|O
S127|of|O
S127|severe|O
S127|pain|O
S127|in|O
S127|patients|O
S127|with|O
S127|cancer|O
S127|in|O
S127|the|O
S127|emergency|O
S127|department|O
S127|setting|O
S127|:|O
S127|A|O
S127|randomized|B-Randomization_Type_Simple
S127|controlled|O
S127|trial|O
S7441|All|O
S7441|patients|B-Blinding_Object_Patients
S7441|and|O
S7441|study|B-Blinding_Object_Others
S7441|personnel|I-Blinding_Object_Others
S7441|were|O
S7441|blinded|O
S7441|to|O
S7441|the|O
S7441|investigational|O
S7441|products|O
S7441|and|O
S7441|doses|O
S7441|.|O
S2774|A|O
S2774|sample|O
S2774|size|O
S2774|of|O
S2774|90|B-Sample_Size_Required
S2774|patients|I-Sample_Size_Required
S2774|in|I-Sample_Size_Required
S2774|each|I-Sample_Size_Required
S2774|treatment|I-Sample_Size_Required
S2774|group|I-Sample_Size_Required
S2774|was|O
S2774|expected|O
S2774|to|O
S2774|provide|O
S2774|80|B-Sample_Size_Calculation_Power_Value
S2774|%|I-Sample_Size_Calculation_Power_Value
S2774|power|O
S2774|to|O
S2774|detect|O
S2774|a|O
S2774|difference|O
S2774|of|O
S2774|20|O
S2774|%|O
S2774|in|O
S2774|the|O
S2774|CSBM|O
S2774|responder|O
S2774|rate|O
S2774|between|O
S2774|the|O
S2774|placebo|O
S2774|group|O
S2774|and|O
S2774|at|O
S2774|least|O
S2774|one|O
S2774|of|O
S2774|the|O
S2774|tenapanor|O
S2774|treatment|O
S2774|groups|O
S2774|.|O
S3915|The|O
S3915|primary|B-Blinding_Object_Investigators
S3915|investigator/treating|I-Blinding_Object_Investigators
S3915|neurologist|I-Blinding_Object_Investigators
S3915|,|O
S3915|independent|B-Blinding_Object_Outcome_Assessors
S3915|evaluating|I-Blinding_Object_Outcome_Assessors
S3915|neurologist|I-Blinding_Object_Outcome_Assessors
S3915|,|O
S3915|physician|B-Blinding_Object_Outcome_Assessors
S3915|evaluating|I-Blinding_Object_Outcome_Assessors
S3915|cardiac|I-Blinding_Object_Outcome_Assessors
S3915|safety|I-Blinding_Object_Outcome_Assessors
S3915|assessments|I-Blinding_Object_Outcome_Assessors
S3915|,|O
S3915|care|B-Blinding_Object_Care_Providers
S3915|providers|I-Blinding_Object_Care_Providers
S3915|,|O
S3915|patients|B-Blinding_Object_Patients
S3915|and|O
S3915|sponsor|B-Blinding_Object_Others
S3915|were|O
S3915|blinded|O
S3915|to|O
S3915|the|O
S3915|treatment|O
S3915|.|O
S5661|Patients|B-Blinding_Object_Patients
S5661|and|O
S5661|evaluators|B-Blinding_Object_Outcome_Assessors
S5661|were|O
S5661|blinded|O
S5661|to|O
S5661|the|O
S5661|treatment|O
S5661|received|O
S5661|.|O
S8357|Seventeen|B-Sample_Size_Actual_at_Outcome_Analysis
S8357|completed|O
S8357|the|O
S8357|6-month|O
S8357|study|O
S8357|,|O
S8357|10|O
S8357|in|O
S8357|the|O
S8357|AI+WL|O
S8357|arm|O
S8357|and|O
S8357|7|O
S8357|in|O
S8357|the|O
S8357|PBO+WL|O
S8357|arm|O
S8357|.|O
S6251|The|O
S6251|trial|O
S6251|consisted|O
S6251|of|O
S6251|a|O
S6251|screening|O
S6251|phase|O
S6251|(|O
S6251|up|O
S6251|to|O
S6251|4|O
S6251|weeks|O
S6251|)|O
S6251|,|O
S6251|a|O
S6251|double-blind|O
S6251|phase|O
S6251|(|O
S6251|minimum|O
S6251|of|O
S6251|12|O
S6251|weeks|O
S6251|)|O
S6251|,|O
S6251|and|O
S6251|an|O
S6251|open-label|B-Blinding_Open_Label
S6251|phase|O
S6251|(|O
S6251|maximum|O
S6251|of|O
S6251|36|O
S6251|weeks|O
S6251|)|O
S6251|.|O
S6435|Allocation|O
S6435|was|O
S6435|concealed|O
S6435|in|O
S6435|sealed|B-Allocation_Concealment_Method
S6435|,|I-Allocation_Concealment_Method
S6435|opaque|I-Allocation_Concealment_Method
S6435|numbered|I-Allocation_Concealment_Method
S6435|envelopes|I-Allocation_Concealment_Method
S6435|that|O
S6435|were|O
S6435|opened|O
S6435|consecutively|O
S6435|after|O
S6435|informed|O
S6435|consent|O
S6435|was|O
S6435|obtained|O
S6435|.|O
S7409|Objective|O
S7409|A|O
S7409|phase|B-Design_Phase_2
S7409|2|I-Design_Phase_2
S7409|,|O
S7409|double‐blind|B-Blinding_Double_Blind
S7409|,|O
S7409|placebo‐controlled|O
S7409|study|O
S7409|to|O
S7409|evaluate|O
S7409|the|O
S7409|efficacy|O
S7409|and|O
S7409|safety|O
S7409|of|O
S7409|erenumab|O
S7409|for|O
S7409|the|O
S7409|prevention|O
S7409|of|O
S7409|episodic|O
S7409|migraine|O
S7409|in|O
S7409|Japanese|B-Settings_Location
S7409|patients|O
S7409|was|O
S7409|conducted|O
S7409|.|O
S1221|Statistical|O
S1221|analysis|O
S1221|The|O
S1221|planned|O
S1221|sample|O
S1221|size|O
S1221|was|O
S1221|120|B-Sample_Size_Required
S1221|patients|O
S1221|,|O
S1221|designed|O
S1221|to|O
S1221|provide|O
S1221|approximately|O
S1221|93|B-Sample_Size_Calculation_Power_Value
S1221|%|I-Sample_Size_Calculation_Power_Value
S1221|power|O
S1221|to|O
S1221|detect|O
S1221|differences|O
S1221|of|O
S1221|100|O
S1221|mL|O
S1221|in|O
S1221|FEV1|O
S1221|AUC0–12|O
S1221|.|O
S5655|Study|O
S5655|design|O
S5655|A|O
S5655|randomized|O
S5655|,|O
S5655|multi-center|B-Settings_Multicenter
S5655|,|O
S5655|double-blinded|B-Blinding_Double_Blind
S5655|,|O
S5655|placebo-controlled|O
S5655|clinical|O
S5655|trial|O
S5655|was|O
S5655|conducted|O
S5655|in|O
S5655|21|B-Settings_Multicenter
S5655|centers|I-Settings_Multicenter
S5655|across|O
S5655|China|B-Settings_Location
S5655|.|O
S1636|Results|O
S1636|Sixty-nine|B-Sample_Size_Actual_at_Enrollment
S1636|patients|O
S1636|were|O
S1636|randomly|O
S1636|assigned|O
S1636|to|O
S1636|receive|O
S1636|TCZ+MTX|O
S1636|and|O
S1636|sixty-three|B-Sample_Size_Actual_at_Enrollment
S1636|to|O
S1636|receive|O
S1636|placebo+MTX|O
S1636|(|O
S1636|figure|O
S1636|1|O
S1636|)|O
S1636|.|O
S5781|Results|O
S5781|Of|O
S5781|343|B-Sample_Size_Actual_at_Enrollment
S5781|randomized|O
S5781|patients|O
S5781|(|O
S5781|mean|O
S5781|age|O
S5781|,|O
S5781|41.8–42.5|O
S5781|years|O
S5781|)|O
S5781|,|O
S5781|the|O
S5781|majority|O
S5781|were|O
S5781|women|O
S5781|(|O
S5781|85.4–90.4|O
S5781|%|O
S5781|)|O
S5781|,|O
S5781|white|O
S5781|(|O
S5781|94.1–96.2|O
S5781|%|O
S5781|)|O
S5781|,|O
S5781|and|O
S5781|had|O
S5781|episodic|O
S5781|migraine|O
S5781|(|O
S5781|62.5–67.9|O
S5781|%|O
S5781|)|O
S5781|.|O
S5940|Randomisation|O
S5940|incorporated|O
S5940|minimisation|B-Randomization_Type_Minimization
S5940|for|O
S5940|age|B-Randomization_Minimization_Criteria
S5940|,|O
S5940|presence|B-Randomization_Minimization_Criteria
S5940|of|I-Randomization_Minimization_Criteria
S5940|diabetes|I-Randomization_Minimization_Criteria
S5940|mellitus|I-Randomization_Minimization_Criteria
S5940|,|O
S5940|extent|B-Randomization_Minimization_Criteria
S5940|of|I-Randomization_Minimization_Criteria
S5940|coronary|I-Randomization_Minimization_Criteria
S5940|artery|I-Randomization_Minimization_Criteria
S5940|disease|I-Randomization_Minimization_Criteria
S5940|,|O
S5940|renal|B-Randomization_Minimization_Criteria
S5940|function|I-Randomization_Minimization_Criteria
S5940|and|O
S5940|surgeon|B-Randomization_Minimization_Criteria
S5940|A|I-Randomization_Minimization_Criteria
S5940|or|I-Randomization_Minimization_Criteria
S5940|B|I-Randomization_Minimization_Criteria
S5940|.|O
S564|Results|O
S564|We|O
S564|randomly|O
S564|assigned|O
S564|208|B-Sample_Size_Actual_at_Enrollment
S564|patients|O
S564|,|O
S564|of|O
S564|whom|O
S564|5|O
S564|(|O
S564|1|O
S564|rhEPO|O
S564|and|O
S564|4|O
S564|placebo|O
S564|)|O
S564|withdrew|O
S564|consent|O
S564|and|O
S564|3|O
S564|(|O
S564|placebo|O
S564|)|O
S564|became|O
S564|ineligible|O
S564|(|O
S564|retinal|O
S564|thrombosis|O
S564|,|O
S564|respiratory|O
S564|insufficiency|O
S564|,|O
S564|SOD1|O
S564|mutation|O
S564|)|O
S564|before|O
S564|receiving|O
S564|treatment|O
S564|;|O
S564|103|B-Sample_Size_Actual_at_Outcome_Analysis
S564|receiving|I-Sample_Size_Actual_at_Outcome_Analysis
S564|rhEPO|I-Sample_Size_Actual_at_Outcome_Analysis
S564|and|I-Sample_Size_Actual_at_Outcome_Analysis
S564|97|I-Sample_Size_Actual_at_Outcome_Analysis
S564|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S564|were|O
S564|eligible|O
S564|for|O
S564|analysis|O
S564|.|O
S4875|Anticipating|O
S4875|dropout|O
S4875|,|O
S4875|the|O
S4875|study|O
S4875|aimed|O
S4875|to|O
S4875|enroll|O
S4875|at|O
S4875|least|O
S4875|720|B-Sample_Size_Target
S4875|participants|O
S4875|.|O
S1771|This|O
S1771|update|O
S1771|set|O
S1771|the|O
S1771|goal|O
S1771|of|O
S1771|enrolling|O
S1771|at|O
S1771|least|O
S1771|71|B-Sample_Size_Target
S1771|participants|O
S1771|and|O
S1771|following|O
S1771|them|O
S1771|until|O
S1771|40|O
S1771|participants|O
S1771|had|O
S1771|received|O
S1771|a|O
S1771|diagnosis|O
S1771|of|O
S1771|type|O
S1771|1|O
S1771|diabetes|O
S1771|.|O
S5292|Safety|O
S5292|and|O
S5292|efficacy|O
S5292|of|O
S5292|iron|O
S5292|isomaltoside|O
S5292|1000/ferric|O
S5292|derisomaltose|O
S5292|versus|O
S5292|iron|O
S5292|sucrose|O
S5292|in|O
S5292|patients|O
S5292|with|O
S5292|chronic|O
S5292|kidney|O
S5292|disease|O
S5292|:|O
S5292|the|O
S5292|FERWON-NEPHRO|O
S5292|randomized|O
S5292|,|O
S5292|open-label|B-Blinding_Open_Label
S5292|,|O
S5292|comparative|O
S5292|trial|O
S5818|Assuming|O
S5818|a|O
S5818|treatment|O
S5818|effect|O
S5818|compared|O
S5818|to|O
S5818|placebo|O
S5818|of|O
S5818|−2.0|O
S5818|MMD|O
S5818|for|O
S5818|both|O
S5818|AMG|O
S5818|301|O
S5818|mg|O
S5818|treatment|O
S5818|groups|O
S5818|and|O
S5818|a|O
S5818|common|O
S5818|SD|O
S5818|of|O
S5818|4.7|O
S5818|MMD|O
S5818|,|O
S5818|the|O
S5818|planned|O
S5818|sample|O
S5818|size|O
S5818|of|O
S5818|135|B-Sample_Size_Required
S5818|patients|I-Sample_Size_Required
S5818|for|I-Sample_Size_Required
S5818|the|I-Sample_Size_Required
S5818|placebo|I-Sample_Size_Required
S5818|group|I-Sample_Size_Required
S5818|,|I-Sample_Size_Required
S5818|100|I-Sample_Size_Required
S5818|patients|I-Sample_Size_Required
S5818|for|I-Sample_Size_Required
S5818|the|I-Sample_Size_Required
S5818|AMG|I-Sample_Size_Required
S5818|301|I-Sample_Size_Required
S5818|420|I-Sample_Size_Required
S5818|mg|I-Sample_Size_Required
S5818|Q2W|I-Sample_Size_Required
S5818|,|I-Sample_Size_Required
S5818|and|I-Sample_Size_Required
S5818|100|I-Sample_Size_Required
S5818|patients|I-Sample_Size_Required
S5818|for|I-Sample_Size_Required
S5818|the|I-Sample_Size_Required
S5818|AMG|I-Sample_Size_Required
S5818|301|I-Sample_Size_Required
S5818|210|I-Sample_Size_Required
S5818|mg|I-Sample_Size_Required
S5818|Q4W|I-Sample_Size_Required
S5818|group|I-Sample_Size_Required
S5818|were|O
S5818|to|O
S5818|provide|O
S5818|≥80|B-Sample_Size_Calculation_Power_Value
S5818|%|I-Sample_Size_Calculation_Power_Value
S5818|power|O
S5818|using|O
S5818|a|O
S5818|two-sample|O
S5818|t-test|O
S5818|for|O
S5818|each|O
S5818|AMG|O
S5818|301|O
S5818|group|O
S5818|versus|O
S5818|placebo|O
S5818|,|O
S5818|with|O
S5818|a|B-Sample_Size_Calculation_Alpha_Value
S5818|two-sided|I-Sample_Size_Calculation_Alpha_Value
S5818|significance|I-Sample_Size_Calculation_Alpha_Value
S5818|level|I-Sample_Size_Calculation_Alpha_Value
S5818|of|I-Sample_Size_Calculation_Alpha_Value
S5818|0.05|I-Sample_Size_Calculation_Alpha_Value
S5818|,|O
S5818|maintaining|O
S5818|a|O
S5818|family-wise|O
S5818|alpha|O
S5818|level|O
S5818|of|O
S5818|0.10|O
S5818|,|O
S5818|assuming|O
S5818|a|O
S5818|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S5818|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S5818|dropout|O
S5818|.|O
S1197|Study|O
S1197|design|O
S1197|and|O
S1197|treatment|O
S1197|This|O
S1197|was|O
S1197|a|O
S1197|randomized|O
S1197|,|O
S1197|incomplete-block|B-Randomization_Type_Block
S1197|,|O
S1197|crossover|B-Design_Crossover
S1197|,|O
S1197|placebo-|B-Blinding_Double_Blind
S1197|(|I-Blinding_Double_Blind
S1197|blinded|I-Blinding_Double_Blind
S1197|)|I-Blinding_Double_Blind
S1197|and|O
S1197|active-|B-Blinding_Open_Label
S1197|(|I-Blinding_Open_Label
S1197|open-label|I-Blinding_Open_Label
S1197|)|I-Blinding_Open_Label
S1197|control|O
S1197|study|O
S1197|(|O
S1197|NCT01566773|O
S1197|)|O
S1197|,|O
S1197|conducted|O
S1197|at|O
S1197|10|B-Settings_Multicenter
S1197|sites|I-Settings_Multicenter
S1197|in|O
S1197|the|O
S1197|USA|B-Settings_Location
S1197|from|O
S1197|11|O
S1197|April|O
S1197|2012|O
S1197|to|O
S1197|10|O
S1197|August|O
S1197|2012|O
S1197|.|O
S6744|Assuming|O
S6744|that|O
S6744|5|O
S6744|%|O
S6744|of|O
S6744|randomized|O
S6744|patients|O
S6744|do|O
S6744|not|O
S6744|receive|O
S6744|any|O
S6744|study|O
S6744|drug|O
S6744|and|O
S6744|with|O
S6744|a|O
S6744|common|O
S6744|SD|O
S6744|of|O
S6744|approximately|O
S6744|20|O
S6744|%|O
S6744|,|O
S6744|the|O
S6744|planned|O
S6744|sample|O
S6744|size|O
S6744|provided|O
S6744|at|O
S6744|least|O
S6744|93|B-Sample_Size_Calculation_Power_Value
S6744|%|I-Sample_Size_Calculation_Power_Value
S6744|power|O
S6744|to|O
S6744|detect|O
S6744|a|O
S6744|treatment|O
S6744|effect|O
S6744|of|O
S6744|at|O
S6744|least|O
S6744|20|O
S6744|%|O
S6744|reduction|O
S6744|for|O
S6744|each|O
S6744|of|O
S6744|the|O
S6744|co-primary|O
S6744|endpoints|O
S6744|in|O
S6744|testing|O
S6744|the|O
S6744|superiority|O
S6744|of|O
S6744|evolocumab|O
S6744|over|O
S6744|ezetimibe|O
S6744|,|O
S6744|based|O
S6744|on|O
S6744|a|O
S6744|two-sided|B-Sample_Size_Calculation_Alpha_Value
S6744|t-test|I-Sample_Size_Calculation_Alpha_Value
S6744|with|I-Sample_Size_Calculation_Alpha_Value
S6744|a|I-Sample_Size_Calculation_Alpha_Value
S6744|significance|I-Sample_Size_Calculation_Alpha_Value
S6744|level|I-Sample_Size_Calculation_Alpha_Value
S6744|of|I-Sample_Size_Calculation_Alpha_Value
S6744|0.05|I-Sample_Size_Calculation_Alpha_Value
S6744|.|O
S1350|With|O
S1350|a|O
S1350|significance|O
S1350|level|O
S1350|of|O
S1350|5|B-Sample_Size_Calculation_Alpha_Value
S1350|%|I-Sample_Size_Calculation_Alpha_Value
S1350|and|O
S1350|a|O
S1350|power|O
S1350|of|O
S1350|80|B-Sample_Size_Calculation_Power_Value
S1350|%|I-Sample_Size_Calculation_Power_Value
S1350|,|O
S1350|a|O
S1350|sample|O
S1350|size|O
S1350|of|O
S1350|at|O
S1350|least|O
S1350|292|B-Sample_Size_Required
S1350|randomised|I-Sample_Size_Required
S1350|patients|I-Sample_Size_Required
S1350|per|I-Sample_Size_Required
S1350|treatment|I-Sample_Size_Required
S1350|group|I-Sample_Size_Required
S1350|was|O
S1350|required|O
S1350|in|O
S1350|order|O
S1350|to|O
S1350|reach|O
S1350|the|O
S1350|required|O
S1350|subject|O
S1350|size|O
S1350|for|O
S1350|the|O
S1350|PPS|O
S1350|.|O
S3750|Forty|B-Sample_Size_Actual_at_Enrollment
S3750|patients|O
S3750|were|O
S3750|randomized|O
S3750|to|O
S3750|either|O
S3750|IAsp|O
S3750|or|O
S3750|FA|O
S3750|.|O
S1314|Study|O
S1314|design|O
S1314|This|O
S1314|study|O
S1314|is|O
S1314|a|O
S1314|phase|B-Design_Phase_3
S1314|III|I-Design_Phase_3
S1314|,|O
S1314|randomised|O
S1314|,|O
S1314|double-blind|B-Blinding_Double_Blind
S1314|,|O
S1314|multinational|O
S1314|,|O
S1314|multicentre|B-Settings_Multicenter
S1314|parallel|B-Design_Parallel_Group
S1314|group|I-Design_Parallel_Group
S1314|study|O
S1314|(|O
S1314|NCT01936181|O
S1314|,|O
S1314|EudraCT|O
S1314|2012-005733-37|O
S1314|)|O
S1314|.|O
S2071|The|O
S2071|randomisation|O
S2071|code|O
S2071|was|O
S2071|generated|O
S2071|by|O
S2071|the|O
S2071|contract|B-Randomization_Personnel
S2071|research|I-Randomization_Personnel
S2071|organisation|I-Randomization_Personnel
S2071|before|O
S2071|the|O
S2071|study|O
S2071|and|O
S2071|provided|O
S2071|to|O
S2071|the|O
S2071|study|O
S2071|centre|O
S2071|pharmacist|O
S2071|,|O
S2071|with|O
S2071|randomisation|O
S2071|numbers|O
S2071|assigned|O
S2071|on|O
S2071|day|O
S2071|−1|O
S2071|.|O
S5480|Methods|O
S5480|Participants|O
S5480|Between|O
S5480|Nov|O
S5480|4|O
S5480|and|O
S5480|Dec|O
S5480|4|O
S5480|,|O
S5480|2008|O
S5480|,|O
S5480|we|O
S5480|did|O
S5480|a|O
S5480|community|O
S5480|based|O
S5480|randomised|O
S5480|placebo-controlled|O
S5480|superiority|B-Design_Comparative_Intent_Superiority
S5480|trial|O
S5480|in|O
S5480|Kabul|B-Settings_Location
S5480|,|I-Settings_Location
S5480|Afghanistan|I-Settings_Location
S5480|,|O
S5480|within|O
S5480|the|O
S5480|catchment|O
S5480|area|O
S5480|of|O
S5480|the|O
S5480|Maiwand|O
S5480|Teaching|O
S5480|Hospital|O
S5480|,|O
S5480|which|O
S5480|serves|O
S5480|an|O
S5480|inner-city|O
S5480|population|O
S5480|.|O
S5317|MATERIALS|O
S5317|AND|O
S5317|METHODS|O
S5317|Trial|O
S5317|design|O
S5317|This|O
S5317|was|O
S5317|a|O
S5317|randomized|O
S5317|,|O
S5317|open-label|B-Blinding_Open_Label
S5317|,|I-Blinding_Open_Label
S5317|comparative|O
S5317|and|O
S5317|multi-centre|B-Settings_Multicenter
S5317|trial|O
S5317|conducted|O
S5317|from|O
S5317|November|O
S5317|2016|O
S5317|to|O
S5317|October|O
S5317|2018|O
S5317|.|O
S1022|This|O
S1022|was|O
S1022|a|O
S1022|prospective|O
S1022|,|O
S1022|randomized|O
S1022|,|O
S1022|single‐blind|B-Blinding_Single_Blind
S1022|study|O
S1022|in|O
S1022|troponin‐negative|O
S1022|ACS|O
S1022|patients|O
S1022|.|O
S1607|Patients|O
S1607|were|O
S1607|stratified|B-Randomization_Type_Stratified
S1607|at|O
S1607|randomisation|O
S1607|by|O
S1607|age|B-Randomization_Stratified_Criteria
S1607|(|I-Randomization_Stratified_Criteria
S1607|<|I-Randomization_Stratified_Criteria
S1607|52|I-Randomization_Stratified_Criteria
S1607|vs|I-Randomization_Stratified_Criteria
S1607|≥52|I-Randomization_Stratified_Criteria
S1607|years|I-Randomization_Stratified_Criteria
S1607|)|I-Randomization_Stratified_Criteria
S1607|,|O
S1607|mean|B-Randomization_Stratified_Criteria
S1607|arterial|I-Randomization_Stratified_Criteria
S1607|blood|I-Randomization_Stratified_Criteria
S1607|pressure|I-Randomization_Stratified_Criteria
S1607|(|I-Randomization_Stratified_Criteria
S1607|<|I-Randomization_Stratified_Criteria
S1607|93.3|I-Randomization_Stratified_Criteria
S1607|vs|I-Randomization_Stratified_Criteria
S1607|≥93.3|I-Randomization_Stratified_Criteria
S1607|mm|I-Randomization_Stratified_Criteria
S1607|Hg|I-Randomization_Stratified_Criteria
S1607|)|I-Randomization_Stratified_Criteria
S1607|and|O
S1607|CRP|B-Randomization_Stratified_Criteria
S1607|(|I-Randomization_Stratified_Criteria
S1607|<|I-Randomization_Stratified_Criteria
S1607|1.66|I-Randomization_Stratified_Criteria
S1607|vs|I-Randomization_Stratified_Criteria
S1607|≥1.66|I-Randomization_Stratified_Criteria
S1607|mg/dL|I-Randomization_Stratified_Criteria
S1607|)|I-Randomization_Stratified_Criteria
S1607|.|O
S6257|Results|O
S6257|in|O
S6257|the|O
S6257|double-blind|B-Blinding_Double_Blind
S6257|phase|O
S6257|have|O
S6257|been|O
S6257|published|O
S6257|elsewhere|O
S6257|as|O
S6257|an|O
S6257|interim|O
S6257|report|O
S6257|(|O
S6257|Abo|O
S6257|,|O
S6257|M.|O
S6257|,|O
S6257|et|O
S6257|al.|O
S6257|,|O
S6257|Prog|O
S6257|.|O
S6450|Assuming|O
S6450|a|O
S6450|30|O
S6450|%|O
S6450|treatment|O
S6450|failure|O
S6450|rate|O
S6450|for|O
S6450|both|O
S6450|treatment|O
S6450|groups|O
S6450|,|O
S6450|we|O
S6450|needed|O
S6450|a|O
S6450|sample|O
S6450|of|O
S6450|128|B-Sample_Size_Required
S6450|patients|I-Sample_Size_Required
S6450|per|I-Sample_Size_Required
S6450|arm|I-Sample_Size_Required
S6450|for|O
S6450|a|O
S6450|one|O
S6450|sided|O
S6450|test|O
S6450|to|O
S6450|rule|O
S6450|out|O
S6450|the|O
S6450|pre-specified|O
S6450|difference|O
S6450|in|O
S6450|the|O
S6450|95|B-Sample_Size_Calculation_Alpha_Value
S6450|%|I-Sample_Size_Calculation_Alpha_Value
S6450|confidence|I-Sample_Size_Calculation_Alpha_Value
S6450|interval|I-Sample_Size_Calculation_Alpha_Value
S6450|of|O
S6450|the|O
S6450|difference|O
S6450|between|O
S6450|groups|O
S6450|,|O
S6450|allowing|O
S6450|for|O
S6450|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S6450|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S6450|non-evaluable|O
S6450|patients|O
S6450|(|O
S6450|α=0.05|O
S6450|,|O
S6450|β=0.8|O
S6450|)|O
S6450|.|O
S1072|Results|O
S1072|Patient|O
S1072|Population|O
S1072|Between|O
S1072|November|O
S1072|2016|O
S1072|and|O
S1072|January|O
S1072|2018|O
S1072|,|O
S1072|315|O
S1072|consecutive|O
S1072|patients|O
S1072|were|O
S1072|screened|O
S1072|;|O
S1072|of|O
S1072|these|O
S1072|,|O
S1072|100|B-Sample_Size_Actual_at_Enrollment
S1072|patients|O
S1072|met|O
S1072|the|O
S1072|inclusion|O
S1072|and|O
S1072|exclusion|O
S1072|criteria|O
S1072|and|O
S1072|were|O
S1072|randomized|O
S1072|to|O
S1072|CTIC|O
S1072|(|O
S1072|n=50|O
S1072|)|O
S1072|versus|O
S1072|eptifibatide|O
S1072|bolus|O
S1072|plus|O
S1072|clopidogrel|O
S1072|(|O
S1072|n=50|O
S1072|;|O
S1072|Figure|O
S1072|2|O
S1072|)|O
S1072|.|O
S696|Methods|O
S696|:|O
S696|This|O
S696|was|O
S696|a|O
S696|randomized|O
S696|,|O
S696|double-blind|B-Blinding_Double_Blind
S696|,|O
S696|placebo-controlled|O
S696|trial|O
S696|of|O
S696|patients|O
S696|from|O
S696|6|O
S696|weeks|O
S696|0|O
S696|days|O
S696|to|O
S696|14|O
S696|weeks|O
S696|6|O
S696|days|O
S696|gestation|O
S696|scheduled|O
S696|to|O
S696|receive|O
S696|surgical|O
S696|abortion|O
S696|at|O
S696|the|O
S696|Duke|B-Settings_Single_Center
S696|Family|I-Settings_Single_Center
S696|Planning|I-Settings_Single_Center
S696|Clinic|I-Settings_Single_Center
S696|.|O
S5187|Randomization|O
S5187|followed|O
S5187|a|B-Randomization_Sequence_Generation_Method
S5187|computer-generated|I-Randomization_Sequence_Generation_Method
S5187|number|I-Randomization_Sequence_Generation_Method
S5187|sequence|I-Randomization_Sequence_Generation_Method
S5187|and|O
S5187|allocation|O
S5187|was|O
S5187|conducted|O
S5187|by|O
S5187|telephone|B-Allocation_Concealment_Method
S5187|.|O
S5188|The|O
S5188|surgeon|B-Blinding_Object_Care_Providers
S5188|performing|O
S5188|the|O
S5188|operation|O
S5188|was|O
S5188|informed|O
S5188|of|O
S5188|patient|O
S5188|participation|O
S5188|in|O
S5188|the|O
S5188|study|O
S5188|but|O
S5188|group|O
S5188|allocation|O
S5188|was|O
S5188|not|O
S5188|revealed|O
S5188|.|O
S3025|Patients|O
S3025|and|O
S3025|methods|O
S3025|A|O
S3025|multicenter|B-Settings_Multicenter
S3025|,|O
S3025|open-label|B-Blinding_Open_Label
S3025|,|O
S3025|phase|B-Design_Phase_1
S3025|I|I-Design_Phase_1
S3025|trial|O
S3025|of|O
S3025|abemaciclib|O
S3025|in|O
S3025|Chinese|O
S3025|patients|O
S3025|with|O
S3025|advanced|O
S3025|and/or|O
S3025|metastatic|O
S3025|cancers|O
S3025|was|O
S3025|conducted|O
S3025|.|O
S1502|Results|O
S1502|Patients|O
S1502|disposition|O
S1502|and|O
S1502|baseline|O
S1502|characteristics|O
S1502|A|O
S1502|total|O
S1502|of|O
S1502|44|B-Sample_Size_Actual_at_Enrollment
S1502|patients|O
S1502|with|O
S1502|PsA|O
S1502|enroled|O
S1502|at|O
S1502|11|B-Settings_Multicenter
S1502|trial|I-Settings_Multicenter
S1502|centres|I-Settings_Multicenter
S1502|were|O
S1502|randomised|O
S1502|.|O
S37|Study|O
S37|Conduct|O
S37|Using|O
S37|a|O
S37|preprogrammed|B-Randomization_Sequence_Generation_Method
S37|interactive|I-Randomization_Sequence_Generation_Method
S37|response|I-Randomization_Sequence_Generation_Method
S37|technology|I-Randomization_Sequence_Generation_Method
S37|system|I-Randomization_Sequence_Generation_Method
S37|,|O
S37|participants|O
S37|were|O
S37|randomized|O
S37|in|O
S37|a|O
S37|1:1|B-Randomization_Ratio
S37|ratio|O
S37|to|O
S37|be|O
S37|vaccinated|O
S37|by|O
S37|intramuscular|O
S37|injection|O
S37|with|O
S37|a|O
S37|half|B-Design_Parallel_Group
S37|or|I-Design_Parallel_Group
S37|full|I-Design_Parallel_Group
S37|dose|I-Design_Parallel_Group
S37|of|I-Design_Parallel_Group
S37|IIV4|I-Design_Parallel_Group
S37|.|O
S1227|Secondary|O
S1227|efficacy|O
S1227|analysis|O
S1227|for|O
S1227|the|O
S1227|primary|O
S1227|efficacy|O
S1227|endpoint|O
S1227|assessed|O
S1227|the|O
S1227|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1227|of|O
S1227|each|O
S1227|treatment|O
S1227|group|O
S1227|to|O
S1227|open-label|O
S1227|tiotropium|O
S1227|using|O
S1227|a|O
S1227|margin|O
S1227|for|O
S1227|clinical|O
S1227|relevance|O
S1227|of|O
S1227|100|O
S1227|mL|O
S1227|.|O
S4995|Randomization|O
S4995|:|O
S4995|Patients|O
S4995|were|O
S4995|randomized|O
S4995|to|O
S4995|receive|O
S4995|periocular|B-Design_Parallel_Group
S4995|triamcinolone|I-Design_Parallel_Group
S4995|acetonide|I-Design_Parallel_Group
S4995|,|I-Design_Parallel_Group
S4995|intravitreal|I-Design_Parallel_Group
S4995|triamcinolone|I-Design_Parallel_Group
S4995|acetonide|I-Design_Parallel_Group
S4995|,|I-Design_Parallel_Group
S4995|or|I-Design_Parallel_Group
S4995|intravitreal|I-Design_Parallel_Group
S4995|dexamethasone|I-Design_Parallel_Group
S4995|implant|I-Design_Parallel_Group
S4995|injections|I-Design_Parallel_Group
S4995|in|O
S4995|an|O
S4995|eligible|O
S4995|eye|O
S4995|.|O
S8501|Participants|B-Blinding_Object_Patients
S8501|and|O
S8501|investigators|B-Blinding_Object_Investigators
S8501|involved|O
S8501|in|O
S8501|the|O
S8501|patient|O
S8501|’|O
S8501|s|O
S8501|follow-up|O
S8501|and|O
S8501|outcome|O
S8501|measurements|O
S8501|were|O
S8501|masked|O
S8501|to|O
S8501|treatment|O
S8501|allocation|O
S8501|during|O
S8501|the|O
S8501|entire|O
S8501|study|O
S8501|duration|O
S8501|by|O
S8501|using|O
S8501|identical|B-Allocation_Concealment_Method
S8501|envelopes|I-Allocation_Concealment_Method
S8501|for|I-Allocation_Concealment_Method
S8501|pills|I-Allocation_Concealment_Method
S8501|.|O
S7863|Setting|O
S7863|99|B-Settings_Multicenter
S7863|general|I-Settings_Multicenter
S7863|practices|I-Settings_Multicenter
S7863|in|O
S7863|England|B-Settings_Location
S7863|,|O
S7863|with|O
S7863|participants|O
S7863|recruited|O
S7863|in|O
S7863|2009-11|O
S7863|.|O
S1770|Because|O
S1770|of|O
S1770|slower-than-expected|O
S1770|rates|O
S1770|of|O
S1770|enrollment|O
S1770|,|O
S1770|the|O
S1770|original|O
S1770|protocol|O
S1770|(|O
S1770|which|O
S1770|called|O
S1770|for|O
S1770|the|O
S1770|enrollment|O
S1770|of|O
S1770|144|O
S1770|participants|O
S1770|)|O
S1770|was|O
S1770|revised|O
S1770|to|O
S1770|detect|O
S1770|a|O
S1770|60|O
S1770|%|O
S1770|(|O
S1770|previously|O
S1770|50|O
S1770|%|O
S1770|)|O
S1770|lower|O
S1770|risk|O
S1770|in|O
S1770|the|O
S1770|teplizumab|O
S1770|group|O
S1770|than|O
S1770|in|O
S1770|the|O
S1770|placebo|O
S1770|group|O
S1770|(|O
S1770|i.e.|O
S1770|,|O
S1770|a|O
S1770|hazard|O
S1770|ratio|O
S1770|of|O
S1770|0.4|O
S1770|)|O
S1770|with|O
S1770|80|B-Sample_Size_Calculation_Power_Value
S1770|%|I-Sample_Size_Calculation_Power_Value
S1770|statistical|O
S1770|power|O
S1770|at|O
S1770|an|O
S1770|alpha|O
S1770|level|O
S1770|of|O
S1770|0.025|B-Sample_Size_Calculation_Alpha_Value
S1770|(|I-Sample_Size_Calculation_Alpha_Value
S1770|one-sided|I-Sample_Size_Calculation_Alpha_Value
S1770|)|I-Sample_Size_Calculation_Alpha_Value
S1770|.|O
S6221|An|O
S6221|additional|B-Design_Parallel_Group
S6221|160|I-Design_Parallel_Group
S6221|U|I-Design_Parallel_Group
S6221|onabotulinumtoxinA|I-Design_Parallel_Group
S6221|(|I-Design_Parallel_Group
S6221|400|I-Design_Parallel_Group
S6221|U|I-Design_Parallel_Group
S6221|group|I-Design_Parallel_Group
S6221|)|I-Design_Parallel_Group
S6221|or|I-Design_Parallel_Group
S6221|placebo|I-Design_Parallel_Group
S6221|(|I-Design_Parallel_Group
S6221|240|I-Design_Parallel_Group
S6221|U|I-Design_Parallel_Group
S6221|group|I-Design_Parallel_Group
S6221|)|I-Design_Parallel_Group
S6221|was|O
S6221|injected|O
S6221|in|O
S6221|the|O
S6221|elbow|O
S6221|flexors|O
S6221|.|O
S5186|We|O
S5186|randomly|O
S5186|allocated|O
S5186|participants|O
S5186|(|O
S5186|1:1|B-Randomization_Ratio
S5186|)|O
S5186|to|O
S5186|either|O
S5186|perioperative|B-Design_Parallel_Group
S5186|intravenous|I-Design_Parallel_Group
S5186|(|I-Design_Parallel_Group
S5186|IV|I-Design_Parallel_Group
S5186|)|I-Design_Parallel_Group
S5186|iron|I-Design_Parallel_Group
S5186|administration|I-Design_Parallel_Group
S5186|(|I-Design_Parallel_Group
S5186|intervention|I-Design_Parallel_Group
S5186|)|I-Design_Parallel_Group
S5186|or|I-Design_Parallel_Group
S5186|usual|I-Design_Parallel_Group
S5186|care|I-Design_Parallel_Group
S5186|.|O
S6905|Results|O
S6905|Patients|O
S6905|Of|O
S6905|1659|O
S6905|initially|O
S6905|screened|O
S6905|patients|O
S6905|,|O
S6905|996|O
S6905|were|O
S6905|enrolled|O
S6905|in|O
S6905|the|O
S6905|placebo-run-in|O
S6905|period|O
S6905|,|O
S6905|and|O
S6905|490|B-Sample_Size_Actual_at_Enrollment
S6905|were|O
S6905|randomized|O
S6905|(|O
S6905|Figure|O
S6905|1|O
S6905|)|O
S6905|.|O
S7940|Primary|O
S7940|outcome|O
S7940|data|O
S7940|were|O
S7940|available|O
S7940|for|O
S7940|379|B-Sample_Size_Actual_at_Outcome_Analysis
S7940|participants|O
S7940|at|O
S7940|one|O
S7940|year|O
S7940|follow-up|O
S7940|(|O
S7940|182|O
S7940|(|O
S7940|68|O
S7940|%|O
S7940|)|O
S7940|in|O
S7940|the|O
S7940|intensive|O
S7940|target|O
S7940|arm|O
S7940|and|O
S7940|197|O
S7940|(|O
S7940|75|O
S7940|%|O
S7940|)|O
S7940|in|O
S7940|the|O
S7940|standard|O
S7940|target|O
S7940|arm|O
S7940|)|O
S7940|.|O
S4699|The|O
S4699|total|O
S4699|sample|O
S4699|size|O
S4699|planned|O
S4699|for|O
S4699|this|O
S4699|study|O
S4699|was|O
S4699|~495|B-Sample_Size_Target
S4699|randomized|O
S4699|patients|O
S4699|.|O
S315|Statistical|O
S315|Analysis|O
S315|The|O
S315|sample|O
S315|size|O
S315|(|O
S315|target|O
S315|number|O
S315|,|O
S315|approximately|O
S315|275|B-Sample_Size_Target
S315|patients|O
S315|)|O
S315|was|O
S315|based|O
S315|mainly|O
S315|on|O
S315|prior|O
S315|study|O
S315|results|O
S315|,|O
S315|including|O
S315|TCS|O
S315|use|O
S315|,|O
S315|which|O
S315|defined|O
S315|an|O
S315|estimated|O
S315|sample|O
S315|size|O
S315|of|O
S315|approximately|O
S315|75|O
S315|patients|O
S315|for|O
S315|active|O
S315|groups|O
S315|and|O
S315|50|O
S315|for|O
S315|the|O
S315|placebo|O
S315|group|O
S315|to|O
S315|adequately|O
S315|power|O
S315|the|O
S315|study|O
S315|.|O
S5489|The|O
S5489|fieldworkers|O
S5489|obtained|O
S5489|written|O
S5489|informed|O
S5489|consent|O
S5489|from|O
S5489|the|O
S5489|mother|O
S5489|,|O
S5489|father|O
S5489|,|O
S5489|or|O
S5489|another|O
S5489|senior|O
S5489|family|O
S5489|member|O
S5489|before|O
S5489|recruitment|O
S5489|;|O
S5489|allocated|O
S5489|the|O
S5489|unique|O
S5489|identification|O
S5489|number|O
S5489|(|O
S5489|sequentially|O
S5489|)|O
S5489|;|O
S5489|and|O
S5489|gave|O
S5489|the|O
S5489|first|O
S5489|dose|O
S5489|of|O
S5489|vitamin|B-Design_Parallel_Group
S5489|D3|I-Design_Parallel_Group
S5489|or|I-Design_Parallel_Group
S5489|placebo|I-Design_Parallel_Group
S5489|.|O
S2623|Results|O
S2623|Demographics|O
S2623|A|O
S2623|total|O
S2623|of|O
S2623|614|B-Sample_Size_Actual_at_Enrollment
S2623|participants|O
S2623|were|O
S2623|randomized|O
S2623|in|O
S2623|this|O
S2623|study|O
S2623|across|O
S2623|9|O
S2623|different|O
S2623|countries|O
S2623|(|O
S2623|Fig|O
S2623|.|O
S5861|A|O
S5861|total|O
S5861|of|O
S5861|305|B-Sample_Size_Actual_at_Outcome_Analysis
S5861|patients|O
S5861|(|O
S5861|88.9|O
S5861|%|O
S5861|)|O
S5861|completed|O
S5861|the|O
S5861|double-blind|O
S5861|treatment|O
S5861|phase|O
S5861|;|O
S5861|124|O
S5861|patients|O
S5861|(|O
S5861|90.5|O
S5861|%|O
S5861|)|O
S5861|receiving|O
S5861|placebo|O
S5861|,|O
S5861|94|O
S5861|patients|O
S5861|(|O
S5861|90.4|O
S5861|%|O
S5861|)|O
S5861|receiving|O
S5861|AMG|O
S5861|301|O
S5861|210|O
S5861|mg|O
S5861|Q4W|O
S5861|,|O
S5861|and|O
S5861|87|O
S5861|patients|O
S5861|(|O
S5861|85.3|O
S5861|%|O
S5861|)|O
S5861|receiving|O
S5861|AMG|O
S5861|301|O
S5861|420|O
S5861|mg|O
S5861|Q2W|O
S5861|.|O
S1461|Patients|O
S1461|were|O
S1461|centrally|O
S1461|randomised|O
S1461|in|O
S1461|blocks|B-Randomization_Type_Block
S1461|of|O
S1461|4|B-Randomization_Block_Size
S1461|(|I-Randomization_Block_Size
S1461|2:2|I-Randomization_Block_Size
S1461|)|I-Randomization_Block_Size
S1461|by|O
S1461|computer-generated|B-Randomization_Sequence_Generation_Method
S1461|random|O
S1461|sequence|O
S1461|to|O
S1461|receive|O
S1461|subcutaneous|O
S1461|injections|O
S1461|of|O
S1461|50|O
S1461|mg|O
S1461|golimumab|B-Design_Parallel_Group
S1461|or|I-Design_Parallel_Group
S1461|placebo|I-Design_Parallel_Group
S1461|,|O
S1461|administrated|O
S1461|every|O
S1461|4|O
S1461|weeks|O
S1461|for|O
S1461|24|O
S1461|weeks|O
S1461|,|O
S1461|both|O
S1461|in|O
S1461|combination|O
S1461|with|O
S1461|MTX|O
S1461|.|O
S1747|TRIAL|O
S1747|DESIGN|O
S1747|AND|O
S1747|INTERVENTION|O
S1747|Participants|O
S1747|were|O
S1747|randomly|O
S1747|assigned|O
S1747|in|O
S1747|a|O
S1747|1:1|B-Randomization_Ratio
S1747|ratio|O
S1747|to|O
S1747|receive|O
S1747|either|O
S1747|teplizumab|B-Design_Parallel_Group
S1747|or|I-Design_Parallel_Group
S1747|placebo|I-Design_Parallel_Group
S1747|.|O
S4982|Methods|O
S4982|Study|O
S4982|Design|O
S4982|:|O
S4982|The|O
S4982|POINT|O
S4982|Trial|O
S4982|was|O
S4982|a|O
S4982|multicenter|B-Settings_Multicenter
S4982|,|O
S4982|randomized|O
S4982|(|O
S4982|allocation|O
S4982|ratio|O
S4982|1:1:1|B-Randomization_Ratio
S4982|)|O
S4982|,|O
S4982|parallel-treatment|B-Design_Parallel_Group
S4982|,|O
S4982|comparative|O
S4982|trial|O
S4982|(|O
S4982|clinicaltrial.gov|O
S4982|identifier|O
S4982|:|O
S4982|NCT02374060|O
S4982|)|O
S4982|.|O
S7016|METHODS|O
S7016|Study|O
S7016|Design|O
S7016|and|O
S7016|Participants|O
S7016|Protocol|O
S7016|MK-1986-002|O
S7016|(|O
S7016|Ventilated|O
S7016|Pneumonia|O
S7016|Treatment|O
S7016|with|O
S7016|Tedizolid|O
S7016|Phosphate|O
S7016|and|O
S7016|Linezolid|O
S7016|[|O
S7016|VITAL|O
S7016|]|O
S7016|)|O
S7016|was|O
S7016|a|O
S7016|randomized|O
S7016|,|O
S7016|double-blind|B-Blinding_Double_Blind
S7016|,|O
S7016|double-dummy|O
S7016|,|O
S7016|phase|B-Design_Phase_3
S7016|3|I-Design_Phase_3
S7016|,|O
S7016|noninferiority|B-Design_Comparative_Intent_NonInferiority
S7016|trial|O
S7016|conducted|O
S7016|at|O
S7016|122|B-Settings_Multicenter
S7016|global|I-Settings_Multicenter
S7016|study|I-Settings_Multicenter
S7016|sites|I-Settings_Multicenter
S7016|in|O
S7016|32|B-Settings_Location
S7016|countries|I-Settings_Location
S7016|from|O
S7016|June|O
S7016|2014|O
S7016|to|O
S7016|June|O
S7016|2018|O
S7016|.|O
S4876|The|O
S4876|statistical|O
S4876|testing|O
S4876|for|O
S4876|the|O
S4876|primary|O
S4876|outcome|O
S4876|was|O
S4876|conducted|O
S4876|at|O
S4876|the|O
S4876|1-sided|B-Sample_Size_Calculation_Alpha_Value
S4876|α|I-Sample_Size_Calculation_Alpha_Value
S4876|=|I-Sample_Size_Calculation_Alpha_Value
S4876|.025|I-Sample_Size_Calculation_Alpha_Value
S4876|level|O
S4876|using|O
S4876|the|O
S4876|upper|O
S4876|bound|O
S4876|of|O
S4876|a|O
S4876|stratified|O
S4876|by|O
S4876|site|O
S4876|Newcombe|O
S4876|binomial|O
S4876|confidence|O
S4876|interval|O
S4876|with|O
S4876|Cochran-Mantel-Haenszel|O
S4876|(|O
S4876|CMH|O
S4876|)|O
S4876|weighting|O
S4876|with|O
S4876|a|O
S4876|noninferiority|O
S4876|margin|O
S4876|of|O
S4876|5|O
S4876|%|O
S4876|.|O
S6699|The|O
S6699|most|O
S6699|common|O
S6699|adverse|O
S6699|events|O
S6699|were|O
S6699|diarrhea|O
S6699|(|O
S6699|9.5|O
S6699|%|O
S6699|)|O
S6699|and|O
S6699|nasopharyngitis|O
S6699|(|O
S6699|12.5|O
S6699|%|O
S6699|)|O
S6699|in|O
S6699|the|O
S6699|ezetimibe|O
S6699|and|O
S6699|evolocumab|O
S6699|groups|O
S6699|,|O
S6699|respectively|O
S6699|,|O
S6699|during|O
S6699|the|O
S6699|double-blind|B-Blinding_Double_Blind
S6699|period|O
S6699|and|O
S6699|nasopharyngitis|O
S6699|(|O
S6699|29|O
S6699|%|O
S6699|)|O
S6699|during|O
S6699|the|O
S6699|open-label|O
S6699|extension|O
S6699|.|O
S8599|The|O
S8599|change|O
S8599|in|O
S8599|mean|O
S8599|carotid|O
S8599|artery|O
S8599|wall|O
S8599|area|O
S8599|was|O
S8599|–3.37|O
S8599|mm2|O
S8599|after|O
S8599|12|O
S8599|months|O
S8599|with|O
S8599|canakinumab|B-Design_Parallel_Group
S8599|versus|I-Design_Parallel_Group
S8599|placebo|I-Design_Parallel_Group
S8599|.|O
S1459|The|O
S1459|study|O
S1459|was|O
S1459|conducted|O
S1459|between|O
S1459|August|O
S1459|2014|O
S1459|and|O
S1459|June|O
S1459|2017|O
S1459|in|O
S1459|11|B-Settings_Multicenter
S1459|rheumatology|I-Settings_Multicenter
S1459|centres|I-Settings_Multicenter
S1459|in|O
S1459|Portugal|B-Settings_Location
S1459|.|O
S3284|Sample|O
S3284|size|O
S3284|For|O
S3284|the|O
S3284|planned|O
S3284|factorial|B-Design_Factorial
S3284|trial|O
S3284|,|O
S3284|we|O
S3284|estimated|O
S3284|that|O
S3284|a|O
S3284|provisional|O
S3284|sample|O
S3284|size|O
S3284|would|O
S3284|be|O
S3284|1498|B-Sample_Size_Required
S3284|women|O
S3284|(|O
S3284|749|O
S3284|per|O
S3284|group|O
S3284|)|O
S3284|.|O
S1710|METHODS|O
S1710|We|O
S1710|conducted|O
S1710|a|O
S1710|phase|B-Design_Phase_2
S1710|2|I-Design_Phase_2
S1710|,|O
S1710|randomized|O
S1710|,|O
S1710|placebo-controlled|O
S1710|,|O
S1710|double-blind|B-Blinding_Double_Blind
S1710|trial|O
S1710|of|O
S1710|teplizumab|O
S1710|(|O
S1710|an|O
S1710|Fc|O
S1710|receptor–nonbinding|O
S1710|anti-CD3|O
S1710|monoclonal|O
S1710|antibody|O
S1710|)|O
S1710|involving|O
S1710|relatives|O
S1710|of|O
S1710|patients|O
S1710|with|O
S1710|type|O
S1710|1|O
S1710|diabetes|O
S1710|who|O
S1710|did|O
S1710|not|O
S1710|have|O
S1710|diabetes|O
S1710|but|O
S1710|were|O
S1710|at|O
S1710|high|O
S1710|risk|O
S1710|for|O
S1710|development|O
S1710|of|O
S1710|clinical|O
S1710|disease|O
S1710|.|O
S5493|Randomisation|O
S5493|and|O
S5493|masking|O
S5493|An|B-Randomization_Personnel
S5493|independent|I-Randomization_Personnel
S5493|statistician|I-Randomization_Personnel
S5493|(|O
S5493|Shabbar|O
S5493|Jaffar|O
S5493|,|O
S5493|London|O
S5493|School|O
S5493|of|O
S5493|Hygiene|O
S5493|and|O
S5493|Tropical|O
S5493|Medicine|O
S5493|,|O
S5493|London|O
S5493|,|O
S5493|UK|O
S5493|)|O
S5493|randomised|O
S5493|unique|O
S5493|identification|O
S5493|numbers|O
S5493|individually|O
S5493|in|O
S5493|fixed|O
S5493|blocks|B-Randomization_Block_Size
S5493|of|I-Randomization_Block_Size
S5493|20|I-Randomization_Block_Size
S5493|to|O
S5493|the|O
S5493|vitamin|B-Design_Parallel_Group
S5493|D3|I-Design_Parallel_Group
S5493|or|I-Design_Parallel_Group
S5493|placebo|I-Design_Parallel_Group
S5493|group|O
S5493|by|O
S5493|use|O
S5493|of|O
S5493|a|B-Randomization_Sequence_Generation_Method
S5493|random|I-Randomization_Sequence_Generation_Method
S5493|number|I-Randomization_Sequence_Generation_Method
S5493|generator|I-Randomization_Sequence_Generation_Method
S5493|with|O
S5493|the|O
S5493|SAS|O
S5493|routine|O
S5493|.|O
S4201|Methods|O
S4201|In|O
S4201|this|O
S4201|randomized|B-Randomization_Type_Simple
S4201|,|O
S4201|active-controlled|O
S4201|,|O
S4201|double-blinded|B-Blinding_Double_Blind
S4201|trial|O
S4201|,|O
S4201|444|B-Sample_Size_Actual_at_Enrollment
S4201|adults|I-Sample_Size_Actual_at_Enrollment
S4201|60|I-Sample_Size_Actual_at_Enrollment
S4201|through|I-Sample_Size_Actual_at_Enrollment
S4201|64|I-Sample_Size_Actual_at_Enrollment
S4201|years|I-Sample_Size_Actual_at_Enrollment
S4201|of|I-Sample_Size_Actual_at_Enrollment
S4201|age|I-Sample_Size_Actual_at_Enrollment
S4201|were|O
S4201|randomized|O
S4201|to|O
S4201|receive|O
S4201|either|O
S4201|a|B-Design_Parallel_Group
S4201|single|I-Design_Parallel_Group
S4201|dose|I-Design_Parallel_Group
S4201|of|I-Design_Parallel_Group
S4201|PCV20|I-Design_Parallel_Group
S4201|followed|I-Design_Parallel_Group
S4201|1|I-Design_Parallel_Group
S4201|month|I-Design_Parallel_Group
S4201|later|I-Design_Parallel_Group
S4201|by|I-Design_Parallel_Group
S4201|saline|I-Design_Parallel_Group
S4201|placebo|I-Design_Parallel_Group
S4201|or|I-Design_Parallel_Group
S4201|a|I-Design_Parallel_Group
S4201|single|I-Design_Parallel_Group
S4201|dose|I-Design_Parallel_Group
S4201|of|I-Design_Parallel_Group
S4201|PCV13|I-Design_Parallel_Group
S4201|followed|I-Design_Parallel_Group
S4201|1|I-Design_Parallel_Group
S4201|month|I-Design_Parallel_Group
S4201|later|I-Design_Parallel_Group
S4201|by|I-Design_Parallel_Group
S4201|23-valent|I-Design_Parallel_Group
S4201|polysaccharide|I-Design_Parallel_Group
S4201|vaccine|I-Design_Parallel_Group
S4201|.|O
S5809|After|O
S5809|an|O
S5809|initial|O
S5809|screening|O
S5809|period|O
S5809|of|O
S5809|≤|O
S5809|3|O
S5809|weeks|O
S5809|followed|O
S5809|by|O
S5809|a|O
S5809|baseline|O
S5809|period|O
S5809|of|O
S5809|4|O
S5809|weeks|O
S5809|,|O
S5809|during|O
S5809|which|O
S5809|patients|O
S5809|were|O
S5809|required|O
S5809|to|O
S5809|complete|O
S5809|a|O
S5809|daily|O
S5809|electronic|O
S5809|headache|O
S5809|diary|O
S5809|,|O
S5809|investigators|O
S5809|confirmed|O
S5809|that|O
S5809|patients|O
S5809|met|O
S5809|eligibility|O
S5809|criteria|O
S5809|and|O
S5809|had|O
S5809|provided|O
S5809|informed|O
S5809|consent|O
S5809|,|O
S5809|patients|O
S5809|were|O
S5809|enrolled|O
S5809|in|O
S5809|the|O
S5809|trial|O
S5809|and|O
S5809|randomized|O
S5809|4:3:3|B-Randomization_Ratio
S5809|to|O
S5809|placebo|B-Design_Parallel_Group
S5809|,|I-Design_Parallel_Group
S5809|AMG|I-Design_Parallel_Group
S5809|301|I-Design_Parallel_Group
S5809|210|I-Design_Parallel_Group
S5809|mg|I-Design_Parallel_Group
S5809|every|I-Design_Parallel_Group
S5809|4|I-Design_Parallel_Group
S5809|weeks|I-Design_Parallel_Group
S5809|(|I-Design_Parallel_Group
S5809|Q4W|I-Design_Parallel_Group
S5809|)|I-Design_Parallel_Group
S5809|,|I-Design_Parallel_Group
S5809|or|I-Design_Parallel_Group
S5809|AMG|I-Design_Parallel_Group
S5809|301|I-Design_Parallel_Group
S5809|420|I-Design_Parallel_Group
S5809|mg|I-Design_Parallel_Group
S5809|every|I-Design_Parallel_Group
S5809|2|I-Design_Parallel_Group
S5809|weeks|I-Design_Parallel_Group
S5809|(|I-Design_Parallel_Group
S5809|Q2W|I-Design_Parallel_Group
S5809|)|I-Design_Parallel_Group
S5809|for|I-Design_Parallel_Group
S5809|12|I-Design_Parallel_Group
S5809|weeks|I-Design_Parallel_Group
S5809|(|O
S5809|Figure|O
S5809|1|O
S5809|)|O
S5809|;|O
S5809|to|O
S5809|maintain|O
S5809|blinding|O
S5809|,|O
S5809|patients|O
S5809|received|O
S5809|a|O
S5809|total|O
S5809|of|O
S5809|six|O
S5809|subcutaneous|O
S5809|injections|O
S5809|Q2W|O
S5809|.|O
S6745|This|O
S6745|case|O
S6745|provided|O
S6745|at|O
S6745|least|O
S6745|85|B-Sample_Size_Calculation_Power_Value
S6745|%|I-Sample_Size_Calculation_Power_Value
S6745|(|O
S6745|93|O
S6745|%|O
S6745|×93|O
S6745|%|O
S6745|)|O
S6745|power|O
S6745|to|O
S6745|detect|O
S6745|significant|O
S6745|treatment|O
S6745|effects|O
S6745|of|O
S6745|the|O
S6745|co-primary|O
S6745|endpoints|O
S6745|.|O
S8030|Participants|O
S8030|received|O
S8030|6.25|B-Design_Parallel_Group
S8030|mg|I-Design_Parallel_Group
S8030|SHP465|I-Design_Parallel_Group
S8030|MAS|I-Design_Parallel_Group
S8030|once|I-Design_Parallel_Group
S8030|daily|I-Design_Parallel_Group
S8030|or|I-Design_Parallel_Group
S8030|placebo|I-Design_Parallel_Group
S8030|for|O
S8030|4|O
S8030|weeks|O
S8030|.|O
S5857|In|O
S5857|total|O
S5857|,|O
S5857|343|B-Sample_Size_Actual_at_Enrollment
S5857|patients|O
S5857|from|O
S5857|46|B-Settings_Multicenter
S5857|sites|I-Settings_Multicenter
S5857|were|O
S5857|randomized|O
S5857|to|O
S5857|treatment|O
S5857|.|O
S6607|STAIRWAY|O
S6607|was|O
S6607|a|O
S6607|patient-|O
S6607|and|O
S6607|outcome|B-Blinding_Object_Outcome_Assessors
S6607|assessor|I-Blinding_Object_Outcome_Assessors
S6607|(|O
S6607|BCVA|O
S6607|and|O
S6607|central|O
S6607|reading|O
S6607|center|O
S6607|)|O
S6607|–masked|O
S6607|trial|O
S6607|that|O
S6607|allowed|O
S6607|for|O
S6607|a|O
S6607|single|O
S6607|investigator|O
S6607|per|O
S6607|site|O
S6607|while|O
S6607|fulfilling|O
S6607|masking|O
S6607|requirements|O
S6607|.|O
S7899|Randomisation|O
S7899|and|O
S7899|masking|O
S7899|The|B-Randomization_Personnel
S7899|central|I-Randomization_Personnel
S7899|study|I-Randomization_Personnel
S7899|team|I-Randomization_Personnel
S7899|at|I-Randomization_Personnel
S7899|the|I-Randomization_Personnel
S7899|University|I-Randomization_Personnel
S7899|of|I-Randomization_Personnel
S7899|Birmingham|I-Randomization_Personnel
S7899|randomised|O
S7899|patients|O
S7899|,|O
S7899|with|O
S7899|minimisation|B-Randomization_Type_Minimization
S7899|based|O
S7899|on|O
S7899|age|B-Randomization_Minimization_Criteria
S7899|,|O
S7899|sex|B-Randomization_Minimization_Criteria
S7899|,|O
S7899|diabetes|B-Randomization_Minimization_Criteria
S7899|mellitus|I-Randomization_Minimization_Criteria
S7899|,|O
S7899|atrial|B-Randomization_Minimization_Criteria
S7899|fibrillation|I-Randomization_Minimization_Criteria
S7899|,|O
S7899|baseline|B-Randomization_Minimization_Criteria
S7899|systolic|I-Randomization_Minimization_Criteria
S7899|blood|I-Randomization_Minimization_Criteria
S7899|pressure|I-Randomization_Minimization_Criteria
S7899|,|O
S7899|and|O
S7899|general|B-Randomization_Minimization_Criteria
S7899|practice|I-Randomization_Minimization_Criteria
S7899|.|O
S7156|Patients|O
S7156|were|O
S7156|randomly|O
S7156|assigned|O
S7156|in|O
S7156|a|O
S7156|1:1|B-Randomization_Ratio
S7156|ratio|O
S7156|by|O
S7156|a|B-Randomization_Sequence_Generation_Method
S7156|centralised|I-Randomization_Sequence_Generation_Method
S7156|24|I-Randomization_Sequence_Generation_Method
S7156|h|I-Randomization_Sequence_Generation_Method
S7156|telephone|I-Randomization_Sequence_Generation_Method
S7156|or|I-Randomization_Sequence_Generation_Method
S7156|web-based|I-Randomization_Sequence_Generation_Method
S7156|randomisation|I-Randomization_Sequence_Generation_Method
S7156|service|I-Randomization_Sequence_Generation_Method
S7156|(|O
S7156|University|O
S7156|of|O
S7156|Aberdeen|O
S7156|,|O
S7156|UK|B-Settings_Location
S7156|)|O
S7156|.|O
S7901|Neither|B-Blinding_Open_Label
S7901|participants|I-Blinding_Open_Label
S7901|nor|I-Blinding_Open_Label
S7901|clinicians|I-Blinding_Open_Label
S7901|were|I-Blinding_Open_Label
S7901|blinded|I-Blinding_Open_Label
S7901|to|I-Blinding_Open_Label
S7901|treatment|I-Blinding_Open_Label
S7901|allocation|I-Blinding_Open_Label
S7901|.|O
S7122|All|O
S7122|participants|B-Blinding_Object_Patients
S7122|,|O
S7122|caregivers|B-Blinding_Object_Care_Providers
S7122|,|O
S7122|and|O
S7122|investigators|B-Blinding_Object_Investigators
S7122|were|O
S7122|masked|O
S7122|to|O
S7122|group|O
S7122|allocation|O
S7122|.|O
S6722|Patients|O
S6722|must|O
S6722|meet|O
S6722|the|O
S6722|LDL-C|O
S6722|threshold|O
S6722|based|O
S6722|on|O
S6722|their|O
S6722|management|O
S6722|category|O
S6722|in|O
S6722|the|O
S6722|2012|O
S6722|Japan|B-Settings_Location
S6722|Atherosclerosis|O
S6722|Society|O
S6722|Guidelines|O
S6722|for|O
S6722|the|O
S6722|Diagnosis|O
S6722|and|O
S6722|Prevention|O
S6722|of|O
S6722|ASCVD|O
S6722|in|O
S6722|Japan|B-Settings_Location
S6722|)|O
S6722|.|O
S1199|Investigators|B-Blinding_Object_Investigators
S1199|and|O
S1199|patients|B-Blinding_Object_Patients
S1199|were|O
S1199|blinded|O
S1199|to|O
S1199|GP|O
S1199|MDI|O
S1199|and|O
S1199|placebo|O
S1199|MDI|O
S1199|treatment|O
S1199|using|O
S1199|non-distinguishable|O
S1199|MDIs|O
S1199|.|O
S6392|Setting|O
S6392|Four|B-Settings_Multicenter
S6392|acute|I-Settings_Multicenter
S6392|care|I-Settings_Multicenter
S6392|hospitals|I-Settings_Multicenter
S6392|in|O
S6392|Israel|B-Settings_Location
S6392|.|O
S4661|METHODS|O
S4661|This|O
S4661|was|O
S4661|a|O
S4661|26‐week|O
S4661|,|O
S4661|double‐blind|B-Blinding_Double_Blind
S4661|,|O
S4661|placebo‐controlled|O
S4661|,|O
S4661|multicentre|B-Settings_Multicenter
S4661|,|O
S4661|randomized|O
S4661|,|O
S4661|parallel‐group|B-Design_Parallel_Group
S4661|,|O
S4661|phase|B-Design_Phase_3
S4661|III|I-Design_Phase_3
S4661|study|O
S4661|in|O
S4661|Asian|B-Settings_Location
S4661|patients|O
S4661|with|O
S4661|T2DM|O
S4661|and|O
S4661|inadequate|O
S4661|glycaemic|O
S4661|control|O
S4661|on|O
S4661|metformin|O
S4661|monotherapy|O
S4661|.|O
S7326|Of|O
S7326|these|O
S7326|,|O
S7326|195|B-Sample_Size_Actual_at_Outcome_Analysis
S7326|patients|O
S7326|(|O
S7326|93.3|O
S7326|%|O
S7326|)|O
S7326|completed|O
S7326|the|O
S7326|12-week|O
S7326|study|O
S7326|.|O
S5445|Methods|O
S5445|We|O
S5445|did|O
S5445|a|O
S5445|randomised|O
S5445|placebo-controlled|O
S5445|trial|O
S5445|to|O
S5445|compare|O
S5445|oral|B-Design_Parallel_Group
S5445|100|I-Design_Parallel_Group
S5445|000|I-Design_Parallel_Group
S5445|IU|I-Design_Parallel_Group
S5445|(|I-Design_Parallel_Group
S5445|2·5|I-Design_Parallel_Group
S5445|mg|I-Design_Parallel_Group
S5445|)|I-Design_Parallel_Group
S5445|vitamin|I-Design_Parallel_Group
S5445|D3|I-Design_Parallel_Group
S5445|with|I-Design_Parallel_Group
S5445|placebo|I-Design_Parallel_Group
S5445|given|O
S5445|to|O
S5445|children|O
S5445|aged|O
S5445|1–11|O
S5445|months|O
S5445|in|O
S5445|Kabul|B-Settings_Location
S5445|,|I-Settings_Location
S5445|Afghanistan|I-Settings_Location
S5445|.|O
S6697|Results|O
S6697|:|O
S6697|Sixty-one|B-Sample_Size_Actual_at_Enrollment
S6697|patients|O
S6697|were|O
S6697|randomized|O
S6697|to|O
S6697|evolocumab|O
S6697|(|O
S6697|n|O
S6697|=|O
S6697|40|O
S6697|)|O
S6697|or|O
S6697|ezetimibe|O
S6697|(|O
S6697|n|O
S6697|=|O
S6697|21|O
S6697|)|O
S6697|.|O
S5224|At|O
S5224|the|O
S5224|time|O
S5224|of|O
S5224|study|O
S5224|termination|O
S5224|,|O
S5224|72|B-Sample_Size_Actual_at_Enrollment
S5224|eligible|O
S5224|patients|O
S5224|were|O
S5224|enrolled|O
S5224|and|O
S5224|randomized|O
S5224|(|O
S5224|intervention|O
S5224|group|O
S5224|n|O
S5224|=|O
S5224|40|O
S5224|,|O
S5224|usual|O
S5224|care|O
S5224|group|O
S5224|n|O
S5224|=|O
S5224|32|O
S5224|)|O
S5224|(|O
S5224|see|O
S5224|Supplemental|O
S5224|Digital|O
S5224|Content|O
S5224|eFigure|O
S5224|1|O
S5224|)|O
S5224|.|O
S2399|Subjects|B-Blinding_Object_Patients
S2399|,|O
S2399|investigators|B-Blinding_Object_Investigators
S2399|,|O
S2399|all|B-Blinding_Object_Others
S2399|other|I-Blinding_Object_Others
S2399|study|I-Blinding_Object_Others
S2399|staff|I-Blinding_Object_Others
S2399|,|O
S2399|laboratories|B-Blinding_Object_Others
S2399|,|O
S2399|and|O
S2399|the|O
S2399|rest|B-Blinding_Object_Others
S2399|of|I-Blinding_Object_Others
S2399|the|I-Blinding_Object_Others
S2399|Sponsor|I-Blinding_Object_Others
S2399|study|I-Blinding_Object_Others
S2399|team|I-Blinding_Object_Others
S2399|were|O
S2399|blinded|O
S2399|to|O
S2399|subject|O
S2399|treatment|O
S2399|assignment|O
S2399|until|O
S2399|the|O
S2399|database|O
S2399|was|O
S2399|locked|O
S2399|at|O
S2399|the|O
S2399|end|O
S2399|of|O
S2399|the|O
S2399|study|O
S2399|.|O
S7431|Patients|O
S7431|and|O
S7431|Methods|O
S7431|Study|O
S7431|Design|O
S7431|This|O
S7431|phase|B-Design_Phase_2
S7431|2|I-Design_Phase_2
S7431|,|O
S7431|randomized|O
S7431|,|O
S7431|double‐blind|B-Blinding_Double_Blind
S7431|,|O
S7431|placebo‐controlled|O
S7431|study|O
S7431|was|O
S7431|conducted|O
S7431|in|O
S7431|Japan|B-Settings_Location
S7431|at|O
S7431|43|B-Settings_Multicenter
S7431|centers|I-Settings_Multicenter
S7431|with|O
S7431|on‐site|O
S7431|headache|O
S7431|specialists|O
S7431|and|O
S7431|enrolled|O
S7431|adult|O
S7431|Japanese|O
S7431|patients|O
S7431|with|O
S7431|a|O
S7431|history|O
S7431|of|O
S7431|episodic|O
S7431|migraine|O
S7431|.|O
S4071|This|O
S4071|phase|B-Design_Phase_2
S4071|2|I-Design_Phase_2
S4071|study|O
S4071|(|O
S4071|V114-008|O
S4071|;|O
S4071|NCT02987972|O
S4071|;|O
S4071|EudraCT|O
S4071|2016-001117-25|O
S4071|)|O
S4071|compared|O
S4071|safety|O
S4071|and|O
S4071|immunogenicity|O
S4071|of|O
S4071|2|O
S4071|clinical|O
S4071|lots|O
S4071|of|O
S4071|V114|O
S4071|(|O
S4071|investigational|O
S4071|15-valent|O
S4071|pneumococcal|O
S4071|vaccine|O
S4071|:|O
S4071|1|O
S4071|,|O
S4071|3|O
S4071|,|O
S4071|4|O
S4071|,|O
S4071|5|O
S4071|,|O
S4071|6A|O
S4071|,|O
S4071|6B|O
S4071|,|O
S4071|7F|O
S4071|,|O
S4071|9V|O
S4071|,|O
S4071|14|O
S4071|,|O
S4071|18C|O
S4071|,|O
S4071|19F|O
S4071|,|O
S4071|19A|O
S4071|,|O
S4071|22F*|O
S4071|,|O
S4071|23F|O
S4071|,|O
S4071|33F*|O
S4071|)|O
S4071|to|O
S4071|13-valent|O
S4071|pneumococcal|O
S4071|conjugate|O
S4071|vaccine|O
S4071|(|O
S4071|PCV13|O
S4071|)|O
S4071|in|O
S4071|healthy|O
S4071|infants|O
S4071|(|O
S4071|*serotypes|O
S4071|unique|O
S4071|to|O
S4071|V114|O
S4071|)|O
S4071|.|O
S6765|Fifty-eight|B-Sample_Size_Actual_at_Outcome_Analysis
S6765|patients|O
S6765|(|O
S6765|95|O
S6765|%|O
S6765|)|O
S6765|completed|O
S6765|the|O
S6765|12-week|O
S6765|double-blind|O
S6765|period|O
S6765|.|O
S1711|Patients|O
S1711|were|O
S1711|randomly|O
S1711|assigned|O
S1711|to|O
S1711|a|O
S1711|single|O
S1711|14-day|O
S1711|course|O
S1711|of|O
S1711|teplizumab|B-Design_Parallel_Group
S1711|or|I-Design_Parallel_Group
S1711|placebo|I-Design_Parallel_Group
S1711|,|O
S1711|and|O
S1711|follow-up|O
S1711|for|O
S1711|progression|O
S1711|to|O
S1711|clinical|O
S1711|type|O
S1711|1|O
S1711|diabetes|O
S1711|was|O
S1711|performed|O
S1711|with|O
S1711|the|O
S1711|use|O
S1711|of|O
S1711|oral|O
S1711|glucose-tolerance|O
S1711|tests|O
S1711|at|O
S1711|6-month|O
S1711|intervals|O
S1711|.|O
S65|Assuming|O
S65|for|O
S65|each|O
S65|strain|O
S65|the|O
S65|same|O
S65|expected|O
S65|seroconversion|O
S65|rates|O
S65|for|O
S65|each|O
S65|vaccine|O
S65|dosing|O
S65|group|O
S65|(|O
S65|90.9|O
S65|%|O
S65|for|O
S65|A/H1N1|O
S65|,|O
S65|95.4|O
S65|%|O
S65|for|O
S65|A/H3N2|O
S65|,|O
S65|72|O
S65|%|O
S65|for|O
S65|B/Victoria|O
S65|and|O
S65|57.5|O
S65|%|O
S65|for|O
S65|B/Yamagata|O
S65|)|O
S65|and|O
S65|a|O
S65|noninferiority|O
S65|margin|O
S65|of|O
S65|10|O
S65|%|O
S65|for|O
S65|each|O
S65|strain|O
S65|,|O
S65|the|O
S65|planned|O
S65|study|O
S65|power|O
S65|was|O
S65|approximately|O
S65|93.2|B-Sample_Size_Calculation_Power_Value
S65|%|I-Sample_Size_Calculation_Power_Value
S65|to|O
S65|demonstrate|O
S65|noninferiority|O
S65|for|O
S65|seroconversion|O
S65|rates|O
S65|.|O
S7302|The|O
S7302|primary|O
S7302|objective|O
S7302|was|O
S7302|to|O
S7302|demonstrate|O
S7302|the|O
S7302|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7302|in|O
S7302|efficacy|O
S7302|of|O
S7302|tofacitinib|O
S7302|MR|O
S7302|11|O
S7302|mg|O
S7302|QD|O
S7302|relative|O
S7302|to|O
S7302|IR|O
S7302|5|O
S7302|mg|O
S7302|BID|O
S7302|.|O
S1073|In|O
S1073|the|O
S1073|CTIC|O
S1073|group|O
S1073|,|O
S1073|the|O
S1073|lesion|O
S1073|could|O
S1073|not|O
S1073|be|O
S1073|crossed|O
S1073|in|O
S1073|1|O
S1073|patient|O
S1073|,|O
S1073|and|O
S1073|PCI|B-Sample_Size_Actual_at_Outcome_Analysis
S1073|was|I-Sample_Size_Actual_at_Outcome_Analysis
S1073|performed|I-Sample_Size_Actual_at_Outcome_Analysis
S1073|in|I-Sample_Size_Actual_at_Outcome_Analysis
S1073|49|I-Sample_Size_Actual_at_Outcome_Analysis
S1073|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S1073|.|O
S6608|Study|B-Blinding_Object_Patients
S6608|participants|I-Blinding_Object_Patients
S6608|and|O
S6608|BCVA|B-Blinding_Object_Outcome_Assessors
S6608|examiners|I-Blinding_Object_Outcome_Assessors
S6608|were|O
S6608|masked|O
S6608|to|O
S6608|treatment|O
S6608|assignment|O
S6608|.|O
S7411|Methods|O
S7411|Patients|O
S7411|were|O
S7411|randomized|O
S7411|to|O
S7411|placebo|B-Design_Parallel_Group
S7411|or|I-Design_Parallel_Group
S7411|erenumab|I-Design_Parallel_Group
S7411|28|I-Design_Parallel_Group
S7411|,|I-Design_Parallel_Group
S7411|70|I-Design_Parallel_Group
S7411|,|I-Design_Parallel_Group
S7411|or|I-Design_Parallel_Group
S7411|140|I-Design_Parallel_Group
S7411|mg|I-Design_Parallel_Group
S7411|administered|O
S7411|subcutaneously|O
S7411|once|O
S7411|per|O
S7411|month|O
S7411|for|O
S7411|6|O
S7411|months|O
S7411|.|O
S601|Treatment|O
S601|was|O
S601|allocated|O
S601|by|O
S601|a|B-Randomization_Sequence_Generation_Method
S601|web-based|I-Randomization_Sequence_Generation_Method
S601|randomisation|I-Randomization_Sequence_Generation_Method
S601|system|I-Randomization_Sequence_Generation_Method
S601|,|O
S601|available|O
S601|24|O
S601|h|O
S601|a|O
S601|day|O
S601|.|O
S3878|Objective|O
S3878|This|O
S3878|double-blind|B-Blinding_Double_Blind
S3878|,|O
S3878|placebo-controlled|O
S3878|,|O
S3878|dose-finding|O
S3878|phase|B-Design_Phase_2
S3878|IIb|I-Design_Phase_2
S3878|study|O
S3878|evaluated|O
S3878|the|O
S3878|efficacy|O
S3878|and|O
S3878|safety|O
S3878|of|O
S3878|ponesimod|O
S3878|,|O
S3878|an|O
S3878|oral|O
S3878|selective|O
S3878|S1P1|O
S3878|receptor|O
S3878|modulator|O
S3878|,|O
S3878|for|O
S3878|the|O
S3878|treatment|O
S3878|of|O
S3878|patients|O
S3878|with|O
S3878|relapsing–remitting|O
S3878|multiple|O
S3878|sclerosis|O
S3878|(|O
S3878|RRMS|O
S3878|)|O
S3878|.|O
S7044|A|O
S7044|sample|O
S7044|size|O
S7044|of|O
S7044|726|B-Sample_Size_Required
S7044|randomized|O
S7044|patients|O
S7044|(|O
S7044|363|O
S7044|per|O
S7044|group|O
S7044|)|O
S7044|was|O
S7044|selected|O
S7044|to|O
S7044|provide|O
S7044|92|B-Sample_Size_Calculation_Power_Value
S7044|%|I-Sample_Size_Calculation_Power_Value
S7044|power|O
S7044|at|O
S7044|a|B-Sample_Size_Calculation_Alpha_Value
S7044|1-sided|I-Sample_Size_Calculation_Alpha_Value
S7044|significance|I-Sample_Size_Calculation_Alpha_Value
S7044|level|I-Sample_Size_Calculation_Alpha_Value
S7044|of|I-Sample_Size_Calculation_Alpha_Value
S7044|0.025|I-Sample_Size_Calculation_Alpha_Value
S7044|,|O
S7044|assuming|O
S7044|a|O
S7044|day|O
S7044|28|O
S7044|ACM|O
S7044|rate|O
S7044|of|O
S7044|20|O
S7044|%|O
S7044|in|O
S7044|both|O
S7044|groups|O
S7044|.|O
S7289|Patients|O
S7289|were|O
S7289|randomized|O
S7289|1:1|B-Randomization_Ratio
S7289|to|O
S7289|receive|O
S7289|oral|B-Design_Parallel_Group
S7289|tofacitinib|I-Design_Parallel_Group
S7289|MR|I-Design_Parallel_Group
S7289|11|I-Design_Parallel_Group
S7289|mg|I-Design_Parallel_Group
S7289|QD|I-Design_Parallel_Group
S7289|or|I-Design_Parallel_Group
S7289|IR|I-Design_Parallel_Group
S7289|5|I-Design_Parallel_Group
S7289|mg|I-Design_Parallel_Group
S7289|BID|I-Design_Parallel_Group
S7289|,|O
S7289|both|O
S7289|with|O
S7289|stable|O
S7289|background|O
S7289|MTX|O
S7289|(|O
S7289|6–16|O
S7289|mg/week|O
S7289|for|O
S7289|⩾6|O
S7289|weeks|O
S7289|before|O
S7289|baseline|O
S7289|;|O
S7289|supplemented|O
S7289|with|O
S7289|folic|O
S7289|acid|O
S7289|or|O
S7289|folinic|O
S7289|acid|O
S7289|)|O
S7289|,|O
S7289|using|O
S7289|an|B-Randomization_Sequence_Generation_Method
S7289|automated|I-Randomization_Sequence_Generation_Method
S7289|Web/telephone|I-Randomization_Sequence_Generation_Method
S7289|system|I-Randomization_Sequence_Generation_Method
S7289|provided|O
S7289|by|O
S7289|Pfizer|O
S7289|Inc|O
S7289|.|O
S2441|Based|O
S2441|on|O
S2441|a|O
S2441|fixed|O
S2441|effects|O
S2441|meta-analysis|O
S2441|of|O
S2441|five|O
S2441|historical|O
S2441|reference|O
S2441|studies|O
S2441|selected|O
S2441|for|O
S2441|their|O
S2441|applicability|O
S2441|to|O
S2441|this|O
S2441|study|O
S2441|,|O
S2441|a|O
S2441|sample|O
S2441|size|O
S2441|of|O
S2441|300|O
S2441|randomized|O
S2441|subjects|O
S2441|per|O
S2441|group|O
S2441|(|O
S2441|600|B-Sample_Size_Required
S2441|total|O
S2441|)|O
S2441|was|O
S2441|chosen|O
S2441|to|O
S2441|provide|O
S2441|adequate|O
S2441|power|O
S2441|for|O
S2441|the|O
S2441|proposed|O
S2441|analyses|O
S2441|.|O
S1004|Methods|O
S1004|and|O
S1004|Results|O
S1004|A|O
S1004|total|O
S1004|of|O
S1004|100|B-Sample_Size_Actual_at_Enrollment
S1004|P2Y12|I-Sample_Size_Actual_at_Enrollment
S1004|naïve|I-Sample_Size_Actual_at_Enrollment
S1004|,|I-Sample_Size_Actual_at_Enrollment
S1004|troponin‐negative|I-Sample_Size_Actual_at_Enrollment
S1004|patients|I-Sample_Size_Actual_at_Enrollment
S1004|with|O
S1004|acute|O
S1004|coronary|O
S1004|syndrome|O
S1004|were|O
S1004|randomized|O
S1004|to|O
S1004|CTIC|O
S1004|(|O
S1004|180|O
S1004|mg|O
S1004|)|O
S1004|versus|O
S1004|eptifibatide|O
S1004|bolus|O
S1004|(|O
S1004|180|O
S1004|μg/kg×2|O
S1004|intravenous|O
S1004|boluses|O
S1004|)|O
S1004|plus|O
S1004|clopidogrel|O
S1004|(|O
S1004|600|O
S1004|mg|O
S1004|)|O
S1004|at|O
S1004|the|O
S1004|time|O
S1004|of|O
S1004|percutaneous|O
S1004|coronary|O
S1004|intervention|O
S1004|.|O
S132|We|O
S132|conducted|O
S132|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S132|comparisons|O
S132|(|O
S132|non-inferiority|O
S132|margin|O
S132|=|O
S132|0.9|O
S132|)|O
S132|of|O
S132|pain|O
S132|change|O
S132|from|O
S132|treatment|O
S132|initiation|O
S132|(|O
S132|T0|O
S132|)|O
S132|to|O
S132|one|O
S132|hour|O
S132|later|O
S132|(|O
S132|T60|O
S132|)|O
S132|.|O
S3241|Randomisation|O
S3241|for|O
S3241|both|O
S3241|comparisons|O
S3241|within|O
S3241|the|O
S3241|trial|O
S3241|was|O
S3241|in|O
S3241|a|O
S3241|1|B-Randomization_Ratio
S3241|to|I-Randomization_Ratio
S3241|1|I-Randomization_Ratio
S3241|allocation|O
S3241|ratio|O
S3241|.|O
S7939|Results|O
S7939|Figure|O
S7939|1|O
S7939|shows|O
S7939|the|O
S7939|trial|O
S7939|profile|O
S7939|;|O
S7939|529|B-Sample_Size_Actual_at_Enrollment
S7939|patients|O
S7939|from|O
S7939|99|B-Settings_Multicenter
S7939|general|I-Settings_Multicenter
S7939|practices|I-Settings_Multicenter
S7939|(|O
S7939|range|O
S7939|1-16|O
S7939|per|O
S7939|practice|O
S7939|)|O
S7939|entered|O
S7939|the|O
S7939|trial|O
S7939|,|O
S7939|and|O
S7939|84|O
S7939|patients|O
S7939|withdrew|O
S7939|from|O
S7939|the|O
S7939|trial|O
S7939|in|O
S7939|the|O
S7939|12|O
S7939|months|O
S7939|after|O
S7939|randomisation|O
S7939|(|O
S7939|52|O
S7939|(|O
S7939|20|O
S7939|%|O
S7939|)|O
S7939|in|O
S7939|the|O
S7939|intensive|O
S7939|target|O
S7939|arm|O
S7939|and|O
S7939|32|O
S7939|(|O
S7939|12|O
S7939|%|O
S7939|)|O
S7939|in|O
S7939|the|O
S7939|standard|O
S7939|target|O
S7939|arm|O
S7939|;|O
S7939|P=0.02|O
S7939|)|O
S7939|.|O
S6714|Randomization|O
S6714|was|O
S6714|stratified|B-Randomization_Type_Stratified
S6714|by|O
S6714|screening|O
S6714|the|O
S6714|LDL-C|B-Randomization_Stratified_Criteria
S6714|level|I-Randomization_Stratified_Criteria
S6714|(|I-Randomization_Stratified_Criteria
S6714|<|I-Randomization_Stratified_Criteria
S6714|or|I-Randomization_Stratified_Criteria
S6714|≥|I-Randomization_Stratified_Criteria
S6714|180|I-Randomization_Stratified_Criteria
S6714|mg/dL|I-Randomization_Stratified_Criteria
S6714|)|I-Randomization_Stratified_Criteria
S6714|and|O
S6714|baseline|B-Randomization_Stratified_Criteria
S6714|statin|I-Randomization_Stratified_Criteria
S6714|use|I-Randomization_Stratified_Criteria
S6714|(|I-Randomization_Stratified_Criteria
S6714|yes|I-Randomization_Stratified_Criteria
S6714|or|I-Randomization_Stratified_Criteria
S6714|no|I-Randomization_Stratified_Criteria
S6714|)|I-Randomization_Stratified_Criteria
S6714|.|O
S5909|Methods|O
S5909|and|O
S5909|results|O
S5909|In|O
S5909|a|O
S5909|randomised|O
S5909|double-blind|B-Blinding_Double_Blind
S5909|placebo-controlled|O
S5909|parallel|B-Design_Parallel_Group
S5909|group|I-Design_Parallel_Group
S5909|clinical|O
S5909|trial|O
S5909|,|O
S5909|87|B-Sample_Size_Actual_at_Enrollment
S5909|patients|O
S5909|undergoing|O
S5909|CABG|O
S5909|surgery|O
S5909|were|O
S5909|randomised|O
S5909|1:1|B-Randomization_Ratio
S5909|to|O
S5909|intravenous|O
S5909|elafin|I-Design_Parallel_Group
S5909|200|I-Design_Parallel_Group
S5909|mg|I-Design_Parallel_Group
S5909|or|I-Design_Parallel_Group
S5909|saline|I-Design_Parallel_Group
S5909|placebo|I-Design_Parallel_Group
S5909|administered|O
S5909|after|O
S5909|induction|O
S5909|of|O
S5909|anaesthesia|O
S5909|and|O
S5909|prior|O
S5909|to|O
S5909|sternotomy|O
S5909|.|O
S6225|In|O
S6225|the|O
S6225|subsequent|O
S6225|open-label|B-Blinding_Open_Label
S6225|phase|O
S6225|,|O
S6225|all|O
S6225|participants|O
S6225|received|O
S6225|repeat|O
S6225|injections|O
S6225|of|O
S6225|400|O
S6225|U|O
S6225|onabotulinumtoxinA|O
S6225|(|O
S6225|target|O
S6225|muscles|O
S6225|and|O
S6225|doses|O
S6225|per|O
S6225|muscle|O
S6225|determined|O
S6225|by|O
S6225|the|O
S6225|physician|O
S6225|)|O
S6225|.|O
S7264|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7264|of|O
S7264|MR|O
S7264|11|O
S7264|mg|O
S7264|QD|O
S7264|to|O
S7264|IR|O
S7264|5|O
S7264|mg|O
S7264|BID|O
S7264|was|O
S7264|not|O
S7264|met|O
S7264|.|O
S5941|To|O
S5941|ensure|O
S5941|blinding|O
S5941|,|O
S5941|study|O
S5941|drugs|O
S5941|were|O
S5941|prepared|O
S5941|by|O
S5941|staff|O
S5941|independent|O
S5941|of|O
S5941|the|O
S5941|study|B-Blinding_Object_Investigators
S5941|investigators|I-Blinding_Object_Investigators
S5941|or|O
S5941|clinical|B-Blinding_Object_Care_Providers
S5941|team|I-Blinding_Object_Care_Providers
S5941|responsible|O
S5941|for|O
S5941|the|O
S5941|patient|O
S5941|’|O
S5941|s|O
S5941|care|O
S5941|.|O
S8271|Aromatase|O
S8271|Inhibitor|O
S8271|Therapy|O
S8271|Participants|O
S8271|were|O
S8271|randomized|O
S8271|by|O
S8271|the|B-Randomization_Personnel
S8271|MEDVAMC|I-Randomization_Personnel
S8271|pharmacy|I-Randomization_Personnel
S8271|from|O
S8271|a|B-Randomization_Sequence_Generation_Method
S8271|list|I-Randomization_Sequence_Generation_Method
S8271|generated|I-Randomization_Sequence_Generation_Method
S8271|by|I-Randomization_Sequence_Generation_Method
S8271|a|I-Randomization_Sequence_Generation_Method
S8271|research|I-Randomization_Sequence_Generation_Method
S8271|biostatistician|I-Randomization_Sequence_Generation_Method
S8271|to|O
S8271|one|O
S8271|of|O
S8271|two|O
S8271|treatment|O
S8271|groups|O
S8271|for|O
S8271|a|O
S8271|total|O
S8271|of|O
S8271|26|O
S8271|weeks|O
S8271|:|O
S8271|AI|B-Design_Parallel_Group
S8271|(|I-Design_Parallel_Group
S8271|anastrozole|I-Design_Parallel_Group
S8271|1|I-Design_Parallel_Group
S8271|mg|I-Design_Parallel_Group
S8271|daily|I-Design_Parallel_Group
S8271|)|I-Design_Parallel_Group
S8271|+|I-Design_Parallel_Group
S8271|WL|I-Design_Parallel_Group
S8271|or|I-Design_Parallel_Group
S8271|PBO|I-Design_Parallel_Group
S8271|+|I-Design_Parallel_Group
S8271|WL|I-Design_Parallel_Group
S8271|.|O
S6252|In|O
S6252|the|O
S6252|double-blind|O
S6252|phase|O
S6252|,|O
S6252|patients|O
S6252|were|O
S6252|randomly|O
S6252|allocated|O
S6252|in|O
S6252|a|O
S6252|1:1|B-Randomization_Ratio
S6252|ratio|O
S6252|to|O
S6252|either|O
S6252|400|B-Design_Parallel_Group
S6252|U|I-Design_Parallel_Group
S6252|onabotulinumtoxinA|I-Design_Parallel_Group
S6252|or|I-Design_Parallel_Group
S6252|240|I-Design_Parallel_Group
S6252|U|I-Design_Parallel_Group
S6252|onabotulinumtoxinA|I-Design_Parallel_Group
S6252|.|O
S6254|The|O
S6254|investigator|B-Blinding_Object_Investigators
S6254|,|O
S6254|study|B-Blinding_Object_Others
S6254|staff|I-Blinding_Object_Others
S6254|at|I-Blinding_Object_Others
S6254|the|I-Blinding_Object_Others
S6254|site|I-Blinding_Object_Others
S6254|,|O
S6254|and|O
S6254|patient|B-Blinding_Object_Patients
S6254|were|O
S6254|blinded|O
S6254|to|O
S6254|the|O
S6254|study|O
S6254|treatment|O
S6254|allocated|O
S6254|to|O
S6254|each|O
S6254|individual|O
S6254|patient|O
S6254|during|O
S6254|the|O
S6254|overall|O
S6254|study|O
S6254|period|O
S6254|.|O
S950|Of|O
S950|154|O
S950|screened|O
S950|participants|O
S950|,|O
S950|130|B-Sample_Size_Actual_at_Enrollment
S950|were|O
S950|randomised|O
S950|to|O
S950|treatment|O
S950|(|O
S950|65|O
S950|per|O
S950|group|O
S950|)|O
S950|and|O
S950|were|O
S950|included|O
S950|in|O
S950|the|O
S950|mITT|O
S950|and|O
S950|safety|O
S950|populations|O
S950|;|O
S950|129|B-Sample_Size_Actual_at_Outcome_Analysis
S950|participants|O
S950|completed|O
S950|the|O
S950|study|O
S950|(|O
S950|Fig|O
S950|.|O
S8113|To|O
S8113|detect|O
S8113|an|O
S8113|assumed|O
S8113|treatment|O
S8113|difference|O
S8113|of|O
S8113|11.9|O
S8113|points|O
S8113|for|O
S8113|ADHD-RS-5-HV|O
S8113|total|O
S8113|score|O
S8113|change|O
S8113|from|O
S8113|baseline|O
S8113|at|O
S8113|week|O
S8113|4|O
S8113|(|O
S8113|assumed|O
S8113|common|O
S8113|standard|O
S8113|deviation|O
S8113|[|O
S8113|SD|O
S8113|]|O
S8113|,|O
S8113|14|O
S8113|)|O
S8113|,|O
S8113|26|B-Sample_Size_Required
S8113|participants|I-Sample_Size_Required
S8113|in|I-Sample_Size_Required
S8113|each|I-Sample_Size_Required
S8113|treatment|I-Sample_Size_Required
S8113|arm|I-Sample_Size_Required
S8113|(|O
S8113|52|B-Sample_Size_Required
S8113|total|O
S8113|participants|O
S8113|)|O
S8113|needed|O
S8113|to|O
S8113|complete|O
S8113|the|O
S8113|study|O
S8113|to|O
S8113|provide|O
S8113|85|B-Sample_Size_Calculation_Power_Value
S8113|%|I-Sample_Size_Calculation_Power_Value
S8113|power|O
S8113|for|O
S8113|a|B-Sample_Size_Calculation_Alpha_Value
S8113|two-sided|I-Sample_Size_Calculation_Alpha_Value
S8113|t|I-Sample_Size_Calculation_Alpha_Value
S8113|test|I-Sample_Size_Calculation_Alpha_Value
S8113|(|I-Sample_Size_Calculation_Alpha_Value
S8113|α|I-Sample_Size_Calculation_Alpha_Value
S8113|=|I-Sample_Size_Calculation_Alpha_Value
S8113|0.05|I-Sample_Size_Calculation_Alpha_Value
S8113|)|I-Sample_Size_Calculation_Alpha_Value
S8113|.|O
S8638|Patient|O
S8638|groups|O
S8638|were|O
S8638|assigned|O
S8638|centrally|O
S8638|according|O
S8638|to|O
S8638|a|B-Randomization_Sequence_Generation_Method
S8638|validated|I-Randomization_Sequence_Generation_Method
S8638|computer-generated|I-Randomization_Sequence_Generation_Method
S8638|randomization|I-Randomization_Sequence_Generation_Method
S8638|code|I-Randomization_Sequence_Generation_Method
S8638|,|O
S8638|stratified|B-Randomization_Type_Stratified
S8638|according|O
S8638|to|O
S8638|glycemic|B-Randomization_Stratified_Criteria
S8638|status|I-Randomization_Stratified_Criteria
S8638|(|I-Randomization_Stratified_Criteria
S8638|T2DM|I-Randomization_Stratified_Criteria
S8638|or|I-Randomization_Stratified_Criteria
S8638|IGT|I-Randomization_Stratified_Criteria
S8638|)|I-Randomization_Stratified_Criteria
S8638|.|O
S2782|treatment|O
S2782|groups|O
S2782|were|O
S2782|compared|O
S2782|with|O
S2782|the|O
S2782|placebo|O
S2782|group|O
S2782|using|O
S2782|a|O
S2782|5|B-Sample_Size_Calculation_Alpha_Value
S2782|%|I-Sample_Size_Calculation_Alpha_Value
S2782|significance|O
S2782|level|O
S2782|.|O
S7119|Methods|O
S7119|We|O
S7119|did|O
S7119|a|O
S7119|multicentre|B-Settings_Multicenter
S7119|,|O
S7119|placebo-controlled|O
S7119|,|O
S7119|parallel-group|B-Design_Parallel_Group
S7119|,|O
S7119|randomised|O
S7119|trial|O
S7119|at|O
S7119|46|B-Settings_Multicenter
S7119|UK|B-Settings_Location
S7119|intensive-care|I-Settings_Multicenter
S7119|units|I-Settings_Multicenter
S7119|between|O
S7119|December|O
S7119|,|O
S7119|2006|O
S7119|,|O
S7119|and|O
S7119|March|O
S7119|,|O
S7119|2010|O
S7119|.|O
S157|Methods|O
S157|Study|O
S157|design|O
S157|and|O
S157|setting|O
S157|This|O
S157|was|O
S157|a|O
S157|single-center|B-Settings_Single_Center
S157|,|O
S157|randomized|B-Randomization_Type_Simple
S157|,|O
S157|open-label|B-Blinding_Open_Label
S157|clinical|O
S157|trial|O
S157|designed|O
S157|to|O
S157|compare|O
S157|IN|B-Design_Parallel_Group
S157|fentanyl|I-Design_Parallel_Group
S157|versus|I-Design_Parallel_Group
S157|IV|I-Design_Parallel_Group
S157|opioids|I-Design_Parallel_Group
S157|in|O
S157|pain|O
S157|intensity|O
S157|reduction|O
S157|by|O
S157|1|O
S157|hour|O
S157|after|O
S157|drug|O
S157|delivery|O
S157|.|O
S1608|Procedures|O
S1608|This|O
S1608|two-arm|O
S1608|,|O
S1608|randomised|O
S1608|,|O
S1608|multicentre|B-Settings_Multicenter
S1608|,|O
S1608|double-blind|B-Blinding_Double_Blind
S1608|,|O
S1608|placebo-controlled|O
S1608|,|O
S1608|parallel-group|B-Design_Parallel_Group
S1608|,|O
S1608|phase|B-Design_Phase_3
S1608|III|I-Design_Phase_3
S1608|study|O
S1608|was|O
S1608|conducted|O
S1608|in|O
S1608|the|O
S1608|USA|B-Settings_Location
S1608|,|I-Settings_Location
S1608|Canada|I-Settings_Location
S1608|and|I-Settings_Location
S1608|the|I-Settings_Location
S1608|UK|I-Settings_Location
S1608|(|O
S1608|figure|O
S1608|1|O
S1608|)|O
S1608|at|O
S1608|34|B-Settings_Multicenter
S1608|sites|I-Settings_Multicenter
S1608|(|O
S1608|the|O
S1608|MEASURE|O
S1608|study|O
S1608|)|O
S1608|.|O
S2364|Results|O
S2364|A|O
S2364|total|O
S2364|of|O
S2364|627|B-Sample_Size_Actual_at_Enrollment
S2364|subjects|O
S2364|were|O
S2364|randomized|O
S2364|1:1|B-Randomization_Ratio
S2364|to|O
S2364|MB02|O
S2364|(|O
S2364|n|O
S2364|=|O
S2364|315|O
S2364|)|O
S2364|or|O
S2364|EU-bevacizumab|O
S2364|(|O
S2364|n|O
S2364|=|O
S2364|312|O
S2364|)|O
S2364|.|O
S1961|Of|O
S1961|the|O
S1961|394|O
S1961|on|O
S1961|study|O
S1961|at|O
S1961|delivery|O
S1961|,|O
S1961|368|B-Sample_Size_Actual_at_Outcome_Analysis
S1961|(|O
S1961|94|O
S1961|%|O
S1961|)|O
S1961|had|O
S1961|either|O
S1961|screening|O
S1961|or|O
S1961|entry|O
S1961|plasma|O
S1961|HIV-1|O
S1961|RNA|O
S1961|viral|O
S1961|load|O
S1961|≥200|O
S1961|copies|O
S1961|per|O
S1961|mL|O
S1961|and|O
S1961|were|O
S1961|thus|O
S1961|eligible|O
S1961|for|O
S1961|the|O
S1961|primary|O
S1961|efficacy|O
S1961|analysis|O
S1961|.|O
S1926|Statistical|O
S1926|Analysis|O
S1926|The|O
S1926|target|O
S1926|sample|O
S1926|size|O
S1926|of|O
S1926|334|B-Sample_Size_Required
S1926|evaluable|I-Sample_Size_Required
S1926|women|I-Sample_Size_Required
S1926|provided|O
S1926|80|B-Sample_Size_Calculation_Power_Value
S1926|%|I-Sample_Size_Calculation_Power_Value
S1926|power|O
S1926|to|O
S1926|detect|O
S1926|a|O
S1926|difference|O
S1926|in|O
S1926|response|O
S1926|proportions|O
S1926|of|O
S1926|75|O
S1926|%|O
S1926|vs.|O
S1926|60|O
S1926|%|O
S1926|with|O
S1926|a|B-Sample_Size_Calculation_Alpha_Value
S1926|two-sided|I-Sample_Size_Calculation_Alpha_Value
S1926|type|I-Sample_Size_Calculation_Alpha_Value
S1926|I|I-Sample_Size_Calculation_Alpha_Value
S1926|error|I-Sample_Size_Calculation_Alpha_Value
S1926|rate|I-Sample_Size_Calculation_Alpha_Value
S1926|of|I-Sample_Size_Calculation_Alpha_Value
S1926|0·05|I-Sample_Size_Calculation_Alpha_Value
S1926|and|O
S1926|allowing|O
S1926|for|O
S1926|two|O
S1926|interim|O
S1926|efficacy|O
S1926|analyses|O
S1926|.|O
S6556|Study|O
S6556|participants|O
S6556|were|O
S6556|enrolled|O
S6556|in|O
S6556|25|B-Settings_Multicenter
S6556|sites|I-Settings_Multicenter
S6556|in|O
S6556|the|O
S6556|US|B-Settings_Location
S6556|from|O
S6556|January|O
S6556|and|O
S6556|March|O
S6556|2017|O
S6556|with|O
S6556|treatment-naive|O
S6556|choroidal|O
S6556|neovascularization|O
S6556|secondary|O
S6556|to|O
S6556|neovascular|O
S6556|age-related|O
S6556|macular|O
S6556|degeneration|O
S6556|and|O
S6556|best-corrected|O
S6556|visual|O
S6556|acuity|O
S6556|(|O
S6556|BCVA|O
S6556|)|O
S6556|Early|O
S6556|Treatment|O
S6556|Diabetic|O
S6556|Retinopathy|O
S6556|Study|O
S6556|letter|O
S6556|score|O
S6556|of|O
S6556|73|O
S6556|(|O
S6556|approximate|O
S6556|Snellen|O
S6556|equivalent|O
S6556|,|O
S6556|20/40|O
S6556|)|O
S6556|to|O
S6556|24|O
S6556|(|O
S6556|approximate|O
S6556|Snellen|O
S6556|equivalent|O
S6556|,|O
S6556|20/320|O
S6556|)|O
S6556|.|O
S6632|Of|O
S6632|71|B-Sample_Size_Actual_at_Outcome_Analysis
S6632|participants|O
S6632|,|O
S6632|64|O
S6632|(|O
S6632|90.1|O
S6632|%|O
S6632|)|O
S6632|attended|O
S6632|the|O
S6632|primary|O
S6632|end|O
S6632|point|O
S6632|week-40|O
S6632|visit|O
S6632|,|O
S6632|and|O
S6632|65|O
S6632|(|O
S6632|91.5|O
S6632|%|O
S6632|)|O
S6632|completed|O
S6632|the|O
S6632|study|O
S6632|through|O
S6632|week|O
S6632|52|O
S6632|.|O
S5295|Methods|O
S5295|In|O
S5295|this|O
S5295|randomized|O
S5295|,|O
S5295|open-label|B-Blinding_Open_Label
S5295|and|O
S5295|multi-centre|B-Settings_Multicenter
S5295|trial|O
S5295|conducted|O
S5295|in|O
S5295|the|O
S5295|USA|B-Settings_Location
S5295|,|O
S5295|patients|O
S5295|were|O
S5295|randomized|O
S5295|2:1|B-Randomization_Ratio
S5295|to|O
S5295|a|O
S5295|single|B-Design_Parallel_Group
S5295|dose|I-Design_Parallel_Group
S5295|of|I-Design_Parallel_Group
S5295|1000|I-Design_Parallel_Group
S5295|mg|I-Design_Parallel_Group
S5295|IIM|I-Design_Parallel_Group
S5295|or|I-Design_Parallel_Group
S5295|iron|I-Design_Parallel_Group
S5295|sucrose|I-Design_Parallel_Group
S5295|(|I-Design_Parallel_Group
S5295|IS|I-Design_Parallel_Group
S5295|)|I-Design_Parallel_Group
S5295|administered|O
S5295|as|O
S5295|200|O
S5295|mg|O
S5295|IV|O
S5295|injections|O
S5295|up|O
S5295|to|O
S5295|five|O
S5295|times|O
S5295|within|O
S5295|a|O
S5295|2-week|O
S5295|period|O
S5295|.|O
S4874|Statistical|O
S4874|Analysis|O
S4874|The|O
S4874|planned|O
S4874|sample|O
S4874|size|O
S4874|of|O
S4874|at|O
S4874|least|O
S4874|668|B-Sample_Size_Required
S4874|evaluable|O
S4874|participants|O
S4874|(|O
S4874|334|O
S4874|per|O
S4874|group|O
S4874|across|O
S4874|all|O
S4874|sites|O
S4874|)|O
S4874|provided|O
S4874|at|O
S4874|least|O
S4874|80|B-Sample_Size_Calculation_Power_Value
S4874|%|I-Sample_Size_Calculation_Power_Value
S4874|power|O
S4874|to|O
S4874|reject|O
S4874|the|O
S4874|null|O
S4874|hypothesis|O
S4874|that|O
S4874|the|O
S4874|proportion|O
S4874|of|O
S4874|participants|O
S4874|with|O
S4874|moderate-to-severe|O
S4874|injection-site|O
S4874|pain|O
S4874|after|O
S4874|aIIV3|O
S4874|is|O
S4874|inferior|O
S4874|to|O
S4874|HD-IIV3|O
S4874|during|O
S4874|days|O
S4874|1|O
S4874|to|O
S4874|8|O
S4874|(|O
S4874|US|O
S4874|Food|O
S4874|and|O
S4874|Drug|O
S4874|Administration|O
S4874|package|O
S4874|inserts|O
S4874|)|O
S4874|.|O
S766|Based|O
S766|on|O
S766|our|O
S766|sample|O
S766|size|O
S766|calculation|O
S766|,|O
S766|we|O
S766|planned|O
S766|to|O
S766|recruit|O
S766|and|O
S766|enroll|O
S766|a|O
S766|total|O
S766|of|O
S766|ninety-six|B-Sample_Size_Required
S766|women|I-Sample_Size_Required
S766|with|O
S766|equal|O
S766|allocation|O
S766|to|O
S766|the|O
S766|placebo|O
S766|and|O
S766|gabapentin|O
S766|groups|O
S766|.|O
S403|Eligible|O
S403|patients|O
S403|were|O
S403|randomised|O
S403|1:1|B-Randomization_Ratio
S403|to|O
S403|receive|O
S403|either|O
S403|filgotinib|B-Design_Parallel_Group
S403|or|I-Design_Parallel_Group
S403|lanraplenib|I-Design_Parallel_Group
S403|in|O
S403|a|O
S403|blinded|O
S403|fashion|O
S403|for|O
S403|up|O
S403|to|O
S403|52|O
S403|weeks|O
S403|.|O
S925|A|O
S925|sufficient|O
S925|number|O
S925|of|O
S925|participants|O
S925|were|O
S925|to|O
S925|be|O
S925|screened|O
S925|to|O
S925|randomise|O
S925|approximately|O
S925|130|B-Sample_Size_Required
S925|(|O
S925|65|O
S925|per|O
S925|group|O
S925|)|O
S925|,|O
S925|to|O
S925|ensure|O
S925|60|O
S925|evaluable|O
S925|participants|O
S925|per|O
S925|group|O
S925|completed|O
S925|the|O
S925|study|O
S925|.|O
S2734|After|O
S2734|a|O
S2734|2-week|O
S2734|screening|O
S2734|period|O
S2734|,|O
S2734|eligible|O
S2734|patients|O
S2734|were|O
S2734|randomly|O
S2734|assigned|O
S2734|in|O
S2734|a|O
S2734|1:1:1:1|B-Randomization_Ratio
S2734|ratio|O
S2734|to|O
S2734|one|O
S2734|of|O
S2734|four|O
S2734|treatment|O
S2734|groups|O
S2734|:|O
S2734|tenapanor|B-Design_Parallel_Group
S2734|5|I-Design_Parallel_Group
S2734|mg|I-Design_Parallel_Group
S2734|,|I-Design_Parallel_Group
S2734|20|I-Design_Parallel_Group
S2734|mg|I-Design_Parallel_Group
S2734|,|I-Design_Parallel_Group
S2734|or|I-Design_Parallel_Group
S2734|50|I-Design_Parallel_Group
S2734|mg|I-Design_Parallel_Group
S2734|twice|I-Design_Parallel_Group
S2734|daily|I-Design_Parallel_Group
S2734|(|I-Design_Parallel_Group
S2734|b.i.d|I-Design_Parallel_Group
S2734|.|I-Design_Parallel_Group
S5024|The|O
S5024|sample|O
S5024|size|O
S5024|required|O
S5024|for|O
S5024|the|O
S5024|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S5024|hypothesis|O
S5024|dictated|O
S5024|the|O
S5024|final|O
S5024|sample|O
S5024|size|O
S5024|for|O
S5024|the|O
S5024|trial|O
S5024|.|O
S6985|A|O
S6985|Phase|B-Design_Phase_3
S6985|3|I-Design_Phase_3
S6985|,|O
S6985|Randomized|O
S6985|,|O
S6985|Double-Blind|B-Blinding_Double_Blind
S6985|Study|O
S6985|Comparing|O
S6985|Tedizolid|O
S6985|Phosphate|O
S6985|and|O
S6985|Linezolid|O
S6985|for|O
S6985|Treatment|O
S6985|of|O
S6985|Ventilated|O
S6985|Gram-Positive|O
S6985|Hospital-Acquired|O
S6985|or|O
S6985|Ventilator-Associated|O
S6985|Bacterial|O
S6985|Pneumonia|O
S633|Sample|O
S633|size|O
S633|estimation|O
S633|On|O
S633|the|O
S633|basis|O
S633|of|O
S633|the|O
S633|results|O
S633|of|O
S633|our|O
S633|pilot|O
S633|study|O
S633|(|O
S633|ie|O
S633|,|O
S633|observed|O
S633|rates|O
S633|of|O
S633|0.56|O
S633|for|O
S633|death|O
S633|and|O
S633|0.33|O
S633|for|O
S633|tracheotomy|O
S633|at|O
S633|18|O
S633|months|O
S633|in|O
S633|the|O
S633|placebo|O
S633|group|O
S633|)|O
S633|,|O
S633|we|O
S633|estimated|O
S633|that|O
S633|we|O
S633|would|O
S633|need|O
S633|a|O
S633|sample|O
S633|size|O
S633|of|O
S633|203|B-Sample_Size_Required
S633|patients|O
S633|followed|O
S633|up|O
S633|for|O
S633|12|O
S633|months|O
S633|to|O
S633|give|O
S633|97|B-Sample_Size_Calculation_Power_Value
S633|%|I-Sample_Size_Calculation_Power_Value
S633|power|O
S633|to|O
S633|detect|O
S633|a|O
S633|significant|O
S633|difference|O
S633|between|O
S633|rhEPO|O
S633|and|O
S633|placebo|O
S633|corresponding|O
S633|to|O
S633|a|O
S633|67|O
S633|%|O
S633|relative|O
S633|reduction|O
S633|of|O
S633|risk|O
S633|of|O
S633|death|O
S633|and|O
S633|74|B-Sample_Size_Calculation_Power_Value
S633|%|I-Sample_Size_Calculation_Power_Value
S633|power|O
S633|to|O
S633|detect|O
S633|a|O
S633|70|O
S633|%|O
S633|relative|O
S633|reduction|O
S633|of|O
S633|risk|O
S633|of|O
S633|respiratory|O
S633|events|O
S633|(|O
S633|tracheotomy|O
S633|or|O
S633|>|O
S633|23|O
S633|h|O
S633|NIV|O
S633|)|O
S633|,|O
S633|with|O
S633|a|B-Sample_Size_Calculation_Alpha_Value
S633|two-sided|I-Sample_Size_Calculation_Alpha_Value
S633|type|I-Sample_Size_Calculation_Alpha_Value
S633|1|I-Sample_Size_Calculation_Alpha_Value
S633|error|I-Sample_Size_Calculation_Alpha_Value
S633|of|I-Sample_Size_Calculation_Alpha_Value
S633|5|I-Sample_Size_Calculation_Alpha_Value
S633|%|I-Sample_Size_Calculation_Alpha_Value
S633|and|O
S633|given|O
S633|an|O
S633|anticipated|O
S633|dropout|O
S633|rate|O
S633|of|O
S633|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S633|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S633|.|O
S6123|Assuming|O
S6123|a|O
S6123|2-sided|B-Sample_Size_Calculation_Alpha_Value
S6123|type|I-Sample_Size_Calculation_Alpha_Value
S6123|I|I-Sample_Size_Calculation_Alpha_Value
S6123|error|I-Sample_Size_Calculation_Alpha_Value
S6123|rate|I-Sample_Size_Calculation_Alpha_Value
S6123|of|I-Sample_Size_Calculation_Alpha_Value
S6123|5|I-Sample_Size_Calculation_Alpha_Value
S6123|%|I-Sample_Size_Calculation_Alpha_Value
S6123|and|O
S6123|a|O
S6123|standard|O
S6123|deviation|O
S6123|(|O
S6123|SD|O
S6123|)|O
S6123|of|O
S6123|3.5|O
S6123|mm|O
S6123|Hg|O
S6123|,|O
S6123|it|O
S6123|was|O
S6123|determined|O
S6123|that|O
S6123|50|O
S6123|subjects|O
S6123|per|O
S6123|treatment|O
S6123|arm|O
S6123|(|O
S6123|total|O
S6123|of|O
S6123|100|B-Sample_Size_Required
S6123|subjects|O
S6123|)|O
S6123|would|O
S6123|have|O
S6123|an|O
S6123|80|B-Sample_Size_Calculation_Power_Value
S6123|%|I-Sample_Size_Calculation_Power_Value
S6123|power|O
S6123|to|O
S6123|detect|O
S6123|a|O
S6123|2.0|O
S6123|mm|O
S6123|Hg|O
S6123|between-treatment|O
S6123|difference|O
S6123|.|O
S1905|Women|O
S1905|were|O
S1905|then|O
S1905|randomised|O
S1905|to|O
S1905|receive|O
S1905|raltegravir|B-Design_Parallel_Group
S1905|400|I-Design_Parallel_Group
S1905|mg|I-Design_Parallel_Group
S1905|twice|I-Design_Parallel_Group
S1905|a|I-Design_Parallel_Group
S1905|day|I-Design_Parallel_Group
S1905|or|I-Design_Parallel_Group
S1905|efavirenz|I-Design_Parallel_Group
S1905|600|I-Design_Parallel_Group
S1905|mg|I-Design_Parallel_Group
S1905|each|I-Design_Parallel_Group
S1905|night|I-Design_Parallel_Group
S1905|in|O
S1905|addition|O
S1905|to|O
S1905|lamivudine|O
S1905|150|O
S1905|mg/zidovudine|O
S1905|300|O
S1905|mg|O
S1905|twice|O
S1905|a|O
S1905|day|O
S1905|(|O
S1905|or|O
S1905|an|O
S1905|alternative|O
S1905|,|O
S1905|locally|O
S1905|supplied|O
S1905|NRTI|O
S1905|regimen|O
S1905|)|O
S1905|from|O
S1905|study|O
S1905|entry|O
S1905|through|O
S1905|delivery|O
S1905|.|O
S7464|Statistical|O
S7464|Analyses|O
S7464|Assuming|O
S7464|a|O
S7464|change|O
S7464|from|O
S7464|baseline|O
S7464|in|O
S7464|mean|O
S7464|MMD|O
S7464|over|O
S7464|months|O
S7464|4‐6|O
S7464|of|O
S7464|–1.12|O
S7464|days|O
S7464|and|O
S7464|–1.30|O
S7464|days|O
S7464|for|O
S7464|the|O
S7464|70‐|O
S7464|and|O
S7464|140‐mg|O
S7464|dose|O
S7464|groups|O
S7464|,|O
S7464|respectively|O
S7464|,|O
S7464|vs|O
S7464|placebo|O
S7464|and|O
S7464|a|O
S7464|common|O
S7464|standard|O
S7464|deviation|O
S7464|of|O
S7464|2.8|O
S7464|days|O
S7464|(|O
S7464|based|O
S7464|on|O
S7464|a|O
S7464|clinical|O
S7464|study|O
S7464|of|O
S7464|topiramate|O
S7464|in|O
S7464|Japanese|O
S7464|patients|O
S7464|with|O
S7464|migraine|O
S7464|,|O
S7464|NCT01081795|O
S7464|)|O
S7464|,|O
S7464|the|O
S7464|planned|O
S7464|sample|O
S7464|size|O
S7464|was|O
S7464|131|B-Sample_Size_Target
S7464|patients|I-Sample_Size_Target
S7464|for|I-Sample_Size_Target
S7464|the|I-Sample_Size_Target
S7464|placebo|I-Sample_Size_Target
S7464|,|I-Sample_Size_Target
S7464|and|I-Sample_Size_Target
S7464|erenumab|I-Sample_Size_Target
S7464|70‐|I-Sample_Size_Target
S7464|and|I-Sample_Size_Target
S7464|140‐mg|I-Sample_Size_Target
S7464|dose|I-Sample_Size_Target
S7464|groups|I-Sample_Size_Target
S7464|,|O
S7464|providing|O
S7464|90|B-Sample_Size_Calculation_Power_Value
S7464|%|I-Sample_Size_Calculation_Power_Value
S7464|and|O
S7464|96|B-Sample_Size_Calculation_Power_Value
S7464|%|I-Sample_Size_Calculation_Power_Value
S7464|power|O
S7464|,|O
S7464|respectively|O
S7464|,|O
S7464|for|O
S7464|a|O
S7464|2‐sided|B-Sample_Size_Calculation_Alpha_Value
S7464|test|I-Sample_Size_Calculation_Alpha_Value
S7464|with|I-Sample_Size_Calculation_Alpha_Value
S7464|significance|I-Sample_Size_Calculation_Alpha_Value
S7464|level|I-Sample_Size_Calculation_Alpha_Value
S7464|of|I-Sample_Size_Calculation_Alpha_Value
S7464|.05|I-Sample_Size_Calculation_Alpha_Value
S7464|to|O
S7464|demonstrate|O
S7464|the|O
S7464|superiority|B-Design_Comparative_Intent_Superiority
S7464|of|O
S7464|erenumab|O
S7464|.|O
S2072|Randomisation|O
S2072|was|O
S2072|balanced|O
S2072|by|O
S2072|permuted|O
S2072|blocks|B-Randomization_Type_Block
S2072|and|O
S2072|stratified|B-Randomization_Type_Stratified
S2072|by|O
S2072|day|B-Randomization_Stratified_Criteria
S2072|−1|I-Randomization_Stratified_Criteria
S2072|body|I-Randomization_Stratified_Criteria
S2072|weight|I-Randomization_Stratified_Criteria
S2072|(|I-Randomization_Stratified_Criteria
S2072|≥80|I-Randomization_Stratified_Criteria
S2072|kg|I-Randomization_Stratified_Criteria
S2072|vs.|I-Randomization_Stratified_Criteria
S2072|<|I-Randomization_Stratified_Criteria
S2072|80|I-Randomization_Stratified_Criteria
S2072|kg|I-Randomization_Stratified_Criteria
S2072|)|I-Randomization_Stratified_Criteria
S2072|,|O
S2072|sex|B-Randomization_Stratified_Criteria
S2072|(|I-Randomization_Stratified_Criteria
S2072|male|I-Randomization_Stratified_Criteria
S2072|vs.|I-Randomization_Stratified_Criteria
S2072|female|I-Randomization_Stratified_Criteria
S2072|)|I-Randomization_Stratified_Criteria
S2072|and|O
S2072|study|B-Randomization_Stratified_Criteria
S2072|centre|I-Randomization_Stratified_Criteria
S2072|.|O
S4329|Participants|O
S4329|with|O
S4329|CHB|O
S4329|infection|O
S4329|≥6|O
S4329|months|O
S4329|and|O
S4329|serum|O
S4329|HBsAg|O
S4329|≥50|O
S4329|IU|O
S4329|ml−1|O
S4329|were|O
S4329|enrolled|O
S4329|from|O
S4329|seven|O
S4329|centers|O
S4329|across|O
S4329|Hong|O
S4329|Kong|O
S4329|and|O
S4329|the|O
S4329|Republic|O
S4329|of|O
S4329|Korea|O
S4329|and|O
S4329|randomized|O
S4329|(|O
S4329|3:1|B-Randomization_Ratio
S4329|within|I-Randomization_Ratio
S4329|each|I-Randomization_Ratio
S4329|dose|I-Randomization_Ratio
S4329|cohort|I-Randomization_Ratio
S4329|)|O
S4329|to|O
S4329|receive|O
S4329|bepirovirsen|B-Design_Parallel_Group
S4329|or|I-Design_Parallel_Group
S4329|placebo|I-Design_Parallel_Group
S4329|via|O
S4329|subcutaneous|O
S4329|injection|O
S4329|twice|O
S4329|weekly|O
S4329|during|O
S4329|weeks|O
S4329|1|O
S4329|and|O
S4329|2|O
S4329|(|O
S4329|days|O
S4329|1|O
S4329|,|O
S4329|4|O
S4329|,|O
S4329|8|O
S4329|and|O
S4329|11|O
S4329|)|O
S4329|and|O
S4329|once|O
S4329|weekly|O
S4329|during|O
S4329|weeks|O
S4329|3|O
S4329|and|O
S4329|4|O
S4329|(|O
S4329|days|O
S4329|15|O
S4329|and|O
S4329|22|O
S4329|)|O
S4329|.|O
S6065|Methods|O
S6065|:|O
S6065|Randomized|O
S6065|subjects|O
S6065|(|O
S6065|1:1|B-Randomization_Ratio
S6065|)|O
S6065|received|O
S6065|omidenepag|O
S6065|isopropyl|O
S6065|0.002|O
S6065|%|O
S6065|QD|O
S6065|(|O
S6065|n=50|O
S6065|)|O
S6065|or|O
S6065|BID|O
S6065|(|O
S6065|n=48|O
S6065|)|O
S6065|for|O
S6065|6|O
S6065|weeks|O
S6065|(|O
S6065|after|O
S6065|a|O
S6065|≤4-week|O
S6065|washout|O
S6065|period|O
S6065|)|O
S6065|.|O
S4892|For|O
S4892|full|O
S4892|analysis|O
S4892|population|O
S4892|1|O
S4892|,|O
S4892|378|B-Sample_Size_Actual_at_Outcome_Analysis
S4892|received|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|aIIV3|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|and|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|377|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|received|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|HD-IIV3|I-Sample_Size_Actual_at_Outcome_Analysis
S4892|because|O
S4892|2|O
S4892|participants|O
S4892|were|O
S4892|missing|O
S4892|symptom|O
S4892|diary|O
S4892|data|O
S4892|(|O
S4892|Figure|O
S4892|1|O
S4892|)|O
S4892|.|O
S5538|By|O
S5538|the|O
S5538|end|O
S5538|of|O
S5538|our|O
S5538|trial|O
S5538|2616|B-Sample_Size_Actual_at_Outcome_Analysis
S5538|of|O
S5538|the|O
S5538|3046|B-Sample_Size_Actual_at_Enrollment
S5538|recruited|O
S5538|children|O
S5538|were|O
S5538|present|O
S5538|in|O
S5538|our|O
S5538|study|O
S5538|and|O
S5538|17|O
S5538|had|O
S5538|died|O
S5538|.|O
S6097|METHODS|O
S6097|Study|O
S6097|Design|O
S6097|This|O
S6097|was|O
S6097|a|O
S6097|phase|B-Design_Phase_2
S6097|2|I-Design_Phase_2
S6097|,|O
S6097|randomized|O
S6097|,|O
S6097|double-masked|B-Blinding_Double_Blind
S6097|,|O
S6097|multicenter|B-Settings_Multicenter
S6097|,|O
S6097|parallel-arm|B-Design_Parallel_Group
S6097|study|O
S6097|assessing|O
S6097|the|O
S6097|safety|O
S6097|and|O
S6097|efficacy|O
S6097|of|O
S6097|omidenepag|O
S6097|isopropyl|O
S6097|0.002|O
S6097|%|O
S6097|QD|O
S6097|and|O
S6097|BID|O
S6097|in|O
S6097|subjects|O
S6097|with|O
S6097|POAG|O
S6097|or|O
S6097|OHT|O
S6097|(|O
S6097|NCT03858894|O
S6097|)|O
S6097|.|O
S7865|Interventions|O
S7865|Intensive|B-Design_Parallel_Group
S7865|systolic|I-Design_Parallel_Group
S7865|blood|I-Design_Parallel_Group
S7865|pressure|I-Design_Parallel_Group
S7865|target|I-Design_Parallel_Group
S7865|(|I-Design_Parallel_Group
S7865|<|I-Design_Parallel_Group
S7865|130|I-Design_Parallel_Group
S7865|mm|I-Design_Parallel_Group
S7865|Hg|I-Design_Parallel_Group
S7865|or|I-Design_Parallel_Group
S7865|10|I-Design_Parallel_Group
S7865|mm|I-Design_Parallel_Group
S7865|Hg|I-Design_Parallel_Group
S7865|reduction|I-Design_Parallel_Group
S7865|from|I-Design_Parallel_Group
S7865|baseline|I-Design_Parallel_Group
S7865|if|I-Design_Parallel_Group
S7865|this|I-Design_Parallel_Group
S7865|was|I-Design_Parallel_Group
S7865|<|I-Design_Parallel_Group
S7865|140|I-Design_Parallel_Group
S7865|mm|I-Design_Parallel_Group
S7865|Hg|I-Design_Parallel_Group
S7865|)|I-Design_Parallel_Group
S7865|or|I-Design_Parallel_Group
S7865|standard|I-Design_Parallel_Group
S7865|target|I-Design_Parallel_Group
S7865|(|I-Design_Parallel_Group
S7865|<|I-Design_Parallel_Group
S7865|140|I-Design_Parallel_Group
S7865|mm|I-Design_Parallel_Group
S7865|Hg|I-Design_Parallel_Group
S7865|)|I-Design_Parallel_Group
S7865|.|O
S7116|Effect|O
S7116|of|O
S7116|intravenous|O
S7116|β-2|O
S7116|agonist|O
S7116|treatment|O
S7116|on|O
S7116|clinical|O
S7116|outcomes|O
S7116|in|O
S7116|acute|O
S7116|respiratory|O
S7116|distress|O
S7116|syndrome|O
S7116|(|O
S7116|BALTI-2|O
S7116|)|O
S7116|:|O
S7116|a|O
S7116|multicentre|B-Settings_Multicenter
S7116|,|O
S7116|randomised|O
S7116|controlled|O
S7116|trial|O
S3652|Results|O
S3652|In|O
S3652|total|O
S3652|,|O
S3652|17|B-Sample_Size_Actual_at_Outcome_Analysis
S3652|participants|O
S3652|completed|O
S3652|the|O
S3652|study|O
S3652|.|O
S8079|Randomization|O
S8079|to|O
S8079|treatment|O
S8079|was|O
S8079|stratified|B-Randomization_Type_Stratified
S8079|by|O
S8079|age|B-Randomization_Stratified_Criteria
S8079|(|I-Randomization_Stratified_Criteria
S8079|6–8|I-Randomization_Stratified_Criteria
S8079|and|I-Randomization_Stratified_Criteria
S8079|9–12|I-Randomization_Stratified_Criteria
S8079|years|I-Randomization_Stratified_Criteria
S8079|)|I-Randomization_Stratified_Criteria
S8079|.|O
S561|The|O
S561|randomisation|O
S561|sequence|O
S561|was|O
S561|computer-generated|B-Randomization_Sequence_Generation_Method
S561|by|O
S561|blocks|B-Randomization_Type_Block
S561|,|O
S561|stratified|B-Randomization_Type_Stratified
S561|by|O
S561|centre|B-Randomization_Stratified_Criteria
S561|,|O
S561|disease|B-Randomization_Stratified_Criteria
S561|severity|I-Randomization_Stratified_Criteria
S561|(|I-Randomization_Stratified_Criteria
S561|ALSFRS-R|I-Randomization_Stratified_Criteria
S561|cut-off|I-Randomization_Stratified_Criteria
S561|score|I-Randomization_Stratified_Criteria
S561|of|I-Randomization_Stratified_Criteria
S561|33|I-Randomization_Stratified_Criteria
S561|)|I-Randomization_Stratified_Criteria
S561|and|O
S561|onset|B-Randomization_Stratified_Criteria
S561|(|I-Randomization_Stratified_Criteria
S561|spinal|I-Randomization_Stratified_Criteria
S561|or|I-Randomization_Stratified_Criteria
S561|bulbar|I-Randomization_Stratified_Criteria
S561|)|I-Randomization_Stratified_Criteria
S561|.|O
S5808|Methods|O
S5808|Trial|O
S5808|design|O
S5808|A|O
S5808|phase|B-Design_Phase_2
S5808|2a|I-Design_Phase_2
S5808|,|O
S5808|multicenter|B-Settings_Multicenter
S5808|,|O
S5808|randomized|O
S5808|,|O
S5808|double-blind|B-Blinding_Double_Blind
S5808|,|O
S5808|placebo-controlled|O
S5808|trial|O
S5808|of|O
S5808|subcutaneous|O
S5808|AMG|O
S5808|301|O
S5808|was|O
S5808|undertaken|O
S5808|in|O
S5808|adults|O
S5808|with|O
S5808|CM|O
S5808|or|O
S5808|EM|O
S5808|who|O
S5808|were|O
S5808|considered|O
S5808|eligible|O
S5808|for|O
S5808|preventive|O
S5808|treatment|O
S5808|and|O
S5808|fulfilled|O
S5808|eligibility|O
S5808|criteria|O
S5808|(|O
S5808|more|O
S5808|detailed|O
S5808|eligibility|O
S5808|criteria|O
S5808|are|O
S5808|provided|O
S5808|in|O
S5808|the|O
S5808|Patients|O
S5808|section|O
S5808|below|O
S5808|;|O
S5808|ClinicalTrials.gov|O
S5808|:|O
S5808|NCT03238781|O
S5808|)|O
S5808|.|O
S4200|This|O
S4200|phase|B-Design_Phase_2
S4200|2|I-Design_Phase_2
S4200|study|O
S4200|evaluated|O
S4200|safety|O
S4200|,|O
S4200|tolerability|O
S4200|,|O
S4200|and|O
S4200|immunogenicity|O
S4200|of|O
S4200|PCV20|O
S4200|in|O
S4200|adults|O
S4200|without|O
S4200|prior|O
S4200|pneumococcal|O
S4200|vaccination|O
S4200|.|O
S1285|Patients|O
S1285|with|O
S1285|moderate|O
S1285|to|O
S1285|severe|O
S1285|RA|O
S1285|despite|O
S1285|methotrexate|O
S1285|therapy|O
S1285|were|O
S1285|randomised|O
S1285|in|O
S1285|a|O
S1285|1:1|B-Randomization_Ratio
S1285|ratio|O
S1285|to|O
S1285|receive|O
S1285|either|O
S1285|SB2|O
S1285|or|O
S1285|INF|O
S1285|of|O
S1285|3|O
S1285|mg/kg|O
S1285|.|O
S3912|Within|O
S3912|each|O
S3912|investigation|O
S3912|site|O
S3912|,|O
S3912|patients|O
S3912|were|O
S3912|randomised|O
S3912|in|O
S3912|a|O
S3912|1:1:1:1|B-Randomization_Ratio
S3912|ratio|O
S3912|to|O
S3912|once-daily|B-Design_Parallel_Group
S3912|treatment|I-Design_Parallel_Group
S3912|with|I-Design_Parallel_Group
S3912|placebo|I-Design_Parallel_Group
S3912|or|I-Design_Parallel_Group
S3912|ponesimod|I-Design_Parallel_Group
S3912|10|I-Design_Parallel_Group
S3912|,|I-Design_Parallel_Group
S3912|20|I-Design_Parallel_Group
S3912|or|I-Design_Parallel_Group
S3912|40|I-Design_Parallel_Group
S3912|mg|I-Design_Parallel_Group
S3912|for|O
S3912|24|O
S3912|weeks|O
S3912|.|O
S8228|Design|O
S8228|:|O
S8228|Randomized|O
S8228|double-blind|B-Blinding_Double_Blind
S8228|placebo-controlled|O
S8228|pilot|O
S8228|trial|O
S8228|.|O
S645|Results|O
S645|Between|O
S645|August|O
S645|2010|O
S645|and|O
S645|November|O
S645|2012|O
S645|,|O
S645|208|B-Sample_Size_Actual_at_Enrollment
S645|of|O
S645|545|O
S645|eligible|O
S645|patients|O
S645|(|O
S645|38|O
S645|%|O
S645|)|O
S645|were|O
S645|randomly|O
S645|allocated|O
S645|to|O
S645|the|O
S645|treatment|O
S645|arms|O
S645|(|O
S645|104|O
S645|in|O
S645|the|O
S645|rhEPO|O
S645|arm|O
S645|and|O
S645|104|O
S645|in|O
S645|the|O
S645|placebo|O
S645|arm|O
S645|;|O
S645|figure|O
S645|1|O
S645|)|O
S645|.|O
S6219|In|O
S6219|the|O
S6219|double-blind|B-Blinding_Double_Blind
S6219|phase|O
S6219|of|O
S6219|this|O
S6219|randomized|B-Randomization_Type_Simple
S6219|,|O
S6219|controlled|O
S6219|trial|O
S6219|,|O
S6219|we|O
S6219|compared|O
S6219|the|O
S6219|efficacy|O
S6219|and|O
S6219|safety|O
S6219|of|O
S6219|400|O
S6219|vs.|O
S6219|240|O
S6219|U|O
S6219|onabotulinumtoxinA|O
S6219|in|O
S6219|patients|O
S6219|with|O
S6219|post-stroke|O
S6219|upper|O
S6219|limb|O
S6219|spasticity|O
S6219|.|O
S5494|By|O
S5494|use|O
S5494|of|O
S5494|the|O
S5494|randomisation|O
S5494|list|O
S5494|,|O
S5494|a|O
S5494|pharmacist|O
S5494|in|O
S5494|the|O
S5494|Department|O
S5494|of|O
S5494|Pharmacy|O
S5494|,|O
S5494|Aga|O
S5494|Khan|O
S5494|University|O
S5494|Hospital|O
S5494|,|O
S5494|Karachi|O
S5494|prepared|O
S5494|100|O
S5494|000|O
S5494|IU|O
S5494|(|O
S5494|2·5|O
S5494|mg|O
S5494|)|O
S5494|of|O
S5494|vitamin|O
S5494|D3|O
S5494|(|O
S5494|cholecalciferol|O
S5494|)|O
S5494|in|O
S5494|olive|O
S5494|oil|O
S5494|(|O
S5494|Sinochem|O
S5494|Ningbo|O
S5494|Laboratory|O
S5494|,|O
S5494|China|O
S5494|)|O
S5494|or|O
S5494|placebo|O
S5494|(|O
S5494|olive|O
S5494|oil|O
S5494|)|O
S5494|in|O
S5494|sealed|B-Allocation_Concealment_Method
S5494|2|I-Allocation_Concealment_Method
S5494|mL|I-Allocation_Concealment_Method
S5494|plastic|I-Allocation_Concealment_Method
S5494|syringes|I-Allocation_Concealment_Method
S5494|labelled|I-Allocation_Concealment_Method
S5494|with|I-Allocation_Concealment_Method
S5494|the|I-Allocation_Concealment_Method
S5494|unique|I-Allocation_Concealment_Method
S5494|identification|I-Allocation_Concealment_Method
S5494|numbers|I-Allocation_Concealment_Method
S5494|.|O
S4961|Precis|O
S4961|In|O
S4961|a|O
S4961|6-month|O
S4961|multicenter|B-Settings_Multicenter
S4961|,|O
S4961|randomized|O
S4961|,|O
S4961|comparative|O
S4961|trial|O
S4961|,|O
S4961|both|O
S4961|intravitreal|O
S4961|triamcinolone|O
S4961|and|O
S4961|intravitreal|O
S4961|dexamethasone|O
S4961|implant|O
S4961|were|O
S4961|superior|B-Design_Comparative_Intent_Superiority
S4961|to|O
S4961|periocular|O
S4961|triamcinolone|O
S4961|for|O
S4961|treating|O
S4961|uveitic|O
S4961|macular|O
S4961|edema|O
S4961|.|O
S3578|Results|O
S3578|Baseline|O
S3578|characteristics|O
S3578|As|O
S3578|depicted|O
S3578|in|O
S3578|the|O
S3578|trial|O
S3578|and|O
S3578|participant|O
S3578|flowchart|O
S3578|,|O
S3578|a|O
S3578|total|O
S3578|of|O
S3578|1009|B-Sample_Size_Actual_at_Enrollment
S3578|women|I-Sample_Size_Actual_at_Enrollment
S3578|were|O
S3578|randomised|O
S3578|and|O
S3578|exposed|O
S3578|,|O
S3578|of|O
S3578|whom|O
S3578|499|O
S3578|were|O
S3578|treated|O
S3578|with|O
S3578|follitropin|O
S3578|delta|O
S3578|in|O
S3578|its|O
S3578|individualised|O
S3578|fixed-dose|O
S3578|regimen|O
S3578|and|O
S3578|510|O
S3578|with|O
S3578|follitropin|O
S3578|alfa|O
S3578|in|O
S3578|a|O
S3578|conventional|O
S3578|and|O
S3578|adjustable|O
S3578|dosing|O
S3578|regimen|O
S3578|(|O
S3578|Fig|O
S3578|.|O
S406|Four|B-Sample_Size_Actual_at_Outcome_Analysis
S406|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S406|in|I-Sample_Size_Actual_at_Outcome_Analysis
S406|the|I-Sample_Size_Actual_at_Outcome_Analysis
S406|filgotinib|I-Sample_Size_Actual_at_Outcome_Analysis
S406|group|I-Sample_Size_Actual_at_Outcome_Analysis
S406|and|I-Sample_Size_Actual_at_Outcome_Analysis
S406|one|I-Sample_Size_Actual_at_Outcome_Analysis
S406|patient|I-Sample_Size_Actual_at_Outcome_Analysis
S406|in|I-Sample_Size_Actual_at_Outcome_Analysis
S406|the|I-Sample_Size_Actual_at_Outcome_Analysis
S406|lanraplenib|I-Sample_Size_Actual_at_Outcome_Analysis
S406|group|I-Sample_Size_Actual_at_Outcome_Analysis
S406|completed|O
S406|week|O
S406|16|O
S406|.|O
S7412|The|O
S7412|primary|O
S7412|endpoint|O
S7412|was|O
S7412|change|O
S7412|from|O
S7412|baseline|O
S7412|in|O
S7412|mean|O
S7412|monthly|O
S7412|migraine|O
S7412|days|O
S7412|over|O
S7412|months|O
S7412|4‐6|O
S7412|of|O
S7412|the|O
S7412|double‐blind|B-Blinding_Double_Blind
S7412|treatment|O
S7412|phase|O
S7412|.|O
S5363|Of|O
S5363|the|O
S5363|1538|O
S5363|patients|O
S5363|enrolled|O
S5363|,|O
S5363|1447|B-Sample_Size_Actual_at_Outcome_Analysis
S5363|(|O
S5363|94|O
S5363|%|O
S5363|)|O
S5363|completed|O
S5363|the|O
S5363|trial|O
S5363|.|O
S3287|The|O
S3287|target|O
S3287|sample|O
S3287|size|O
S3287|of|O
S3287|the|O
S3287|initial|O
S3287|phase|O
S3287|was|O
S3287|determined|O
S3287|to|O
S3287|be|O
S3287|about|O
S3287|90|B-Sample_Size_Target
S3287|participants|O
S3287|to|O
S3287|allow|O
S3287|reasonably|O
S3287|precise|O
S3287|estimates|O
S3287|of|O
S3287|the|O
S3287|variables|O
S3287|for|O
S3287|the|O
S3287|main|O
S3287|trial|O
S3287|.|O
S1567|Methods|O
S1567|Randomised|O
S1567|,|O
S1567|multicentre|B-Settings_Multicenter
S1567|,|O
S1567|two-part|O
S1567|,|O
S1567|phase|B-Design_Phase_3
S1567|III|I-Design_Phase_3
S1567|trial|O
S1567|(|O
S1567|24-week|O
S1567|double-blind|B-Blinding_Double_Blind
S1567|,|O
S1567|80-week|O
S1567|open-label|B-Blinding_Open_Label
S1567|)|O
S1567|,|O
S1567|MEASURE|O
S1567|,|O
S1567|evaluated|O
S1567|lipid|O
S1567|and|O
S1567|lipoprotein|O
S1567|levels|O
S1567|,|O
S1567|high-density|O
S1567|lipoprotein|O
S1567|(|O
S1567|HDL|O
S1567|)|O
S1567|particle|O
S1567|composition|O
S1567|,|O
S1567|markers|O
S1567|of|O
S1567|coagulation|O
S1567|,|O
S1567|thrombosis|O
S1567|and|O
S1567|vascular|O
S1567|function|O
S1567|by|O
S1567|pulse|O
S1567|wave|O
S1567|velocity|O
S1567|(|O
S1567|PWV|O
S1567|)|O
S1567|in|O
S1567|132|B-Sample_Size_Actual_at_Enrollment
S1567|patients|O
S1567|with|O
S1567|RA|O
S1567|who|O
S1567|received|O
S1567|TCZ|B-Design_Parallel_Group
S1567|or|I-Design_Parallel_Group
S1567|placebo|I-Design_Parallel_Group
S1567|.|O
S7757|At|O
S7757|the|O
S7757|start|O
S7757|of|O
S7757|the|O
S7757|treatment|O
S7757|period|O
S7757|,|O
S7757|participants|O
S7757|were|O
S7757|randomized|O
S7757|1:1|B-Randomization_Ratio
S7757|to|O
S7757|double-blind|B-Blinding_Double_Blind
S7757|treatment|O
S7757|with|O
S7757|either|O
S7757|faster|O
S7757|aspart|O
S7757|or|O
S7757|IAsp|O
S7757|delivered|O
S7757|in|O
S7757|a|O
S7757|basal-bolus|O
S7757|regimen|O
S7757|with|O
S7757|once-daily|O
S7757|insulin|O
S7757|degludec|O
S7757|with|O
S7757|or|O
S7757|without|O
S7757|metformin|O
S7757|.|O
S405|Results|O
S405|Nine|B-Sample_Size_Actual_at_Enrollment
S405|patients|O
S405|were|O
S405|randomised|O
S405|to|O
S405|receive|O
S405|filgotinib|O
S405|(|O
S405|n=5|O
S405|)|O
S405|or|O
S405|lanraplenib|O
S405|(|O
S405|n=4|O
S405|)|O
S405|.|O
S6691|Evolocumab|O
S6691|vs.|O
S6691|Ezetimibe|O
S6691|in|O
S6691|Statin-Intolerant|O
S6691|Hyperlipidemic|O
S6691|Japanese|B-Settings_Location
S6691|Patients|O
S6691|:|O
S6691|Phase|B-Design_Phase_3
S6691|3|I-Design_Phase_3
S6691|GAUSS-4|O
S6691|Trial|O
S2070|Subjects|O
S2070|were|O
S2070|randomised|O
S2070|(|O
S2070|1:1|B-Randomization_Ratio
S2070|)|O
S2070|to|O
S2070|receive|O
S2070|CT‐P17|O
S2070|AI|O
S2070|or|O
S2070|CT‐P17|O
S2070|PFS|O
S2070|(|O
S2070|day|O
S2070|1|O
S2070|)|O
S2070|followed|O
S2070|by|O
S2070|PK|O
S2070|,|O
S2070|safety|O
S2070|and|O
S2070|immunogenicity|O
S2070|assessment|O
S2070|over|O
S2070|the|O
S2070|10‐week|O
S2070|study|O
S2070|period|O
S2070|(|O
S2070|until|O
S2070|end‐of‐study|O
S2070|visit|O
S2070|[|O
S2070|day|O
S2070|71|O
S2070|]|O
S2070|)|O
S2070|.|O
S1782|RESULTS|O
S1782|PARTICIPANTS|O
S1782|Of|O
S1782|the|O
S1782|112|O
S1782|potential|O
S1782|participants|O
S1782|who|O
S1782|were|O
S1782|screened|O
S1782|for|O
S1782|eligibility|O
S1782|,|O
S1782|76|B-Sample_Size_Actual_at_Enrollment
S1782|underwent|O
S1782|randomization|O
S1782|—|O
S1782|44|O
S1782|to|O
S1782|the|O
S1782|teplizumab|O
S1782|group|O
S1782|and|O
S1782|32|O
S1782|to|O
S1782|the|O
S1782|placebo|O
S1782|group|O
S1782|(|O
S1782|Fig|O
S1782|.|O
S3285|This|O
S3285|would|O
S3285|give|O
S3285|80|B-Sample_Size_Calculation_Power_Value
S3285|%|I-Sample_Size_Calculation_Power_Value
S3285|power|O
S3285|,|O
S3285|α|O
S3285|0.05|B-Sample_Size_Calculation_Alpha_Value
S3285|,|O
S3285|to|O
S3285|show|O
S3285|a|O
S3285|reduction|O
S3285|in|O
S3285|the|O
S3285|primary|O
S3285|composite|O
S3285|endpoint|O
S3285|(|O
S3285|fetal|O
S3285|death|O
S3285|or|O
S3285|severe|O
S3285|morbidity|O
S3285|)|O
S3285|from|O
S3285|6|O
S3285|%|O
S3285|to|O
S3285|3|O
S3285|%|O
S3285|.|O
S5608|Methods|O
S5608|This|O
S5608|was|O
S5608|a|O
S5608|randomized|O
S5608|,|O
S5608|multi-center|B-Settings_Multicenter
S5608|,|O
S5608|double-blind|B-Blinding_Double_Blind
S5608|,|O
S5608|placebo-controlled|O
S5608|clinical|O
S5608|trial|O
S5608|conducted|O
S5608|in|O
S5608|21|B-Settings_Multicenter
S5608|centers|I-Settings_Multicenter
S5608|across|O
S5608|China|B-Settings_Location
S5608|.|O
S1458|Methods|O
S1458|Study|O
S1458|design|O
S1458|GO-DACT|O
S1458|was|O
S1458|a|O
S1458|multicentre|B-Settings_Multicenter
S1458|,|O
S1458|investigator-initiated|O
S1458|,|O
S1458|randomised|O
S1458|,|O
S1458|double-blind|B-Blinding_Double_Blind
S1458|,|O
S1458|placebo-controlled|O
S1458|,|O
S1458|phase|B-Design_Phase_3
S1458|3b|I-Design_Phase_3
S1458|trial|O
S1458|of|O
S1458|golimumab|B-Design_Parallel_Group
S1458|plus|I-Design_Parallel_Group
S1458|MTX|I-Design_Parallel_Group
S1458|versus|I-Design_Parallel_Group
S1458|placebo|I-Design_Parallel_Group
S1458|plus|I-Design_Parallel_Group
S1458|MTX|I-Design_Parallel_Group
S1458|,|O
S1458|in|O
S1458|MTX-naive|O
S1458|and|O
S1458|bDMARDs-naive|O
S1458|patients|O
S1458|with|O
S1458|PsA|O
S1458|and|O
S1458|active|O
S1458|dactylitis|O
S1458|.|O
S2927|Using|O
S2927|a|O
S2927|permuted|O
S2927|block|B-Randomization_Type_Block
S2927|randomization|I-Randomization_Type_Block
S2927|method|O
S2927|,|O
S2927|children|O
S2927|were|O
S2927|assigned|O
S2927|in|O
S2927|a|O
S2927|2:1|B-Randomization_Ratio
S2927|ratio|O
S2927|to|O
S2927|receive|O
S2927|a|O
S2927|single|O
S2927|dose|O
S2927|of|O
S2927|oral|O
S2927|baloxavir|O
S2927|on|O
S2927|day|O
S2927|1|O
S2927|(|O
S2927|2|O
S2927|mg/kg|O
S2927|for|O
S2927|those|O
S2927|weighing|O
S2927|<|O
S2927|20|O
S2927|kg|O
S2927|and|O
S2927|a|O
S2927|single|O
S2927|dose|O
S2927|of|O
S2927|40|O
S2927|mg|O
S2927|for|O
S2927|those|O
S2927|weighing|O
S2927|≥20|O
S2927|kg|O
S2927|)|O
S2927|,|O
S2927|or|O
S2927|oral|O
S2927|oseltamivir|O
S2927|twice|O
S2927|daily|O
S2927|according|O
S2927|to|O
S2927|prescribing|O
S2927|information|O
S2927|(|O
S2927|30|O
S2927|mg|O
S2927|for|O
S2927|patients|O
S2927|weighing|O
S2927|≤15|O
S2927|kg|O
S2927|,|O
S2927|45|O
S2927|mg|O
S2927|for|O
S2927|>|O
S2927|15–≤23|O
S2927|kg|O
S2927|,|O
S2927|60|O
S2927|mg|O
S2927|for|O
S2927|>|O
S2927|23–≤40|O
S2927|kg|O
S2927|,|O
S2927|and|O
S2927|75|O
S2927|mg|O
S2927|for|O
S2927|>|O
S2927|40|O
S2927|kg|O
S2927|)|O
S2927|on|O
S2927|days|O
S2927|1–5|O
S2927|.|O
S2765|The|O
S2765|interactive|B-Randomization_Sequence_Generation_Method
S2765|web|I-Randomization_Sequence_Generation_Method
S2765|response|I-Randomization_Sequence_Generation_Method
S2765|system|I-Randomization_Sequence_Generation_Method
S2765|determined|O
S2765|which|O
S2765|drug|O
S2765|package|O
S2765|the|O
S2765|center|O
S2765|should|O
S2765|administer|O
S2765|to|O
S2765|the|O
S2765|patient|O
S2765|based|O
S2765|on|O
S2765|a|O
S2765|randomization|O
S2765|schedule|O
S2765|where|O
S2765|each|O
S2765|treatment|O
S2765|was|O
S2765|allocated|O
S2765|once|O
S2765|using|O
S2765|a|O
S2765|block|B-Randomization_Type_Block
S2765|size|O
S2765|of|O
S2765|four|B-Randomization_Block_Size
S2765|within|O
S2765|each|O
S2765|study|O
S2765|site|O
S2765|.|O
S4074|Primary|O
S4074|immunogenicity|O
S4074|endpoint|O
S4074|was|O
S4074|to|O
S4074|demonstrate|O
S4074|noninferiority|B-Design_Comparative_Intent_NonInferiority
S4074|of|O
S4074|V114|O
S4074|Lot|O
S4074|1|O
S4074|and|O
S4074|V114|O
S4074|Lot|O
S4074|2|O
S4074|relative|O
S4074|to|O
S4074|PCV13|O
S4074|based|O
S4074|on|O
S4074|proportion|O
S4074|of|O
S4074|infants|O
S4074|achieving|O
S4074|serotype-specific|O
S4074|IgG|O
S4074|concentration|O
S4074|≥0.35|O
S4074|µg/mL|O
S4074|for|O
S4074|13|O
S4074|serotypes|O
S4074|shared|O
S4074|with|O
S4074|PCV13|O
S4074|at|O
S4074|1|O
S4074|month|O
S4074|postdose|O
S4074|3|O
S4074|(|O
S4074|PD3|O
S4074|)|O
S4074|.|O
S3184|Interventions|O
S3184|Ursodeoxycholic|B-Design_Parallel_Group
S3184|acid|I-Design_Parallel_Group
S3184|500|I-Design_Parallel_Group
S3184|mg|I-Design_Parallel_Group
S3184|twice|I-Design_Parallel_Group
S3184|daily|I-Design_Parallel_Group
S3184|or|I-Design_Parallel_Group
S3184|placebo|I-Design_Parallel_Group
S3184|increased|O
S3184|as|O
S3184|necessary|O
S3184|for|O
S3184|symptomatic|O
S3184|or|O
S3184|biochemical|O
S3184|improvement|O
S3184|until|O
S3184|delivery|O
S3184|;|O
S3184|early|O
S3184|term|O
S3184|delivery|O
S3184|(|O
S3184|induction|O
S3184|or|O
S3184|delivery|O
S3184|started|O
S3184|between|O
S3184|37+0|O
S3184|and|O
S3184|37+6|O
S3184|)|O
S3184|or|O
S3184|expectant|O
S3184|management|O
S3184|(|O
S3184|spontaneous|O
S3184|labour|O
S3184|awaited|O
S3184|until|O
S3184|40|O
S3184|weeks|O
S3184|’|O
S3184|gestation|O
S3184|or|O
S3184|caesarean|O
S3184|section|O
S3184|undertaken|O
S3184|by|O
S3184|normal|O
S3184|obstetric|O
S3184|guidelines|O
S3184|,|O
S3184|usually|O
S3184|after|O
S3184|39|O
S3184|weeks|O
S3184|’|O
S3184|gestation|O
S3184|)|O
S3184|.|O
S4641|Materials|O
S4641|and|O
S4641|methods|O
S4641|A|O
S4641|26‐week|O
S4641|,|O
S4641|double‐blind|O
S4641|study|O
S4641|of|O
S4641|506|B-Sample_Size_Actual_at_Enrollment
S4641|Asian|B-Settings_Location
S4641|patients|O
S4641|(|O
S4641|80.2|O
S4641|%|O
S4641|from|O
S4641|mainland|O
S4641|China|B-Settings_Location
S4641|)|O
S4641|,|O
S4641|randomized|O
S4641|1:1:1|B-Randomization_Ratio
S4641|to|O
S4641|placebo|B-Design_Parallel_Group
S4641|,|I-Design_Parallel_Group
S4641|ertugliflozin|I-Design_Parallel_Group
S4641|5‐|I-Design_Parallel_Group
S4641|or|I-Design_Parallel_Group
S4641|15|I-Design_Parallel_Group
S4641|mg|I-Design_Parallel_Group
S4641|,|O
S4641|was|O
S4641|performed|O
S4641|.|O
S3180|Design|O
S3180|First|B-Design_Phase_1
S3180|phase|I-Design_Phase_1
S3180|of|O
S3180|a|O
S3180|semifactorial|B-Design_Factorial
S3180|randomised|O
S3180|controlled|O
S3180|trial|O
S3180|.|O
S473|It|O
S473|was|O
S473|ultimately|O
S473|limited|O
S473|to|O
S473|nine|B-Sample_Size_Actual_at_Enrollment
S473|patients|O
S473|who|O
S473|were|O
S473|randomised|O
S473|to|O
S473|receive|O
S473|filgotinib|O
S473|(|O
S473|five|O
S473|patients|O
S473|)|O
S473|or|O
S473|lanraplenib|O
S473|(|O
S473|four|O
S473|patients|O
S473|)|O
S473|(|O
S473|figure|O
S473|1|O
S473|)|O
S473|.|O
S3749|This|O
S3749|is|O
S3749|a|O
S3749|single-center|B-Settings_Single_Center
S3749|randomized|B-Randomization_Type_Simple
S3749|open|B-Blinding_Open_Label
S3749|label|I-Blinding_Open_Label
S3749|active-controlled|O
S3749|crossover|B-Design_Crossover
S3749|trial|O
S3749|comparing|O
S3749|efficacy|O
S3749|and|O
S3749|safety|O
S3749|of|O
S3749|fast|O
S3749|acting|O
S3749|insulin|O
S3749|aspart|O
S3749|(|O
S3749|FA|O
S3749|)|O
S3749|(|O
S3749|FIASP®|O
S3749|)|O
S3749|versus|O
S3749|insulin|O
S3749|aspart|O
S3749|(|O
S3749|IAsp|O
S3749|)|O
S3749|(|O
S3749|NovoLog®|O
S3749|)|O
S3749|when|O
S3749|used|O
S3749|in|O
S3749|the|O
S3749|Medtronic|O
S3749|670G|O
S3749|system|O
S3749|in|O
S3749|auto|O
S3749|mode|O
S3749|in|O
S3749|patients|O
S3749|with|O
S3749|type|O
S3749|1|O
S3749|diabetes|O
S3749|.|O
S5609|Four|B-Sample_Size_Actual_at_Enrollment
S5609|hundred|I-Sample_Size_Actual_at_Enrollment
S5609|forty|I-Sample_Size_Actual_at_Enrollment
S5609|adults|I-Sample_Size_Actual_at_Enrollment
S5609|with|O
S5609|knee|O
S5609|OA|O
S5609|received|O
S5609|a|B-Design_Parallel_Group
S5609|single|I-Design_Parallel_Group
S5609|6|I-Design_Parallel_Group
S5609|ml|I-Design_Parallel_Group
S5609|Hylan|I-Design_Parallel_Group
S5609|G-F|I-Design_Parallel_Group
S5609|20|I-Design_Parallel_Group
S5609|or|I-Design_Parallel_Group
S5609|placebo|I-Design_Parallel_Group
S5609|injection|I-Design_Parallel_Group
S5609|and|O
S5609|were|O
S5609|evaluated|O
S5609|for|O
S5609|clinical|O
S5609|efficacy|O
S5609|and|O
S5609|safety|O
S5609|outcomes|O
S5609|over|O
S5609|26|O
S5609|weeks|O
S5609|.|O
S3055|Materials|O
S3055|and|O
S3055|Methods|O
S3055|Study|O
S3055|Design|O
S3055|This|O
S3055|clinical|O
S3055|study|O
S3055|was|O
S3055|a|O
S3055|multicenter|B-Settings_Multicenter
S3055|,|O
S3055|open-label|B-Blinding_Open_Label
S3055|,|O
S3055|phase|B-Design_Phase_1
S3055|I|I-Design_Phase_1
S3055|study|O
S3055|of|O
S3055|oral|O
S3055|abemaciclib|O
S3055|(|O
S3055|LY2835219|O
S3055|;|O
S3055|Eli|O
S3055|Lilly|O
S3055|and|O
S3055|Company|O
S3055|,|O
S3055|Indianapolis|O
S3055|,|O
S3055|IN|O
S3055|,|O
S3055|USA|O
S3055|)|O
S3055|,|O
S3055|in|O
S3055|Chinese|O
S3055|patients|O
S3055|with|O
S3055|advanced|O
S3055|and/or|O
S3055|metastatic|O
S3055|cancers|O
S3055|.|O
S3775|Materials|O
S3775|and|O
S3775|Methods|O
S3775|Study|O
S3775|design|O
S3775|This|O
S3775|is|O
S3775|a|O
S3775|single-center|B-Settings_Single_Center
S3775|randomized|B-Randomization_Type_Simple
S3775|open|B-Blinding_Open_Label
S3775|label|I-Blinding_Open_Label
S3775|active-controlled|O
S3775|crossover|B-Design_Crossover
S3775|trial|O
S3775|with|O
S3775|a|O
S3775|2-week|O
S3775|run|O
S3775|in|O
S3775|period|O
S3775|and|O
S3775|two|B-Design_Crossover_Period_Treatment
S3775|7-week|I-Design_Crossover_Period_Treatment
S3775|treatment|I-Design_Crossover_Period_Treatment
S3775|periods|I-Design_Crossover_Period_Treatment
S3775|comparing|O
S3775|FA|O
S3775|versus|O
S3775|IAsp|O
S3775|in|O
S3775|the|O
S3775|Medtronic|O
S3775|MiniMed|O
S3775|670G|O
S3775|system|O
S3775|in|O
S3775|participants|O
S3775|with|O
S3775|T1DM|O
S3775|.|O
S2293|Nearly|B-Sample_Size_Actual_at_Outcome_Analysis
S2293|all|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|96|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2293|completed|O
S2293|all|O
S2293|protocol-defined|O
S2293|study|O
S2293|visits|O
S2293|,|O
S2293|with|O
S2293|similar|O
S2293|discontinuation|O
S2293|and|O
S2293|withdrawal|O
S2293|rates|O
S2293|between|O
S2293|treatment|O
S2293|groups|O
S2293|(|O
S2293|Fig|O
S2293|.|O
S4717|Safety|O
S4717|endpoints|O
S4717|of|O
S4717|a|O
S4717|priori|O
S4717|interest|O
S4717|(|O
S4717|Tier|O
S4717|1|O
S4717|AEs|O
S4717|of|O
S4717|GMI|O
S4717|by|O
S4717|gender|O
S4717|,|O
S4717|UTI|O
S4717|,|O
S4717|symptomatic|O
S4717|hypoglycaemia|O
S4717|and|O
S4717|hypovolaemia|O
S4717|)|O
S4717|were|O
S4717|assessed|O
S4717|using|O
S4717|95|O
S4717|%|O
S4717|confidence|O
S4717|intervals|O
S4717|(|O
S4717|CI|O
S4717|)|O
S4717|,|O
S4717|and|O
S4717|P‐values|O
S4717|provided|O
S4717|without|O
S4717|multiplicity|O
S4717|control|O
S4717|using|O
S4717|the|O
S4717|Miettinen|O
S4717|and|O
S4717|Nurminen|O
S4717|method.23|O
S4717|RESULTS|O
S4717|Patient|O
S4717|disposition|O
S4717|and|O
S4717|baseline|O
S4717|characteristics|O
S4717|In|O
S4717|total|O
S4717|,|O
S4717|506|B-Sample_Size_Actual_at_Enrollment
S4717|patients|O
S4717|were|O
S4717|randomized|O
S4717|(|O
S4717|Supporting|O
S4717|Information|O
S4717|Table|O
S4717|S1|O
S4717|)|O
S4717|,|O
S4717|including|O
S4717|406|O
S4717|patients|O
S4717|in|O
S4717|mainland|O
S4717|China|O
S4717|.|O
S2777|A|O
S2777|closed|O
S2777|testing|O
S2777|procedure|O
S2777|was|O
S2777|used|O
S2777|to|O
S2777|control|O
S2777|the|O
S2777|experiment-wise|O
S2777|type|O
S2777|I|O
S2777|error|O
S2777|rate|O
S2777|at|O
S2777|the|O
S2777|5|B-Sample_Size_Calculation_Alpha_Value
S2777|%|I-Sample_Size_Calculation_Alpha_Value
S2777|significance|O
S2777|level|O
S2777|.|O
S4367|The|O
S4367|trial|O
S4367|was|O
S4367|composed|O
S4367|of|O
S4367|a|O
S4367|double-blinded|B-Blinding_Double_Blind
S4367|,|O
S4367|randomized|O
S4367|,|O
S4367|placebo-controlled|O
S4367|,|O
S4367|dose-escalation|O
S4367|study|O
S4367|in|O
S4367|treatment-naïve|O
S4367|patients|O
S4367|(|O
S4367|n|O
S4367|=|O
S4367|24|B-Sample_Size_Actual_at_Enrollment
S4367|)|O
S4367|and|O
S4367|an|O
S4367|add-on|O
S4367|exploratory|O
S4367|cohort|O
S4367|of|O
S4367|patients|O
S4367|already|O
S4367|receiving|O
S4367|stable|O
S4367|NA|O
S4367|regimens|O
S4367|(|O
S4367|on-NA|O
S4367|patients|O
S4367|;|O
S4367|n|O
S4367|=|O
S4367|7|B-Sample_Size_Actual_at_Enrollment
S4367|)|O
S4367|(|O
S4367|Supplementary|O
S4367|Fig|O
S4367|.|O
S3563|Based|O
S3563|on|O
S3563|a|O
S3563|prespecified|O
S3563|non-inferiority|O
S3563|limit|O
S3563|of|O
S3563|−10.0|O
S3563|%|O
S3563|(|O
S3563|absolute|O
S3563|)|O
S3563|and|O
S3563|an|O
S3563|assumed|O
S3563|ongoing|O
S3563|pregnancy|O
S3563|rate|O
S3563|of|O
S3563|32.2|O
S3563|%|O
S3563|in|O
S3563|both|O
S3563|treatment|O
S3563|groups|O
S3563|,|O
S3563|the|O
S3563|trial|O
S3563|was|O
S3563|designed|O
S3563|to|O
S3563|have|O
S3563|90|B-Sample_Size_Calculation_Power_Value
S3563|%|I-Sample_Size_Calculation_Power_Value
S3563|power|O
S3563|achieving|O
S3563|the|O
S3563|primary|O
S3563|objective|O
S3563|.|O
S3242|Women|O
S3242|who|O
S3242|were|O
S3242|eligible|O
S3242|for|O
S3242|both|O
S3242|were|O
S3242|permitted|O
S3242|to|O
S3242|participate|O
S3242|in|O
S3242|either|O
S3242|or|O
S3242|both|O
S3242|factorial|B-Design_Factorial
S3242|comparisons|O
S3242|.|O
S4947|Design|O
S4947|:|O
S4947|Multicenter|B-Settings_Multicenter
S4947|randomized|O
S4947|clinical|O
S4947|trial|O
S4947|Participants|O
S4947|:|O
S4947|Patients|O
S4947|with|O
S4947|uveitic|O
S4947|macular|O
S4947|edema|O
S4947|Methods|O
S4947|:|O
S4947|Patients|O
S4947|were|O
S4947|randomized|O
S4947|1:1:1|B-Randomization_Ratio
S4947|to|O
S4947|receive|O
S4947|one|O
S4947|of|O
S4947|the|O
S4947|three|O
S4947|therapies|O
S4947|.|O
S2949|RESULTS|O
S2949|Patient|O
S2949|Disposition|O
S2949|and|O
S2949|Characteristics|O
S2949|This|O
S2949|study|O
S2949|was|O
S2949|performed|O
S2949|between|O
S2949|November|O
S2949|20|O
S2949|,|O
S2949|2018|O
S2949|and|O
S2949|August|O
S2949|27|O
S2949|,|O
S2949|2019|O
S2949|at|O
S2949|36|O
S2949|sites|O
S2949|across|O
S2949|6|O
S2949|countries|O
S2949|(|O
S2949|USA|B-Settings_Location
S2949|,|I-Settings_Location
S2949|Poland|I-Settings_Location
S2949|,|I-Settings_Location
S2949|Spain|I-Settings_Location
S2949|,|I-Settings_Location
S2949|Costa|I-Settings_Location
S2949|Rica|I-Settings_Location
S2949|,|I-Settings_Location
S2949|Mexico|I-Settings_Location
S2949|and|I-Settings_Location
S2949|Russia|I-Settings_Location
S2949|)|O
S2949|.|O
S5495|The|O
S5495|vitamin|B-Design_Parallel_Group
S5495|D3|I-Design_Parallel_Group
S5495|and|I-Design_Parallel_Group
S5495|the|I-Design_Parallel_Group
S5495|placebo|I-Design_Parallel_Group
S5495|were|O
S5495|the|O
S5495|same|O
S5495|colour|O
S5495|(|O
S5495|pale|O
S5495|yellow|O
S5495|)|O
S5495|,|O
S5495|taste|O
S5495|,|O
S5495|and|O
S5495|quantity|O
S5495|(|O
S5495|0·5|O
S5495|mL|O
S5495|)|O
S5495|and|O
S5495|therefore|O
S5495|the|O
S5495|study|B-Blinding_Object_Others
S5495|staff|I-Blinding_Object_Others
S5495|and|O
S5495|the|O
S5495|families|B-Blinding_Object_Others
S5495|did|O
S5495|not|O
S5495|know|O
S5495|to|O
S5495|which|O
S5495|group|O
S5495|the|O
S5495|children|O
S5495|were|O
S5495|assigned|O
S5495|.|O
S8076|At|O
S8076|the|O
S8076|start|O
S8076|of|O
S8076|the|O
S8076|double-blind|O
S8076|treatment|O
S8076|period|O
S8076|,|O
S8076|participants|O
S8076|were|O
S8076|randomized|O
S8076|1:1|B-Randomization_Ratio
S8076|to|O
S8076|6.25|B-Design_Parallel_Group
S8076|mg|I-Design_Parallel_Group
S8076|SHP465|I-Design_Parallel_Group
S8076|MAS|I-Design_Parallel_Group
S8076|once|I-Design_Parallel_Group
S8076|daily|I-Design_Parallel_Group
S8076|or|I-Design_Parallel_Group
S8076|placebo|I-Design_Parallel_Group
S8076|.|O
S7060|Overall|O
S7060|,|O
S7060|295|B-Sample_Size_Actual_at_Outcome_Analysis
S7060|(|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|80.6|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|%|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|)|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|and|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|293|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|(|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|81.4|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|%|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|)|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|in|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|the|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|tedizolid|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|and|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|linezolid|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|groups|I-Sample_Size_Actual_at_Outcome_Analysis
S7060|,|O
S7060|respectively|O
S7060|,|O
S7060|received|O
S7060|any|O
S7060|adjunctive|O
S7060|gram-negative|O
S7060|therapy|O
S7060|(|O
S7060|Table|O
S7060|1|O
S7060|)|O
S7060|.|O
S2251|All|B-Blinding_Object_Outcome_Assessors
S2251|site|I-Blinding_Object_Outcome_Assessors
S2251|personnel|I-Blinding_Object_Outcome_Assessors
S2251|involved|I-Blinding_Object_Outcome_Assessors
S2251|in|I-Blinding_Object_Outcome_Assessors
S2251|efficacy|I-Blinding_Object_Outcome_Assessors
S2251|and|I-Blinding_Object_Outcome_Assessors
S2251|safety|I-Blinding_Object_Outcome_Assessors
S2251|assessments|I-Blinding_Object_Outcome_Assessors
S2251|were|O
S2251|also|O
S2251|blinded|O
S2251|to|O
S2251|assigned|O
S2251|treatment|O
S2251|during|O
S2251|the|O
S2251|study|O
S2251|.|O
S1327|The|O
S1327|study|O
S1327|was|O
S1327|conducted|O
S1327|in|O
S1327|73|B-Settings_Multicenter
S1327|centres|I-Settings_Multicenter
S1327|in|O
S1327|11|B-Settings_Location
S1327|countries|I-Settings_Location
S1327|from|I-Settings_Location
S1327|Europe|I-Settings_Location
S1327|and|I-Settings_Location
S1327|Asia|I-Settings_Location
S1327|.|O
S7259|Patients|O
S7259|were|O
S7259|randomized|O
S7259|to|O
S7259|tofacitinib|B-Design_Parallel_Group
S7259|MR|I-Design_Parallel_Group
S7259|11|I-Design_Parallel_Group
S7259|mg|I-Design_Parallel_Group
S7259|QD|I-Design_Parallel_Group
S7259|(|I-Design_Parallel_Group
S7259|n|I-Design_Parallel_Group
S7259|=|I-Design_Parallel_Group
S7259|104|I-Design_Parallel_Group
S7259|)|I-Design_Parallel_Group
S7259|or|I-Design_Parallel_Group
S7259|IR|I-Design_Parallel_Group
S7259|5|I-Design_Parallel_Group
S7259|mg|I-Design_Parallel_Group
S7259|BID|I-Design_Parallel_Group
S7259|(|I-Design_Parallel_Group
S7259|n|I-Design_Parallel_Group
S7259|=|I-Design_Parallel_Group
S7259|105|I-Design_Parallel_Group
S7259|)|I-Design_Parallel_Group
S7259|,|O
S7259|with|O
S7259|stable|O
S7259|MTX|O
S7259|.|O
S1865|Raltegravir|O
S1865|Versus|O
S1865|Efavirenz|O
S1865|in|O
S1865|Antiretroviral-Naive|O
S1865|Pregnant|O
S1865|Women|O
S1865|Living|O
S1865|With|O
S1865|HIV|O
S1865|(|O
S1865|NICHD|O
S1865|P1081|O
S1865|)|O
S1865|:|O
S1865|An|O
S1865|Open-Label|B-Blinding_Open_Label
S1865|,|O
S1865|Randomised|O
S1865|,|O
S1865|Controlled|O
S1865|,|O
S1865|Phase|B-Design_Phase_4
S1865|4|I-Design_Phase_4
S1865|Trial|O
S5446|Randomisation|O
S5446|was|O
S5446|by|O
S5446|use|O
S5446|of|O
S5446|a|B-Randomization_Sequence_Generation_Method
S5446|computer-generated|I-Randomization_Sequence_Generation_Method
S5446|list|I-Randomization_Sequence_Generation_Method
S5446|.|O
S3238|The|O
S3238|random|O
S3238|allocation|O
S3238|sequence|O
S3238|for|O
S3238|each|O
S3238|comparison|O
S3238|was|O
S3238|generated|O
S3238|by|O
S3238|using|O
S3238|a|O
S3238|specific|O
S3238|function|O
S3238|(|O
S3238|-ralloc-|O
S3238|)|O
S3238|in|O
S3238|Stata|O
S3238|(|O
S3238|StataCorp|O
S3238|,|O
S3238|College|O
S3238|Station|O
S3238|,|O
S3238|TX|O
S3238|)|O
S3238|software|O
S3238|within|O
S3238|the|O
S3238|clinical|O
S3238|unit|O
S3238|using|O
S3238|randomly|O
S3238|varying|O
S3238|block|B-Randomization_Type_Block
S3238|sizes|O
S3238|of|O
S3238|two|B-Randomization_Block_Size
S3238|,|I-Randomization_Block_Size
S3238|four|I-Randomization_Block_Size
S3238|,|I-Randomization_Block_Size
S3238|and|I-Randomization_Block_Size
S3238|six|I-Randomization_Block_Size
S3238|.|O
S1249|The|O
S1249|proportion|O
S1249|of|O
S1249|patients|O
S1249|who|O
S1249|had|O
S1249|achieved|O
S1249|onset|O
S1249|of|O
S1249|action|O
S1249|by|O
S1249|15|O
S1249|min|O
S1249|post-dose|O
S1249|ranged|O
S1249|from|O
S1249|7|O
S1249|%|O
S1249|with|O
S1249|GP|O
S1249|MDI|O
S1249|0.6|O
S1249|μg|O
S1249|to|O
S1249|30|O
S1249|%|O
S1249|with|O
S1249|GP|O
S1249|MDI|O
S1249|9|O
S1249|μg|O
S1249|(|O
S1249|29|O
S1249|%|O
S1249|with|O
S1249|GP|O
S1249|MDI|O
S1249|18|O
S1249|μg|O
S1249|)|O
S1249|,|O
S1249|and|O
S1249|39|O
S1249|%|O
S1249|for|O
S1249|open-label|B-Blinding_Open_Label
S1249|tiotropium|O
S1249|,|O
S1249|compared|O
S1249|with|O
S1249|4|O
S1249|%|O
S1249|for|O
S1249|placebo|O
S1249|MDI|O
S1249|.|O
S1900|Randomisation|O
S1900|and|O
S1900|Masking|O
S1900|Participants|O
S1900|were|O
S1900|randomly|O
S1900|allocated|O
S1900|to|O
S1900|one|B-Design_Parallel_Group
S1900|of|I-Design_Parallel_Group
S1900|two|I-Design_Parallel_Group
S1900|ART|I-Design_Parallel_Group
S1900|regimens|I-Design_Parallel_Group
S1900|,|I-Design_Parallel_Group
S1900|one|I-Design_Parallel_Group
S1900|raltegravir-based|I-Design_Parallel_Group
S1900|and|I-Design_Parallel_Group
S1900|one|I-Design_Parallel_Group
S1900|efavirenz|I-Design_Parallel_Group
S1900|-based|I-Design_Parallel_Group
S1900|.|O
S2391|Material|O
S2391|and|O
S2391|Methods|O
S2391|Study|O
S2391|Design|O
S2391|and|O
S2391|Participants|O
S2391|This|O
S2391|multinational|B-Settings_Multicenter
S2391|,|O
S2391|double-blind|B-Blinding_Double_Blind
S2391|,|O
S2391|randomized|O
S2391|,|O
S2391|parallel|B-Design_Parallel_Group
S2391|group|I-Design_Parallel_Group
S2391|,|O
S2391|phase|B-Design_Phase_3
S2391|III|I-Design_Phase_3
S2391|clinical|O
S2391|comparability|O
S2391|study|O
S2391|(|O
S2391|STELLA|O
S2391|)|O
S2391|was|O
S2391|conducted|O
S2391|in|O
S2391|93|B-Settings_Multicenter
S2391|centers|I-Settings_Multicenter
S2391|in|O
S2391|the|O
S2391|following|O
S2391|16|B-Settings_Location
S2391|countries|I-Settings_Location
S2391|:|I-Settings_Location
S2391|Brazil|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Bulgaria|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Chile|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Georgia|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Greece|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Hungary|I-Settings_Location
S2391|,|I-Settings_Location
S2391|India|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Lebanon|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Malaysia|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Mexico|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Philippines|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Russia|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Serbia|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Thailand|I-Settings_Location
S2391|,|I-Settings_Location
S2391|Turkey|I-Settings_Location
S2391|,|I-Settings_Location
S2391|and|I-Settings_Location
S2391|Ukraine|I-Settings_Location
S2391|.|O
S697|Participants|O
S697|were|O
S697|administered|O
S697|600mg|O
S697|of|O
S697|oral|B-Design_Parallel_Group
S697|gabapentin|I-Design_Parallel_Group
S697|versus|I-Design_Parallel_Group
S697|placebo|I-Design_Parallel_Group
S697|with|O
S697|usual|O
S697|oral|O
S697|pain|O
S697|management|O
S697|.|O
S4398|Patients|O
S4398|were|O
S4398|randomized|O
S4398|(|O
S4398|3:1|B-Randomization_Ratio
S4398|within|I-Randomization_Ratio
S4398|each|I-Randomization_Ratio
S4398|dose|I-Randomization_Ratio
S4398|cohort|I-Randomization_Ratio
S4398|)|O
S4398|to|O
S4398|bepirovirsen|B-Design_Parallel_Group
S4398|or|I-Design_Parallel_Group
S4398|placebo|I-Design_Parallel_Group
S4398|according|O
S4398|to|O
S4398|the|O
S4398|randomization|O
S4398|schedule|O
S4398|(|O
S4398|permuted|O
S4398|block|B-Randomization_Type_Block
S4398|)|O
S4398|.|O
S4718|Overall|O
S4718|,|O
S4718|465|B-Sample_Size_Actual_at_Outcome_Analysis
S4718|(|O
S4718|92|O
S4718|%|O
S4718|)|O
S4718|patients|O
S4718|completed|O
S4718|the|O
S4718|study|O
S4718|medication|O
S4718|.|O
S7157|Randomisation|O
S7157|was|O
S7157|minimised|B-Randomization_Type_Minimization
S7157|by|O
S7157|centre|B-Randomization_Minimization_Criteria
S7157|,|O
S7157|PaO2/FIO2|B-Randomization_Minimization_Criteria
S7157|ratio|I-Randomization_Minimization_Criteria
S7157|(|I-Randomization_Minimization_Criteria
S7157|≤50|I-Randomization_Minimization_Criteria
S7157|,|I-Randomization_Minimization_Criteria
S7157|51–99|I-Randomization_Minimization_Criteria
S7157|,|I-Randomization_Minimization_Criteria
S7157|or|I-Randomization_Minimization_Criteria
S7157|≥100|I-Randomization_Minimization_Criteria
S7157|mm|I-Randomization_Minimization_Criteria
S7157|Hg|I-Randomization_Minimization_Criteria
S7157|)|I-Randomization_Minimization_Criteria
S7157|,|O
S7157|and|O
S7157|age|B-Randomization_Minimization_Criteria
S7157|(|I-Randomization_Minimization_Criteria
S7157|<|I-Randomization_Minimization_Criteria
S7157|64|I-Randomization_Minimization_Criteria
S7157|,|I-Randomization_Minimization_Criteria
S7157|65–84|I-Randomization_Minimization_Criteria
S7157|,|I-Randomization_Minimization_Criteria
S7157|≥85|I-Randomization_Minimization_Criteria
S7157|years|I-Randomization_Minimization_Criteria
S7157|)|I-Randomization_Minimization_Criteria
S7157|.|O
S7408|A|O
S7408|Randomized|O
S7408|Phase|B-Design_Phase_2
S7408|2|I-Design_Phase_2
S7408|Study|O
S7408|of|O
S7408|Erenumab|O
S7408|for|O
S7408|the|O
S7408|Prevention|O
S7408|of|O
S7408|Episodic|O
S7408|Migraine|O
S7408|in|O
S7408|Japanese|B-Settings_Location
S7408|Adults|O
S7028|Patients|B-Blinding_Object_Patients
S7028|,|O
S7028|the|O
S7028|study|B-Blinding_Object_Others
S7028|sponsor|I-Blinding_Object_Others
S7028|,|O
S7028|site|B-Blinding_Object_Investigators
S7028|investigators|I-Blinding_Object_Investigators
S7028|,|O
S7028|and|O
S7028|study|B-Blinding_Object_Care_Providers
S7028|staff|I-Blinding_Object_Care_Providers
S7028|involved|I-Blinding_Object_Care_Providers
S7028|in|I-Blinding_Object_Care_Providers
S7028|clinical|I-Blinding_Object_Care_Providers
S7028|care/evaluations|I-Blinding_Object_Care_Providers
S7028|were|O
S7028|all|O
S7028|blinded|O
S7028|to|O
S7028|treatment|O
S7028|assignments|O
S7028|.|O
S1872|(|O
S1872|Clinicaltrials.gov|O
S1872|:|O
S1872|NCT01618305|O
S1872|)|O
S1872|Findings|O
S1872|From|O
S1872|September|O
S1872|2013|O
S1872|to|O
S1872|December|O
S1872|2018|O
S1872|,|O
S1872|408|B-Sample_Size_Actual_at_Enrollment
S1872|women|I-Sample_Size_Actual_at_Enrollment
S1872|were|O
S1872|randomized|O
S1872|(|O
S1872|206|O
S1872|RAL|O
S1872|,|O
S1872|202|O
S1872|EFV|O
S1872|)|O
S1872|and|O
S1872|394|O
S1872|delivered|O
S1872|on-study|O
S1872|(|O
S1872|200|O
S1872|RAL|O
S1872|,|O
S1872|194|O
S1872|EFV|O
S1872|)|O
S1872|;|O
S1872|307|B-Sample_Size_Actual_at_Outcome_Analysis
S1872|were|O
S1872|included|O
S1872|in|O
S1872|the|O
S1872|primary|O
S1872|efficacy|O
S1872|analysis|O
S1872|(|O
S1872|153|O
S1872|RAL|O
S1872|,|O
S1872|154|O
S1872|EFV|O
S1872|)|O
S1872|.|O
S3182|Participants|O
S3182|125|B-Sample_Size_Actual_at_Enrollment
S3182|women|I-Sample_Size_Actual_at_Enrollment
S3182|with|O
S3182|intrahepatic|O
S3182|cholestasis|O
S3182|of|O
S3182|pregnancy|O
S3182|(|O
S3182|pruritus|O
S3182|and|O
S3182|raised|O
S3182|levels|O
S3182|of|O
S3182|serum|O
S3182|bile|O
S3182|acids|O
S3182|)|O
S3182|or|O
S3182|pruritus|O
S3182|and|O
S3182|raised|O
S3182|alanine|O
S3182|transaminase|O
S3182|levels|O
S3182|(|O
S3182|>|O
S3182|100|O
S3182|IU/L|O
S3182|)|O
S3182|recruited|O
S3182|after|O
S3182|24|O
S3182|weeks|O
S3182|’|O
S3182|gestation|O
S3182|and|O
S3182|followed|O
S3182|until|O
S3182|delivery|O
S3182|.|O
S305|Blinded|B-Allocation_Concealment_Method
S305|,|I-Allocation_Concealment_Method
S305|coded|I-Allocation_Concealment_Method
S305|kits|I-Allocation_Concealment_Method
S305|with|I-Allocation_Concealment_Method
S305|study|I-Allocation_Concealment_Method
S305|drug|I-Allocation_Concealment_Method
S305|in|I-Allocation_Concealment_Method
S305|prefilled|I-Allocation_Concealment_Method
S305|syringes|I-Allocation_Concealment_Method
S305|and|I-Allocation_Concealment_Method
S305|boxes|I-Allocation_Concealment_Method
S305|masked|O
S305|the|O
S305|treatment|O
S305|assignments|O
S305|.|O
S2291|Results|O
S2291|Trial|O
S2291|population|O
S2291|The|O
S2291|ITT|O
S2291|population|O
S2291|included|O
S2291|800|B-Sample_Size_Actual_at_Enrollment
S2291|patients|O
S2291|who|O
S2291|underwent|O
S2291|randomization|O
S2291|(|O
S2291|FF/UMEC/VI|O
S2291|,|O
S2291|N|O
S2291|=|O
S2291|400|O
S2291|;|O
S2291|TIO|O
S2291|,|O
S2291|N|O
S2291|=|O
S2291|400|O
S2291|;|O
S2291|Fig|O
S2291|.|O
S2787|treatment|O
S2787|group|O
S2787|was|O
S2787|compared|O
S2787|with|O
S2787|the|O
S2787|placebo|O
S2787|group|O
S2787|using|O
S2787|a|O
S2787|5|B-Sample_Size_Calculation_Alpha_Value
S2787|%|I-Sample_Size_Calculation_Alpha_Value
S2787|significance|O
S2787|level|O
S2787|.|O
S4106|It|O
S4106|was|O
S4106|conducted|O
S4106|from|O
S4106|March|O
S4106|21|O
S4106|,|O
S4106|2017|O
S4106|,|O
S4106|through|O
S4106|July|O
S4106|9|O
S4106|,|O
S4106|2019|O
S4106|,|O
S4106|at|O
S4106|47|B-Settings_Multicenter
S4106|sites|I-Settings_Multicenter
S4106|(|O
S4106|Finland|B-Settings_Location
S4106|[|I-Settings_Location
S4106|8|I-Settings_Location
S4106|]|I-Settings_Location
S4106|,|I-Settings_Location
S4106|Spain|I-Settings_Location
S4106|[|I-Settings_Location
S4106|2|I-Settings_Location
S4106|]|I-Settings_Location
S4106|,|I-Settings_Location
S4106|Israel|I-Settings_Location
S4106|[|I-Settings_Location
S4106|3|I-Settings_Location
S4106|]|I-Settings_Location
S4106|,|I-Settings_Location
S4106|Denmark|I-Settings_Location
S4106|[|I-Settings_Location
S4106|2|I-Settings_Location
S4106|]|I-Settings_Location
S4106|,|I-Settings_Location
S4106|Canada|I-Settings_Location
S4106|[|I-Settings_Location
S4106|3|I-Settings_Location
S4106|]|I-Settings_Location
S4106|and|I-Settings_Location
S4106|the|I-Settings_Location
S4106|United|I-Settings_Location
S4106|States|I-Settings_Location
S4106|[|I-Settings_Location
S4106|29|I-Settings_Location
S4106|]|I-Settings_Location
S4106|)|O
S4106|.|O
S1316|Patients|O
S1316|were|O
S1316|randomised|O
S1316|in|O
S1316|a|O
S1316|1:1|B-Randomization_Ratio
S1316|ratio|O
S1316|to|O
S1316|receive|O
S1316|either|B-Design_Parallel_Group
S1316|SB2|I-Design_Parallel_Group
S1316|or|I-Design_Parallel_Group
S1316|INF|I-Design_Parallel_Group
S1316|of|I-Design_Parallel_Group
S1316|3|I-Design_Parallel_Group
S1316|mg/kg|I-Design_Parallel_Group
S1316|intravenously|O
S1316|.|O
S7728|RESEARCH|O
S7728|DESIGN|O
S7728|AND|O
S7728|METHODS|O
S7728|This|O
S7728|multicenter|B-Settings_Multicenter
S7728|,|O
S7728|double-blind|B-Blinding_Double_Blind
S7728|,|O
S7728|treat-to-target|O
S7728|trial|O
S7728|randomized|B-Randomization_Type_Simple
S7728|participants|O
S7728|to|O
S7728|faster|O
S7728|aspart|B-Design_Parallel_Group
S7728|(|I-Design_Parallel_Group
S7728|n|I-Design_Parallel_Group
S7728|=|I-Design_Parallel_Group
S7728|546|I-Design_Parallel_Group
S7728|)|I-Design_Parallel_Group
S7728|or|I-Design_Parallel_Group
S7728|IAsp|I-Design_Parallel_Group
S7728|(|I-Design_Parallel_Group
S7728|n|I-Design_Parallel_Group
S7728|=|I-Design_Parallel_Group
S7728|545|I-Design_Parallel_Group
S7728|)|I-Design_Parallel_Group
S7728|.|O
S1317|Randomisation|O
S1317|and|O
S1317|treatment|O
S1317|allocation|O
S1317|was|O
S1317|implemented|O
S1317|through|O
S1317|an|B-Randomization_Sequence_Generation_Method
S1317|interactive|I-Randomization_Sequence_Generation_Method
S1317|web|I-Randomization_Sequence_Generation_Method
S1317|responsive|I-Randomization_Sequence_Generation_Method
S1317|system|I-Randomization_Sequence_Generation_Method
S1317|(|O
S1317|Cenduit|O
S1317|LLC|O
S1317|,|O
S1317|see|O
S1317|online|O
S1317|supplementary|O
S1317|appendix|O
S1317|S3-1|O
S1317|)|O
S1317|.|O
S5521|Assuming|O
S5521|a|O
S5521|20|B-Sample_Size_Calculation_Dropout_Rate_Value
S5521|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S5521|loss|O
S5521|to|O
S5521|follow-up|O
S5521|and|O
S5521|allowing|O
S5521|for|O
S5521|protocol|O
S5521|violations|O
S5521|we|O
S5521|intended|O
S5521|to|O
S5521|recruit|O
S5521|3050|B-Sample_Size_Target
S5521|children|O
S5521|for|O
S5521|18|O
S5521|months|O
S5521|follow-up|O
S5521|.|O
S6274|In|O
S6274|the|O
S6274|open-label|B-Blinding_Open_Label
S6274|phase|O
S6274|,|O
S6274|patients|O
S6274|received|O
S6274|400|O
S6274|U|O
S6274|of|O
S6274|onabotulinumtoxinA|O
S6274|up|O
S6274|to|O
S6274|3|O
S6274|times|O
S6274|with|O
S6274|a|O
S6274|minimum|O
S6274|interval|O
S6274|of|O
S6274|12|O
S6274|weeks|O
S6274|between|O
S6274|injections|O
S6274|.|O
S555|Erythropoietin|O
S555|in|O
S555|amyotrophic|O
S555|lateral|O
S555|sclerosis|O
S555|:|O
S555|a|O
S555|multicentre|B-Settings_Multicenter
S555|,|O
S555|randomised|O
S555|,|O
S555|double|B-Blinding_Double_Blind
S555|blind|I-Blinding_Double_Blind
S555|,|O
S555|placebo|O
S555|controlled|O
S555|,|O
S555|phase|B-Design_Phase_3
S555|III|I-Design_Phase_3
S555|study|O
S3513|All|O
S3513|investigators|B-Blinding_Object_Investigators
S3513|,|O
S3513|embryologists|B-Blinding_Object_Others
S3513|and|O
S3513|central|B-Blinding_Object_Others
S3513|laboratory|I-Blinding_Object_Others
S3513|personnel|I-Blinding_Object_Others
S3513|were|O
S3513|blinded|O
S3513|to|O
S3513|the|O
S3513|individual|O
S3513|treatment|O
S3513|allocation|O
S3513|.|O
S8275|The|O
S8275|rest|O
S8275|of|O
S8275|the|O
S8275|research|O
S8275|team|O
S8275|including|O
S8275|the|O
S8275|principal|B-Blinding_Object_Investigators
S8275|investigator|I-Blinding_Object_Investigators
S8275|,|O
S8275|research|B-Blinding_Object_Others
S8275|coordinator|I-Blinding_Object_Others
S8275|,|O
S8275|dietitian|B-Blinding_Object_Others
S8275|,|O
S8275|and|O
S8275|exercise|B-Blinding_Object_Others
S8275|physiologist|I-Blinding_Object_Others
S8275|were|O
S8275|blinded|O
S8275|as|O
S8275|to|O
S8275|the|O
S8275|randomization|O
S8275|of|O
S8275|the|O
S8275|participants|O
S8275|until|O
S8275|the|O
S8275|end|O
S8275|of|O
S8275|the|O
S8275|study|O
S8275|.|O
S4999|Randomization|O
S4999|tables|O
S4999|were|O
S4999|prepared|O
S4999|by|O
S4999|the|B-Randomization_Personnel
S4999|coordinating|I-Randomization_Personnel
S4999|center|O
S4999|and|O
S4999|assignments|O
S4999|were|O
S4999|revealed|O
S4999|via|O
S4999|a|B-Randomization_Sequence_Generation_Method
S4999|web|I-Randomization_Sequence_Generation_Method
S4999|portal|I-Randomization_Sequence_Generation_Method
S4999|after|O
S4999|patients|O
S4999|were|O
S4999|enrolled|O
S4999|in|O
S4999|the|O
S4999|trial|O
S4999|and|O
S4999|all|O
S4999|baseline|O
S4999|data|O
S4999|were|O
S4999|collected|O
S4999|.|O
S1229|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1229|was|O
S1229|only|O
S1229|determined|O
S1229|for|O
S1229|a|O
S1229|treatment|O
S1229|group|O
S1229|if|O
S1229|the|O
S1229|lower|O
S1229|bound|O
S1229|of|O
S1229|the|O
S1229|95|O
S1229|%|O
S1229|confidence|O
S1229|interval|O
S1229|(|O
S1229|CI|O
S1229|)|O
S1229|for|O
S1229|the|O
S1229|difference|O
S1229|was|O
S1229|above|O
S1229|−100|O
S1229|mL|O
S1229|and|O
S1229|if|O
S1229|all|O
S1229|higher|O
S1229|dose|O
S1229|levels|O
S1229|were|O
S1229|statistically|O
S1229|significantly|O
S1229|non-inferior|B-Design_Comparative_Intent_NonInferiority
S1229|to|O
S1229|open-label|B-Blinding_Open_Label
S1229|tiotropium|O
S1229|.|O
S2536|Methods|O
S2536|This|O
S2536|26-week|O
S2536|,|O
S2536|randomised|O
S2536|,|O
S2536|double-blind|B-Blinding_Double_Blind
S2536|,|O
S2536|placebo-controlled|O
S2536|phase|B-Design_Phase_2
S2536|IIb|I-Design_Phase_2
S2536|study|O
S2536|enrolled|O
S2536|symptomatic|O
S2536|patients|O
S2536|with|O
S2536|mild-to-moderate|O
S2536|COPD|O
S2536|at|O
S2536|risk|O
S2536|for|O
S2536|exacerbations|O
S2536|.|O
S2919|MATERIALS|O
S2919|AND|O
S2919|METHODS|O
S2919|Trial|O
S2919|Design|O
S2919|and|O
S2919|Participants|O
S2919|This|O
S2919|was|O
S2919|a|O
S2919|global|O
S2919|,|O
S2919|multicenter|B-Settings_Multicenter
S2919|,|O
S2919|double-blind|B-Blinding_Double_Blind
S2919|,|O
S2919|randomized|O
S2919|,|O
S2919|active|O
S2919|controlled|O
S2919|trial|O
S2919|of|O
S2919|the|O
S2919|safety|O
S2919|,|O
S2919|pharmacokinetics|O
S2919|and|O
S2919|efficacy|O
S2919|of|O
S2919|a|O
S2919|single|O
S2919|oral|O
S2919|dose|O
S2919|of|O
S2919|baloxavir|O
S2919|versus|O
S2919|twice-daily|O
S2919|(|O
S2919|for|O
S2919|5|O
S2919|days|O
S2919|)|O
S2919|oral|O
S2919|oseltamivir|O
S2919|,|O
S2919|in|O
S2919|otherwise|O
S2919|healthy|O
S2919|children|O
S2919|with|O
S2919|influenza|O
S2919|.|O
S3813|Accounting|O
S3813|for|O
S3813|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S3813|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S3813|dropouts|O
S3813|,|O
S3813|a|O
S3813|total|O
S3813|of|O
S3813|40|B-Sample_Size_Actual_at_Enrollment
S3813|subjects|O
S3813|were|O
S3813|randomized|O
S3813|.|O
S3748|24|O
S3748|,|O
S3748|25|O
S3748|Fast|O
S3748|Acting|O
S3748|Insulin|O
S3748|Aspart|O
S3748|Compared|O
S3748|with|O
S3748|Insulin|O
S3748|Aspart|O
S3748|in|O
S3748|the|O
S3748|Medtronic|O
S3748|670G|O
S3748|Hybrid|O
S3748|Closed|O
S3748|Loop|O
S3748|System|O
S3748|in|O
S3748|Type|O
S3748|1|O
S3748|Diabetes|O
S3748|:|O
S3748|An|O
S3748|Open|B-Blinding_Open_Label
S3748|Label|I-Blinding_Open_Label
S3748|Crossover|B-Design_Crossover
S3748|Study|O
S4404|All|O
S4404|participants|B-Blinding_Object_Patients
S4404|,|O
S4404|study|B-Blinding_Object_Others
S4404|monitors|I-Blinding_Object_Others
S4404|,|O
S4404|study|B-Blinding_Object_Care_Providers
S4404|center|I-Blinding_Object_Care_Providers
S4404|personnel|I-Blinding_Object_Care_Providers
S4404|and|O
S4404|contract|B-Blinding_Object_Others
S4404|research|I-Blinding_Object_Others
S4404|organization|I-Blinding_Object_Others
S4404|personnel|I-Blinding_Object_Others
S4404|were|O
S4404|blinded|O
S4404|to|O
S4404|treatment|O
S4404|assignment|O
S4404|.|O
S5496|Fieldworkers|O
S5496|allocated|O
S5496|children|O
S5496|to|O
S5496|randomisation|O
S5496|groups|O
S5496|during|O
S5496|recruitment|O
S5496|and|O
S5496|gave|O
S5496|vitamin|B-Design_Parallel_Group
S5496|D|I-Design_Parallel_Group
S5496|or|I-Design_Parallel_Group
S5496|placebo|I-Design_Parallel_Group
S5496|.|O
S6903|Following|O
S6903|a|O
S6903|prespecified|O
S6903|blinded|O
S6903|sample|O
S6903|size|O
S6903|reestimation|O
S6903|(|O
S6903|based|O
S6903|on|O
S6903|an|O
S6903|overall|O
S6903|SD=8.8|O
S6903|mm|O
S6903|Hg|O
S6903|observed|O
S6903|in|O
S6903|the|O
S6903|first|O
S6903|119|O
S6903|patients|O
S6903|)|O
S6903|,|O
S6903|the|O
S6903|size|O
S6903|of|O
S6903|the|O
S6903|per-protocol|O
S6903|set|O
S6903|was|O
S6903|reduced|O
S6903|to|O
S6903|66|B-Sample_Size_Required
S6903|patients|I-Sample_Size_Required
S6903|per|I-Sample_Size_Required
S6903|group|I-Sample_Size_Required
S6903|.|O
S5022|The|O
S5022|sample|O
S5022|size|O
S5022|was|O
S5022|selected|O
S5022|to|O
S5022|provide|O
S5022|a|O
S5022|minimum|O
S5022|of|O
S5022|90|O
S5022|%|O
S5022|power|O
S5022|for|O
S5022|the|O
S5022|superiority|B-Design_Comparative_Intent_Superiority
S5022|hypotheses|O
S5022|(|O
S5022|intravitreal|O
S5022|triamcinolone|O
S5022|injection|O
S5022|and|O
S5022|dexamethasone|O
S5022|implant|O
S5022|superior|O
S5022|to|O
S5022|periocular|O
S5022|injection|O
S5022|)|O
S5022|and|O
S5022|80|O
S5022|%|O
S5022|power|O
S5022|for|O
S5022|the|O
S5022|non-inferiority|O
S5022|hypothesis|O
S5022|(|O
S5022|intravitreal|O
S5022|dexamethasone|O
S5022|implant|O
S5022|non-inferior|O
S5022|to|O
S5022|intravitreal|O
S5022|triamcinolone|O
S5022|injection|O
S5022|)|O
S5022|.|O
S587|Consecutive|O
S587|patients|O
S587|were|O
S587|screened|O
S587|for|O
S587|eligibility|O
S587|at|O
S587|all|O
S587|the|O
S587|25|B-Settings_Multicenter
S587|Italian|B-Settings_Location
S587|ALS|I-Settings_Multicenter
S587|centres|I-Settings_Multicenter
S587|.|O
S5362|RESULTS|O
S5362|Patients|O
S5362|A|O
S5362|total|O
S5362|of|O
S5362|2560|O
S5362|patients|O
S5362|were|O
S5362|screened|O
S5362|,|O
S5362|of|O
S5362|whom|O
S5362|1538|B-Sample_Size_Actual_at_Enrollment
S5362|were|O
S5362|randomized|O
S5362|2:1|O
S5362|to|O
S5362|IIM|O
S5362|(|O
S5362|n|O
S5362|=|O
S5362|1027|O
S5362|)|O
S5362|or|O
S5362|IS|O
S5362|(|O
S5362|n|O
S5362|=|O
S5362|511|O
S5362|)|O
S5362|.|O
S5782|A|O
S5782|total|O
S5782|of|O
S5782|305|B-Sample_Size_Actual_at_Outcome_Analysis
S5782|patients|O
S5782|completed|O
S5782|treatment|O
S5782|(|O
S5782|placebo|O
S5782|,|O
S5782|n|O
S5782|=|O
S5782|124|O
S5782|;|O
S5782|AMG|O
S5782|301|O
S5782|210|O
S5782|mg|O
S5782|,|O
S5782|n|O
S5782|=|O
S5782|94|O
S5782|;|O
S5782|AMG|O
S5782|301|O
S5782|420|O
S5782|mg|O
S5782|,|O
S5782|n|O
S5782|=|O
S5782|87|O
S5782|)|O
S5782|.|O
S4695|Assuming|O
S4695|a|O
S4695|standard|O
S4695|deviation|O
S4695|(|O
S4695|SD|O
S4695|)|O
S4695|of|O
S4695|1.0|O
S4695|%|O
S4695|,|O
S4695|a|O
S4695|sample|O
S4695|size|O
S4695|of|O
S4695|105|O
S4695|patients|O
S4695|from|O
S4695|mainland|O
S4695|China|O
S4695|per|O
S4695|group|O
S4695|(|O
S4695|315|O
S4695|in|O
S4695|total|O
S4695|)|O
S4695|provided|O
S4695|~95|B-Sample_Size_Calculation_Power_Value
S4695|%|I-Sample_Size_Calculation_Power_Value
S4695|power|O
S4695|to|O
S4695|detect|O
S4695|a|O
S4695|difference|O
S4695|in|O
S4695|HbA1c|O
S4695|change|O
S4695|from|O
S4695|baseline|O
S4695|of|O
S4695|0.5|O
S4695|%|O
S4695|between|O
S4695|each|O
S4695|ertugliflozin|O
S4695|dose|O
S4695|and|O
S4695|placebo|O
S4695|(|O
S4695|and|O
S4695|~90|B-Sample_Size_Calculation_Power_Value
S4695|%|I-Sample_Size_Calculation_Power_Value
S4695|power|O
S4695|for|O
S4695|detecting|O
S4695|this|O
S4695|difference|O
S4695|for|O
S4695|both|O
S4695|doses|O
S4695|vs.|O
S4695|placebo|O
S4695|)|O
S4695|using|O
S4695|a|O
S4695|two‐sided|O
S4695|0.05|B-Sample_Size_Calculation_Alpha_Value
S4695|alpha|O
S4695|level|O
S4695|test|O
S4695|.|O
S451|Treatment|O
S451|protocol|O
S451|Subjects|O
S451|were|O
S451|randomised|O
S451|in|O
S451|a|O
S451|1:1|B-Randomization_Ratio
S451|ratio|O
S451|to|O
S451|receive|O
S451|once|O
S451|daily|O
S451|oral|O
S451|doses|O
S451|of|O
S451|either|O
S451|filgotinib|B-Design_Parallel_Group
S451|200|I-Design_Parallel_Group
S451|mg|I-Design_Parallel_Group
S451|(|I-Design_Parallel_Group
S451|plus|I-Design_Parallel_Group
S451|placebo|I-Design_Parallel_Group
S451|to|I-Design_Parallel_Group
S451|match|I-Design_Parallel_Group
S451|(|I-Design_Parallel_Group
S451|PTM|I-Design_Parallel_Group
S451|)|I-Design_Parallel_Group
S451|lanraplenib|I-Design_Parallel_Group
S451|)|I-Design_Parallel_Group
S451|or|I-Design_Parallel_Group
S451|lanraplenib|I-Design_Parallel_Group
S451|30|I-Design_Parallel_Group
S451|mg|I-Design_Parallel_Group
S451|(|I-Design_Parallel_Group
S451|plus|I-Design_Parallel_Group
S451|PTM|I-Design_Parallel_Group
S451|filgotinib|I-Design_Parallel_Group
S451|)|I-Design_Parallel_Group
S451|.|O
S3678|Participants|B-Blinding_Object_Patients
S3678|,|O
S3678|investigator|B-Blinding_Object_Investigators
S3678|site|I-Blinding_Object_Investigators
S3678|staff|I-Blinding_Object_Investigators
S3678|and|O
S3678|the|O
S3678|sponsor|B-Blinding_Object_Others
S3678|study|I-Blinding_Object_Others
S3678|team|I-Blinding_Object_Others
S3678|were|O
S3678|blinded|O
S3678|to|O
S3678|the|O
S3678|study|O
S3678|treatment|O
S3678|.|O
S741|To|O
S741|maintain|O
S741|double-blinding|O
S741|for|O
S741|both|O
S741|investigators|B-Blinding_Object_Investigators
S741|and|O
S741|participants|B-Blinding_Object_Patients
S741|,|O
S741|individuals|B-Randomization_Personnel
S741|not|I-Randomization_Personnel
S741|associated|I-Randomization_Personnel
S741|with|I-Randomization_Personnel
S741|study|I-Randomization_Personnel
S741|conduct|I-Randomization_Personnel
S741|created|O
S741|the|O
S741|randomization|O
S741|sequence|O
S741|and|O
S741|allocation|O
S741|containers|O
S741|.|O
S7180|The|O
S7180|target|O
S7180|sample|O
S7180|size|O
S7180|of|O
S7180|1334|B-Sample_Size_Required
S7180|gave|O
S7180|90|B-Sample_Size_Calculation_Power_Value
S7180|%|I-Sample_Size_Calculation_Power_Value
S7180|power|O
S7180|at|O
S7180|p|B-Sample_Size_Calculation_Alpha_Value
S7180|<|I-Sample_Size_Calculation_Alpha_Value
S7180|0·05|I-Sample_Size_Calculation_Alpha_Value
S7180|to|O
S7180|detect|O
S7180|a|O
S7180|risk|O
S7180|ratio|O
S7180|(|O
S7180|RR|O
S7180|)|O
S7180|of|O
S7180|0·8|O
S7180|for|O
S7180|28-day|O
S7180|mortality|O
S7180|between|O
S7180|the|O
S7180|salbutamol|O
S7180|and|O
S7180|placebo|O
S7180|groups|O
S7180|with|O
S7180|a|O
S7180|3|B-Sample_Size_Calculation_Dropout_Rate_Value
S7180|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S7180|loss|O
S7180|of|O
S7180|patients|O
S7180|for|O
S7180|the|O
S7180|primary|O
S7180|outcome|O
S7180|,|O
S7180|with|O
S7180|the|O
S7180|assumption|O
S7180|that|O
S7180|the|O
S7180|28-day|O
S7180|mortality|O
S7180|in|O
S7180|the|O
S7180|placebo|O
S7180|group|O
S7180|was|O
S7180|44|O
S7180|%|O
S7180|.|O
S764|For|O
S764|our|O
S764|primary|O
S764|outcome|O
S764|we|O
S764|assumed|O
S764|a|O
S764|standard|O
S764|deviation|O
S764|of|O
S764|26-mm|O
S764|on|O
S764|the|O
S764|100-mm|O
S764|VAS|O
S764|for|O
S764|pain|O
S764|,|O
S764|as|O
S764|reported|O
S764|from|O
S764|prior|O
S764|abortion|O
S764|pain|O
S764|research|O
S764|studies|O
S764|,|O
S764|and|O
S764|a|O
S764|type|O
S764|I|O
S764|error|O
S764|rate|O
S764|of|O
S764|0.05|B-Sample_Size_Calculation_Alpha_Value
S764|,|O
S764|and|O
S764|determined|O
S764|the|O
S764|number|O
S764|of|O
S764|participants|O
S764|needed|O
S764|to|O
S764|achieve|O
S764|80|B-Sample_Size_Calculation_Power_Value
S764|%|I-Sample_Size_Calculation_Power_Value
S764|power|O
S764|to|O
S764|detect|O
S764|a|O
S764|15-mm|O
S764|difference|O
S764|in|O
S764|pain|O
S764|at|O
S764|five|O
S764|minutes|O
S764|post-procedure|O
S764|.|O
S10|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S10|of|O
S10|both|O
S10|hemagglutination|O
S10|inhibition|O
S10|geometric|O
S10|mean|O
S10|titers|O
S10|and|O
S10|seroconversion|O
S10|rates|O
S10|was|O
S10|demonstrated|O
S10|for|O
S10|all|O
S10|4|O
S10|vaccine|O
S10|strains|O
S10|for|O
S10|the|O
S10|full|O
S10|dose|O
S10|versus|O
S10|the|O
S10|half|O
S10|dose|O
S10|.|O
S2533|Declarations|O
S2533|CXCR2|O
S2533|antagonist|O
S2533|for|O
S2533|patients|O
S2533|with|O
S2533|chronic|O
S2533|obstructive|O
S2533|pulmonary|O
S2533|disease|O
S2533|with|O
S2533|chronic|O
S2533|mucus|O
S2533|hypersecretion|O
S2533|:|O
S2533|a|O
S2533|phase|B-Design_Phase_2
S2533|2b|I-Design_Phase_2
S2533|trial|O
S7201|326|B-Sample_Size_Actual_at_Enrollment
S7201|patients|O
S7201|were|O
S7201|randomly|O
S7201|assigned|O
S7201|to|O
S7201|receive|O
S7201|either|O
S7201|salbutamol|B-Design_Parallel_Group
S7201|or|I-Design_Parallel_Group
S7201|placebo|I-Design_Parallel_Group
S7201|.|O
S909|Participants|O
S909|were|O
S909|stratified|B-Randomization_Type_Stratified
S909|according|O
S909|to|O
S909|baseline|B-Randomization_Stratified_Criteria
S909|MGI|I-Randomization_Stratified_Criteria
S909|score|I-Randomization_Stratified_Criteria
S909|(|I-Randomization_Stratified_Criteria
S909|low|I-Randomization_Stratified_Criteria
S909|:|I-Randomization_Stratified_Criteria
S909|≤|I-Randomization_Stratified_Criteria
S909|2.00|I-Randomization_Stratified_Criteria
S909|;|I-Randomization_Stratified_Criteria
S909|high|I-Randomization_Stratified_Criteria
S909|:|I-Randomization_Stratified_Criteria
S909|>|I-Randomization_Stratified_Criteria
S909|2.00|I-Randomization_Stratified_Criteria
S909|)|I-Randomization_Stratified_Criteria
S909|and|O
S909|sex|B-Randomization_Stratified_Criteria
S909|(|I-Randomization_Stratified_Criteria
S909|female/male|I-Randomization_Stratified_Criteria
S909|)|I-Randomization_Stratified_Criteria
S909|.|O
S6137|RESULTS|O
S6137|Subject|O
S6137|Disposition|O
S6137|A|O
S6137|total|O
S6137|of|O
S6137|98|B-Sample_Size_Actual_at_Enrollment
S6137|subjects|O
S6137|were|O
S6137|randomized|O
S6137|into|O
S6137|the|O
S6137|study|O
S6137|and|O
S6137|were|O
S6137|included|O
S6137|in|O
S6137|the|O
S6137|intention-to-treat|O
S6137|population|O
S6137|(|O
S6137|QD|O
S6137|,|O
S6137|n|O
S6137|=|O
S6137|50|O
S6137|;|O
S6137|BID|O
S6137|,|O
S6137|n|O
S6137|=|O
S6137|48|O
S6137|)|O
S6137|.|O
S8600|High-sensitivity|O
S8600|C-reactive|O
S8600|protein|O
S8600|was|O
S8600|significantly|O
S8600|reduced|O
S8600|by|O
S8600|canakinumab|B-Design_Parallel_Group
S8600|compared|I-Design_Parallel_Group
S8600|with|I-Design_Parallel_Group
S8600|placebo|I-Design_Parallel_Group
S8600|at|O
S8600|3|O
S8600|months|O
S8600|(|O
S8600|geometric|O
S8600|mean|O
S8600|ratio|O
S8600|[|O
S8600|GMR|O
S8600|]|O
S8600|:|O
S8600|0.568|O
S8600|;|O
S8600|95|O
S8600|%|O
S8600|confidence|O
S8600|interval|O
S8600|[|O
S8600|CI|O
S8600|]|O
S8600|:|O
S8600|0.436|O
S8600|to|O
S8600|0.740|O
S8600|;|O
S8600|p|O
S8600|<|O
S8600|0.0001|O
S8600|)|O
S8600|and|O
S8600|12|O
S8600|months|O
S8600|(|O
S8600|GMR|O
S8600|:|O
S8600|0.56|O
S8600|;|O
S8600|95|O
S8600|%|O
S8600|CI|O
S8600|:|O
S8600|0.414|O
S8600|to|O
S8600|0.758|O
S8600|;|O
S8600|p|O
S8600|=|O
S8600|0.0002|O
S8600|)|O
S8600|.|O
S3812|Sample|O
S3812|size|O
S3812|and|O
S3812|statistical|O
S3812|analysis|O
S3812|It|O
S3812|was|O
S3812|calculated|O
S3812|that|O
S3812|there|O
S3812|is|O
S3812|at|O
S3812|least|O
S3812|80|B-Sample_Size_Calculation_Power_Value
S3812|%|I-Sample_Size_Calculation_Power_Value
S3812|power|O
S3812|to|O
S3812|detect|O
S3812|a|O
S3812|treatment|O
S3812|difference|O
S3812|with|O
S3812|36|B-Sample_Size_Required
S3812|subjects|O
S3812|.|O
S6564|Results|O
S6564|Of|O
S6564|76|B-Sample_Size_Actual_at_Enrollment
S6564|participants|O
S6564|enrolled|O
S6564|(|O
S6564|mean|O
S6564|[|O
S6564|SD|O
S6564|]|O
S6564|age|O
S6564|,|O
S6564|78.5|O
S6564|[|O
S6564|8.5|O
S6564|]|O
S6564|years|O
S6564|;|O
S6564|age|O
S6564|range|O
S6564|,|O
S6564|56-94|O
S6564|years|O
S6564|;|O
S6564|41|O
S6564|women|O
S6564|[|O
S6564|58|O
S6564|%|O
S6564|]|O
S6564|;|O
S6564|69|O
S6564|white|O
S6564|[|O
S6564|97|O
S6564|%|O
S6564|]|O
S6564|)|O
S6564|,|O
S6564|16|O
S6564|(|O
S6564|21.0|O
S6564|%|O
S6564|)|O
S6564|were|O
S6564|randomized|O
S6564|to|O
S6564|ranibizumab|O
S6564|every|O
S6564|4|O
S6564|weeks|O
S6564|,|O
S6564|29|O
S6564|(|O
S6564|38.2|O
S6564|%|O
S6564|)|O
S6564|to|O
S6564|faricimab|O
S6564|every|O
S6564|12|O
S6564|weeks|O
S6564|,|O
S6564|and|O
S6564|31|O
S6564|(|O
S6564|40.8|O
S6564|%|O
S6564|)|O
S6564|to|O
S6564|faricimab|O
S6564|every|O
S6564|16|O
S6564|weeks|O
S6564|.|O
S5027|Based|O
S5027|upon|O
S5027|these|O
S5027|assumptions|O
S5027|,|O
S5027|a|O
S5027|sample|O
S5027|size|O
S5027|of|O
S5027|89|O
S5027|independent|O
S5027|eyes|O
S5027|per|O
S5027|treatment|O
S5027|group|O
S5027|provided|O
S5027|80|O
S5027|%|O
S5027|power|O
S5027|to|O
S5027|demonstrate|O
S5027|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S5027|of|O
S5027|the|O
S5027|intravitreal|O
S5027|dexamethasone|O
S5027|implant|O
S5027|as|O
S5027|compared|O
S5027|to|O
S5027|intravitreal|O
S5027|triamcinolone|O
S5027|injection|O
S5027|with|O
S5027|a|O
S5027|one-sided|O
S5027|type|O
S5027|I|O
S5027|error|O
S5027|rate|O
S5027|of|O
S5027|0.01667|O
S5027|.|O
S7754|Research|O
S7754|Design|O
S7754|and|O
S7754|Methods|O
S7754|Trial|O
S7754|Design|O
S7754|In|O
S7754|this|O
S7754|phase|B-Design_Phase_3
S7754|3b|I-Design_Phase_3
S7754|,|O
S7754|multicenter|B-Settings_Multicenter
S7754|,|O
S7754|active-controlled|O
S7754|,|O
S7754|treat-to-target|O
S7754|,|O
S7754|randomized|B-Randomization_Type_Simple
S7754|,|O
S7754|parallel-group|B-Design_Parallel_Group
S7754|trial|O
S7754|(|O
S7754|ClinicalTrials.gov|O
S7754|:|O
S7754|NCT03268005|O
S7754|)|O
S7754|,|O
S7754|faster|O
S7754|aspart|O
S7754|was|O
S7754|compared|O
S7754|with|O
S7754|IAsp|O
S7754|,|O
S7754|both|O
S7754|in|O
S7754|combination|O
S7754|with|O
S7754|insulin|O
S7754|degludec|O
S7754|with|O
S7754|or|O
S7754|without|O
S7754|metformin|O
S7754|,|O
S7754|in|O
S7754|adults|O
S7754|with|O
S7754|type|O
S7754|2|O
S7754|diabetes|O
S7754|not|O
S7754|optimally|O
S7754|controlled|O
S7754|with|O
S7754|basal-bolus|O
S7754|treatment|O
S7754|(|O
S7754|Supplementary|O
S7754|Fig|O
S7754|.|O
S743|Participants|O
S743|received|O
S743|both|O
S743|usual|O
S743|perioperative|O
S743|pain|O
S743|management|O
S743|and|O
S743|either|O
S743|oral|B-Design_Parallel_Group
S743|placebo|I-Design_Parallel_Group
S743|or|I-Design_Parallel_Group
S743|gabapentin|I-Design_Parallel_Group
S743|600|I-Design_Parallel_Group
S743|mg|I-Design_Parallel_Group
S743|one|O
S743|to|O
S743|two|O
S743|hours|O
S743|prior|O
S743|to|O
S743|uterine|O
S743|aspiration|O
S743|allocated|O
S743|by|O
S743|the|O
S743|clinic|O
S743|nurse|O
S743|,|O
S743|as|O
S743|is|O
S743|standard|O
S743|practice|O
S743|in|O
S743|our|O
S743|clinic|O
S743|.|O
S2698|Tenapanor|O
S2698|Treatment|O
S2698|of|O
S2698|Patients|O
S2698|With|O
S2698|Constipation-Predominant|O
S2698|Irritable|O
S2698|Bowel|O
S2698|Syndrome|O
S2698|:|O
S2698|A|O
S2698|Phase|B-Design_Phase_2
S2698|2|I-Design_Phase_2
S2698|,|O
S2698|Randomized|O
S2698|,|O
S2698|Placebo-Controlled|O
S2698|Efficacy|O
S2698|and|O
S2698|Safety|O
S2698|Trial|O
S1228|Other|O
S1228|secondary|O
S1228|efficacy|O
S1228|analyses|O
S1228|involved|O
S1228|superiority|O
S1228|comparisons|O
S1228|of|O
S1228|secondary|O
S1228|endpoints|O
S1228|for|O
S1228|each|O
S1228|treatment|O
S1228|group|O
S1228|versus|O
S1228|placebo|O
S1228|MDI|O
S1228|and|O
S1228|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1228|comparisons|O
S1228|versus|O
S1228|open-label|B-Blinding_Open_Label
S1228|tiotropium|O
S1228|.|O
S2735|;|I-Design_Parallel_Group
S2735|dosed|I-Design_Parallel_Group
S2735|as|I-Design_Parallel_Group
S2735|the|I-Design_Parallel_Group
S2735|hydrochloride|I-Design_Parallel_Group
S2735|salt|I-Design_Parallel_Group
S2735|)|I-Design_Parallel_Group
S2735|or|I-Design_Parallel_Group
S2735|placebo|I-Design_Parallel_Group
S2735|b.i.d|I-Design_Parallel_Group
S2735|.|O
S6860|Randomization|O
S6860|was|O
S6860|implemented|O
S6860|by|O
S6860|Interactive|B-Randomization_Sequence_Generation_Method
S6860|Response|I-Randomization_Sequence_Generation_Method
S6860|Technology|I-Randomization_Sequence_Generation_Method
S6860|and|O
S6860|performed|O
S6860|using|O
S6860|a|O
S6860|central|B-Randomization_Sequence_Generation_Method
S6860|randomization|I-Randomization_Sequence_Generation_Method
S6860|list|I-Randomization_Sequence_Generation_Method
S6860|,|O
S6860|unstratified|O
S6860|and|O
S6860|with|O
S6860|a|O
S6860|block|B-Randomization_Type_Block
S6860|size|I-Randomization_Type_Block
S6860|of|O
S6860|6|B-Randomization_Block_Size
S6860|,|O
S6860|generated|O
S6860|and|O
S6860|kept|O
S6860|by|O
S6860|a|O
S6860|group|B-Randomization_Personnel
S6860|external|I-Randomization_Personnel
S6860|to|I-Randomization_Personnel
S6860|the|I-Randomization_Personnel
S6860|study|I-Randomization_Personnel
S6860|sponsor|I-Randomization_Personnel
S6860|.|O
S6907|A|O
S6907|total|O
S6907|of|O
S6907|430|B-Sample_Size_Actual_at_Outcome_Analysis
S6907|patients|O
S6907|completed|O
S6907|the|O
S6907|8-week|O
S6907|treatment|O
S6907|period|O
S6907|.|O
S2951|In|O
S2951|total|O
S2951|,|O
S2951|169|B-Sample_Size_Actual_at_Outcome_Analysis
S2951|children|I-Sample_Size_Actual_at_Outcome_Analysis
S2951|(|O
S2951|96|O
S2951|%|O
S2951|)|O
S2951|completed|O
S2951|the|O
S2951|trial|O
S2951|(|O
S2951|Fig|O
S2951|.|O
S8450|A|O
S8450|single|B-Settings_Single_Center
S8450|center|I-Settings_Single_Center
S8450|parallel|B-Design_Parallel_Group
S8450|double-blind|B-Blinding_Double_Blind
S8450|randomized|O
S8450|clinical|O
S8450|trial|O
S8450|with|O
S8450|6|O
S8450|months|O
S8450|of|O
S8450|follow-up|O
S8450|was|O
S8450|performed|O
S8450|in|O
S8450|patients|O
S8450|with|O
S8450|persistent|O
S8450|IGT|O
S8450|after|O
S8450|12|O
S8450|months|O
S8450|of|O
S8450|treatment|O
S8450|with|O
S8450|metformin|O
S8450|and|O
S8450|lifestyle|O
S8450|;|O
S8450|patients|O
S8450|were|O
S8450|randomized|B-Randomization_Type_Simple
S8450|to|O
S8450|continue|O
S8450|with|O
S8450|metformin|O
S8450|850|O
S8450|mg|O
S8450|twice|O
S8450|daily|O
S8450|(|O
S8450|M|O
S8450|group|O
S8450|,|O
S8450|n|O
S8450|=|O
S8450|12|O
S8450|)|O
S8450|or|O
S8450|linagliptin/metformin|O
S8450|2.5/850|O
S8450|mg|O
S8450|twice|O
S8450|daily|O
S8450|(|O
S8450|LM|O
S8450|group|O
S8450|,|O
S8450|n|O
S8450|=|O
S8450|19|O
S8450|)|O
S8450|.|O
S4133|RESULTS|O
S4133|Study|O
S4133|Population|O
S4133|Of|O
S4133|the|O
S4133|1051|B-Sample_Size_Actual_at_Enrollment
S4133|participants|O
S4133|randomized|O
S4133|,|O
S4133|1044|O
S4133|participants|O
S4133|received|O
S4133|at|O
S4133|least|O
S4133|1|O
S4133|dose|O
S4133|of|O
S4133|study|O
S4133|vaccine|O
S4133|,|O
S4133|927|O
S4133|(|O
S4133|88.2|O
S4133|%|O
S4133|)|O
S4133|completed|O
S4133|the|O
S4133|4-dose|O
S4133|vaccine|O
S4133|regimen|O
S4133|and|O
S4133|921|B-Sample_Size_Actual_at_Outcome_Analysis
S4133|completed|O
S4133|the|O
S4133|final|O
S4133|study|O
S4133|visit|O
S4133|(|O
S4133|87.6|O
S4133|%|O
S4133|)|O
S4133|(|O
S4133|Figure|O
S4133|,|O
S4133|Supplemental|O
S4133|Digital|O
S4133|Content|O
S4133|2|O
S4133|,|O
S4133|http|O
S4133|:|O
S4133|//links.lww.com/INF/E54|O
S4133|)|O
S4133|.|O
S302|After|O
S302|a|O
S302|screening|O
S302|period|O
S302|not|O
S302|exceeding|O
S302|30|O
S302|days|O
S302|and|O
S302|after|O
S302|eligibility|O
S302|requirements|O
S302|were|O
S302|confirmed|O
S302|on|O
S302|day|O
S302|1|O
S302|(|O
S302|baseline|O
S302|)|O
S302|,|O
S302|screening|O
S302|numbers|O
S302|were|O
S302|entered|O
S302|into|O
S302|an|O
S302|interactive|B-Randomization_Sequence_Generation_Method
S302|web|I-Randomization_Sequence_Generation_Method
S302|response|I-Randomization_Sequence_Generation_Method
S302|system|I-Randomization_Sequence_Generation_Method
S302|,|O
S302|and|O
S302|patients|O
S302|were|O
S302|randomized|B-Randomization_Type_Simple
S302|2:3:3:3|B-Randomization_Ratio
S302|to|O
S302|matching|O
S302|placebo|O
S302|every|O
S302|2|O
S302|weeks|O
S302|or|O
S302|to|O
S302|subcutaneous|O
S302|injections|O
S302|of|O
S302|lebrikizumab|O
S302|at|O
S302|the|O
S302|following|O
S302|doses|O
S302|:|O
S302|125|O
S302|mg|O
S302|every|O
S302|4|O
S302|weeks|O
S302|(|O
S302|250-mg|O
S302|loading|O
S302|dose|O
S302|[|O
S302|LD|O
S302|]|O
S302|)|O
S302|,|O
S302|250|O
S302|mg|O
S302|every|O
S302|4|O
S302|weeks|O
S302|(|O
S302|500-mg|O
S302|LD|O
S302|)|O
S302|,|O
S302|or|O
S302|250|O
S302|mg|O
S302|every|O
S302|2|O
S302|weeks|O
S302|(|O
S302|500-mg|O
S302|LD|O
S302|at|O
S302|baseline|O
S302|and|O
S302|week|O
S302|2|O
S302|)|O
S302|.|O
S3500|Materials|O
S3500|and|O
S3500|methods|O
S3500|Trial|O
S3500|design|O
S3500|This|O
S3500|was|O
S3500|a|O
S3500|randomised|O
S3500|,|O
S3500|controlled|O
S3500|,|O
S3500|assessor-blind|B-Blinding_Single_Blind
S3500|,|O
S3500|parallel|B-Design_Parallel_Group
S3500|groups|I-Design_Parallel_Group
S3500|,|O
S3500|multi-centre|B-Settings_Multicenter
S3500|,|O
S3500|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S3500|trial|O
S3500|comparing|O
S3500|the|O
S3500|efficacy|O
S3500|and|O
S3500|safety|O
S3500|of|O
S3500|follitropin|O
S3500|delta|O
S3500|in|O
S3500|its|O
S3500|individualised|O
S3500|fixed-dose|O
S3500|regimen|O
S3500|with|O
S3500|follitropin|O
S3500|alfa|O
S3500|in|O
S3500|a|O
S3500|conventional|O
S3500|adjustable|O
S3500|dosing|O
S3500|regimen|O
S3500|in|O
S3500|Asian|O
S3500|women|O
S3500|undergoing|O
S3500|their|O
S3500|first|O
S3500|ovarian|O
S3500|stimulation|O
S3500|cycle|O
S3500|.|O
S604|Masking|O
S604|RhEPO|O
S604|(|O
S604|Eprex|O
S604|)|O
S604|was|O
S604|purchased|O
S604|from|O
S604|Janssen-Cilag|O
S604|SpA|O
S604|(|O
S604|Cologno|O
S604|Monzese|O
S604|,|O
S604|Italy|O
S604|)|O
S604|by|O
S604|the|O
S604|coordinating|O
S604|centre|O
S604|and|O
S604|directly|O
S604|shipped|O
S604|to|O
S604|the|O
S604|company|O
S604|(|O
S604|Pierrel|O
S604|Research|O
S604|IMP|O
S604|srl|O
S604|,|O
S604|Cantù|O
S604|,|O
S604|Italy|O
S604|)|O
S604|in|O
S604|charge|O
S604|of|O
S604|preparing|O
S604|the|O
S604|investigational|O
S604|drug|O
S604|(|O
S604|rhEPO|O
S604|or|O
S604|1|O
S604|cc|O
S604|of|O
S604|saline|O
S604|)|O
S604|in|O
S604|syringes|O
S604|of|O
S604|identical|O
S604|appearance|O
S604|,|O
S604|sealed|B-Allocation_Concealment_Method
S604|in|I-Allocation_Concealment_Method
S604|sequentially|I-Allocation_Concealment_Method
S604|numbered|I-Allocation_Concealment_Method
S604|identical|I-Allocation_Concealment_Method
S604|containers|I-Allocation_Concealment_Method
S604|according|O
S604|to|O
S604|the|O
S604|allocation|O
S604|sequence|O
S604|.|O
S7590|Study|B-Blinding_Object_Patients
S7590|participants|I-Blinding_Object_Patients
S7590|,|O
S7590|investigators|B-Blinding_Object_Investigators
S7590|,|O
S7590|and|O
S7590|site|O
S7590|and|O
S7590|sponsor|B-Blinding_Object_Others
S7590|staff|I-Blinding_Object_Others
S7590|were|O
S7590|all|O
S7590|blinded|O
S7590|to|O
S7590|the|O
S7590|treatment|O
S7590|assignment|O
S7590|.|O
S8524|Of|O
S8524|the|O
S8524|31|B-Sample_Size_Actual_at_Enrollment
S8524|patients|O
S8524|enrolled|O
S8524|in|O
S8524|the|O
S8524|study|O
S8524|,|O
S8524|12|O
S8524|were|O
S8524|randomly|O
S8524|assigned|O
S8524|to|O
S8524|Metformin|O
S8524|group|O
S8524|(|O
S8524|7|O
S8524|with|O
S8524|isolated|O
S8524|IGT|O
S8524|and|O
S8524|5|O
S8524|with|O
S8524|combined|O
S8524|IFG|O
S8524|+|O
S8524|IGT|O
S8524|)|O
S8524|and|O
S8524|19|O
S8524|to|O
S8524|linagliptin|O
S8524|+|O
S8524|metformin|O
S8524|group|O
S8524|(|O
S8524|9|O
S8524|with|O
S8524|isolated|O
S8524|IGT|O
S8524|and|O
S8524|10|O
S8524|with|O
S8524|combined|O
S8524|IFG|O
S8524|+|O
S8524|IGT|O
S8524|)|O
S8524|;|O
S8524|however|O
S8524|,|O
S8524|2|O
S8524|patients|O
S8524|in|O
S8524|the|O
S8524|metformin|O
S8524|group|O
S8524|and|O
S8524|4|O
S8524|in|O
S8524|the|O
S8524|linagliptin|O
S8524|+|O
S8524|metformin|O
S8524|group|O
S8524|were|O
S8524|excluded|O
S8524|from|O
S8524|the|O
S8524|study|O
S8524|because|O
S8524|they|O
S8524|did|O
S8524|not|O
S8524|attend|O
S8524|their|O
S8524|follow-up|O
S8524|appointments|O
S8524|(|O
S8524|Fig|O
S8524|.|O
S2705|Results|O
S2705|:|O
S2705|Overall|O
S2705|,|O
S2705|356|B-Sample_Size_Actual_at_Enrollment
S2705|patients|O
S2705|were|O
S2705|randomized|O
S2705|(|O
S2705|mean|O
S2705|age|O
S2705|:|O
S2705|45.7|O
S2705|years|O
S2705|;|O
S2705|86.8|O
S2705|%|O
S2705|women|O
S2705|)|O
S2705|and|O
S2705|304|B-Sample_Size_Actual_at_Outcome_Analysis
S2705|completed|O
S2705|the|O
S2705|study|O
S2705|.|O
S7578|Twenty-nine|B-Settings_Multicenter
S7578|centers|I-Settings_Multicenter
S7578|in|O
S7578|5|O
S7578|countries|O
S7578|randomized|O
S7578|at|O
S7578|least|O
S7578|one|O
S7578|participant|O
S7578|:|O
S7578|8|O
S7578|centers|O
S7578|in|O
S7578|the|O
S7578|Russian|B-Settings_Location
S7578|Federation|I-Settings_Location
S7578|,|O
S7578|7|O
S7578|each|O
S7578|in|O
S7578|Spain|B-Settings_Location
S7578|and|O
S7578|the|O
S7578|United|B-Settings_Location
S7578|States|I-Settings_Location
S7578|,|O
S7578|4|O
S7578|in|O
S7578|Canada|B-Settings_Location
S7578|,|O
S7578|and|O
S7578|3|O
S7578|in|O
S7578|Germany|B-Settings_Location
S7578|.|O
S6|Results|O
S6|:|O
S6|The|O
S6|study|O
S6|included|O
S6|1950|B-Sample_Size_Actual_at_Enrollment
S6|children|I-Sample_Size_Actual_at_Enrollment
S6|.|O
S2045|Results|O
S2045|Of|O
S2045|193|B-Sample_Size_Actual_at_Enrollment
S2045|subjects|O
S2045|who|O
S2045|were|O
S2045|randomised|O
S2045|(|O
S2045|98|O
S2045|CT‐P17|O
S2045|AI|O
S2045|;|O
S2045|95|O
S2045|CT‐P17|O
S2045|PFS|O
S2045|)|O
S2045|,|O
S2045|180|B-Sample_Size_Actual_at_Outcome_Analysis
S2045|received|O
S2045|study|O
S2045|drug|O
S2045|.|O
S64|For|O
S64|the|O
S64|1600|B-Sample_Size_Actual_at_Enrollment
S64|participants|O
S64|who|O
S64|were|O
S64|to|O
S64|be|O
S64|randomly|O
S64|assigned|O
S64|to|O
S64|the|O
S64|immunogenicity|O
S64|subset|O
S64|,|O
S64|assuming|O
S64|an|O
S64|attrition|O
S64|rate|O
S64|of|O
S64|20|B-Sample_Size_Calculation_Dropout_Rate_Value
S64|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S64|,|O
S64|a|O
S64|1-sided|B-Sample_Size_Calculation_Alpha_Value
S64|alpha|I-Sample_Size_Calculation_Alpha_Value
S64|of|I-Sample_Size_Calculation_Alpha_Value
S64|2.5|I-Sample_Size_Calculation_Alpha_Value
S64|%|I-Sample_Size_Calculation_Alpha_Value
S64|for|O
S64|each|O
S64|test|O
S64|,|O
S64|the|O
S64|same|O
S64|expected|O
S64|GMTs|O
S64|for|O
S64|each|O
S64|dose|O
S64|group|O
S64|,|O
S64|a|O
S64|standard|O
S64|deviation|O
S64|of|O
S64|log|O
S64|titers|O
S64|against|O
S64|each|O
S64|strain|O
S64|of|O
S64|0.7|O
S64|and|O
S64|a|O
S64|noninferiority|B-Design_Comparative_Intent_NonInferiority
S64|margin|O
S64|of|O
S64|0.667|O
S64|,|O
S64|the|O
S64|study|O
S64|power|O
S64|was|O
S64|approximately|O
S64|97.6|B-Sample_Size_Calculation_Power_Value
S64|%|I-Sample_Size_Calculation_Power_Value
S64|to|O
S64|demonstrate|O
S64|noninferiority|O
S64|for|O
S64|GMTs|O
S64|.|O
S7645|Results|O
S7645|Patient|O
S7645|population|O
S7645|Of|O
S7645|211|O
S7645|patients|O
S7645|screened|O
S7645|,|O
S7645|103|B-Sample_Size_Actual_at_Enrollment
S7645|(|O
S7645|49|O
S7645|%|O
S7645|)|O
S7645|met|O
S7645|the|O
S7645|eligibility|O
S7645|criteria|O
S7645|and|O
S7645|were|O
S7645|randomized|O
S7645|to|O
S7645|the|O
S7645|placebo|O
S7645|group|O
S7645|(|O
S7645|n|O
S7645|=|O
S7645|20|O
S7645|)|O
S7645|or|O
S7645|one|O
S7645|of|O
S7645|the|O
S7645|four|O
S7645|daprodustat|O
S7645|cohorts|O
S7645|(|O
S7645|n|O
S7645|=|O
S7645|83|O
S7645|in|O
S7645|total|O
S7645|)|O
S7645|(|O
S7645|Fig|O
S7645|.|O
S557|Methods|O
S557|Patients|O
S557|with|O
S557|probable|O
S557|laboratory-supported|O
S557|,|O
S557|probable|O
S557|or|O
S557|definite|O
S557|ALS|O
S557|were|O
S557|enrolled|O
S557|by|O
S557|25|B-Settings_Multicenter
S557|Italian|B-Settings_Location
S557|centres|I-Settings_Multicenter
S557|and|O
S557|randomly|O
S557|assigned|O
S557|(|O
S557|1:1|B-Randomization_Ratio
S557|)|O
S557|to|O
S557|receive|O
S557|intravenous|B-Design_Parallel_Group
S557|rhEPO|I-Design_Parallel_Group
S557|40|I-Design_Parallel_Group
S557|000|I-Design_Parallel_Group
S557|IU|I-Design_Parallel_Group
S557|or|I-Design_Parallel_Group
S557|placebo|I-Design_Parallel_Group
S557|fortnightly|O
S557|as|O
S557|add-on|O
S557|treatment|O
S557|to|O
S557|riluzole|O
S557|100|O
S557|mg|O
S557|daily|O
S557|for|O
S557|12|O
S557|months|O
S557|.|O
S1610|Patients|O
S1610|who|O
S1610|,|O
S1610|despite|O
S1610|scheduled|O
S1610|infusions|O
S1610|of|O
S1610|double-blind|O
S1610|study|O
S1610|medication|O
S1610|at|O
S1610|weeks|O
S1610|8|O
S1610|and|O
S1610|12|O
S1610|,|O
S1610|did|O
S1610|not|O
S1610|achieve|O
S1610|≥20|O
S1610|%|O
S1610|improvement|O
S1610|from|O
S1610|baseline|O
S1610|in|O
S1610|SJC|O
S1610|and|O
S1610|TJC|O
S1610|at|O
S1610|week|O
S1610|16|O
S1610|were|O
S1610|offered|O
S1610|escape|O
S1610|therapy|O
S1610|with|O
S1610|open-label|B-Blinding_Open_Label
S1610|TCZ|O
S1610|8|O
S1610|mg/kg|O
S1610|.|O
S5970|In|O
S5970|85|B-Sample_Size_Actual_at_Enrollment
S5970|of|O
S5970|the|O
S5970|87|O
S5970|patients|O
S5970|,|O
S5970|the|O
S5970|trial|O
S5970|infusion|O
S5970|was|O
S5970|administered|O
S5970|as|O
S5970|planned|O
S5970|.|O
S6694|Methods|O
S6694|:|O
S6694|This|O
S6694|study|O
S6694|was|O
S6694|conducted|O
S6694|in|O
S6694|a|O
S6694|12-week|O
S6694|,|O
S6694|double-blind|B-Blinding_Double_Blind
S6694|period|O
S6694|followed|O
S6694|by|O
S6694|an|O
S6694|open-label|B-Blinding_Open_Label
S6694|extension|O
S6694|designed|O
S6694|to|O
S6694|characterize|O
S6694|1|O
S6694|year|O
S6694|of|O
S6694|evolocumab|O
S6694|treatment|O
S6694|.|O
S6713|Eligible|O
S6713|patients|O
S6713|were|O
S6713|randomized|O
S6713|at|O
S6713|2:2:1:1|B-Randomization_Ratio
S6713|into|O
S6713|four|O
S6713|groups|O
S6713|:|O
S6713|420|O
S6713|mg|O
S6713|evolocumab|O
S6713|every|O
S6713|4|O
S6713|weeks|O
S6713|(|O
S6713|Q4W|O
S6713|)|O
S6713|+|O
S6713|oral|O
S6713|placebo|O
S6713|daily|O
S6713|,|O
S6713|140|O
S6713|mg|O
S6713|evolocumab|O
S6713|every|O
S6713|2|O
S6713|weeks|O
S6713|(|O
S6713|Q2W|O
S6713|)|O
S6713|+|O
S6713|oral|O
S6713|placebo|O
S6713|daily|O
S6713|,|O
S6713|subcutaneous|O
S6713|(|O
S6713|SC|O
S6713|)|O
S6713|placebo|O
S6713|Q4W|O
S6713|+|O
S6713|10|O
S6713|mg|O
S6713|ezetimibe|O
S6713|daily|O
S6713|,|O
S6713|and|O
S6713|SC|O
S6713|placebo|O
S6713|Q2W|O
S6713|+|O
S6713|10|O
S6713|mg|O
S6713|ezetimibe|O
S6713|daily|O
S6713|.|O
S599|Randomisation|O
S599|was|O
S599|stratified|B-Randomization_Type_Stratified
S599|by|O
S599|centre|B-Randomization_Stratified_Criteria
S599|,|O
S599|disease|B-Randomization_Stratified_Criteria
S599|severity|I-Randomization_Stratified_Criteria
S599|(|I-Randomization_Stratified_Criteria
S599|ALSFRS-R|I-Randomization_Stratified_Criteria
S599|≤33|I-Randomization_Stratified_Criteria
S599|vs|I-Randomization_Stratified_Criteria
S599|>|I-Randomization_Stratified_Criteria
S599|33|I-Randomization_Stratified_Criteria
S599|)|I-Randomization_Stratified_Criteria
S599|and|O
S599|onset|B-Randomization_Stratified_Criteria
S599|(|I-Randomization_Stratified_Criteria
S599|spinal|I-Randomization_Stratified_Criteria
S599|or|I-Randomization_Stratified_Criteria
S599|bulbar|I-Randomization_Stratified_Criteria
S599|)|I-Randomization_Stratified_Criteria
S599|,|O
S599|with|O
S599|a|O
S599|block|B-Randomization_Type_Block
S599|size|O
S599|of|O
S599|four|B-Randomization_Block_Size
S599|within|O
S599|each|O
S599|centre|O
S599|.|O
S6395|Interventions|O
S6395|Trimethoprim-sulfamethoxazole|B-Design_Parallel_Group
S6395|320|I-Design_Parallel_Group
S6395|mg/1600|I-Design_Parallel_Group
S6395|mg|I-Design_Parallel_Group
S6395|twice|I-Design_Parallel_Group
S6395|daily|I-Design_Parallel_Group
S6395|versus|I-Design_Parallel_Group
S6395|vancomycin|I-Design_Parallel_Group
S6395|1|I-Design_Parallel_Group
S6395|g|I-Design_Parallel_Group
S6395|twice|I-Design_Parallel_Group
S6395|daily|I-Design_Parallel_Group
S6395|for|O
S6395|a|O
S6395|minimum|O
S6395|of|O
S6395|seven|O
S6395|days|O
S6395|and|O
S6395|then|O
S6395|by|O
S6395|indication|O
S6395|.|O
S331|Week|O
S331|16|O
S331|completion|O
S331|rates|O
S331|were|O
S331|greater|O
S331|for|O
S331|lebrikizumab-treated|O
S331|patients|O
S331|vs|O
S331|placebo-treated|O
S331|patients|O
S331|(|O
S331|44.2|B-Sample_Size_Actual_at_Outcome_Analysis
S331|%|I-Sample_Size_Actual_at_Outcome_Analysis
S331|[|I-Sample_Size_Actual_at_Outcome_Analysis
S331|23|I-Sample_Size_Actual_at_Outcome_Analysis
S331|of|I-Sample_Size_Actual_at_Outcome_Analysis
S331|52|I-Sample_Size_Actual_at_Outcome_Analysis
S331|]|I-Sample_Size_Actual_at_Outcome_Analysis
S331|for|I-Sample_Size_Actual_at_Outcome_Analysis
S331|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S331|and|I-Sample_Size_Actual_at_Outcome_Analysis
S331|79.5|I-Sample_Size_Actual_at_Outcome_Analysis
S331|%|I-Sample_Size_Actual_at_Outcome_Analysis
S331|[|I-Sample_Size_Actual_at_Outcome_Analysis
S331|58|I-Sample_Size_Actual_at_Outcome_Analysis
S331|of|I-Sample_Size_Actual_at_Outcome_Analysis
S331|73|I-Sample_Size_Actual_at_Outcome_Analysis
S331|]|I-Sample_Size_Actual_at_Outcome_Analysis
S331|,|I-Sample_Size_Actual_at_Outcome_Analysis
S331|77.5|I-Sample_Size_Actual_at_Outcome_Analysis
S331|%|I-Sample_Size_Actual_at_Outcome_Analysis
S331|[|I-Sample_Size_Actual_at_Outcome_Analysis
S331|62|I-Sample_Size_Actual_at_Outcome_Analysis
S331|of|I-Sample_Size_Actual_at_Outcome_Analysis
S331|80|I-Sample_Size_Actual_at_Outcome_Analysis
S331|]|I-Sample_Size_Actual_at_Outcome_Analysis
S331|,|I-Sample_Size_Actual_at_Outcome_Analysis
S331|and|I-Sample_Size_Actual_at_Outcome_Analysis
S331|77.3|I-Sample_Size_Actual_at_Outcome_Analysis
S331|%|I-Sample_Size_Actual_at_Outcome_Analysis
S331|[|I-Sample_Size_Actual_at_Outcome_Analysis
S331|58|I-Sample_Size_Actual_at_Outcome_Analysis
S331|of|I-Sample_Size_Actual_at_Outcome_Analysis
S331|75|I-Sample_Size_Actual_at_Outcome_Analysis
S331|]|I-Sample_Size_Actual_at_Outcome_Analysis
S331|for|I-Sample_Size_Actual_at_Outcome_Analysis
S331|125|I-Sample_Size_Actual_at_Outcome_Analysis
S331|mg|I-Sample_Size_Actual_at_Outcome_Analysis
S331|of|I-Sample_Size_Actual_at_Outcome_Analysis
S331|lebrikizumab|I-Sample_Size_Actual_at_Outcome_Analysis
S331|every|I-Sample_Size_Actual_at_Outcome_Analysis
S331|4|I-Sample_Size_Actual_at_Outcome_Analysis
S331|weeks|I-Sample_Size_Actual_at_Outcome_Analysis
S331|,|I-Sample_Size_Actual_at_Outcome_Analysis
S331|250|I-Sample_Size_Actual_at_Outcome_Analysis
S331|mg|I-Sample_Size_Actual_at_Outcome_Analysis
S331|every|I-Sample_Size_Actual_at_Outcome_Analysis
S331|4|I-Sample_Size_Actual_at_Outcome_Analysis
S331|weeks|I-Sample_Size_Actual_at_Outcome_Analysis
S331|,|I-Sample_Size_Actual_at_Outcome_Analysis
S331|and|I-Sample_Size_Actual_at_Outcome_Analysis
S331|250|I-Sample_Size_Actual_at_Outcome_Analysis
S331|mg|I-Sample_Size_Actual_at_Outcome_Analysis
S331|every|I-Sample_Size_Actual_at_Outcome_Analysis
S331|2|I-Sample_Size_Actual_at_Outcome_Analysis
S331|weeks|I-Sample_Size_Actual_at_Outcome_Analysis
S331|[|O
S331|hereinafter|O
S331|,|O
S331|the|O
S331|3|O
S331|lebrikizumab|O
S331|groups|O
S331|,|O
S331|respectively|O
S331|]|O
S331|)|O
S331|.|O
S4265|Overall|O
S4265|,|O
S4265|94.8|O
S4265|%|O
S4265|of|O
S4265|subjects|O
S4265|completed|O
S4265|the|O
S4265|visit|O
S4265|occurring|O
S4265|1|O
S4265|month|O
S4265|after|O
S4265|vaccination|O
S4265|2|O
S4265|,|O
S4265|95.3|O
S4265|%|O
S4265|completed|O
S4265|the|O
S4265|6-month|O
S4265|telephone|O
S4265|visit|O
S4265|,|O
S4265|and|O
S4265|91.0|B-Sample_Size_Actual_at_Outcome_Analysis
S4265|%|I-Sample_Size_Actual_at_Outcome_Analysis
S4265|completed|O
S4265|the|O
S4265|study|O
S4265|.|O
S5049|Results|O
S5049|Characteristics|O
S5049|at|O
S5049|Enrollment|O
S5049|:|O
S5049|Between|O
S5049|June|O
S5049|2015|O
S5049|and|O
S5049|July|O
S5049|2017|O
S5049|,|O
S5049|192|B-Sample_Size_Actual_at_Enrollment
S5049|patients|O
S5049|(|O
S5049|235|O
S5049|eyes|O
S5049|with|O
S5049|uveitic|O
S5049|macular|O
S5049|edema|O
S5049|)|O
S5049|were|O
S5049|enrolled|O
S5049|.|O
S2246|Methods|O
S2246|Trial|O
S2246|design|O
S2246|Study|O
S2246|207626|O
S2246|(|O
S2246|NCT03474081|O
S2246|)|O
S2246|was|O
S2246|a|O
S2246|12-week|O
S2246|,|O
S2246|Phase|B-Design_Phase_4
S2246|IV|I-Design_Phase_4
S2246|,|O
S2246|parallel-group|B-Design_Parallel_Group
S2246|,|O
S2246|active-controlled|O
S2246|,|O
S2246|double-blind|B-Blinding_Double_Blind
S2246|,|O
S2246|double-dummy|O
S2246|,|O
S2246|randomized|O
S2246|,|O
S2246|multicenter|B-Settings_Multicenter
S2246|study|O
S2246|comparing|O
S2246|once-daily|O
S2246|single-inhaler|O
S2246|FF/UMEC/VI|O
S2246|with|O
S2246|TIO|O
S2246|monotherapy|O
S2246|in|O
S2246|patients|O
S2246|with|O
S2246|symptomatic|O
S2246|COPD|O
S2246|and|O
S2246|moderate-to-very-severe|O
S2246|airflow|O
S2246|limitation|O
S2246|.|O
S7810|A|O
S7810|total|O
S7810|of|O
S7810|1,062|O
S7810|participants|O
S7810|(|O
S7810|97.3|O
S7810|%|O
S7810|)|O
S7810|completed|O
S7810|the|O
S7810|trial|O
S7810|,|O
S7810|while|O
S7810|1,053|B-Sample_Size_Actual_at_Outcome_Analysis
S7810|participants|O
S7810|(|O
S7810|96.5|O
S7810|%|O
S7810|)|O
S7810|completed|O
S7810|the|O
S7810|16-week|O
S7810|treatment|O
S7810|period|O
S7810|without|O
S7810|premature|O
S7810|discontinuation|O
S7810|of|O
S7810|randomized|O
S7810|treatment|O
S7810|(|O
S7810|Supplementary|O
S7810|Fig|O
S7810|.|O
S3261|Interventions|O
S3261|Women|O
S3261|in|O
S3261|the|O
S3261|first|O
S3261|comparison|O
S3261|were|O
S3261|randomised|O
S3261|to|O
S3261|ursodeoxycholic|B-Design_Parallel_Group
S3261|acid|I-Design_Parallel_Group
S3261|(|I-Design_Parallel_Group
S3261|250|I-Design_Parallel_Group
S3261|mg|I-Design_Parallel_Group
S3261|dose|I-Design_Parallel_Group
S3261|;|I-Design_Parallel_Group
S3261|Ursofalk|I-Design_Parallel_Group
S3261|,|I-Design_Parallel_Group
S3261|Dr|I-Design_Parallel_Group
S3261|Falk|I-Design_Parallel_Group
S3261|Pharma|I-Design_Parallel_Group
S3261|,|I-Design_Parallel_Group
S3261|Buckinghamshire|I-Design_Parallel_Group
S3261|)|I-Design_Parallel_Group
S3261|,|I-Design_Parallel_Group
S3261|or|I-Design_Parallel_Group
S3261|to|I-Design_Parallel_Group
S3261|placebo|I-Design_Parallel_Group
S3261|capsules|I-Design_Parallel_Group
S3261|(|O
S3261|Dr|O
S3261|Falk|O
S3261|Pharma|O
S3261|)|O
S3261|identical|O
S3261|in|O
S3261|appearance|O
S3261|and|O
S3261|taste|O
S3261|to|O
S3261|the|O
S3261|study|O
S3261|drug|O
S3261|(|O
S3261|white|O
S3261|,|O
S3261|opaque|O
S3261|,|O
S3261|hard|O
S3261|gelatin|O
S3261|capsule|O
S3261|)|O
S3261|.|O
S1888|The|O
S1888|trial|O
S1888|enrolled|O
S1888|participants|O
S1888|at|O
S1888|19|B-Settings_Multicenter
S1888|clinic|I-Settings_Multicenter
S1888|and|I-Settings_Multicenter
S1888|hospital|I-Settings_Multicenter
S1888|sites|I-Settings_Multicenter
S1888|in|O
S1888|Brazil|B-Settings_Location
S1888|(|I-Settings_Location
S1888|7|I-Settings_Location
S1888|)|I-Settings_Location
S1888|,|I-Settings_Location
S1888|Tanzania|I-Settings_Location
S1888|(|I-Settings_Location
S1888|1|I-Settings_Location
S1888|)|I-Settings_Location
S1888|,|I-Settings_Location
S1888|South|I-Settings_Location
S1888|Africa|I-Settings_Location
S1888|(|I-Settings_Location
S1888|1|I-Settings_Location
S1888|)|I-Settings_Location
S1888|,|I-Settings_Location
S1888|Thailand|I-Settings_Location
S1888|(|I-Settings_Location
S1888|3|I-Settings_Location
S1888|)|I-Settings_Location
S1888|,|I-Settings_Location
S1888|Argentina|I-Settings_Location
S1888|(|I-Settings_Location
S1888|2|I-Settings_Location
S1888|)|I-Settings_Location
S1888|,|I-Settings_Location
S1888|and|I-Settings_Location
S1888|the|I-Settings_Location
S1888|US|I-Settings_Location
S1888|(|I-Settings_Location
S1888|5|I-Settings_Location
S1888|)|I-Settings_Location
S1888|.|O
S7262|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7262|was|O
S7262|declared|O
S7262|if|O
S7262|the|O
S7262|upper|O
S7262|bound|O
S7262|of|O
S7262|the|O
S7262|two-sided|O
S7262|95|O
S7262|%|O
S7262|CI|O
S7262|for|O
S7262|the|O
S7262|difference|O
S7262|in|O
S7262|change|O
S7262|from|O
S7262|baseline|O
S7262|in|O
S7262|DAS28-4|O
S7262|(|O
S7262|CRP|O
S7262|)|O
S7262|at|O
S7262|week|O
S7262|12|O
S7262|was|O
S7262|<|O
S7262|0.6|O
S7262|.|O
S6760|Results|O
S6760|Patient|O
S6760|Disposition|O
S6760|A|O
S6760|total|O
S6760|of|O
S6760|61|B-Sample_Size_Actual_at_Enrollment
S6760|patients|O
S6760|were|O
S6760|randomized|O
S6760|(|O
S6760|evolocumab|O
S6760|,|O
S6760|n|O
S6760|=|O
S6760|40|O
S6760|;|O
S6760|ezetimibe|O
S6760|,|O
S6760|n|O
S6760|=|O
S6760|21|O
S6760|)|O
S6760|(|O
S6760|Fig|O
S6760|.|O
S54|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S54|with|O
S54|respect|O
S54|to|O
S54|fever|O
S54|was|O
S54|considered|O
S54|demonstrated|O
S54|if|O
S54|the|O
S54|upper|O
S54|bound|O
S54|of|O
S54|the|O
S54|2-sided|O
S54|95|O
S54|%|O
S54|confidence|O
S54|interval|O
S54|(|O
S54|CI|O
S54|)|O
S54|of|O
S54|the|O
S54|fever|O
S54|rate|O
S54|difference|O
S54|between|O
S54|participants|O
S54|receiving|O
S54|full-dose|O
S54|vaccine|O
S54|and|O
S54|participants|O
S54|receiving|O
S54|half-dose|O
S54|vaccine|O
S54|was|O
S54|<|O
S54|5|O
S54|%|O
S54|.|O
S607|Patients|B-Blinding_Object_Patients
S607|,|O
S607|neurologists|B-Blinding_Object_Care_Providers
S607|,|O
S607|laboratory|B-Blinding_Object_Others
S607|biologists/technicians|I-Blinding_Object_Others
S607|(|O
S607|two|O
S607|at|O
S607|each|O
S607|centre|O
S607|)|O
S607|and|O
S607|a|O
S607|statistician|B-Blinding_Object_Others
S607|were|O
S607|masked|O
S607|to|O
S607|treatment|O
S607|allocation|O
S607|and|O
S607|did|O
S607|not|O
S607|have|O
S607|access|O
S607|to|O
S607|any|O
S607|data|O
S607|related|O
S607|to|O
S607|rhEPO|O
S607|haematopoietic|O
S607|activity|O
S607|.|O
S1034|Patients|B-Blinding_Object_Patients
S1034|were|O
S1034|blinded|O
S1034|to|O
S1034|the|O
S1034|study|O
S1034|drugs|O
S1034|.|O
S4264|RESULTS|O
S4264|Study|O
S4264|Population|O
S4264|Among|O
S4264|444|B-Sample_Size_Actual_at_Enrollment
S4264|subjects|O
S4264|randomized|O
S4264|(|O
S4264|n|O
S4264|=|O
S4264|222|O
S4264|,|O
S4264|PCV20/saline|O
S4264|;|O
S4264|n|O
S4264|=|O
S4264|222|O
S4264|,|O
S4264|PCV13/PPSV23|O
S4264|)|O
S4264|,|O
S4264|443|O
S4264|received|O
S4264|vaccination|O
S4264|1|O
S4264|and|O
S4264|427|O
S4264|received|O
S4264|vaccination|O
S4264|2|O
S4264|(|O
S4264|Figure|O
S4264|2|O
S4264|)|O
S4264|.|O
S2950|Of|O
S2950|the|O
S2950|176|B-Sample_Size_Actual_at_Enrollment
S2950|children|I-Sample_Size_Actual_at_Enrollment
S2950|enrolled|O
S2950|,|O
S2950|117|O
S2950|(|O
S2950|66.5|O
S2950|%|O
S2950|)|O
S2950|and|O
S2950|59|O
S2950|(|O
S2950|33.5|O
S2950|%|O
S2950|)|O
S2950|patients|O
S2950|were|O
S2950|randomized|O
S2950|into|O
S2950|the|O
S2950|baloxavir|O
S2950|and|O
S2950|oseltamivir|O
S2950|groups|O
S2950|,|O
S2950|respectively|O
S2950|.|O
S6858|Eligible|O
S6858|patients|O
S6858|were|O
S6858|then|O
S6858|randomly|O
S6858|assigned|O
S6858|to|O
S6858|placebo|B-Design_Parallel_Group
S6858|,|I-Design_Parallel_Group
S6858|aprocitentan|I-Design_Parallel_Group
S6858|,|I-Design_Parallel_Group
S6858|or|I-Design_Parallel_Group
S6858|lisinopril|I-Design_Parallel_Group
S6858|treatment|I-Design_Parallel_Group
S6858|groups|I-Design_Parallel_Group
S6858|.|O
S5348|Power|O
S5348|and|O
S5348|statistical|O
S5348|methods|O
S5348|With|O
S5348|1000|O
S5348|patients|O
S5348|treated|O
S5348|with|O
S5348|IIM|O
S5348|and|O
S5348|500|O
S5348|patients|O
S5348|treated|O
S5348|with|O
S5348|IS|O
S5348|,|O
S5348|there|O
S5348|was|O
S5348|100|B-Sample_Size_Calculation_Power_Value
S5348|%|I-Sample_Size_Calculation_Power_Value
S5348|power|O
S5348|to|O
S5348|demonstrate|O
S5348|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S5348|of|O
S5348|IIM|O
S5348|versus|O
S5348|IS|O
S5348|in|O
S5348|the|O
S5348|co-primary|O
S5348|efficacy|O
S5348|endpoint|O
S5348|,|O
S5348|change|O
S5348|in|O
S5348|Hb|O
S5348|from|O
S5348|baseline|O
S5348|to|O
S5348|Week|O
S5348|8|O
S5348|,|O
S5348|using|O
S5348|a|O
S5348|non-inferiority|O
S5348|margin|O
S5348|of|O
S5348|–0.5|O
S5348|g/dL|O
S5348|and|O
S5348|assuming|O
S5348|a|O
S5348|common|O
S5348|SD|O
S5348|of|O
S5348|1.5|O
S5348|g/dL|O
S5348|in|O
S5348|Hb|O
S5348|.|O
S2763|Statistical|O
S2763|methods|O
S2763|A|O
S2763|computer-generated|B-Randomization_Sequence_Generation_Method
S2763|randomization|O
S2763|scheme|O
S2763|was|O
S2763|made|O
S2763|available|O
S2763|to|O
S2763|all|O
S2763|clinical|O
S2763|centers|O
S2763|participating|O
S2763|in|O
S2763|the|O
S2763|study|O
S2763|via|O
S2763|an|B-Randomization_Sequence_Generation_Method
S2763|interactive|I-Randomization_Sequence_Generation_Method
S2763|web|I-Randomization_Sequence_Generation_Method
S2763|response|I-Randomization_Sequence_Generation_Method
S2763|system|I-Randomization_Sequence_Generation_Method
S2763|.|O
S3914|Patient|O
S3914|randomisation|O
S3914|was|O
S3914|stratified|B-Randomization_Type_Stratified
S3914|by|O
S3914|centre|B-Randomization_Stratified_Criteria
S3914|using|O
S3914|a|O
S3914|block|B-Randomization_Type_Block
S3914|size|O
S3914|of|O
S3914|four|B-Randomization_Block_Size
S3914|for|I-Randomization_Block_Size
S3914|the|I-Randomization_Block_Size
S3914|first|I-Randomization_Block_Size
S3914|two|I-Randomization_Block_Size
S3914|blocks|I-Randomization_Block_Size
S3914|and|I-Randomization_Block_Size
S3914|eight|I-Randomization_Block_Size
S3914|thereafter|I-Randomization_Block_Size
S3914|.|O
S6264|At|O
S6264|the|O
S6264|start|O
S6264|of|O
S6264|the|O
S6264|double-blind|B-Blinding_Double_Blind
S6264|phase|O
S6264|(|O
S6264|week|O
S6264|0|O
S6264|)|O
S6264|,|O
S6264|patients|O
S6264|in|O
S6264|both|O
S6264|groups|O
S6264|received|O
S6264|an|O
S6264|injection|O
S6264|of|O
S6264|240|O
S6264|U|O
S6264|in|O
S6264|6|O
S6264|forearm|O
S6264|muscles|O
S6264|(|O
S6264|flexor|O
S6264|carpi|O
S6264|radialis|O
S6264|,|O
S6264|flexor|O
S6264|carpi|O
S6264|ulnaris|O
S6264|,|O
S6264|flexor|O
S6264|digitorum|O
S6264|profundus|O
S6264|,|O
S6264|flexor|O
S6264|digitorum|O
S6264|superficialis|O
S6264|,|O
S6264|flexor|O
S6264|pollicis|O
S6264|longus|O
S6264|,|O
S6264|and|O
S6264|adductor|O
S6264|pollicis|O
S6264|)|O
S6264|.|O
S6551|Key|O
S6551|Points|O
S6551|Question|O
S6551|How|O
S6551|does|O
S6551|extended|O
S6551|dosing|O
S6551|with|O
S6551|faricimab|O
S6551|compare|O
S6551|with|O
S6551|monthly|O
S6551|ranibizumab|O
S6551|in|O
S6551|treating|O
S6551|patients|O
S6551|with|O
S6551|neovascular|O
S6551|age-related|O
S6551|macular|O
S6551|degeneration|O
S6551|?|O
S6551|Findings|O
S6551|In|O
S6551|this|O
S6551|phase|B-Design_Phase_2
S6551|2|I-Design_Phase_2
S6551|randomized|O
S6551|clinical|O
S6551|trial|O
S6551|of|O
S6551|faricimab|O
S6551|in|O
S6551|76|B-Sample_Size_Actual_at_Enrollment
S6551|patients|O
S6551|,|O
S6551|vision|O
S6551|gains|O
S6551|from|O
S6551|baseline|O
S6551|were|O
S6551|+9.6|O
S6551|,|O
S6551|+10.1|O
S6551|,|O
S6551|and|O
S6551|+11.4|O
S6551|letters|O
S6551|for|O
S6551|the|O
S6551|monthly|O
S6551|ranibizumab|O
S6551|,|O
S6551|faricimab|O
S6551|every-12-weeks|O
S6551|,|O
S6551|and|O
S6551|faricimab|O
S6551|every-16-weeks|O
S6551|arms|O
S6551|,|O
S6551|respectively|O
S6551|,|O
S6551|at|O
S6551|week|O
S6551|52|O
S6551|.|O
S271|Design|O
S271|,|O
S271|Setting|O
S271|,|O
S271|and|O
S271|Participants|O
S271|A|O
S271|phase|B-Design_Phase_2
S271|2b|I-Design_Phase_2
S271|,|O
S271|double-blind|B-Blinding_Double_Blind
S271|,|O
S271|placebo-controlled|O
S271|,|O
S271|dose-ranging|O
S271|randomized|O
S271|clinical|O
S271|trial|O
S271|of|O
S271|lebrikizumab|O
S271|injections|O
S271|every|O
S271|4|O
S271|weeks|O
S271|or|O
S271|every|O
S271|2|O
S271|weeks|O
S271|was|O
S271|conducted|O
S271|from|O
S271|January|O
S271|23|O
S271|,|O
S271|2018|O
S271|,|O
S271|to|O
S271|May|O
S271|23|O
S271|,|O
S271|2019|O
S271|,|O
S271|at|O
S271|57|B-Settings_Multicenter
S271|US|B-Settings_Location
S271|centers|I-Settings_Multicenter
S271|.|O
S1748|Randomization|O
S1748|was|O
S1748|stratified|B-Randomization_Type_Stratified
S1748|according|O
S1748|to|O
S1748|TrialNet|B-Randomization_Stratified_Criteria
S1748|site|I-Randomization_Stratified_Criteria
S1748|,|O
S1748|age|B-Randomization_Stratified_Criteria
S1748|(|I-Randomization_Stratified_Criteria
S1748|<|I-Randomization_Stratified_Criteria
S1748|18|I-Randomization_Stratified_Criteria
S1748|years|I-Randomization_Stratified_Criteria
S1748|or|I-Randomization_Stratified_Criteria
S1748|≥18|I-Randomization_Stratified_Criteria
S1748|years|I-Randomization_Stratified_Criteria
S1748|)|I-Randomization_Stratified_Criteria
S1748|,|O
S1748|and|O
S1748|second|B-Randomization_Stratified_Criteria
S1748|oral|I-Randomization_Stratified_Criteria
S1748|glucose-tolerance|I-Randomization_Stratified_Criteria
S1748|test|I-Randomization_Stratified_Criteria
S1748|result|I-Randomization_Stratified_Criteria
S1748|before|I-Randomization_Stratified_Criteria
S1748|treatment|I-Randomization_Stratified_Criteria
S1748|(|I-Randomization_Stratified_Criteria
S1748|impaired|I-Randomization_Stratified_Criteria
S1748|tolerance|I-Randomization_Stratified_Criteria
S1748|,|I-Randomization_Stratified_Criteria
S1748|normal|I-Randomization_Stratified_Criteria
S1748|tolerance|I-Randomization_Stratified_Criteria
S1748|,|I-Randomization_Stratified_Criteria
S1748|or|I-Randomization_Stratified_Criteria
S1748|diabetes|I-Randomization_Stratified_Criteria
S1748|)|I-Randomization_Stratified_Criteria
S1748|.|O
S4696|Assuming|O
S4696|a|O
S4696|dropout|O
S4696|rate|O
S4696|of|O
S4696|20|B-Sample_Size_Calculation_Dropout_Rate_Value
S4696|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S4696|at|O
S4696|week|O
S4696|26|O
S4696|(|O
S4696|i.e|O
S4696|.|O
S3700|Results|O
S3700|Participants|O
S3700|In|O
S3700|total|O
S3700|,|O
S3700|18|B-Sample_Size_Actual_at_Enrollment
S3700|eligible|O
S3700|participants|O
S3700|were|O
S3700|assigned|O
S3700|to|O
S3700|the|O
S3700|study|O
S3700|treatment|O
S3700|,|O
S3700|and|O
S3700|17|B-Sample_Size_Actual_at_Outcome_Analysis
S3700|(|O
S3700|94.4|O
S3700|%|O
S3700|)|O
S3700|completed|O
S3700|the|O
S3700|double‐blind|O
S3700|treatment|O
S3700|and|O
S3700|follow‐up|O
S3700|period|O
S3700|(|O
S3700|Fig|O
S3700|.|O
S3643|A|O
S3643|phase|B-Design_Phase_1
S3643|I|I-Design_Phase_1
S3643|,|O
S3643|randomized|O
S3643|,|O
S3643|double‐blind|B-Blinding_Double_Blind
S3643|study|O
S3643|to|O
S3643|assess|O
S3643|the|O
S3643|safety|O
S3643|,|O
S3643|tolerability|O
S3643|and|O
S3643|efficacy|O
S3643|of|O
S3643|the|O
S3643|topical|O
S3643|RORC2|O
S3643|inverse|O
S3643|agonist|O
S3643|PF‐06763809|O
S3643|in|O
S3643|participants|O
S3643|with|O
S3643|mild‐to‐moderate|O
S3643|plaque|O
S3643|psoriasis|O
S7258|Methods|O
S7258|Phase|B-Design_Phase_3
S7258|III|I-Design_Phase_3
S7258|,|O
S7258|randomized|B-Randomization_Type_Simple
S7258|,|O
S7258|double-blind|B-Blinding_Double_Blind
S7258|,|O
S7258|double-dummy|O
S7258|,|O
S7258|12-week|O
S7258|study|O
S7258|.|O
S8080|Interactive|B-Randomization_Sequence_Generation_Method
S8080|web|I-Randomization_Sequence_Generation_Method
S8080|response|I-Randomization_Sequence_Generation_Method
S8080|technology|I-Randomization_Sequence_Generation_Method
S8080|automatically|O
S8080|assigned|O
S8080|a|O
S8080|treatment|O
S8080|to|O
S8080|each|O
S8080|individual|O
S8080|.|O
S7303|A|O
S7303|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7303|margin|O
S7303|of|O
S7303|0.6|O
S7303|for|O
S7303|the|O
S7303|treatment|O
S7303|difference|O
S7303|of|O
S7303|tofacitinib|O
S7303|MR|O
S7303|11|O
S7303|mg|O
S7303|QD|O
S7303|vs|O
S7303|IR|O
S7303|5|O
S7303|mg|O
S7303|BID|O
S7303|was|O
S7303|requested|O
S7303|by|O
S7303|the|O
S7303|Japanese|O
S7303|Pharmaceuticals|O
S7303|and|O
S7303|Medical|O
S7303|Devices|O
S7303|Agency|O
S7303|.|O
S1433|Patients|O
S1433|with|O
S1433|PsA|O
S1433|along|O
S1433|with|O
S1433|active|O
S1433|dactylitis|O
S1433|and|O
S1433|naive|O
S1433|to|O
S1433|MTX|O
S1433|and|O
S1433|biologic|O
S1433|disease-modifying|O
S1433|antirheumatic|O
S1433|drugs|O
S1433|(|O
S1433|bDMARDs|O
S1433|)|O
S1433|were|O
S1433|randomly|O
S1433|assigned|O
S1433|to|O
S1433|golimumab|B-Design_Parallel_Group
S1433|or|I-Design_Parallel_Group
S1433|placebo|I-Design_Parallel_Group
S1433|,|O
S1433|both|O
S1433|in|O
S1433|combination|O
S1433|with|O
S1433|MTX|O
S1433|.|O
S6272|In|O
S6272|the|O
S6272|double-blind|B-Blinding_Double_Blind
S6272|phase|O
S6272|,|O
S6272|the|O
S6272|regimen|O
S6272|and|O
S6272|frequency/intensity|O
S6272|of|O
S6272|concurrent|O
S6272|rehabilitation|O
S6272|therapy|O
S6272|were|O
S6272|not|O
S6272|to|O
S6272|be|O
S6272|changed|O
S6272|.|O
S4322|Safety|O
S4322|,|O
S4322|tolerability|O
S4322|and|O
S4322|antiviral|O
S4322|activity|O
S4322|of|O
S4322|the|O
S4322|antisense|O
S4322|oligonucleotide|O
S4322|bepirovirsen|O
S4322|in|O
S4322|patients|O
S4322|with|O
S4322|chronic|O
S4322|hepatitis|O
S4322|B|O
S4322|:|O
S4322|a|O
S4322|phase|B-Design_Phase_2
S4322|2|I-Design_Phase_2
S4322|randomized|O
S4322|controlled|O
S4322|trial|O
S6901|Assuming|O
S6901|a|O
S6901|maximum|O
S6901|difference|O
S6901|versus|O
S6901|placebo|O
S6901|of|O
S6901|5|O
S6901|mm|O
S6901|Hg|O
S6901|and|O
S6901|an|O
S6901|SD|O
S6901|of|O
S6901|9|O
S6901|mm|O
S6901|Hg|O
S6901|for|O
S6901|the|O
S6901|change|O
S6901|from|O
S6901|baseline|O
S6901|in|O
S6901|SiDBP|O
S6901|,|O
S6901|we|O
S6901|calculated|O
S6901|that|O
S6901|70|O
S6901|patients|O
S6901|per|O
S6901|group|O
S6901|would|O
S6901|provide|O
S6901|90|B-Sample_Size_Calculation_Power_Value
S6901|%|I-Sample_Size_Calculation_Power_Value
S6901|power|O
S6901|to|O
S6901|detect|O
S6901|a|O
S6901|dose-response|O
S6901|with|O
S6901|MCP-Modeling|O
S6901|in|O
S6901|the|O
S6901|per-protocol|O
S6901|set|O
S6901|(|O
S6901|420|O
S6901|patients|O
S6901|)|O
S6901|.|O
S25|The|O
S25|study|O
S25|was|O
S25|conducted|O
S25|between|O
S25|September|O
S25|2016|O
S25|and|O
S25|March|O
S25|2017|O
S25|at|O
S25|38|B-Settings_Multicenter
S25|sites|I-Settings_Multicenter
S25|in|O
S25|the|O
S25|United|B-Settings_Location
S25|States|I-Settings_Location
S25|(|O
S25|ClinicalTrials.gov|O
S25|no|O
S25|.|O
S56|Assuming|O
S56|a|O
S56|total|O
S56|planned|O
S56|enrollment|O
S56|sample|O
S56|size|O
S56|of|O
S56|approximately|O
S56|2190|B-Sample_Size_Target
S56|(|O
S56|1095|O
S56|per|O
S56|group|O
S56|)|O
S56|,|O
S56|an|O
S56|attrition|O
S56|rate|O
S56|of|O
S56|5|B-Sample_Size_Calculation_Dropout_Rate_Value
S56|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S56|,|O
S56|a|O
S56|1-sided|B-Sample_Size_Calculation_Alpha_Value
S56|alpha|I-Sample_Size_Calculation_Alpha_Value
S56|of|I-Sample_Size_Calculation_Alpha_Value
S56|2.5|I-Sample_Size_Calculation_Alpha_Value
S56|%|I-Sample_Size_Calculation_Alpha_Value
S56|,|O
S56|an|O
S56|expected|O
S56|14.3|O
S56|%|O
S56|rate|O
S56|of|O
S56|fever|O
S56|,|O
S56|and|O
S56|a|O
S56|noninferiority|O
S56|margin|O
S56|of|O
S56|5|O
S56|%|O
S56|,|O
S56|the|O
S56|study|O
S56|was|O
S56|powered|O
S56|at|O
S56|approximately|O
S56|90|B-Sample_Size_Calculation_Power_Value
S56|%|I-Sample_Size_Calculation_Power_Value
S56|to|O
S56|demonstrate|O
S56|noninferiority|B-Design_Comparative_Intent_NonInferiority
S56|for|O
S56|fever|O
S56|.|O
S3916|The|O
S3916|investigators|B-Blinding_Object_Investigators
S3916|and|O
S3916|sponsor|B-Blinding_Object_Others
S3916|were|O
S3916|blinded|O
S3916|to|O
S3916|the|O
S3916|lymphocyte|O
S3916|count|O
S3916|results|O
S3916|and|O
S3916|first-dose|O
S3916|effects|O
S3916|of|O
S3916|ponesimod|O
S3916|,|O
S3916|unless|O
S3916|alerted|O
S3916|for|O
S3916|safety|O
S3916|reasons|O
S3916|.|O
S2397|Randomization|O
S2397|and|O
S2397|Masking|O
S2397|Subjects|O
S2397|were|O
S2397|randomly|O
S2397|assigned|O
S2397|(|O
S2397|1:1|B-Randomization_Ratio
S2397|ratio|O
S2397|)|O
S2397|by|O
S2397|Interactive|B-Randomization_Sequence_Generation_Method
S2397|Web|I-Randomization_Sequence_Generation_Method
S2397|Response|I-Randomization_Sequence_Generation_Method
S2397|System|I-Randomization_Sequence_Generation_Method
S2397|(|I-Randomization_Sequence_Generation_Method
S2397|IWRS|I-Randomization_Sequence_Generation_Method
S2397|)|I-Randomization_Sequence_Generation_Method
S2397|to|O
S2397|receive|O
S2397|MB02|O
S2397|or|O
S2397|EU-bevacizumab|O
S2397|according|O
S2397|to|O
S2397|a|O
S2397|pre-specified|O
S2397|blocked|B-Randomization_Type_Block
S2397|randomization|O
S2397|scheme|O
S2397|.|O
S4669|Randomization|O
S4669|was|O
S4669|stratified|B-Randomization_Type_Stratified
S4669|by|O
S4669|“|B-Randomization_Stratified_Criteria
S4669|Mainland|I-Randomization_Stratified_Criteria
S4669|China|I-Randomization_Stratified_Criteria
S4669|”|I-Randomization_Stratified_Criteria
S4669|and|I-Randomization_Stratified_Criteria
S4669|“|I-Randomization_Stratified_Criteria
S4669|Other|I-Randomization_Stratified_Criteria
S4669|”|I-Randomization_Stratified_Criteria
S4669|.|O
S2121|Overall|O
S2121|,|O
S2121|175|B-Sample_Size_Actual_at_Outcome_Analysis
S2121|(|O
S2121|90.7|O
S2121|%|O
S2121|)|O
S2121|subjects|O
S2121|completed|O
S2121|the|O
S2121|study|O
S2121|.|O
S2701|Methods|O
S2701|:|O
S2701|In|O
S2701|this|O
S2701|phase|B-Design_Phase_2
S2701|2|I-Design_Phase_2
S2701|,|O
S2701|double-blind|B-Blinding_Double_Blind
S2701|study|O
S2701|,|O
S2701|patients|O
S2701|with|O
S2701|IBS-C|O
S2701|(|O
S2701|Rome|O
S2701|III|O
S2701|criteria|O
S2701|)|O
S2701|were|O
S2701|randomized|O
S2701|(|O
S2701|1:1:1:1|B-Randomization_Ratio
S2701|)|O
S2701|to|O
S2701|receive|O
S2701|tenapanor|B-Design_Parallel_Group
S2701|5|I-Design_Parallel_Group
S2701|mg|I-Design_Parallel_Group
S2701|,|I-Design_Parallel_Group
S2701|20|I-Design_Parallel_Group
S2701|mg|I-Design_Parallel_Group
S2701|,|I-Design_Parallel_Group
S2701|or|I-Design_Parallel_Group
S2701|50|I-Design_Parallel_Group
S2701|mg|I-Design_Parallel_Group
S2701|b.i.d.|I-Design_Parallel_Group
S2701|,|I-Design_Parallel_Group
S2701|or|I-Design_Parallel_Group
S2701|placebo|I-Design_Parallel_Group
S2701|b.i.d|I-Design_Parallel_Group
S2701|.|I-Design_Parallel_Group
S6114|Randomization|O
S6114|and|O
S6114|Masking|O
S6114|Permuted-block|B-Randomization_Type_Block
S6114|randomization|O
S6114|was|O
S6114|used|O
S6114|to|O
S6114|randomize|O
S6114|eligible|O
S6114|subjects|O
S6114|1:1|B-Randomization_Ratio
S6114|(|O
S6114|by|O
S6114|Interactive|B-Randomization_Sequence_Generation_Method
S6114|Response|I-Randomization_Sequence_Generation_Method
S6114|Technology|I-Randomization_Sequence_Generation_Method
S6114|)|O
S6114|to|O
S6114|receive|O
S6114|omidenepag|O
S6114|isopropyl|O
S6114|0.002|O
S6114|%|O
S6114|either|O
S6114|QD|O
S6114|(|O
S6114|vehicle|O
S6114|at|O
S6114|8:00|O
S6114|am|O
S6114|and|O
S6114|omidenepag|O
S6114|isopropyl|O
S6114|at|O
S6114|8:00|O
S6114|pm|O
S6114|±60|O
S6114|min|O
S6114|)|O
S6114|,|O
S6114|or|O
S6114|BID|O
S6114|(|O
S6114|8:00|O
S6114|am|O
S6114|and|O
S6114|8:00|O
S6114|pm|O
S6114|±60|O
S6114|min|O
S6114|)|O
S6114|,|O
S6114|1|O
S6114|drop/eye|O
S6114|for|O
S6114|6|O
S6114|weeks|O
S6114|.|O
S284|If|O
S284|these|O
S284|findings|O
S284|replicate|O
S284|in|O
S284|phase|B-Design_Phase_3
S284|3|I-Design_Phase_3
S284|studies|O
S284|,|O
S284|lebrikizumab|O
S284|may|O
S284|meaningfully|O
S284|advance|O
S284|the|O
S284|standard|O
S284|of|O
S284|care|O
S284|for|O
S284|moderate|O
S284|to|O
S284|severe|O
S284|AD|O
S284|.|O
S3648|Methods|O
S3648|This|O
S3648|was|O
S3648|a|O
S3648|randomized|O
S3648|,|O
S3648|double‐blind|B-Blinding_Double_Blind
S3648|,|O
S3648|first‐in‐human|O
S3648|study|O
S3648|(|O
S3648|trial|O
S3648|registration|O
S3648|:|O
S3648|ClinicalTrials.gov|O
S3648|NCT03469336|O
S3648|)|O
S3648|.|O
S5211|To|O
S5211|reduce|O
S5211|the|O
S5211|risk|O
S5211|of|O
S5211|a|O
S5211|perioperative|O
S5211|allogeneic|O
S5211|transfusion|O
S5211|event|O
S5211|from|O
S5211|30|O
S5211|%|O
S5211|to|O
S5211|15|O
S5211|%|O
S5211|(|O
S5211|a|O
S5211|50|O
S5211|%|O
S5211|risk|O
S5211|reduction|O
S5211|)|O
S5211|with|O
S5211|a|O
S5211|power|O
S5211|of|O
S5211|β|O
S5211|=|O
S5211|0.8|B-Sample_Size_Calculation_Power_Value
S5211|and|O
S5211|a|O
S5211|significance|O
S5211|level|O
S5211|of|O
S5211|α|O
S5211|=|O
S5211|0.05|B-Sample_Size_Calculation_Alpha_Value
S5211|,|O
S5211|it|O
S5211|was|O
S5211|determined|O
S5211|that|O
S5211|a|O
S5211|total|O
S5211|of|O
S5211|121|B-Sample_Size_Required
S5211|patients|I-Sample_Size_Required
S5211|in|I-Sample_Size_Required
S5211|each|I-Sample_Size_Required
S5211|group|I-Sample_Size_Required
S5211|would|O
S5211|be|O
S5211|needed|O
S5211|.|O
S1712|RESULTS|O
S1712|A|O
S1712|total|O
S1712|of|O
S1712|76|B-Sample_Size_Actual_at_Enrollment
S1712|participants|O
S1712|(|O
S1712|55|O
S1712|[|O
S1712|72|O
S1712|%|O
S1712|]|O
S1712|of|O
S1712|whom|O
S1712|were|O
S1712|≤18|O
S1712|years|O
S1712|of|O
S1712|age|O
S1712|)|O
S1712|underwent|O
S1712|randomization|O
S1712|—|O
S1712|44|O
S1712|to|O
S1712|the|O
S1712|teplizumab|O
S1712|group|O
S1712|and|O
S1712|32|O
S1712|to|O
S1712|the|O
S1712|placebo|O
S1712|group|O
S1712|.|O
S3964|The|O
S3964|underlying|O
S3964|assumption|O
S3964|for|O
S3964|the|O
S3964|sample|O
S3964|size|O
S3964|calculation|O
S3964|was|O
S3964|a|O
S3964|50|O
S3964|%|O
S3964|decrease|O
S3964|in|O
S3964|the|O
S3964|mean|O
S3964|cumulative|O
S3964|number|O
S3964|of|O
S3964|new|O
S3964|Gd+|O
S3964|lesions|O
S3964|from|O
S3964|weeks|O
S3964|12|O
S3964|to|O
S3964|24|O
S3964|in|O
S3964|at|O
S3964|least|O
S3964|one|O
S3964|ponesimod|O
S3964|treatment|O
S3964|group|O
S3964|compared|O
S3964|with|O
S3964|placebo|O
S3964|and|O
S3964|assuming|O
S3964|a|O
S3964|mean|O
S3964|of|O
S3964|eight|O
S3964|lesions|O
S3964|under|O
S3964|placebo|O
S3964|;|O
S3964|the|O
S3964|anticipated|O
S3964|sample|O
S3964|size|O
S3964|of|O
S3964|90|B-Sample_Size_Required
S3964|evaluable|I-Sample_Size_Required
S3964|patients|I-Sample_Size_Required
S3964|per|I-Sample_Size_Required
S3964|group|I-Sample_Size_Required
S3964|had|O
S3964|a|O
S3964|90|B-Sample_Size_Calculation_Power_Value
S3964|%|I-Sample_Size_Calculation_Power_Value
S3964|power|O
S3964|to|O
S3964|detect|O
S3964|a|O
S3964|significant|O
S3964|difference|O
S3964|between|O
S3964|ponesimod|O
S3964|groups|O
S3964|and|O
S3964|placebo|O
S3964|.|O
S600|The|O
S600|Neuroepidemiology|O
S600|Unit|O
S600|at|O
S600|the|O
S600|coordinating|O
S600|centre|O
S600|,|O
S600|independent|O
S600|of|O
S600|the|O
S600|study|O
S600|,|O
S600|generated|O
S600|the|O
S600|computer-based|B-Randomization_Sequence_Generation_Method
S600|randomisation|I-Randomization_Sequence_Generation_Method
S600|sequence|I-Randomization_Sequence_Generation_Method
S600|known|O
S600|only|O
S600|to|O
S600|two|O
S600|staff|O
S600|persons|O
S600|and|O
S600|the|O
S600|drug|O
S600|dispenser|O
S600|.|O
S8675|Results|O
S8675|Of|O
S8675|450|O
S8675|patients|O
S8675|screened|O
S8675|,|O
S8675|189|B-Sample_Size_Actual_at_Enrollment
S8675|were|O
S8675|randomized|O
S8675|to|O
S8675|receive|O
S8675|either|O
S8675|placebo|O
S8675|(|O
S8675|n|O
S8675|=|O
S8675|94|O
S8675|)|O
S8675|or|O
S8675|canakinumab|O
S8675|150|O
S8675|mg|O
S8675|(|O
S8675|n|O
S8675|=|O
S8675|95|O
S8675|)|O
S8675|.|O
S1349|Sample|O
S1349|size|O
S1349|was|O
S1349|calculated|O
S1349|assuming|O
S1349|this|O
S1349|equivalence|O
S1349|margin|O
S1349|of|O
S1349|±15|O
S1349|%|O
S1349|,|O
S1349|an|O
S1349|effect|O
S1349|size|O
S1349|of|O
S1349|57|O
S1349|%|O
S1349|and|O
S1349|a|O
S1349|20|B-Sample_Size_Calculation_Dropout_Rate_Value
S1349|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1349|dropout|O
S1349|rate|O
S1349|.|O
S851|Background|O
S851|This|O
S851|examiner-blind|B-Blinding_Single_Blind
S851|,|O
S851|stratified|B-Randomization_Stratified_Criteria
S851|,|O
S851|parallel|B-Design_Parallel_Group
S851|study|O
S851|aimed|O
S851|to|O
S851|evaluate|O
S851|the|O
S851|anti-gingivitis|O
S851|efficacy|O
S851|of|O
S851|a|O
S851|non-aqueous|O
S851|(|O
S851|anhydrous|O
S851|)|O
S851|0.454|O
S851|%|O
S851|w/w|O
S851|stannous|O
S851|fluoride|O
S851|toothpaste|O
S851|(|O
S851|‘|O
S851|Test|O
S851|’|O
S851|)|O
S851|versus|O
S851|a|O
S851|sodium|O
S851|monofluorophosphate|O
S851|toothpaste|O
S851|(|O
S851|‘|O
S851|Control|O
S851|’|O
S851|)|O
S851|in|O
S851|people|O
S851|with|O
S851|clinically-confirmed|O
S851|mild-moderate|O
S851|gingivitis|O
S851|.|O
S6859|After|O
S6859|8|O
S6859|weeks|O
S6859|of|O
S6859|double-blind|B-Blinding_Double_Blind
S6859|treatment|O
S6859|,|O
S6859|all|O
S6859|patients|O
S6859|entered|O
S6859|a|O
S6859|2-week|O
S6859|single-blind|O
S6859|,|O
S6859|placebo|O
S6859|withdrawal|O
S6859|period|O
S6859|.|O
S4697|either|O
S4697|patients|O
S4697|who|O
S4697|discontinued|O
S4697|from|O
S4697|the|O
S4697|study|O
S4697|,|O
S4697|discontinued|O
S4697|study|O
S4697|medication|O
S4697|or|O
S4697|took|O
S4697|rescue|O
S4697|medication|O
S4697|and|O
S4697|were|O
S4697|censored|O
S4697|)|O
S4697|,|O
S4697|~396|B-Sample_Size_Required
S4697|patients|O
S4697|from|O
S4697|mainland|O
S4697|China|O
S4697|(|O
S4697|132|O
S4697|per|O
S4697|group|O
S4697|)|O
S4697|were|O
S4697|to|O
S4697|be|O
S4697|randomized|O
S4697|.|O
S1288|Results|O
S1288|584|B-Sample_Size_Actual_at_Enrollment
S1288|subjects|O
S1288|were|O
S1288|randomised|O
S1288|into|O
S1288|SB2|O
S1288|(|O
S1288|N=291|O
S1288|;|O
S1288|290|O
S1288|analysed|O
S1288|)|O
S1288|or|O
S1288|INF|O
S1288|(|O
S1288|N=293|O
S1288|)|O
S1288|.|O
S4072|Methods|O
S4072|:|O
S4072|Healthy|O
S4072|infants|O
S4072|6–12|O
S4072|weeks|O
S4072|old|O
S4072|were|O
S4072|randomized|B-Randomization_Type_Simple
S4072|to|O
S4072|receive|O
S4072|a|O
S4072|4-dose|O
S4072|regimen|O
S4072|of|O
S4072|V114|O
S4072|Lot|O
S4072|1|O
S4072|,|O
S4072|V114|O
S4072|Lot|O
S4072|2|O
S4072|or|O
S4072|PCV13|O
S4072|at|O
S4072|2|O
S4072|,|O
S4072|4|O
S4072|,|O
S4072|6|O
S4072|and|O
S4072|12–15|O
S4072|months|O
S4072|old|O
S4072|.|O
S2039|Randomised|O
S2039|,|O
S2039|phase|B-Design_Phase_1
S2039|I|I-Design_Phase_1
S2039|pharmacokinetic|O
S2039|study|O
S2039|of|O
S2039|adalimumab|O
S2039|biosimilar|O
S2039|CT‐P17|O
S2039|(|O
S2039|40|O
S2039|mg/0.4|O
S2039|mL|O
S2039|)|O
S2039|by|O
S2039|autoinjector|O
S2039|and|O
S2039|prefilled|O
S2039|syringe|O
S2039|in|O
S2039|healthy|O
S2039|subjects|O
S6443|After|O
S6443|randomisation|O
S6443|,|O
S6443|no|B-Blinding_Open_Label
S6443|blinding|I-Blinding_Open_Label
S6443|was|O
S6443|performed|O
S6443|,|O
S6443|but|O
S6443|outcomes|O
S6443|were|O
S6443|adjudicated|O
S6443|blinded|O
S6443|to|O
S6443|allocation|O
S6443|.|O
S4105|METHODS|O
S4105|Study|O
S4105|Design|O
S4105|This|O
S4105|randomized|B-Randomization_Type_Simple
S4105|,|O
S4105|multisite|B-Settings_Multicenter
S4105|,|O
S4105|double-blind|B-Blinding_Double_Blind
S4105|phase|B-Design_Phase_2
S4105|2|I-Design_Phase_2
S4105|study|O
S4105|compared|O
S4105|the|O
S4105|safety|O
S4105|,|O
S4105|tolerability|O
S4105|and|O
S4105|immunogenicity|O
S4105|profiles|O
S4105|of|O
S4105|2|O
S4105|different|O
S4105|lots|O
S4105|of|O
S4105|V114|O
S4105|compared|O
S4105|with|O
S4105|PCV13|O
S4105|in|O
S4105|healthy|O
S4105|infants|O
S4105|6–12|O
S4105|weeks|O
S4105|of|O
S4105|age|O
S4105|.|O
S439|Methods|O
S439|Patients|O
S439|This|O
S439|Food|O
S439|and|O
S439|Drug|O
S439|Administration—approved|O
S439|phase|B-Design_Phase_2
S439|II|I-Design_Phase_2
S439|,|O
S439|multicentre|B-Settings_Multicenter
S439|,|O
S439|randomised|O
S439|,|O
S439|double-blind|B-Blinding_Double_Blind
S439|trial|O
S439|was|O
S439|conducted|O
S439|from|O
S439|September|O
S439|2017|O
S439|through|O
S439|February|O
S439|2020|O
S439|at|O
S439|15|B-Settings_Multicenter
S439|centres|I-Settings_Multicenter
S439|in|O
S439|the|O
S439|USA|B-Settings_Location
S439|.|O
S3911|Study|O
S3911|design|O
S3911|and|O
S3911|procedures|O
S3911|This|O
S3911|was|O
S3911|a|O
S3911|prospective|O
S3911|,|O
S3911|multicentre|B-Settings_Multicenter
S3911|and|O
S3911|multinational|O
S3911|(|O
S3911|94|B-Settings_Multicenter
S3911|centres|I-Settings_Multicenter
S3911|in|O
S3911|23|B-Settings_Location
S3911|countries|I-Settings_Location
S3911|,|I-Settings_Location
S3911|including|I-Settings_Location
S3911|Europe|I-Settings_Location
S3911|,|I-Settings_Location
S3911|Australia|I-Settings_Location
S3911|,|I-Settings_Location
S3911|Canada|I-Settings_Location
S3911|and|I-Settings_Location
S3911|USA|I-Settings_Location
S3911|)|O
S3911|,|O
S3911|randomised|O
S3911|,|O
S3911|double-blind|B-Blinding_Double_Blind
S3911|,|O
S3911|placebo-controlled|O
S3911|,|O
S3911|four-arm|O
S3911|,|O
S3911|parallel-group|B-Design_Parallel_Group
S3911|,|O
S3911|dose-finding|O
S3911|phase|B-Design_Phase_2
S3911|IIb|I-Design_Phase_2
S3911|study|O
S3911|,|O
S3911|conducted|O
S3911|in|O
S3911|accordance|O
S3911|with|O
S3911|the|O
S3911|Declaration|O
S3911|of|O
S3911|Helsinki|O
S3911|and|O
S3911|adhering|O
S3911|to|O
S3911|the|O
S3911|International|O
S3911|Conference|O
S3911|on|O
S3911|Harmonisation|O
S3911|Guidelines|O
S3911|for|O
S3911|Good|O
S3911|Clinical|O
S3911|Practice|O
S3911|.|O
S5447|Vitamin|B-Design_Parallel_Group
S5447|D|I-Design_Parallel_Group
S5447|or|I-Design_Parallel_Group
S5447|placebo|I-Design_Parallel_Group
S5447|was|O
S5447|given|O
S5447|by|O
S5447|fieldworkers|O
S5447|once|O
S5447|every|O
S5447|3|O
S5447|months|O
S5447|for|O
S5447|18|O
S5447|months|O
S5447|.|O
S2274|Statistical|O
S2274|analysis|O
S2274|Sample|O
S2274|size|O
S2274|was|O
S2274|based|O
S2274|on|O
S2274|the|O
S2274|primary|O
S2274|endpoint|O
S2274|of|O
S2274|trough|O
S2274|FEV1|O
S2274|at|O
S2274|Day|O
S2274|85|O
S2274|and|O
S2274|assumed|O
S2274|90|B-Sample_Size_Calculation_Power_Value
S2274|%|I-Sample_Size_Calculation_Power_Value
S2274|power|O
S2274|,|O
S2274|a|B-Sample_Size_Calculation_Alpha_Value
S2274|two-sided|I-Sample_Size_Calculation_Alpha_Value
S2274|1|I-Sample_Size_Calculation_Alpha_Value
S2274|%|I-Sample_Size_Calculation_Alpha_Value
S2274|significance|I-Sample_Size_Calculation_Alpha_Value
S2274|level|I-Sample_Size_Calculation_Alpha_Value
S2274|,|O
S2274|an|O
S2274|estimate|O
S2274|of|O
S2274|residual|O
S2274|standard|O
S2274|deviation|O
S2274|of|O
S2274|240|O
S2274|mL|O
S2274|(|O
S2274|based|O
S2274|on|O
S2274|mixed|O
S2274|model|O
S2274|repeated|O
S2274|measures|O
S2274|[|O
S2274|MMRM|O
S2274|]|O
S2274|analyses|O
S2274|of|O
S2274|the|O
S2274|Phase|O
S2274|III|O
S2274|IMPACT|O
S2274|study|O
S2274|)|O
S2274|and|O
S2274|a|O
S2274|treatment|O
S2274|difference|O
S2274|of|O
S2274|70|O
S2274|mL|O
S2274|.|O
S6449|Sample|O
S6449|size|O
S6449|and|O
S6449|analysis|O
S6449|To|O
S6449|establish|O
S6449|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S6449|,|O
S6449|we|O
S6449|allowed|O
S6449|a|O
S6449|difference|O
S6449|of|O
S6449|up|O
S6449|to|O
S6449|15|O
S6449|%|O
S6449|in|O
S6449|the|O
S6449|primary|O
S6449|outcome|O
S6449|.|O
S6587|Methods|O
S6587|STAIRWAY|O
S6587|was|O
S6587|a|O
S6587|phase|B-Design_Phase_2
S6587|2|I-Design_Phase_2
S6587|,|O
S6587|multicenter|B-Settings_Multicenter
S6587|,|O
S6587|randomized|O
S6587|,|O
S6587|active|O
S6587|comparator–controlled|O
S6587|,|O
S6587|participant-|O
S6587|and|O
S6587|outcome-assessor|B-Blinding_Object_Outcome_Assessors
S6587|masked|O
S6587|,|O
S6587|parallel-group|B-Design_Parallel_Group
S6587|,|O
S6587|52-week|O
S6587|clinical|O
S6587|trial|O
S6587|conducted|O
S6587|at|O
S6587|25|B-Settings_Multicenter
S6587|sites|I-Settings_Multicenter
S6587|in|O
S6587|the|O
S6587|United|B-Settings_Location
S6587|States|I-Settings_Location
S6587|between|O
S6587|January|O
S6587|and|O
S6587|March|O
S6587|2017|O
S6587|.|O
S1437|Results|O
S1437|Twenty-one|B-Sample_Size_Actual_at_Enrollment
S1437|patients|I-Sample_Size_Actual_at_Enrollment
S1437|received|O
S1437|golimumab|O
S1437|plus|O
S1437|MTX|O
S1437|and|O
S1437|23|O
S1437|MTX|O
S1437|monotherapy|O
S1437|for|O
S1437|24|O
S1437|weeks|O
S1437|.|O
S5813|Randomization|O
S5813|was|O
S5813|stratified|B-Randomization_Type_Stratified
S5813|by|O
S5813|baseline|B-Randomization_Stratified_Criteria
S5813|migraine|I-Randomization_Stratified_Criteria
S5813|frequency|I-Randomization_Stratified_Criteria
S5813|(|I-Randomization_Stratified_Criteria
S5813|CM|I-Randomization_Stratified_Criteria
S5813|versus|I-Randomization_Stratified_Criteria
S5813|EM|I-Randomization_Stratified_Criteria
S5813|)|I-Randomization_Stratified_Criteria
S5813|and|O
S5813|geographical|B-Randomization_Stratified_Criteria
S5813|region|I-Randomization_Stratified_Criteria
S5813|(|I-Randomization_Stratified_Criteria
S5813|North|I-Randomization_Stratified_Criteria
S5813|America|I-Randomization_Stratified_Criteria
S5813|vs.|I-Randomization_Stratified_Criteria
S5813|rest|I-Randomization_Stratified_Criteria
S5813|of|I-Randomization_Stratified_Criteria
S5813|world|I-Randomization_Stratified_Criteria
S5813|)|I-Randomization_Stratified_Criteria
S5813|.|O
S2732|We|O
S2732|therefore|O
S2732|conducted|O
S2732|the|O
S2732|present|O
S2732|phase|O
S2732|2|O
S2732|study|O
S2732|to|O
S2732|assess|O
S2732|the|O
S2732|efficacy|O
S2732|and|O
S2732|safety|O
S2732|of|O
S2732|three|O
S2732|,|O
S2732|twice-daily|O
S2732|doses|O
S2732|of|O
S2732|tenapanor|O
S2732|(|O
S2732|5|O
S2732|,|O
S2732|20|O
S2732|,|O
S2732|and|O
S2732|50|O
S2732|mg|O
S2732|)|O
S2732|for|O
S2732|the|O
S2732|treatment|O
S2732|of|O
S2732|patients|O
S2732|with|O
S2732|IBS-C.|O
S2732|Methods|O
S2732|Study|O
S2732|design|O
S2732|This|O
S2732|was|O
S2732|a|O
S2732|multicenter|B-Settings_Multicenter
S2732|,|O
S2732|phase|B-Design_Phase_2
S2732|2|I-Design_Phase_2
S2732|,|O
S2732|randomized|O
S2732|,|O
S2732|double-blind|B-Blinding_Double_Blind
S2732|,|O
S2732|placebo-controlled|O
S2732|study|O
S2732|conducted|O
S2732|at|O
S2732|79|B-Settings_Multicenter
S2732|sites|I-Settings_Multicenter
S2732|in|O
S2732|the|O
S2732|USA|B-Settings_Location
S2732|(|O
S2732|ClinicalTrials.gov|O
S2732|identifier|O
S2732|:|O
S2732|NCT01923428|O
S2732|)|O
S2732|between|O
S2732|August|O
S2732|2013|O
S2732|and|O
S2732|October|O
S2732|2014|O
S2732|(|O
S2732|last|O
S2732|patient|O
S2732|last|O
S2732|visit|O
S2732|July|O
S2732|2014|O
S2732|)|O
S2732|.|O
S2249|Eligible|O
S2249|patients|O
S2249|were|O
S2249|then|O
S2249|randomized|O
S2249|1:1|B-Randomization_Ratio
S2249|(|O
S2249|using|O
S2249|an|B-Randomization_Sequence_Generation_Method
S2249|Interactive|I-Randomization_Sequence_Generation_Method
S2249|Web|I-Randomization_Sequence_Generation_Method
S2249|Response|I-Randomization_Sequence_Generation_Method
S2249|System|I-Randomization_Sequence_Generation_Method
S2249|)|O
S2249|to|O
S2249|receive|O
S2249|either|O
S2249|FF/UMEC/VI|O
S2249|100/62.5/25|O
S2249|mcg|O
S2249|via|O
S2249|ELLIPTA|O
S2249|and|O
S2249|placebo|O
S2249|via|O
S2249|HandiHaler|O
S2249|or|O
S2249|TIO|O
S2249|18|O
S2249|mcg|O
S2249|via|O
S2249|HandiHaler|O
S2249|and|O
S2249|placebo|O
S2249|via|O
S2249|ELLIPTA|O
S2249|,|O
S2249|all|O
S2249|taken|O
S2249|once|O
S2249|daily|O
S2249|in|O
S2249|the|O
S2249|morning|O
S2249|(|O
S2249|Visit|O
S2249|2|O
S2249|)|O
S2249|.|O
S7923|Statistical|O
S7923|analysis|O
S7923|We|O
S7923|estimated|O
S7923|that|O
S7923|a|O
S7923|sample|O
S7923|size|O
S7923|of|O
S7923|305|B-Sample_Size_Required
S7923|patients|I-Sample_Size_Required
S7923|in|I-Sample_Size_Required
S7923|each|I-Sample_Size_Required
S7923|group|I-Sample_Size_Required
S7923|would|O
S7923|detect|O
S7923|a|O
S7923|5|O
S7923|mm|O
S7923|Hg|O
S7923|difference|O
S7923|in|O
S7923|systolic|O
S7923|blood|O
S7923|pressure|O
S7923|between|O
S7923|groups|O
S7923|with|O
S7923|90|B-Sample_Size_Calculation_Power_Value
S7923|%|I-Sample_Size_Calculation_Power_Value
S7923|power|O
S7923|at|O
S7923|a|O
S7923|significance|O
S7923|level|O
S7923|of|O
S7923|5|B-Sample_Size_Calculation_Alpha_Value
S7923|%|I-Sample_Size_Calculation_Alpha_Value
S7923|assuming|O
S7923|a|O
S7923|standard|O
S7923|deviation|O
S7923|of|O
S7923|17.5|O
S7923|mm|O
S7923|Hg|O
S7923|,|O
S7923|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S7923|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|loss|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|to|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|follow-up|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|,|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|5|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|mortality|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|,|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|and|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|10|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|major|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|vascular|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|events|I-Sample_Size_Calculation_Dropout_Rate_Value
S7923|.|O
S2227|This|O
S2227|12-week|O
S2227|,|O
S2227|double-blind|B-Blinding_Double_Blind
S2227|,|O
S2227|double-dummy|O
S2227|study|O
S2227|randomized|O
S2227|800|B-Sample_Size_Actual_at_Enrollment
S2227|symptomatic|O
S2227|moderate-to-very-severe|O
S2227|COPD|O
S2227|patients|O
S2227|receiving|O
S2227|tiotropium|B-Design_Parallel_Group
S2227|(|I-Design_Parallel_Group
S2227|TIO|I-Design_Parallel_Group
S2227|)|I-Design_Parallel_Group
S2227|for|I-Design_Parallel_Group
S2227|≥3|I-Design_Parallel_Group
S2227|months|I-Design_Parallel_Group
S2227|to|I-Design_Parallel_Group
S2227|once-daily|I-Design_Parallel_Group
S2227|fluticasone|I-Design_Parallel_Group
S2227|furoate/umeclidinium/vilanterol|I-Design_Parallel_Group
S2227|(|I-Design_Parallel_Group
S2227|FF/UMEC/VI|I-Design_Parallel_Group
S2227|)|I-Design_Parallel_Group
S2227|100/62.5/25|I-Design_Parallel_Group
S2227|mcg|I-Design_Parallel_Group
S2227|via|I-Design_Parallel_Group
S2227|ELLIPTA|I-Design_Parallel_Group
S2227|(|I-Design_Parallel_Group
S2227|n|I-Design_Parallel_Group
S2227|=|I-Design_Parallel_Group
S2227|400|I-Design_Parallel_Group
S2227|)|I-Design_Parallel_Group
S2227|or|I-Design_Parallel_Group
S2227|TIO|I-Design_Parallel_Group
S2227|18|I-Design_Parallel_Group
S2227|mcg|I-Design_Parallel_Group
S2227|via|I-Design_Parallel_Group
S2227|HandiHaler|I-Design_Parallel_Group
S2227|(|I-Design_Parallel_Group
S2227|n|I-Design_Parallel_Group
S2227|=|I-Design_Parallel_Group
S2227|400|I-Design_Parallel_Group
S2227|)|I-Design_Parallel_Group
S2227|plus|I-Design_Parallel_Group
S2227|matched|I-Design_Parallel_Group
S2227|placebo|I-Design_Parallel_Group
S2227|.|O
S3913|Patients|O
S3913|were|O
S3913|randomised|O
S3913|by|O
S3913|assignment|O
S3913|of|O
S3913|a|O
S3913|unique|O
S3913|randomisation|O
S3913|number|O
S3913|using|O
S3913|an|B-Randomization_Sequence_Generation_Method
S3913|interactive|I-Randomization_Sequence_Generation_Method
S3913|voice|I-Randomization_Sequence_Generation_Method
S3913|or|I-Randomization_Sequence_Generation_Method
S3913|web|I-Randomization_Sequence_Generation_Method
S3913|response|I-Randomization_Sequence_Generation_Method
S3913|system|I-Randomization_Sequence_Generation_Method
S3913|,|O
S3913|supplied|O
S3913|by|O
S3913|an|O
S3913|independent|O
S3913|service|O
S3913|provider|O
S3913|(|O
S3913|ICON|O
S3913|Clinical|O
S3913|,|O
S3913|Research|O
S3913|,|O
S3913|USA|O
S3913|)|O
S3913|.|O
S4122|The|O
S4122|statistical|O
S4122|criterion|O
S4122|for|O
S4122|noninferiority|B-Design_Comparative_Intent_NonInferiority
S4122|corresponds|O
S4122|to|O
S4122|the|O
S4122|lower|O
S4122|bound|O
S4122|of|O
S4122|the|O
S4122|adjusted|O
S4122|95|O
S4122|%|O
S4122|confidence|O
S4122|interval|O
S4122|(|O
S4122|CI|O
S4122|)|O
S4122|of|O
S4122|the|O
S4122|proportion|O
S4122|difference|O
S4122|(|O
S4122|V114|O
S4122|−|O
S4122|PCV13|O
S4122|)|O
S4122|being|O
S4122|greater|O
S4122|than|O
S4122|−0.15|O
S4122|for|O
S4122|each|O
S4122|of|O
S4122|the|O
S4122|13|O
S4122|shared|O
S4122|serotypes|O
S4122|.|O
S6061|A|O
S6061|Randomized|O
S6061|Phase|B-Design_Phase_2
S6061|2|I-Design_Phase_2
S6061|Trial|O
S6061|Comparing|O
S6061|Omidenepag|O
S6061|Isopropyl|O
S6061|0.002|O
S6061|%|O
S6061|Once|O
S6061|and|O
S6061|Twice|O
S6061|Daily|O
S6061|in|O
S6061|Subjects|O
S6061|With|O
S6061|Primary|O
S6061|Open-angle|O
S6061|Glaucoma|O
S6061|or|O
S6061|Ocular|O
S6061|Hypertension|O
S6061|(|O
S6061|SPECTRUM-6|O
S6061|)|O
S2247|The|O
S2247|study|O
S2247|was|O
S2247|conducted|O
S2247|in|O
S2247|72|B-Settings_Multicenter
S2247|centers|I-Settings_Multicenter
S2247|in|O
S2247|three|B-Settings_Location
S2247|countries|I-Settings_Location
S2247|(|I-Settings_Location
S2247|Poland|I-Settings_Location
S2247|,|I-Settings_Location
S2247|Russian|I-Settings_Location
S2247|Federation|I-Settings_Location
S2247|,|I-Settings_Location
S2247|and|I-Settings_Location
S2247|the|I-Settings_Location
S2247|USA|I-Settings_Location
S2247|)|I-Settings_Location
S2247|from|O
S2247|March|O
S2247|2018|O
S2247|to|O
S2247|July|O
S2247|2019|O
S2247|.|O
S8657|Statistical|O
S8657|analyses|O
S8657|Sample|O
S8657|size|O
S8657|was|O
S8657|calculated|O
S8657|from|O
S8657|the|O
S8657|study|O
S8657|of|O
S8657|Lee|O
S8657|et|O
S8657|al..|O
S8657|To|O
S8657|detect|O
S8657|a|O
S8657|35|O
S8657|%|O
S8657|change|O
S8657|in|O
S8657|aortic|O
S8657|distensibility|O
S8657|or|O
S8657|an|O
S8657|11|O
S8657|%|O
S8657|change|O
S8657|in|O
S8657|plaque|O
S8657|burden|O
S8657|at|O
S8657|12|O
S8657|months|O
S8657|to|O
S8657|achieve|O
S8657|a|O
S8657|power|O
S8657|of|O
S8657|0.8|B-Sample_Size_Calculation_Power_Value
S8657|and|O
S8657|nominal|O
S8657|p|O
S8657|<|O
S8657|0.05|B-Sample_Size_Calculation_Alpha_Value
S8657|(|I-Sample_Size_Calculation_Alpha_Value
S8657|2-sided|I-Sample_Size_Calculation_Alpha_Value
S8657|)|I-Sample_Size_Calculation_Alpha_Value
S8657|,|O
S8657|60|B-Sample_Size_Required
S8657|patients|I-Sample_Size_Required
S8657|per|I-Sample_Size_Required
S8657|group|I-Sample_Size_Required
S8657|were|I-Sample_Size_Required
S8657|required|I-Sample_Size_Required
S8657|.|O
S6460|Results|O
S6460|We|O
S6460|evaluated|O
S6460|782|O
S6460|patients|O
S6460|with|O
S6460|clinically|O
S6460|significant|O
S6460|MRSA|O
S6460|isolates|O
S6460|,|O
S6460|of|O
S6460|whom|O
S6460|252|B-Sample_Size_Actual_at_Enrollment
S6460|were|O
S6460|included|O
S6460|.|O
S7314|No|O
S7314|formal|O
S7314|hypothesis|O
S7314|tests|O
S7314|were|O
S7314|conducted|O
S7314|except|O
S7314|for|O
S7314|the|O
S7314|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7314|in|O
S7314|primary|O
S7314|end|O
S7314|point|O
S7314|.|O
S2889|Children|O
S2889|were|O
S2889|randomized|O
S2889|2:1|B-Randomization_Ratio
S2889|to|O
S2889|receive|O
S2889|either|O
S2889|a|O
S2889|single|B-Design_Parallel_Group
S2889|dose|I-Design_Parallel_Group
S2889|of|I-Design_Parallel_Group
S2889|oral|I-Design_Parallel_Group
S2889|baloxavir|I-Design_Parallel_Group
S2889|or|I-Design_Parallel_Group
S2889|oral|I-Design_Parallel_Group
S2889|oseltamivir|I-Design_Parallel_Group
S2889|twice|O
S2889|daily|O
S2889|for|O
S2889|5|O
S2889|days|O
S2889|.|O
S6598|Randomization|O
S6598|Participants|O
S6598|were|O
S6598|randomized|O
S6598|1:2:2|B-Randomization_Ratio
S6598|to|O
S6598|receive|O
S6598|intravitreal|O
S6598|ranibizumab|O
S6598|,|O
S6598|0.5|O
S6598|mg|O
S6598|,|O
S6598|every|O
S6598|4|O
S6598|weeks|O
S6598|;|O
S6598|faricimab|O
S6598|,|O
S6598|6.0|O
S6598|mg|O
S6598|,|O
S6598|every|O
S6598|12|O
S6598|weeks|O
S6598|after|O
S6598|initiation|O
S6598|(|O
S6598|4|O
S6598|total|O
S6598|injections|O
S6598|every|O
S6598|4|O
S6598|weeks|O
S6598|from|O
S6598|baseline|O
S6598|to|O
S6598|week|O
S6598|12|O
S6598|)|O
S6598|;|O
S6598|or|O
S6598|faricimab|O
S6598|,|O
S6598|6.0|O
S6598|mg|O
S6598|,|O
S6598|every|O
S6598|16|O
S6598|weeks|O
S6598|after|O
S6598|initiation|O
S6598|(|O
S6598|4|O
S6598|total|O
S6598|injections|O
S6598|every|O
S6598|4|O
S6598|weeks|O
S6598|from|O
S6598|baseline|O
S6598|to|O
S6598|week|O
S6598|12|O
S6598|)|O
S6598|.|O
S926|With|O
S926|this|O
S926|number|O
S926|per|O
S926|group|O
S926|,|O
S926|it|O
S926|was|O
S926|estimated|O
S926|to|O
S926|detect|O
S926|a|O
S926|0.1|O
S926|difference|O
S926|in|O
S926|BI|O
S926|(|O
S926|standard|O
S926|deviation|O
S926|[|O
S926|SD|O
S926|]|O
S926|=|O
S926|0.17|O
S926|)|O
S926|with|O
S926|90|B-Sample_Size_Calculation_Power_Value
S926|%|I-Sample_Size_Calculation_Power_Value
S926|power|O
S926|and|O
S926|a|B-Sample_Size_Calculation_Alpha_Value
S926|2-sided|I-Sample_Size_Calculation_Alpha_Value
S926|5|I-Sample_Size_Calculation_Alpha_Value
S926|%|I-Sample_Size_Calculation_Alpha_Value
S926|significance|I-Sample_Size_Calculation_Alpha_Value
S926|level|I-Sample_Size_Calculation_Alpha_Value
S926|.|O
S7305|Typically|O
S7305|,|O
S7305|a|O
S7305|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7305|margin|O
S7305|that|O
S7305|represents|O
S7305|⩾50|O
S7305|%|O
S7305|of|O
S7305|the|O
S7305|placebo-adjusted|O
S7305|control|O
S7305|drug|O
S7305|effect|O
S7305|is|O
S7305|suggested|O
S7305|;|O
S7305|thus|O
S7305|,|O
S7305|a|O
S7305|particularly|O
S7305|stringent|O
S7305|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7305|margin|O
S7305|was|O
S7305|used|O
S7305|in|O
S7305|the|O
S7305|present|O
S7305|study|O
S7305|.|O
S3026|Patients|O
S3026|were|O
S3026|randomized|B-Randomization_Type_Simple
S3026|(|O
S3026|1:1|B-Randomization_Ratio
S3026|)|O
S3026|to|O
S3026|oral|B-Design_Parallel_Group
S3026|abemaciclib|I-Design_Parallel_Group
S3026|150|I-Design_Parallel_Group
S3026|or|I-Design_Parallel_Group
S3026|200|I-Design_Parallel_Group
S3026|mg|I-Design_Parallel_Group
S3026|every|O
S3026|12|O
S3026|h|O
S3026|on|O
S3026|a|O
S3026|28-day|O
S3026|cycle|O
S3026|.|O
S8635|After|O
S8635|consent|O
S8635|,|O
S8635|eligible|O
S8635|patients|O
S8635|were|O
S8635|randomized|O
S8635|(|O
S8635|1:1|B-Randomization_Ratio
S8635|)|O
S8635|to|O
S8635|receive|O
S8635|canakinumab|B-Design_Parallel_Group
S8635|150|I-Design_Parallel_Group
S8635|mg|I-Design_Parallel_Group
S8635|or|I-Design_Parallel_Group
S8635|placebo|I-Design_Parallel_Group
S8635|,|O
S8635|subcutaneously|O
S8635|,|O
S8635|monthly|O
S8635|for|O
S8635|12|O
S8635|months|O
S8635|.|O
S5025|For|O
S5025|the|O
S5025|first|O
S5025|two|O
S5025|superiority|O
S5025|hypotheses|O
S5025|and|O
S5025|based|O
S5025|on|O
S5025|the|O
S5025|assumptions|O
S5025|above|O
S5025|,|O
S5025|a|O
S5025|sample|O
S5025|size|O
S5025|of|O
S5025|267|B-Sample_Size_Required
S5025|(|O
S5025|89|O
S5025|per|O
S5025|arm|O
S5025|)|O
S5025|provided|O
S5025|98|B-Sample_Size_Calculation_Power_Value
S5025|%|I-Sample_Size_Calculation_Power_Value
S5025|power|O
S5025|to|O
S5025|detect|O
S5025|a|O
S5025|greater|O
S5025|reduction|O
S5025|in|O
S5025|retinal|O
S5025|thickness|O
S5025|from|O
S5025|25|O
S5025|%|O
S5025|for|O
S5025|periocular|O
S5025|injection|O
S5025|to|O
S5025|40|O
S5025|%|O
S5025|for|O
S5025|intravitreal|O
S5025|injection|O
S5025|or|O
S5025|dexamethasone|O
S5025|implant|O
S5025|on|O
S5025|the|O
S5025|log|O
S5025|scale|O
S5025|,|O
S5025|i.e.|O
S5025|,|O
S5025|difference|O
S5025|in|O
S5025|log|O
S5025|change|O
S5025|in|O
S5025|retinal|O
S5025|thickness|O
S5025|of|O
S5025|log|O
S5025|(|O
S5025|0.6|O
S5025|)|O
S5025|vs.|O
S5025|log|O
S5025|(|O
S5025|0.75|O
S5025|)|O
S5025|,|O
S5025|with|O
S5025|a|B-Sample_Size_Calculation_Alpha_Value
S5025|two-sided|I-Sample_Size_Calculation_Alpha_Value
S5025|type|I-Sample_Size_Calculation_Alpha_Value
S5025|I|I-Sample_Size_Calculation_Alpha_Value
S5025|error|I-Sample_Size_Calculation_Alpha_Value
S5025|rate|I-Sample_Size_Calculation_Alpha_Value
S5025|of|I-Sample_Size_Calculation_Alpha_Value
S5025|0.01667|I-Sample_Size_Calculation_Alpha_Value
S5025|.|O
S1373|Two|B-Sample_Size_Actual_at_Outcome_Analysis
S1373|hundred|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|and|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|forty-six|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|from|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|the|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|SB2|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|treatment|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|group|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|and|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|259|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|from|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|the|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|INF|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|treatment|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|group|I-Sample_Size_Actual_at_Outcome_Analysis
S1373|completed|O
S1373|the|O
S1373|week|O
S1373|30|O
S1373|visit|O
S1373|;|O
S1373|the|O
S1373|most|O
S1373|common|O
S1373|reason|O
S1373|for|O
S1373|withdrawal|O
S1373|was|O
S1373|due|O
S1373|to|O
S1373|AEs|O
S1373|and|O
S1373|withdrawal|O
S1373|of|O
S1373|consent|O
S1373|(|O
S1373|figure|O
S1373|1|O
S1373|)|O
S1373|.|O
S2041|Methods|O
S2041|This|O
S2041|phase|B-Design_Phase_1
S2041|I|I-Design_Phase_1
S2041|,|O
S2041|open‐label|B-Blinding_Open_Label
S2041|study|O
S2041|(|O
S2041|ClinicalTrials.gov|O
S2041|:|O
S2041|NCT04295356|O
S2041|)|O
S2041|randomised|O
S2041|subjects|O
S2041|(|O
S2041|1:1|B-Randomization_Ratio
S2041|)|O
S2041|to|O
S2041|receive|O
S2041|a|B-Design_Parallel_Group
S2041|single|I-Design_Parallel_Group
S2041|40‐mg|I-Design_Parallel_Group
S2041|(|I-Design_Parallel_Group
S2041|100|I-Design_Parallel_Group
S2041|mg/mL|I-Design_Parallel_Group
S2041|)|I-Design_Parallel_Group
S2041|dose|I-Design_Parallel_Group
S2041|of|I-Design_Parallel_Group
S2041|CT‐P17|I-Design_Parallel_Group
S2041|AI|I-Design_Parallel_Group
S2041|or|I-Design_Parallel_Group
S2041|CT‐P17|I-Design_Parallel_Group
S2041|PFS|I-Design_Parallel_Group
S2041|.|O
S4846|Participants|B-Blinding_Object_Patients
S4846|and|O
S4846|study|B-Blinding_Object_Outcome_Assessors
S4846|staff|I-Blinding_Object_Outcome_Assessors
S4846|performing|O
S4846|data|O
S4846|collection|O
S4846|and|O
S4846|analysis|O
S4846|were|O
S4846|blinded|O
S4846|to|O
S4846|treatment|O
S4846|allocation|O
S4846|.|O
S3312|Overall|O
S3312|,|O
S3312|111|B-Sample_Size_Actual_at_Enrollment
S3312|women|O
S3312|participated|O
S3312|in|O
S3312|the|O
S3312|ursodeoxycholic|O
S3312|acid|O
S3312|comparison|O
S3312|;|O
S3312|at|O
S3312|randomisation|O
S3312|28|O
S3312|(|O
S3312|25|O
S3312|%|O
S3312|)|O
S3312|had|O
S3312|severe|O
S3312|disease|O
S3312|(|O
S3312|bile|O
S3312|acid|O
S3312|levels|O
S3312|>|O
S3312|40|O
S3312|µmol/L|O
S3312|)|O
S3312|,|O
S3312|71|O
S3312|(|O
S3312|64|O
S3312|%|O
S3312|)|O
S3312|mild|O
S3312|disease|O
S3312|(|O
S3312|≤40|O
S3312|µmol/L|O
S3312|)|O
S3312|,|O
S3312|and|O
S3312|12|O
S3312|(|O
S3312|11|O
S3312|%|O
S3312|)|O
S3312|normal|O
S3312|bile|O
S3312|acid|O
S3312|levels|O
S3312|with|O
S3312|raised|O
S3312|alanine|O
S3312|transaminase|O
S3312|levels|O
S3312|.|O
S5812|Before|O
S5812|the|O
S5812|start|O
S5812|of|O
S5812|the|O
S5812|trial|O
S5812|,|O
S5812|an|B-Randomization_Sequence_Generation_Method
S5812|interactive|I-Randomization_Sequence_Generation_Method
S5812|voice|I-Randomization_Sequence_Generation_Method
S5812|response/interactive|I-Randomization_Sequence_Generation_Method
S5812|web|I-Randomization_Sequence_Generation_Method
S5812|response|I-Randomization_Sequence_Generation_Method
S5812|system|I-Randomization_Sequence_Generation_Method
S5812|was|O
S5812|used|O
S5812|to|O
S5812|facilitate|O
S5812|randomization|O
S5812|and|O
S5812|stratification|O
S5812|,|O
S5812|and|O
S5812|the|O
S5812|randomization|O
S5812|treatment|O
S5812|assignment|O
S5812|was|O
S5812|generated|O
S5812|by|O
S5812|the|O
S5812|sponsor|B-Randomization_Personnel
S5812|’|I-Randomization_Personnel
S5812|s|I-Randomization_Personnel
S5812|Global|I-Randomization_Personnel
S5812|Randomization|I-Randomization_Personnel
S5812|and|I-Randomization_Personnel
S5812|Blinding|I-Randomization_Personnel
S5812|group|I-Randomization_Personnel
S5812|independent|O
S5812|of|O
S5812|the|O
S5812|study|O
S5812|.|O
S5659|The|O
S5659|randomization|O
S5659|and|O
S5659|treatment|O
S5659|allocation|O
S5659|were|O
S5659|performed|O
S5659|centrally|O
S5659|by|O
S5659|an|B-Randomization_Sequence_Generation_Method
S5659|interactive|I-Randomization_Sequence_Generation_Method
S5659|voice|I-Randomization_Sequence_Generation_Method
S5659|response|I-Randomization_Sequence_Generation_Method
S5659|system|I-Randomization_Sequence_Generation_Method
S5659|(|I-Randomization_Sequence_Generation_Method
S5659|IVRS|I-Randomization_Sequence_Generation_Method
S5659|)|I-Randomization_Sequence_Generation_Method
S5659|with|I-Randomization_Sequence_Generation_Method
S5659|simple|I-Randomization_Sequence_Generation_Method
S5659|sequential|I-Randomization_Sequence_Generation_Method
S5659|allocation|I-Randomization_Sequence_Generation_Method
S5659|from|O
S5659|blocked|B-Randomization_Type_Block
S5659|randomization|I-Randomization_Type_Block
S5659|schedule|O
S5659|without|O
S5659|stratifying|O
S5659|factors|O
S5659|(|O
S5659|including|O
S5659|site|O
S5659|)|O
S5659|.|O
S5157|This|O
S5157|randomized|B-Randomization_Type_Simple
S5157|controlled|O
S5157|trial|O
S5157|aimed|O
S5157|to|O
S5157|determine|O
S5157|whether|O
S5157|perioperative|O
S5157|IV|O
S5157|iron|O
S5157|reduced|O
S5157|the|O
S5157|need|O
S5157|for|O
S5157|ABT|O
S5157|.|O
S4|Methods|O
S4|:|O
S4|In|O
S4|this|O
S4|phase|B-Design_Phase_4
S4|IV|I-Design_Phase_4
S4|,|O
S4|randomized|B-Randomization_Type_Simple
S4|,|O
S4|observer-blinded|B-Blinding_Object_Others
S4|,|O
S4|multi-center|B-Settings_Multicenter
S4|study|O
S4|,|O
S4|healthy|O
S4|children|O
S4|6–35|O
S4|months|O
S4|of|O
S4|age|O
S4|were|O
S4|randomized|O
S4|1:1|B-Randomization_Ratio
S4|to|O
S4|be|O
S4|vaccinated|O
S4|with|O
S4|a|O
S4|half|B-Design_Parallel_Group
S4|or|I-Design_Parallel_Group
S4|full|I-Design_Parallel_Group
S4|dose|I-Design_Parallel_Group
S4|of|I-Design_Parallel_Group
S4|IIV4|I-Design_Parallel_Group
S4|(|O
S4|NCT02915302|O
S4|)|O
S4|.|O
S7288|Study|O
S7288|design|O
S7288|This|O
S7288|was|O
S7288|a|O
S7288|phase|B-Design_Phase_3
S7288|III|I-Design_Phase_3
S7288|,|O
S7288|randomized|B-Randomization_Type_Simple
S7288|,|O
S7288|double-blind|B-Blinding_Double_Blind
S7288|,|O
S7288|double-dummy|O
S7288|,|O
S7288|parallel-group|B-Design_Parallel_Group
S7288|,|O
S7288|12-week|O
S7288|study|O
S7288|(|O
S7288|ClinicalTrials.gov|O
S7288|:|O
S7288|NCT02281552|O
S7288|)|O
S7288|.|O
S5339|The|O
S5339|randomization|O
S5339|list|O
S5339|was|O
S5339|prepared|O
S5339|by|O
S5339|the|O
S5339|data|O
S5339|management|O
S5339|vendor|O
S5339|using|O
S5339|the|O
S5339|randomization|B-Randomization_Sequence_Generation_Method
S5339|module|I-Randomization_Sequence_Generation_Method
S5339|in|I-Randomization_Sequence_Generation_Method
S5339|Informatics|I-Randomization_Sequence_Generation_Method
S5339|ClinPhone|I-Randomization_Sequence_Generation_Method
S5339|RTSM|I-Randomization_Sequence_Generation_Method
S5339|service|I-Randomization_Sequence_Generation_Method
S5339|.|O
S1165|GP|O
S1165|MDI|O
S1165|18|O
S1165|μg|O
S1165|was|O
S1165|non-inferior|B-Design_Comparative_Intent_NonInferiority
S1165|to|O
S1165|open-label|B-Blinding_Open_Label
S1165|tiotropium|O
S1165|for|O
S1165|peak|O
S1165|change|O
S1165|in|O
S1165|FEV1|O
S1165|on|O
S1165|Day|O
S1165|1|O
S1165|and|O
S1165|morning|O
S1165|pre-dose|O
S1165|trough|O
S1165|FEV1|O
S1165|on|O
S1165|Day|O
S1165|14|O
S1165|.|O
S2537|Patients|O
S2537|received|O
S2537|danirixin|B-Design_Parallel_Group
S2537|5|I-Design_Parallel_Group
S2537|,|I-Design_Parallel_Group
S2537|10|I-Design_Parallel_Group
S2537|,|I-Design_Parallel_Group
S2537|25|I-Design_Parallel_Group
S2537|,|I-Design_Parallel_Group
S2537|35|I-Design_Parallel_Group
S2537|or|I-Design_Parallel_Group
S2537|50|I-Design_Parallel_Group
S2537|mg|I-Design_Parallel_Group
S2537|twice|I-Design_Parallel_Group
S2537|daily|I-Design_Parallel_Group
S2537|or|I-Design_Parallel_Group
S2537|placebo|I-Design_Parallel_Group
S2537|in|O
S2537|addition|O
S2537|to|O
S2537|standard|O
S2537|of|O
S2537|care|O
S2537|.|O
S1030|Randomization|O
S1030|was|O
S1030|based|O
S1030|on|O
S1030|a|B-Randomization_Sequence_Generation_Method
S1030|simple|I-Randomization_Sequence_Generation_Method
S1030|computer‐generated|I-Randomization_Sequence_Generation_Method
S1030|list|I-Randomization_Sequence_Generation_Method
S1030|that|O
S1030|was|O
S1030|placed|O
S1030|in|O
S1030|sealed|B-Allocation_Concealment_Method
S1030|envelopes|I-Allocation_Concealment_Method
S1030|.|O
S6904|Also|O
S6904|accounting|O
S6904|for|O
S6904|less|O
S6904|exclusion|O
S6904|from|O
S6904|the|O
S6904|per-protocol|O
S6904|set|O
S6904|(|O
S6904|17|B-Sample_Size_Calculation_Dropout_Rate_Value
S6904|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S6904|)|O
S6904|,|O
S6904|the|O
S6904|sample|O
S6904|size|O
S6904|was|O
S6904|reduced|O
S6904|to|O
S6904|480|B-Sample_Size_Target
S6904|patients|O
S6904|.|O
S5158|Methods|O
S5158|:|O
S5158|Between|O
S5158|August|O
S5158|2011|O
S5158|and|O
S5158|November|O
S5158|2014|O
S5158|,|O
S5158|72|B-Sample_Size_Actual_at_Enrollment
S5158|patients|O
S5158|with|O
S5158|IDA|O
S5158|were|O
S5158|assigned|O
S5158|to|O
S5158|receive|O
S5158|either|O
S5158|IV|B-Design_Parallel_Group
S5158|iron|I-Design_Parallel_Group
S5158|or|I-Design_Parallel_Group
S5158|usual|I-Design_Parallel_Group
S5158|care|I-Design_Parallel_Group
S5158|.|O
S4887|Eight|O
S4887|participants|O
S4887|withdrew|O
S4887|,|O
S4887|and|O
S4887|13|O
S4887|additional|O
S4887|participants|O
S4887|did|O
S4887|not|O
S4887|meet|O
S4887|eligibility|O
S4887|criteria|O
S4887|,|O
S4887|yielding|O
S4887|757|B-Sample_Size_Actual_at_Enrollment
S4887|randomized|O
S4887|participants|O
S4887|;|O
S4887|378|O
S4887|received|O
S4887|aIIV3|O
S4887|and|O
S4887|379|O
S4887|received|O
S4887|HD-IIV3|O
S4887|in|O
S4887|full|O
S4887|analysis|O
S4887|population|O
S4887|2|O
S4887|(|O
S4887|Figure|O
S4887|1|O
S4887|)|O
S4887|.|O
S5778|Methods|O
S5778|In|O
S5778|a|O
S5778|double-blind|B-Blinding_Double_Blind
S5778|trial|O
S5778|,|O
S5778|patients|O
S5778|were|O
S5778|randomized|O
S5778|4:3:3|B-Randomization_Ratio
S5778|to|O
S5778|placebo|B-Design_Parallel_Group
S5778|,|I-Design_Parallel_Group
S5778|AMG|I-Design_Parallel_Group
S5778|301|I-Design_Parallel_Group
S5778|210|I-Design_Parallel_Group
S5778|mg|I-Design_Parallel_Group
S5778|every|I-Design_Parallel_Group
S5778|4|I-Design_Parallel_Group
S5778|weeks|I-Design_Parallel_Group
S5778|,|I-Design_Parallel_Group
S5778|or|I-Design_Parallel_Group
S5778|AMG|I-Design_Parallel_Group
S5778|301|I-Design_Parallel_Group
S5778|420|I-Design_Parallel_Group
S5778|mg|I-Design_Parallel_Group
S5778|every|O
S5778|2|O
S5778|weeks|O
S5778|for|O
S5778|12|O
S5778|weeks|O
S5778|.|O
S1245|Open-label|B-Blinding_Open_Label
S1245|tiotropium|O
S1245|demonstrated|O
S1245|a|O
S1245|statistically|O
S1245|and|O
S1245|clinically|O
S1245|significant|O
S1245|increase|O
S1245|versus|O
S1245|placebo|O
S1245|MDI|O
S1245|in|O
S1245|FEV1|O
S1245|AUC0–12|O
S1245|on|O
S1245|Day|O
S1245|14|O
S1245|(|O
S1245|LSM|O
S1245|difference|O
S1245|,|O
S1245|224|O
S1245|mL|O
S1245|;|O
S1245|p|O
S1245|<|O
S1245|0.0001|O
S1245|)|O
S1245|.|O
S402|Methods|O
S402|This|O
S402|was|O
S402|a|O
S402|phase|B-Design_Phase_2
S402|II|I-Design_Phase_2
S402|,|O
S402|randomised|O
S402|,|O
S402|double-blind|B-Blinding_Double_Blind
S402|trial|O
S402|conducted|O
S402|at|O
S402|15|B-Settings_Multicenter
S402|centres|I-Settings_Multicenter
S402|in|O
S402|the|O
S402|USA|B-Settings_Location
S402|to|O
S402|evaluate|O
S402|the|O
S402|safety|O
S402|and|O
S402|efficacy|O
S402|of|O
S402|filgotinib|O
S402|or|O
S402|lanraplenib|O
S402|for|O
S402|the|O
S402|treatment|O
S402|of|O
S402|LMN|O
S402|.|O
S3512|The|O
S3512|randomisation|O
S3512|was|O
S3512|stratified|B-Randomization_Type_Stratified
S3512|by|O
S3512|centre|B-Randomization_Stratified_Criteria
S3512|and|O
S3512|age|B-Randomization_Stratified_Criteria
S3512|(|I-Randomization_Stratified_Criteria
S3512|<|I-Randomization_Stratified_Criteria
S3512|35|I-Randomization_Stratified_Criteria
S3512|,|I-Randomization_Stratified_Criteria
S3512|35–37|I-Randomization_Stratified_Criteria
S3512|and|I-Randomization_Stratified_Criteria
S3512|38–40|I-Randomization_Stratified_Criteria
S3512|years|I-Randomization_Stratified_Criteria
S3512|)|I-Randomization_Stratified_Criteria
S3512|using|O
S3512|a|O
S3512|block|B-Randomization_Type_Block
S3512|size|O
S3512|of|O
S3512|four|B-Randomization_Block_Size
S3512|.|O
S739|Allocation|O
S739|concealment|O
S739|was|O
S739|maintained|O
S739|by|O
S739|identically|B-Allocation_Concealment_Method
S739|labeled|I-Allocation_Concealment_Method
S739|,|I-Allocation_Concealment_Method
S739|sealed|I-Allocation_Concealment_Method
S739|,|I-Allocation_Concealment_Method
S739|sequentially|I-Allocation_Concealment_Method
S739|numbered|I-Allocation_Concealment_Method
S739|opaque|I-Allocation_Concealment_Method
S739|pill|I-Allocation_Concealment_Method
S739|containers|I-Allocation_Concealment_Method
S739|.|O
S5337|Randomization|O
S5337|Patients|O
S5337|were|O
S5337|randomized|O
S5337|in|O
S5337|a|O
S5337|2:1|O
S5337|ratio|O
S5337|to|O
S5337|receive|O
S5337|IIM|B-Design_Parallel_Group
S5337|or|I-Design_Parallel_Group
S5337|IS|I-Design_Parallel_Group
S5337|using|O
S5337|stratified|B-Randomization_Type_Stratified
S5337|block|B-Randomization_Type_Block
S5337|randomization|O
S5337|according|O
S5337|to|O
S5337|eGFR|B-Randomization_Stratified_Criteria
S5337|at|I-Randomization_Stratified_Criteria
S5337|screening|I-Randomization_Stratified_Criteria
S5337|(|I-Randomization_Stratified_Criteria
S5337|<|I-Randomization_Stratified_Criteria
S5337|46|I-Randomization_Stratified_Criteria
S5337|,|I-Randomization_Stratified_Criteria
S5337|46–|I-Randomization_Stratified_Criteria
S5337|<|I-Randomization_Stratified_Criteria
S5337|60|I-Randomization_Stratified_Criteria
S5337|or|I-Randomization_Stratified_Criteria
S5337|60–|I-Randomization_Stratified_Criteria
S5337|<|I-Randomization_Stratified_Criteria
S5337|90|I-Randomization_Stratified_Criteria
S5337|mL/min/1.73|I-Randomization_Stratified_Criteria
S5337|m2|I-Randomization_Stratified_Criteria
S5337|)|I-Randomization_Stratified_Criteria
S5337|and|O
S5337|baseline|B-Randomization_Stratified_Criteria
S5337|cardiovascular|I-Randomization_Stratified_Criteria
S5337|risk|I-Randomization_Stratified_Criteria
S5337|(|I-Randomization_Stratified_Criteria
S5337|history|I-Randomization_Stratified_Criteria
S5337|of|I-Randomization_Stratified_Criteria
S5337|myocardial|I-Randomization_Stratified_Criteria
S5337|infarction|I-Randomization_Stratified_Criteria
S5337|,|I-Randomization_Stratified_Criteria
S5337|stroke|I-Randomization_Stratified_Criteria
S5337|or|I-Randomization_Stratified_Criteria
S5337|congestive|I-Randomization_Stratified_Criteria
S5337|heart|I-Randomization_Stratified_Criteria
S5337|failure|I-Randomization_Stratified_Criteria
S5337|;|I-Randomization_Stratified_Criteria
S5337|yes/no|I-Randomization_Stratified_Criteria
S5337|)|I-Randomization_Stratified_Criteria
S5337|.|O
S5972|Full|O
S5972|data|O
S5972|to|O
S5972|calculate|O
S5972|the|O
S5972|AUC|O
S5972|for|O
S5972|cTnI|O
S5972|(|O
S5972|primary|O
S5972|outcome|O
S5972|)|O
S5972|were|O
S5972|obtained|O
S5972|in|O
S5972|83|B-Sample_Size_Actual_at_Outcome_Analysis
S5972|patients|O
S5972|(|O
S5972|95|O
S5972|%|O
S5972|)|O
S5972|.|O
S5955|It|O
S5955|was|O
S5955|analysed|O
S5955|using|O
S5955|a|O
S5955|generalised|O
S5955|linear|O
S5955|model|O
S5955|,|O
S5955|including|O
S5955|terms|O
S5955|for|O
S5955|the|O
S5955|treatment|O
S5955|allocation|O
S5955|and|O
S5955|the|O
S5955|variables|O
S5955|on|O
S5955|which|O
S5955|the|O
S5955|randomisation|O
S5955|was|O
S5955|minimised|B-Randomization_Type_Minimization
S5955|.|O
S277|Results|O
S277|A|O
S277|total|O
S277|of|O
S277|280|B-Sample_Size_Actual_at_Enrollment
S277|patients|O
S277|(|O
S277|mean|O
S277|[|O
S277|SD|O
S277|]|O
S277|age|O
S277|,|O
S277|39.3|O
S277|[|O
S277|17.5|O
S277|]|O
S277|years|O
S277|;|O
S277|166|O
S277|[|O
S277|59.3|O
S277|%|O
S277|]|O
S277|female|O
S277|)|O
S277|were|O
S277|randomized|O
S277|to|O
S277|placebo|O
S277|(|O
S277|n|O
S277|=|O
S277|52|O
S277|)|O
S277|or|O
S277|to|O
S277|lebrikizumab|O
S277|at|O
S277|doses|O
S277|of|O
S277|125|O
S277|mg|O
S277|every|O
S277|4|O
S277|weeks|O
S277|(|O
S277|n|O
S277|=|O
S277|73|O
S277|)|O
S277|,|O
S277|250|O
S277|mg|O
S277|every|O
S277|4|O
S277|weeks|O
S277|(|O
S277|n|O
S277|=|O
S277|80|O
S277|)|O
S277|,|O
S277|or|O
S277|250|O
S277|mg|O
S277|every|O
S277|2|O
S277|weeks|O
S277|(|O
S277|n|O
S277|=|O
S277|75|O
S277|)|O
S277|.|O
S6245|Study|O
S6245|Design|O
S6245|This|O
S6245|was|O
S6245|a|O
S6245|phase|B-Design_Phase_3
S6245|3|I-Design_Phase_3
S6245|,|O
S6245|multicenter|B-Settings_Multicenter
S6245|,|O
S6245|randomized|B-Randomization_Type_Simple
S6245|,|O
S6245|double-blind|B-Blinding_Double_Blind
S6245|,|O
S6245|placebo-controlled|O
S6245|clinical|O
S6245|trial|O
S6245|,|O
S6245|conducted|O
S6245|at|O
S6245|38|B-Settings_Multicenter
S6245|medical|I-Settings_Multicenter
S6245|institutions|I-Settings_Multicenter
S6245|in|O
S6245|Japan|B-Settings_Location
S6245|from|O
S6245|August|O
S6245|2017|O
S6245|through|O
S6245|January|O
S6245|2019|O
S6245|.|O
S8273|In|O
S8273|order|O
S8273|to|O
S8273|assure|O
S8273|blinding|O
S8273|,|O
S8273|randomization|O
S8273|was|O
S8273|performed|O
S8273|by|O
S8273|the|O
S8273|study|B-Randomization_Personnel
S8273|statistician|I-Randomization_Personnel
S8273|who|O
S8273|forwarded|O
S8273|the|O
S8273|randomization|B-Randomization_Sequence_Generation_Method
S8273|list|I-Randomization_Sequence_Generation_Method
S8273|to|O
S8273|the|O
S8273|research|O
S8273|pharmacist|O
S8273|who|O
S8273|in-turn|O
S8273|dispensed|O
S8273|the|O
S8273|study|O
S8273|drug|O
S8273|directly|O
S8273|to|O
S8273|the|O
S8273|subjects|O
S8273|.|O
S1958|Results|O
S1958|From|O
S1958|September|O
S1958|2013|O
S1958|to|O
S1958|December|O
S1958|2018|O
S1958|,|O
S1958|a|O
S1958|total|O
S1958|of|O
S1958|408|B-Sample_Size_Actual_at_Enrollment
S1958|pregnant|I-Sample_Size_Actual_at_Enrollment
S1958|women|I-Sample_Size_Actual_at_Enrollment
S1958|(|O
S1958|206|O
S1958|randomized|O
S1958|to|O
S1958|raltegravir|O
S1958|,|O
S1958|202|O
S1958|to|O
S1958|efavirenz|O
S1958|)|O
S1958|were|O
S1958|enrolled|O
S1958|at|O
S1958|sites|O
S1958|in|O
S1958|Argentina|O
S1958|(|O
S1958|N=20|O
S1958|)|O
S1958|,|O
S1958|Brazil|O
S1958|(|O
S1958|N=190|O
S1958|)|O
S1958|,|O
S1958|South|O
S1958|Africa|O
S1958|(|O
S1958|N=60|O
S1958|)|O
S1958|,|O
S1958|Tanzania|O
S1958|(|O
S1958|N=84|O
S1958|)|O
S1958|,|O
S1958|Thailand|O
S1958|(|O
S1958|N=47|O
S1958|)|O
S1958|,|O
S1958|and|O
S1958|the|O
S1958|US|O
S1958|(|O
S1958|N=7|O
S1958|)|O
S1958|;|O
S1958|205|O
S1958|(|O
S1958|50|O
S1958|%|O
S1958|)|O
S1958|enrolled|O
S1958|from|O
S1958|20|O
S1958|to|O
S1958|less|O
S1958|than|O
S1958|28|O
S1958|weeks|O
S1958|gestation|O
S1958|,|O
S1958|and|O
S1958|203|O
S1958|(|O
S1958|50|O
S1958|%|O
S1958|)|O
S1958|from|O
S1958|28|O
S1958|to|O
S1958|less|O
S1958|than|O
S1958|37|O
S1958|weeks|O
S1958|gestation|O
S1958|.|O
S267|Key|O
S267|Points|O
S267|Question|O
S267|Is|O
S267|lebrikizumab|O
S267|,|O
S267|a|O
S267|novel|O
S267|,|O
S267|high-affinity|O
S267|,|O
S267|monoclonal|O
S267|antibody|O
S267|targeting|O
S267|interleukin|O
S267|13|O
S267|that|O
S267|selectively|O
S267|inhibits|O
S267|interleukin|O
S267|13|O
S267|signaling|O
S267|,|O
S267|efficacious|O
S267|and|O
S267|safe|O
S267|in|O
S267|adults|O
S267|with|O
S267|moderate|O
S267|to|O
S267|severe|O
S267|atopic|O
S267|dermatitis|O
S267|?|O
S267|Findings|O
S267|Among|O
S267|280|B-Sample_Size_Actual_at_Enrollment
S267|patients|O
S267|with|O
S267|moderate|O
S267|to|O
S267|severe|O
S267|atopic|O
S267|dermatitis|O
S267|in|O
S267|this|O
S267|phase|O
S267|2b|O
S267|,|O
S267|placebo-controlled|O
S267|randomized|O
S267|clinical|O
S267|trial|O
S267|,|O
S267|lebrikizumab|O
S267|statistically|O
S267|significantly|O
S267|improved|O
S267|measures|O
S267|of|O
S267|clinical|O
S267|manifestations|O
S267|of|O
S267|atopic|O
S267|dermatitis|O
S267|,|O
S267|pruritus|O
S267|,|O
S267|and|O
S267|quality|O
S267|of|O
S267|life|O
S267|in|O
S267|a|O
S267|dose-dependent|O
S267|manner|O
S267|vs|O
S267|placebo|O
S267|during|O
S267|16|O
S267|weeks|O
S267|of|O
S267|treatment|O
S267|.|O
S7809|Results|O
S7809|Trial|O
S7809|Participants|O
S7809|Participants|O
S7809|(|O
S7809|n|O
S7809|=|O
S7809|1,091|B-Sample_Size_Actual_at_Enrollment
S7809|)|O
S7809|were|O
S7809|randomized|O
S7809|to|O
S7809|faster|O
S7809|aspart|O
S7809|(|O
S7809|n|O
S7809|=|O
S7809|546|O
S7809|)|O
S7809|or|O
S7809|IAsp|O
S7809|(|O
S7809|n|O
S7809|=|O
S7809|545|O
S7809|)|O
S7809|,|O
S7809|and|O
S7809|99.6|O
S7809|%|O
S7809|(|O
S7809|n|O
S7809|=|O
S7809|544|O
S7809|)|O
S7809|and|O
S7809|99.8|O
S7809|%|O
S7809|(|O
S7809|n|O
S7809|=|O
S7809|544|O
S7809|)|O
S7809|of|O
S7809|participants|O
S7809|,|O
S7809|respectively|O
S7809|,|O
S7809|were|O
S7809|exposed|O
S7809|to|O
S7809|randomized|O
S7809|trial|O
S7809|product|O
S7809|.|O
S161|We|O
S161|selected|O
S161|a|O
S161|sample|O
S161|size|O
S161|of|O
S161|84|B-Sample_Size_Target
S161|(|O
S161|42|O
S161|per|O
S161|group|O
S161|)|O
S161|to|O
S161|have|O
S161|80|B-Sample_Size_Calculation_Power_Value
S161|%|I-Sample_Size_Calculation_Power_Value
S161|power|O
S161|to|O
S161|detect|O
S161|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S161|of|O
S161|IN|O
S161|fentanyl|O
S161|versus|O
S161|IV|O
S161|hydromorphone|O
S161|using|O
S161|a|O
S161|one-sided|O
S161|,|O
S161|two-sample|O
S161|t-test|O
S161|,|O
S161|with|O
S161|a|O
S161|non-inferiority|O
S161|margin|O
S161|of|O
S161|0.9|O
S161|and|O
S161|an|O
S161|alpha|O
S161|of|O
S161|0.05|B-Sample_Size_Calculation_Alpha_Value
S161|.|O
S2043|Equivalence|B-Design_Comparative_Intent_Equivalence
S2043|was|O
S2043|determined|O
S2043|if|O
S2043|the|O
S2043|90|O
S2043|%|O
S2043|confidence|O
S2043|interval|O
S2043|for|O
S2043|the|O
S2043|geometric|O
S2043|least‐squares|O
S2043|mean|O
S2043|ratio|O
S2043|was|O
S2043|within|O
S2043|the|O
S2043|80–125|O
S2043|%|O
S2043|equivalence|O
S2043|margin|O
S2043|.|O
S4997|Randomization|O
S4997|was|O
S4997|undertaken|O
S4997|using|O
S4997|permuted|B-Randomization_Type_Block
S4997|blocks|I-Randomization_Type_Block
S4997|of|O
S4997|varying|B-Randomization_Block_Size
S4997|lengths|I-Randomization_Block_Size
S4997|to|O
S4997|yield|O
S4997|the|O
S4997|expected|O
S4997|1:1:1|B-Randomization_Ratio
S4997|allocation|O
S4997|ratio|O
S4997|and|O
S4997|stratified|B-Randomization_Type_Stratified
S4997|by|O
S4997|the|O
S4997|presence|B-Randomization_Stratified_Criteria
S4997|or|I-Randomization_Stratified_Criteria
S4997|absence|I-Randomization_Stratified_Criteria
S4997|of|I-Randomization_Stratified_Criteria
S4997|concomitant|I-Randomization_Stratified_Criteria
S4997|systemic|I-Randomization_Stratified_Criteria
S4997|treatment|I-Randomization_Stratified_Criteria
S4997|for|I-Randomization_Stratified_Criteria
S4997|uveitis|I-Randomization_Stratified_Criteria
S4997|(|O
S4997|e.g|O
S4997|.|O
S4789|Key|O
S4789|Points|O
S4789|Question|O
S4789|What|O
S4789|are|O
S4789|the|O
S4789|comparative|O
S4789|safety|O
S4789|,|O
S4789|reactogenicity|O
S4789|,|O
S4789|and|O
S4789|short-term|O
S4789|effects|O
S4789|of|O
S4789|vaccination|O
S4789|on|O
S4789|health-related|O
S4789|quality|O
S4789|of|O
S4789|life|O
S4789|after|O
S4789|trivalent|O
S4789|adjuvanted|O
S4789|inactivated|O
S4789|influenza|O
S4789|vaccine|O
S4789|(|O
S4789|aIIV3|O
S4789|)|O
S4789|or|O
S4789|trivalent|O
S4789|high-dose|O
S4789|inactivated|O
S4789|influenza|O
S4789|vaccine|O
S4789|(|O
S4789|HD-IIV3|O
S4789|)|O
S4789|in|O
S4789|adults|O
S4789|aged|O
S4789|65|O
S4789|years|O
S4789|and|O
S4789|older|O
S4789|?|O
S4789|Findings|O
S4789|In|O
S4789|this|O
S4789|randomized|O
S4789|clinical|O
S4789|trial|O
S4789|of|O
S4789|757|B-Sample_Size_Actual_at_Enrollment
S4789|older|I-Sample_Size_Actual_at_Enrollment
S4789|adults|I-Sample_Size_Actual_at_Enrollment
S4789|(|O
S4789|378|O
S4789|receiving|O
S4789|aIIV3|O
S4789|and|O
S4789|379|O
S4789|receiving|O
S4789|HD-IIV3|O
S4789|)|O
S4789|,|O
S4789|the|O
S4789|proportion|O
S4789|of|O
S4789|participants|O
S4789|with|O
S4789|moderate-to-severe|O
S4789|injection-site|O
S4789|pain|O
S4789|(|O
S4789|primary|O
S4789|outcome|O
S4789|)|O
S4789|was|O
S4789|not|O
S4789|higher|O
S4789|after|O
S4789|aIIV3|O
S4789|than|O
S4789|HD-IIV3|O
S4789|.|O
S5184|METHODS|O
S5184|This|O
S5184|was|O
S5184|a|O
S5184|randomized|B-Randomization_Type_Simple
S5184|controlled|O
S5184|trial|O
S5184|.|O
S1202|Following|O
S1202|screening|O
S1202|,|O
S1202|patients|O
S1202|were|O
S1202|randomized|O
S1202|using|O
S1202|an|B-Randomization_Sequence_Generation_Method
S1202|interactive|I-Randomization_Sequence_Generation_Method
S1202|web|I-Randomization_Sequence_Generation_Method
S1202|response|I-Randomization_Sequence_Generation_Method
S1202|system|I-Randomization_Sequence_Generation_Method
S1202|to|O
S1202|one|O
S1202|of|O
S1202|120|O
S1202|pre-defined|O
S1202|treatment|O
S1202|sequences|O
S1202|,|O
S1202|comprising|O
S1202|four|O
S1202|out|O
S1202|of|O
S1202|the|O
S1202|eight|O
S1202|possible|O
S1202|treatments|O
S1202|.|O
S3226|Methods|O
S3226|We|O
S3226|undertook|O
S3226|a|O
S3226|semifactorial|B-Design_Factorial
S3226|randomised|O
S3226|controlled|O
S3226|trial|O
S3226|of|O
S3226|two|O
S3226|interventions|O
S3226|in|O
S3226|women|O
S3226|with|O
S3226|intrahepatic|O
S3226|cholestasis|O
S3226|of|O
S3226|pregnancy|O
S3226|at|O
S3226|nine|B-Settings_Multicenter
S3226|maternity|I-Settings_Multicenter
S3226|units|I-Settings_Multicenter
S3226|in|O
S3226|the|O
S3226|United|B-Settings_Location
S3226|Kingdom|I-Settings_Location
S3226|.|O
S3111|All|O
S3111|25|B-Sample_Size_Actual_at_Outcome_Analysis
S3111|patients|O
S3111|(|O
S3111|100|O
S3111|%|O
S3111|)|O
S3111|reported|O
S3111|at|O
S3111|least|O
S3111|one|O
S3111|treatment-emergent|O
S3111|AE|O
S3111|(|O
S3111|TEAE|O
S3111|)|O
S3111|of|O
S3111|any|O
S3111|grade|O
S3111|and|O
S3111|the|O
S3111|safety|O
S3111|profiles|O
S3111|were|O
S3111|comparable|O
S3111|in|O
S3111|both|O
S3111|cohorts|O
S3111|(|O
S3111|Table|O
S3111|2|O
S3111|)|O
S3111|.|O
S7121|Randomisation|O
S7121|was|O
S7121|done|O
S7121|by|O
S7121|a|B-Randomization_Sequence_Generation_Method
S7121|central|I-Randomization_Sequence_Generation_Method
S7121|telephone|I-Randomization_Sequence_Generation_Method
S7121|or|I-Randomization_Sequence_Generation_Method
S7121|web-based|I-Randomization_Sequence_Generation_Method
S7121|randomisation|I-Randomization_Sequence_Generation_Method
S7121|service|I-Randomization_Sequence_Generation_Method
S7121|with|O
S7121|minmisation|B-Randomization_Type_Minimization
S7121|by|O
S7121|centre|B-Randomization_Minimization_Criteria
S7121|,|O
S7121|pressure|B-Randomization_Minimization_Criteria
S7121|of|I-Randomization_Minimization_Criteria
S7121|arterial|I-Randomization_Minimization_Criteria
S7121|oxygen|I-Randomization_Minimization_Criteria
S7121|to|I-Randomization_Minimization_Criteria
S7121|fractional|I-Randomization_Minimization_Criteria
S7121|inspired|I-Randomization_Minimization_Criteria
S7121|oxygen|I-Randomization_Minimization_Criteria
S7121|concentration|I-Randomization_Minimization_Criteria
S7121|(|I-Randomization_Minimization_Criteria
S7121|PaO2/FIO2|I-Randomization_Minimization_Criteria
S7121|)|I-Randomization_Minimization_Criteria
S7121|ratio|I-Randomization_Minimization_Criteria
S7121|,|O
S7121|and|O
S7121|age|B-Randomization_Minimization_Criteria
S7121|.|O
S1256|GP|O
S1256|MDI|O
S1256|18|O
S1256|and|O
S1256|9|O
S1256|μg|O
S1256|were|O
S1256|non-inferior|B-Design_Comparative_Intent_NonInferiority
S1256|to|O
S1256|open-label|B-Blinding_Open_Label
S1256|tiotropium|O
S1256|for|O
S1256|change|O
S1256|from|O
S1256|baseline|O
S1256|in|O
S1256|morning|O
S1256|pre-dose|O
S1256|trough|O
S1256|FEV1|O
S1256|,|O
S1256|using|O
S1256|the|O
S1256|pre-specified|O
S1256|margin|O
S1256|of|O
S1256|100|O
S1256|mL|O
S1256|,|O
S1256|on|O
S1256|Days|O
S1256|7|O
S1256|and|O
S1256|14|O
S1256|.|O
S6391|Design|O
S6391|Parallel|B-Design_Parallel_Group
S6391|,|O
S6391|open|B-Blinding_Open_Label
S6391|label|I-Blinding_Open_Label
S6391|,|O
S6391|randomised|O
S6391|controlled|O
S6391|trial|O
S6391|.|O
S3822|Thus|O
S3822|,|O
S3822|the|O
S3822|final|O
S3822|analysis|O
S3822|was|O
S3822|based|O
S3822|on|O
S3822|data|O
S3822|from|O
S3822|37|B-Sample_Size_Actual_at_Outcome_Analysis
S3822|patients|O
S3822|.|O
S7479|Results|O
S7479|Patient|O
S7479|Disposition|O
S7479|and|O
S7479|Baseline|O
S7479|Characteristics|O
S7479|A|O
S7479|total|O
S7479|of|O
S7479|475|B-Sample_Size_Actual_at_Enrollment
S7479|patients|O
S7479|were|O
S7479|randomized|O
S7479|–|O
S7479|136|O
S7479|to|O
S7479|placebo|O
S7479|,|O
S7479|67|O
S7479|to|O
S7479|erenumab|O
S7479|28|O
S7479|mg|O
S7479|,|O
S7479|135|O
S7479|to|O
S7479|erenumab|O
S7479|70|O
S7479|mg|O
S7479|,|O
S7479|and|O
S7479|137|O
S7479|to|O
S7479|erenumab|O
S7479|140|O
S7479|mg|O
S7479|(|O
S7479|Fig|O
S7479|.|O
S4668|On|O
S4668|day|O
S4668|1|O
S4668|(|O
S4668|randomization|O
S4668|)|O
S4668|,|O
S4668|each|O
S4668|participant|O
S4668|was|O
S4668|assigned|O
S4668|(|O
S4668|1:1:1|B-Randomization_Ratio
S4668|)|O
S4668|to|O
S4668|oral|O
S4668|,|O
S4668|once‐daily|O
S4668|ertugliflozin|O
S4668|5|O
S4668|mg|O
S4668|,|O
S4668|15|O
S4668|mg|O
S4668|or|O
S4668|placebo|O
S4668|using|O
S4668|a|O
S4668|computer‐generated|B-Randomization_Sequence_Generation_Method
S4668|randomization|I-Randomization_Sequence_Generation_Method
S4668|code|I-Randomization_Sequence_Generation_Method
S4668|based|O
S4668|on|O
S4668|the|O
S4668|method|O
S4668|of|O
S4668|random|O
S4668|permuted|O
S4668|blocks|B-Randomization_Type_Block
S4668|.|O
S7166|Infusion|O
S7166|syringes|O
S7166|were|O
S7166|prepared|O
S7166|immediately|O
S7166|before|O
S7166|use|O
S7166|by|O
S7166|the|O
S7166|nurse|O
S7166|and|O
S7166|contained|O
S7166|two|O
S7166|ampoules|O
S7166|of|O
S7166|the|O
S7166|blinded|O
S7166|solutions|O
S7166|(|O
S7166|salbutamol|B-Design_Parallel_Group
S7166|or|I-Design_Parallel_Group
S7166|placebo|I-Design_Parallel_Group
S7166|)|O
S7166|diluted|O
S7166|with|O
S7166|40|O
S7166|mL|O
S7166|of|O
S7166|saline|O
S7166|in|O
S7166|a|O
S7166|50|O
S7166|mL|O
S7166|syringe|O
S7166|.|O
S3879|Methods|O
S3879|464|B-Sample_Size_Actual_at_Enrollment
S3879|patients|O
S3879|were|O
S3879|randomised|O
S3879|to|O
S3879|receive|O
S3879|once-daily|B-Design_Parallel_Group
S3879|oral|I-Design_Parallel_Group
S3879|ponesimod|I-Design_Parallel_Group
S3879|10|I-Design_Parallel_Group
S3879|,|I-Design_Parallel_Group
S3879|20|I-Design_Parallel_Group
S3879|or|I-Design_Parallel_Group
S3879|40|I-Design_Parallel_Group
S3879|mg|I-Design_Parallel_Group
S3879|,|I-Design_Parallel_Group
S3879|or|I-Design_Parallel_Group
S3879|placebo|I-Design_Parallel_Group
S3879|for|O
S3879|24|O
S3879|weeks|O
S3879|.|O
S3781|Procedures|O
S3781|After|O
S3781|a|O
S3781|2-week|O
S3781|screening|O
S3781|period|O
S3781|,|O
S3781|participants|O
S3781|were|O
S3781|randomized|O
S3781|in|O
S3781|a|O
S3781|1:1|B-Randomization_Ratio
S3781|manner|O
S3781|to|O
S3781|either|O
S3781|open|O
S3781|label|O
S3781|IAsp|O
S3781|or|O
S3781|FA|O
S3781|.|O
S6718|Patients|O
S6718|Eligible|O
S6718|patients|O
S6718|were|O
S6718|men|O
S6718|and|O
S6718|women|O
S6718|,|O
S6718|aged|O
S6718|20–80|O
S6718|years|O
S6718|and|O
S6718|Japanese|B-Settings_Location
S6718|by|O
S6718|self-identification|O
S6718|,|O
S6718|for|O
S6718|whom|O
S6718|at|O
S6718|least|O
S6718|two|O
S6718|statins|O
S6718|failed|O
S6718|because|O
S6718|of|O
S6718|myalgia|O
S6718|(|O
S6718|muscle|O
S6718|pain|O
S6718|,|O
S6718|ache|O
S6718|,|O
S6718|or|O
S6718|weakness|O
S6718|without|O
S6718|creatinine|O
S6718|kinase|O
S6718|[|O
S6718|CK|O
S6718|]|O
S6718|elevation|O
S6718|)|O
S6718|,|O
S6718|myositis|O
S6718|(|O
S6718|muscle|O
S6718|symptoms|O
S6718|with|O
S6718|increased|O
S6718|CK|O
S6718|levels|O
S6718|)|O
S6718|,|O
S6718|or|O
S6718|rhabdomyolysis|O
S6718|(|O
S6718|defined|O
S6718|as|O
S6718|CK|O
S6718|>|O
S6718|10|O
S6718|×|O
S6718|upper|O
S6718|limit|O
S6718|normal|O
S6718|[|O
S6718|ULN|O
S6718|]|O
S6718|)|O
S6718|.|O
S1745|In|O
S1745|eight|O
S1745|participants|O
S1745|(|O
S1745|five|O
S1745|in|O
S1745|the|O
S1745|teplizumab|O
S1745|group|O
S1745|and|O
S1745|three|O
S1745|in|O
S1745|the|O
S1745|placebo|O
S1745|group|O
S1745|)|O
S1745|,|O
S1745|the|O
S1745|second|O
S1745|pretreatment|O
S1745|oral|O
S1745|glucose-tolerance|O
S1745|test|O
S1745|was|O
S1745|performed|O
S1745|on|O
S1745|the|O
S1745|first|O
S1745|day|O
S1745|of|O
S1745|administration|O
S1745|of|O
S1745|teplizumab|B-Design_Parallel_Group
S1745|or|I-Design_Parallel_Group
S1745|placebo|I-Design_Parallel_Group
S1745|.|O
S1491|Statistical|O
S1491|analysis|O
S1491|We|O
S1491|estimated|O
S1491|that|O
S1491|a|O
S1491|sample|O
S1491|size|O
S1491|of|O
S1491|90|B-Sample_Size_Required
S1491|patients|O
S1491|was|O
S1491|required|O
S1491|to|O
S1491|detect|O
S1491|a|O
S1491|difference|O
S1491|in|O
S1491|DSS|O
S1491|of|O
S1491|2.52|O
S1491|between|O
S1491|groups|O
S1491|(|O
S1491|absolute|O
S1491|change|O
S1491|from|O
S1491|GO-REVEAL|O
S1491|trial|O
S1491|)|O
S1491|,|O
S1491|assuming|O
S1491|a|O
S1491|SD|O
S1491|of|O
S1491|4.01|O
S1491|,|O
S1491|with|O
S1491|a|O
S1491|0.05|B-Sample_Size_Calculation_Alpha_Value
S1491|significance|O
S1491|level|O
S1491|,|O
S1491|80|B-Sample_Size_Calculation_Power_Value
S1491|%|I-Sample_Size_Calculation_Power_Value
S1491|power|O
S1491|and|O
S1491|accounting|O
S1491|for|O
S1491|a|O
S1491|dropout|O
S1491|rate|O
S1491|of|O
S1491|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S1491|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1491|.|O
S130|Methods|O
S130|We|O
S130|randomized|B-Randomization_Type_Simple
S130|82|B-Sample_Size_Actual_at_Enrollment
S130|patients|O
S130|from|O
S130|a|B-Settings_Single_Center
S130|comprehensive|I-Settings_Single_Center
S130|cancer|I-Settings_Single_Center
S130|center|I-Settings_Single_Center
S130|ED|I-Settings_Single_Center
S130|to|O
S130|receive|O
S130|INF|B-Design_Parallel_Group
S130|(|I-Design_Parallel_Group
S130|n|I-Design_Parallel_Group
S130|=|I-Design_Parallel_Group
S130|42|I-Design_Parallel_Group
S130|)|I-Design_Parallel_Group
S130|or|I-Design_Parallel_Group
S130|IVH|I-Design_Parallel_Group
S130|(|I-Design_Parallel_Group
S130|n|I-Design_Parallel_Group
S130|=|I-Design_Parallel_Group
S130|40|I-Design_Parallel_Group
S130|)|I-Design_Parallel_Group
S130|.|O
S6389|Trimethoprim-sulfamethoxazole|B-Design_Parallel_Group
S6389|versus|I-Design_Parallel_Group
S6389|vancomycin|I-Design_Parallel_Group
S6389|for|O
S6389|severe|O
S6389|infections|O
S6389|caused|O
S6389|by|O
S6389|meticillin|O
S6389|resistant|O
S6389|Staphylococcus|O
S6389|aureus|O
S6389|:|O
S6389|randomised|O
S6389|controlled|O
S6389|trial|O
S76|The|O
S76|study|O
S76|was|O
S76|completed|O
S76|by|O
S76|890|B-Sample_Size_Actual_at_Outcome_Analysis
S76|(|I-Sample_Size_Actual_at_Outcome_Analysis
S76|93.2|I-Sample_Size_Actual_at_Outcome_Analysis
S76|%|I-Sample_Size_Actual_at_Outcome_Analysis
S76|)|I-Sample_Size_Actual_at_Outcome_Analysis
S76|participants|I-Sample_Size_Actual_at_Outcome_Analysis
S76|in|I-Sample_Size_Actual_at_Outcome_Analysis
S76|the|I-Sample_Size_Actual_at_Outcome_Analysis
S76|half-dose|I-Sample_Size_Actual_at_Outcome_Analysis
S76|group|I-Sample_Size_Actual_at_Outcome_Analysis
S76|and|O
S76|917|B-Sample_Size_Actual_at_Outcome_Analysis
S76|(|I-Sample_Size_Actual_at_Outcome_Analysis
S76|92.2|I-Sample_Size_Actual_at_Outcome_Analysis
S76|%|I-Sample_Size_Actual_at_Outcome_Analysis
S76|)|I-Sample_Size_Actual_at_Outcome_Analysis
S76|in|I-Sample_Size_Actual_at_Outcome_Analysis
S76|the|I-Sample_Size_Actual_at_Outcome_Analysis
S76|full-dose|I-Sample_Size_Actual_at_Outcome_Analysis
S76|group|I-Sample_Size_Actual_at_Outcome_Analysis
S76|.|O
S4399|The|O
S4399|investigator|O
S4399|(|O
S4399|or|O
S4399|designee|O
S4399|)|O
S4399|obtained|O
S4399|the|O
S4399|unique|O
S4399|study|O
S4399|treatment|O
S4399|number|O
S4399|via|O
S4399|an|O
S4399|interactive|B-Randomization_Sequence_Generation_Method
S4399|voice/internet|I-Randomization_Sequence_Generation_Method
S4399|response|I-Randomization_Sequence_Generation_Method
S4399|system|I-Randomization_Sequence_Generation_Method
S4399|.|O
S8133|Of|O
S8133|the|O
S8133|88|O
S8133|participants|O
S8133|in|O
S8133|the|O
S8133|safety|O
S8133|set|O
S8133|(|O
S8133|placebo|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|43|O
S8133|;|O
S8133|SHP465|O
S8133|MAS|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|45|O
S8133|)|O
S8133|,|O
S8133|87|O
S8133|were|O
S8133|included|O
S8133|in|O
S8133|the|O
S8133|full|O
S8133|analysis|O
S8133|set|O
S8133|(|O
S8133|placebo|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|42|O
S8133|;|O
S8133|SHP465|O
S8133|MAS|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|45|O
S8133|)|O
S8133|and|O
S8133|83|B-Sample_Size_Actual_at_Outcome_Analysis
S8133|completed|O
S8133|the|O
S8133|study|O
S8133|(|O
S8133|placebo|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|41|O
S8133|;|O
S8133|SHP465|O
S8133|MAS|O
S8133|,|O
S8133|n|O
S8133|=|O
S8133|42|O
S8133|)|O
S8133|.|O
S2562|Following|O
S2562|a|O
S2562|screening|O
S2562|visit|O
S2562|and|O
S2562|completion|O
S2562|of|O
S2562|the|O
S2562|run-in|O
S2562|period|O
S2562|assessments|O
S2562|,|O
S2562|participants|O
S2562|were|O
S2562|randomised|O
S2562|(|B-Randomization_Ratio
S2562|1:1:1:1:1:1|I-Randomization_Ratio
S2562|)|I-Randomization_Ratio
S2562|using|O
S2562|an|O
S2562|interactive|B-Randomization_Sequence_Generation_Method
S2562|voice|I-Randomization_Sequence_Generation_Method
S2562|response|I-Randomization_Sequence_Generation_Method
S2562|system|I-Randomization_Sequence_Generation_Method
S2562|to|O
S2562|receive|O
S2562|oral|O
S2562|danirixin|O
S2562|hydrobromide|O
S2562|salt|O
S2562|tablets|O
S2562|(|O
S2562|5|O
S2562|,|O
S2562|10|O
S2562|,|O
S2562|25|O
S2562|,|O
S2562|35|O
S2562|or|O
S2562|50|O
S2562|mg|O
S2562|)|O
S2562|or|O
S2562|placebo|O
S2562|tablets|O
S2562|for|O
S2562|24|O
S2562|weeks|O
S2562|(|O
S2562|in|O
S2562|addition|O
S2562|to|O
S2562|COPD|O
S2562|standard-of-care|O
S2562|)|O
S2562|.|O
S1158|Methods|O
S1158|This|O
S1158|randomized|O
S1158|,|O
S1158|double-blind|B-Blinding_Double_Blind
S1158|,|O
S1158|chronic-dosing|O
S1158|,|O
S1158|balanced|B-Randomization_Type_Block
S1158|incomplete-block|I-Randomization_Type_Block
S1158|,|O
S1158|placebo-controlled|O
S1158|,|O
S1158|crossover|B-Design_Crossover
S1158|study|O
S1158|compared|O
S1158|six|O
S1158|doses|O
S1158|of|O
S1158|GP|O
S1158|MDI|O
S1158|(|O
S1158|18|O
S1158|,|O
S1158|9|O
S1158|,|O
S1158|4.6|O
S1158|,|O
S1158|2.4|O
S1158|,|O
S1158|1.2|O
S1158|,|O
S1158|and|O
S1158|0.6|O
S1158|μg|O
S1158|,|O
S1158|twice|O
S1158|daily|O
S1158|[|O
S1158|BID|O
S1158|]|O
S1158|)|O
S1158|with|O
S1158|placebo|O
S1158|MDI|O
S1158|BID|O
S1158|and|O
S1158|open-label|B-Blinding_Open_Label
S1158|tiotropium|O
S1158|dry|O
S1158|powder|O
S1158|inhaler|O
S1158|(|O
S1158|18|O
S1158|μg|O
S1158|,|O
S1158|once|O
S1158|daily|O
S1158|[|O
S1158|QD|O
S1158|]|O
S1158|)|O
S1158|in|O
S1158|patients|O
S1158|with|O
S1158|moderate-to-severe|O
S1158|COPD|O
S1158|.|O
S6610|Central|B-Blinding_Object_Outcome_Assessors
S6610|reading|I-Blinding_Object_Outcome_Assessors
S6610|center|I-Blinding_Object_Outcome_Assessors
S6610|personnel|I-Blinding_Object_Outcome_Assessors
S6610|,|O
S6610|study|B-Blinding_Object_Others
S6610|vendors|I-Blinding_Object_Others
S6610|,|O
S6610|and|O
S6610|the|O
S6610|sponsor|B-Blinding_Object_Others
S6610|and|I-Blinding_Object_Others
S6610|its|I-Blinding_Object_Others
S6610|agents|I-Blinding_Object_Others
S6610|were|O
S6610|masked|O
S6610|to|O
S6610|study|O
S6610|eye|O
S6610|drug|O
S6610|assignment|O
S6610|.|O
S6228|The|O
S6228|dosing|O
S6228|data|O
S6228|in|O
S6228|the|O
S6228|open-label|B-Blinding_Open_Label
S6228|phase|O
S6228|will|O
S6228|inform|O
S6228|optimal|O
S6228|use|O
S6228|of|O
S6228|onabotulinumtoxinA|O
S6228|in|O
S6228|clinical|O
S6228|practice|O
S6228|(|O
S6228|ClinicalTrials.gov|O
S6228|:|O
S6228|NCT03261167|O
S6228|)|O
S6228|.|O
S2276|Assuming|O
S2276|an|O
S2276|8|B-Sample_Size_Calculation_Dropout_Rate_Value
S2276|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|withdrawal|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|rate|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|during|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|the|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|run-in|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|period|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|and|O
S2276|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S2276|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|withdrawal|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|rate|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|during|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|the|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|study|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|period|I-Sample_Size_Calculation_Dropout_Rate_Value
S2276|,|O
S2276|it|O
S2276|was|O
S2276|aimed|O
S2276|to|O
S2276|enroll|O
S2276|~848|O
S2276|patients|O
S2276|into|O
S2276|the|O
S2276|4-week|O
S2276|run-in|O
S2276|period|O
S2276|in|O
S2276|order|O
S2276|to|O
S2276|randomize|O
S2276|780|O
S2276|patients|O
S2276|.|O
S7306|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7306|was|O
S7306|to|O
S7306|be|O
S7306|declared|O
S7306|if|O
S7306|the|O
S7306|upper|O
S7306|bound|O
S7306|of|O
S7306|the|O
S7306|two-sided|O
S7306|95|O
S7306|%|O
S7306|CI|O
S7306|for|O
S7306|the|O
S7306|difference|O
S7306|in|O
S7306|DAS28-4|O
S7306|(|O
S7306|CRP|O
S7306|)|O
S7306|between|O
S7306|treatment|O
S7306|groups|O
S7306|was|O
S7306|<|O
S7306|0.6|O
S7306|.|O
S1462|Patients|B-Blinding_Object_Patients
S1462|and|O
S1462|investigators|B-Blinding_Object_Investigators
S1462|were|O
S1462|blind|O
S1462|to|O
S1462|treatment|O
S1462|by|O
S1462|providing|O
S1462|identical|O
S1462|prefilled|O
S1462|syringes|O
S1462|(|O
S1462|MSD|O
S1462|Pharmaceutics|O
S1462|)|O
S1462|.|O
S7726|A|O
S7726|Randomized|B-Randomization_Type_Simple
S7726|Trial|O
S7726|Evaluating|O
S7726|the|O
S7726|Efficacy|O
S7726|and|O
S7726|Safety|O
S7726|of|O
S7726|Fast-Acting|O
S7726|Insulin|O
S7726|Aspart|O
S7726|Compared|O
S7726|With|O
S7726|Insulin|O
S7726|Aspart|O
S7726|,|O
S7726|Both|O
S7726|in|O
S7726|Combination|O
S7726|With|O
S7726|Insulin|O
S7726|Degludec|O
S7726|With|O
S7726|or|O
S7726|Without|O
S7726|Metformin|O
S7726|,|O
S7726|in|O
S7726|Adults|O
S7726|With|O
S7726|Type|O
S7726|2|O
S7726|Diabetes|O
S7726|(|O
S7726|ONSET|O
S7726|9|O
S7726|)|O
S1282|A|O
S1282|randomised|O
S1282|,|O
S1282|double-blind|B-Blinding_Double_Blind
S1282|,|O
S1282|phase|B-Design_Phase_3
S1282|III|I-Design_Phase_3
S1282|study|O
S1282|comparing|O
S1282|SB2|O
S1282|,|O
S1282|an|O
S1282|infliximab|O
S1282|biosimilar|O
S1282|,|O
S1282|to|O
S1282|the|O
S1282|infliximab|O
S1282|reference|O
S1282|product|O
S1282|Remicade|O
S1282|in|O
S1282|patients|O
S1282|with|O
S1282|moderate|O
S1282|to|O
S1282|severe|O
S1282|rheumatoid|O
S1282|arthritis|O
S1282|despite|O
S1282|methotrexate|O
S1282|therapy|O
S8033|Results|O
S8033|:|O
S8033|Of|O
S8033|89|B-Sample_Size_Actual_at_Enrollment
S8033|randomized|O
S8033|participants|O
S8033|,|O
S8033|83|B-Sample_Size_Actual_at_Outcome_Analysis
S8033|completed|O
S8033|the|O
S8033|study|O
S8033|(|O
S8033|placebo|O
S8033|,|O
S8033|n|O
S8033|=|O
S8033|41|O
S8033|;|O
S8033|SHP465|O
S8033|MAS|O
S8033|,|O
S8033|n|O
S8033|=|O
S8033|42|O
S8033|)|O
S8033|.|O
S6425|Methods|O
S6425|This|O
S6425|was|O
S6425|an|O
S6425|open|B-Blinding_Open_Label
S6425|label|I-Blinding_Open_Label
S6425|,|O
S6425|parallel|B-Design_Parallel_Group
S6425|,|O
S6425|one|B-Randomization_Ratio
S6425|to|I-Randomization_Ratio
S6425|one|I-Randomization_Ratio
S6425|randomised|O
S6425|controlled|O
S6425|trial|O
S6425|,|O
S6425|conducted|O
S6425|in|O
S6425|four|B-Settings_Multicenter
S6425|acute|I-Settings_Multicenter
S6425|care|I-Settings_Multicenter
S6425|hospitals|I-Settings_Multicenter
S6425|(|O
S6425|Rabin|O
S6425|Medical|O
S6425|Center|O
S6425|,|O
S6425|Petah-Tikva|O
S6425|(|O
S6425|192|O
S6425|patients|O
S6425|)|O
S6425|;|O
S6425|Rambam|O
S6425|Health|O
S6425|Care|O
S6425|Campus|O
S6425|(|O
S6425|38|O
S6425|patients|O
S6425|)|O
S6425|;|O
S6425|Holy|O
S6425|Family|O
S6425|Hospital|O
S6425|Nazareth|O
S6425|(|O
S6425|7|O
S6425|patients|O
S6425|)|O
S6425|;|O
S6425|Wolfson|O
S6425|Medical|O
S6425|Center|O
S6425|(|O
S6425|6|O
S6425|patients|O
S6425|)|O
S6425|)|O
S6425|in|O
S6425|Israel|B-Settings_Location
S6425|,|O
S6425|between|O
S6425|July|O
S6425|2007|O
S6425|and|O
S6425|April|O
S6425|2014|O
S6425|.|O
S1927|Assuming|O
S1927|5|B-Sample_Size_Calculation_Dropout_Rate_Value
S1927|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|of|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|women|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|were|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|non-evaluable|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|,|O
S1927|and|O
S1927|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S1927|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|were|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|excluded|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|due|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|to|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|genotypic|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|resistance|I-Sample_Size_Calculation_Dropout_Rate_Value
S1927|,|O
S1927|target|O
S1927|enrollment|O
S1927|was|O
S1927|394|B-Sample_Size_Target
S1927|women|O
S1927|(|O
S1927|approximately|O
S1927|197|O
S1927|per|O
S1927|arm|O
S1927|)|O
S1927|.|O
S3501|The|O
S3501|trial|O
S3501|was|O
S3501|conducted|O
S3501|at|O
S3501|26|B-Settings_Multicenter
S3501|investigational|I-Settings_Multicenter
S3501|sites|I-Settings_Multicenter
S3501|(|O
S3501|Supplementary|O
S3501|Table|O
S3501|SI|O
S3501|)|O
S3501|in|O
S3501|the|O
S3501|following|O
S3501|countries/regions|O
S3501|:|O
S3501|mainland|B-Settings_Location
S3501|China|I-Settings_Location
S3501|,|I-Settings_Location
S3501|South|I-Settings_Location
S3501|Korea|I-Settings_Location
S3501|,|I-Settings_Location
S3501|Taiwan|I-Settings_Location
S3501|and|I-Settings_Location
S3501|Vietnam|I-Settings_Location
S3501|.|O
S6558|Interventions|O
S6558|Participants|O
S6558|were|O
S6558|randomized|O
S6558|1:2:2|B-Randomization_Ratio
S6558|to|O
S6558|receive|O
S6558|intravitreal|O
S6558|ranibizumab|O
S6558|,|O
S6558|0.5|O
S6558|mg|O
S6558|,|O
S6558|every|O
S6558|4|O
S6558|weeks|O
S6558|or|O
S6558|faricimab|O
S6558|,|O
S6558|6.0|O
S6558|mg|O
S6558|,|O
S6558|every|O
S6558|12|O
S6558|or|O
S6558|16|O
S6558|weeks|O
S6558|.|O
S7572|Methods|O
S7572|Study|O
S7572|design|O
S7572|This|O
S7572|was|O
S7572|a|O
S7572|randomized|B-Randomization_Type_Simple
S7572|,|O
S7572|double-blinded|B-Blinding_Double_Blind
S7572|,|O
S7572|dose-ranging|O
S7572|,|O
S7572|placebo-controlled|O
S7572|,|O
S7572|parallel|B-Design_Parallel_Group
S7572|group|I-Design_Parallel_Group
S7572|study|O
S7572|.|O
S7325|In|O
S7325|total|O
S7325|,|O
S7325|209|B-Sample_Size_Actual_at_Enrollment
S7325|patients|O
S7325|participated|O
S7325|in|O
S7325|this|O
S7325|study|O
S7325|:|O
S7325|104|O
S7325|received|O
S7325|tofacitinib|O
S7325|MR|O
S7325|11|O
S7325|mg|O
S7325|QD|O
S7325|,|O
S7325|and|O
S7325|105|O
S7325|received|O
S7325|tofacitinib|O
S7325|IR|O
S7325|5|O
S7325|mg|O
S7325|BID|O
S7325|.|O
S3022|A|O
S3022|Randomized|B-Randomization_Type_Simple
S3022|Phase|O
S3022|I|O
S3022|Study|O
S3022|of|O
S3022|Abemaciclib|O
S3022|in|O
S3022|Chinese|O
S3022|Patients|O
S3022|with|O
S3022|Advanced|O
S3022|and/or|O
S3022|Metastatic|O
S3022|Cancers|O
S4640|Aim|O
S4640|Phase|B-Design_Phase_3
S4640|III|I-Design_Phase_3
S4640|,|O
S4640|randomized|O
S4640|,|O
S4640|double‐blind|B-Blinding_Double_Blind
S4640|study|O
S4640|evaluating|O
S4640|the|O
S4640|efficacy|O
S4640|and|O
S4640|safety|O
S4640|of|O
S4640|ertugliflozin|O
S4640|in|O
S4640|Asian|O
S4640|patients|O
S4640|with|O
S4640|type|O
S4640|2|O
S4640|diabetes|O
S4640|mellitus|O
S4640|(|O
S4640|T2DM|O
S4640|)|O
S4640|inadequately|O
S4640|controlled|O
S4640|on|O
S4640|metformin|O
S4640|,|O
S4640|including|O
S4640|evaluation|O
S4640|in|O
S4640|the|O
S4640|China|O
S4640|subpopulation|O
S4640|.|O
S2400|Randomization|O
S2400|was|O
S2400|stratified|B-Randomization_Type_Stratified
S2400|by|O
S2400|sex|B-Randomization_Stratified_Criteria
S2400|(|I-Randomization_Stratified_Criteria
S2400|male/female|I-Randomization_Stratified_Criteria
S2400|)|I-Randomization_Stratified_Criteria
S2400|,|O
S2400|smoking|B-Randomization_Stratified_Criteria
S2400|status|I-Randomization_Stratified_Criteria
S2400|(|I-Randomization_Stratified_Criteria
S2400|smoker/non-smoker|I-Randomization_Stratified_Criteria
S2400|)|I-Randomization_Stratified_Criteria
S2400|,|O
S2400|disease|B-Randomization_Stratified_Criteria
S2400|diagnosis|I-Randomization_Stratified_Criteria
S2400|(|I-Randomization_Stratified_Criteria
S2400|newly|I-Randomization_Stratified_Criteria
S2400|diagnosed/recurrent|I-Randomization_Stratified_Criteria
S2400|disease|I-Randomization_Stratified_Criteria
S2400|)|I-Randomization_Stratified_Criteria
S2400|and|O
S2400|disease|B-Randomization_Stratified_Criteria
S2400|stage|I-Randomization_Stratified_Criteria
S2400|(|I-Randomization_Stratified_Criteria
S2400|Stage|I-Randomization_Stratified_Criteria
S2400|IIIB/Stage|I-Randomization_Stratified_Criteria
S2400|IV|I-Randomization_Stratified_Criteria
S2400|)|I-Randomization_Stratified_Criteria
S2400|.|O
S7154|The|O
S7154|active|O
S7154|and|O
S7154|placebo|O
S7154|drug|O
S7154|components|O
S7154|of|O
S7154|the|O
S7154|infusions|O
S7154|were|O
S7154|packaged|O
S7154|identically|O
S7154|into|O
S7154|numbered|O
S7154|treatment|O
S7154|packs|O
S7154|,|O
S7154|each|O
S7154|containing|O
S7154|5|O
S7154|mL|O
S7154|of|O
S7154|either|O
S7154|salbutamol|B-Design_Parallel_Group
S7154|sulphate|I-Design_Parallel_Group
S7154|BP|I-Design_Parallel_Group
S7154|(|I-Design_Parallel_Group
S7154|1|I-Design_Parallel_Group
S7154|mg/mL|I-Design_Parallel_Group
S7154|in|I-Design_Parallel_Group
S7154|a|I-Design_Parallel_Group
S7154|sterile|I-Design_Parallel_Group
S7154|isotonic|I-Design_Parallel_Group
S7154|solution|I-Design_Parallel_Group
S7154|,|I-Design_Parallel_Group
S7154|GlaxoSmithKline|I-Design_Parallel_Group
S7154|,|I-Design_Parallel_Group
S7154|Middlesex|I-Design_Parallel_Group
S7154|,|I-Design_Parallel_Group
S7154|UK|I-Design_Parallel_Group
S7154|)|I-Design_Parallel_Group
S7154|or|I-Design_Parallel_Group
S7154|placebo|I-Design_Parallel_Group
S7154|(|O
S7154|0·9|O
S7154|%|O
S7154|sterile|O
S7154|sodium|O
S7154|chloride|O
S7154|)|O
S7154|.|O
S8500|Randomization|O
S8500|was|O
S8500|performed|O
S8500|using|O
S8500|an|B-Randomization_Sequence_Generation_Method
S8500|electronic|I-Randomization_Sequence_Generation_Method
S8500|random|I-Randomization_Sequence_Generation_Method
S8500|numbers|I-Randomization_Sequence_Generation_Method
S8500|assignment|I-Randomization_Sequence_Generation_Method
S8500|system|I-Randomization_Sequence_Generation_Method
S8500|by|O
S8500|a|O
S8500|Nutritionist|O
S8500|who|O
S8500|was|O
S8500|not|O
S8500|involved|O
S8500|in|O
S8500|the|O
S8500|study|O
S8500|.|O
S729|This|O
S729|study|O
S729|was|O
S729|performed|O
S729|at|O
S729|the|O
S729|Duke|B-Settings_Single_Center
S729|Family|I-Settings_Single_Center
S729|Planning|I-Settings_Single_Center
S729|Clinic|I-Settings_Single_Center
S729|at|O
S729|the|O
S729|Duke|O
S729|Gynecology|O
S729|Outpatient|O
S729|Clinic|O
S729|.|O
S1749|The|O
S1749|treatment-group|O
S1749|assignments|O
S1749|were|O
S1749|double-masked|B-Blinding_Double_Blind
S1749|.|O
S3247|After|O
S3247|randomisation|O
S3247|to|O
S3247|the|O
S3247|ursodeoxycholic|B-Design_Parallel_Group
S3247|acid|I-Design_Parallel_Group
S3247|or|I-Design_Parallel_Group
S3247|placebo|I-Design_Parallel_Group
S3247|comparison|O
S3247|,|O
S3247|an|O
S3247|online|O
S3247|prescription|O
S3247|form|O
S3247|was|O
S3247|generated|O
S3247|for|O
S3247|printing|O
S3247|.|O
S1370|Among|O
S1370|805|O
S1370|patients|O
S1370|screened|O
S1370|,|O
S1370|584|B-Sample_Size_Actual_at_Enrollment
S1370|patients|O
S1370|were|O
S1370|randomised|O
S1370|(|O
S1370|SB2|O
S1370|,|O
S1370|N=291|O
S1370|and|O
S1370|INF|O
S1370|,|O
S1370|N=293|O
S1370|,|O
S1370|figure|O
S1370|1|O
S1370|)|O
S1370|.|O
S6712|This|O
S6712|study|O
S6712|was|O
S6712|conducted|O
S6712|in|O
S6712|a|O
S6712|12-week|O
S6712|,|O
S6712|double-blind|B-Blinding_Double_Blind
S6712|period|O
S6712|followed|O
S6712|by|O
S6712|an|O
S6712|open-label|B-Blinding_Open_Label
S6712|extension|O
S6712|period|O
S6712|designed|O
S6712|to|O
S6712|characterize|O
S6712|the|O
S6712|safety|O
S6712|and|O
S6712|efficacy|O
S6712|of|O
S6712|52|O
S6712|weeks|O
S6712|of|O
S6712|evolocumab|O
S6712|treatment|O
S6712|.|O
S6270|Concomitant|O
S6270|use|O
S6270|of|O
S6270|centrally|O
S6270|acting|O
S6270|muscle|O
S6270|relaxants|O
S6270|was|O
S6270|allowed|O
S6270|if|O
S6270|the|O
S6270|patient|O
S6270|had|O
S6270|been|O
S6270|using|O
S6270|them|O
S6270|before|O
S6270|participating|O
S6270|in|O
S6270|the|O
S6270|trial|O
S6270|,|O
S6270|but|O
S6270|the|O
S6270|dose|O
S6270|was|O
S6270|not|O
S6270|to|O
S6270|be|O
S6270|changed|O
S6270|from|O
S6270|the|O
S6270|screening|O
S6270|phase|O
S6270|until|O
S6270|the|O
S6270|completion|O
S6270|of|O
S6270|the|O
S6270|double-blind|B-Blinding_Double_Blind
S6270|phase|O
S6270|.|O
S7143|Methods|O
S7143|Study|O
S7143|design|O
S7143|and|O
S7143|participants|O
S7143|We|O
S7143|undertook|O
S7143|a|O
S7143|multicentre|B-Settings_Multicenter
S7143|,|O
S7143|pragmatic|O
S7143|,|O
S7143|double-blind|B-Blinding_Double_Blind
S7143|,|O
S7143|placebo-controlled|O
S7143|,|O
S7143|parallel-group|B-Design_Parallel_Group
S7143|,|O
S7143|randomised|O
S7143|trial|O
S7143|at|O
S7143|46|B-Settings_Multicenter
S7143|UK|B-Settings_Location
S7143|intensive-care|I-Settings_Multicenter
S7143|units|I-Settings_Multicenter
S7143|between|O
S7143|December|O
S7143|,|O
S7143|2006|O
S7143|,|O
S7143|and|O
S7143|March|O
S7143|,|O
S7143|2010|O
S7143|.|O
S3240|Randomisation|O
S3240|was|O
S3240|stratified|B-Randomization_Type_Stratified
S3240|by|O
S3240|the|B-Randomization_Stratified_Criteria
S3240|gestation|I-Randomization_Stratified_Criteria
S3240|at|I-Randomization_Stratified_Criteria
S3240|recruitment|I-Randomization_Stratified_Criteria
S3240|for|I-Randomization_Stratified_Criteria
S3240|the|I-Randomization_Stratified_Criteria
S3240|ursodeoxycholic|I-Randomization_Stratified_Criteria
S3240|acid|I-Randomization_Stratified_Criteria
S3240|comparison|I-Randomization_Stratified_Criteria
S3240|and|O
S3240|by|O
S3240|trial|B-Randomization_Stratified_Criteria
S3240|centre|I-Randomization_Stratified_Criteria
S3240|for|O
S3240|both|O
S3240|comparisons|O
S3240|.|O
S3292|In|O
S3292|all|O
S3292|analyses|O
S3292|,|O
S3292|regression|O
S3292|methods|O
S3292|were|O
S3292|used|O
S3292|and|O
S3292|adjustment|O
S3292|made|O
S3292|for|O
S3292|stratification|B-Randomization_Type_Stratified
S3292|variables|O
S3292|(|O
S3292|gestation|B-Randomization_Stratified_Criteria
S3292|at|I-Randomization_Stratified_Criteria
S3292|recruitment|I-Randomization_Stratified_Criteria
S3292|for|I-Randomization_Stratified_Criteria
S3292|ursodeoxycholic|I-Randomization_Stratified_Criteria
S3292|acid|I-Randomization_Stratified_Criteria
S3292|trial|I-Randomization_Stratified_Criteria
S3292|only|O
S3292|,|O
S3292|and|O
S3292|study|B-Randomization_Stratified_Criteria
S3292|centre|I-Randomization_Stratified_Criteria
S3292|for|O
S3292|both|O
S3292|trials|O
S3292|)|O
S3292|and|O
S3292|for|O
S3292|potential|O
S3292|confounders|O
S3292|(|O
S3292|baseline|O
S3292|bile|O
S3292|acid|O
S3292|levels|O
S3292|,|O
S3292|and|O
S3292|others|O
S3292|where|O
S3292|the|O
S3292|imbalance|O
S3292|was|O
S3292|substantial|O
S3292|)|O
S3292|.|O
S7868|Results|O
S7868|529|B-Sample_Size_Actual_at_Enrollment
S7868|patients|O
S7868|(|O
S7868|mean|O
S7868|age|O
S7868|72|O
S7868|)|O
S7868|were|O
S7868|enrolled|O
S7868|,|O
S7868|266|O
S7868|to|O
S7868|the|O
S7868|intensive|O
S7868|target|O
S7868|arm|O
S7868|and|O
S7868|263|O
S7868|to|O
S7868|the|O
S7868|standard|O
S7868|target|O
S7868|arm|O
S7868|,|O
S7868|of|O
S7868|whom|O
S7868|379|B-Sample_Size_Actual_at_Outcome_Analysis
S7868|were|O
S7868|included|O
S7868|in|O
S7868|the|O
S7868|primary|O
S7868|analysis|O
S7868|(|O
S7868|182|O
S7868|(|O
S7868|68|O
S7868|%|O
S7868|)|O
S7868|intensive|O
S7868|arm|O
S7868|;|O
S7868|197|O
S7868|(|O
S7868|75|O
S7868|%|O
S7868|)|O
S7868|standard|O
S7868|arm|O
S7868|)|O
S7868|.|O
S1611|At|O
S1611|completion|O
S1611|of|O
S1611|the|O
S1611|24-week|O
S1611|randomised|O
S1611|treatment|O
S1611|period|O
S1611|,|O
S1611|all|O
S1611|patients|O
S1611|were|O
S1611|offered|O
S1611|open-label|B-Blinding_Open_Label
S1611|treatment|O
S1611|with|O
S1611|TCZ|O
S1611|8|O
S1611|mg/kg|O
S1611|plus|O
S1611|MTX|O
S1611|.|O
S296|Methods|O
S296|This|O
S296|randomized|O
S296|clinical|O
S296|trial|O
S296|was|O
S296|conducted|O
S296|at|O
S296|57|B-Settings_Multicenter
S296|US|B-Settings_Location
S296|centers|I-Settings_Multicenter
S296|.|O
S71|Due|O
S71|to|O
S71|lower|O
S71|than|O
S71|expected|O
S71|recruitment|O
S71|,|O
S71|1950|B-Sample_Size_Actual_at_Enrollment
S71|participants|O
S71|were|O
S71|enrolled|O
S71|in|O
S71|the|O
S71|study|O
S71|instead|O
S71|of|O
S71|the|O
S71|planned|O
S71|2190|O
S71|(|O
S71|Fig|O
S71|.|O
S4986|Twenty-six|B-Settings_Multicenter
S4986|clinical|I-Settings_Multicenter
S4986|centers|I-Settings_Multicenter
S4986|(|O
S4986|23|B-Settings_Location
S4986|in|I-Settings_Location
S4986|the|I-Settings_Location
S4986|United|I-Settings_Location
S4986|States|I-Settings_Location
S4986|and|I-Settings_Location
S4986|one|I-Settings_Location
S4986|center|I-Settings_Location
S4986|each|I-Settings_Location
S4986|in|I-Settings_Location
S4986|Australia|I-Settings_Location
S4986|,|I-Settings_Location
S4986|Canada|I-Settings_Location
S4986|,|I-Settings_Location
S4986|and|I-Settings_Location
S4986|the|I-Settings_Location
S4986|United|I-Settings_Location
S4986|Kingdom|I-Settings_Location
S4986|)|O
S4986|participated|O
S4986|in|O
S4986|the|O
S4986|trial|O
S4986|(|O
S4986|see|O
S4986|Appendix|O
S4986|1|O
S4986|,|O
S4986|available|O
S4986|at|O
S4986|http|O
S4986|:|O
S4986|//aaojournal.org|O
S4986|)|O
S4986|.|O
S1193|Patients|O
S1193|using|O
S1193|oral|O
S1193|β-agonists|O
S1193|,|O
S1193|inhaled|O
S1193|LABAs|O
S1193|,|O
S1193|LABA/ICS|O
S1193|combination|O
S1193|inhalers|O
S1193|,|O
S1193|phosphodiesterase|O
S1193|inhibitors|O
S1193|,|O
S1193|mast|O
S1193|cell|O
S1193|stabilizers|O
S1193|,|O
S1193|leukotriene|O
S1193|antagonists|O
S1193|,|O
S1193|or|O
S1193|tiotropium|O
S1193|,|O
S1193|discontinued|O
S1193|these|O
S1193|for|O
S1193|the|O
S1193|duration|O
S1193|of|O
S1193|the|O
S1193|trial|O
S1193|and|O
S1193|instead|O
S1193|received|O
S1193|open-label|B-Blinding_Open_Label
S1193|ipratropium|O
S1193|four|O
S1193|times|O
S1193|daily|O
S1193|during|O
S1193|the|O
S1193|run-in|O
S1193|period|O
S1193|.|O
S3671|Study|O
S3671|design|O
S3671|This|O
S3671|study|O
S3671|(|O
S3671|trial|O
S3671|registration|O
S3671|:|O
S3671|ClinicalTrials.gov|O
S3671|NCT03469336|O
S3671|)|O
S3671|was|O
S3671|conducted|O
S3671|between|O
S3671|24|O
S3671|April|O
S3671|2018|O
S3671|and|O
S3671|20|O
S3671|March|O
S3671|2019|O
S3671|at|O
S3671|two|B-Settings_Multicenter
S3671|sites|I-Settings_Multicenter
S3671|in|O
S3671|Germany|B-Settings_Location
S3671|.|O
S2069|SUBJECTS|O
S2069|AND|O
S2069|METHODS|O
S2069|Study|O
S2069|design|O
S2069|and|O
S2069|procedures|O
S2069|This|O
S2069|phase|B-Design_Phase_1
S2069|I|I-Design_Phase_1
S2069|,|O
S2069|randomised|O
S2069|,|O
S2069|open‐label|B-Blinding_Open_Label
S2069|,|O
S2069|2‐arm|O
S2069|,|O
S2069|parallel‐group|B-Design_Parallel_Group
S2069|study|O
S2069|was|O
S2069|conducted|O
S2069|at|O
S2069|2|B-Settings_Multicenter
S2069|US|I-Settings_Multicenter
S2069|PPD|I-Settings_Multicenter
S2069|Development|I-Settings_Multicenter
S2069|sites|I-Settings_Multicenter
S2069|(|O
S2069|Austin|B-Settings_Location
S2069|,|I-Settings_Location
S2069|TX|I-Settings_Location
S2069|;|I-Settings_Location
S2069|Las|I-Settings_Location
S2069|Vegas|I-Settings_Location
S2069|,|I-Settings_Location
S2069|NV|I-Settings_Location
S2069|)|O
S2069|.|O
S8594|Objectives|O
S8594|The|O
S8594|goal|O
S8594|of|O
S8594|this|O
S8594|study|O
S8594|was|O
S8594|to|O
S8594|evaluate|O
S8594|the|O
S8594|effects|O
S8594|of|O
S8594|IL-1β|O
S8594|inhibition|O
S8594|with|O
S8594|canakinumab|B-Design_Parallel_Group
S8594|versus|I-Design_Parallel_Group
S8594|placebo|I-Design_Parallel_Group
S8594|on|O
S8594|arterial|O
S8594|structure|O
S8594|and|O
S8594|function|O
S8594|,|O
S8594|determined|O
S8594|by|O
S8594|magnetic|O
S8594|resonance|O
S8594|imaging|O
S8594|.|O
S1255|GP|O
S1255|MDI|O
S1255|18|O
S1255|and|O
S1255|9|O
S1255|μg|O
S1255|were|O
S1255|non-inferior|B-Design_Comparative_Intent_NonInferiority
S1255|to|O
S1255|open-label|B-Blinding_Open_Label
S1255|tiotropium|O
S1255|for|O
S1255|peak|O
S1255|change|O
S1255|from|O
S1255|baseline|O
S1255|in|O
S1255|FEV1|O
S1255|on|O
S1255|Day|O
S1255|1|O
S1255|,|O
S1255|but|O
S1255|this|O
S1255|was|O
S1255|not|O
S1255|replicated|O
S1255|on|O
S1255|Days|O
S1255|7|O
S1255|and|O
S1255|14|O
S1255|.|O
S1503|Forty-two|B-Sample_Size_Actual_at_Outcome_Analysis
S1503|completed|O
S1503|the|O
S1503|study|O
S1503|,|O
S1503|with|O
S1503|one|O
S1503|patient|O
S1503|on|O
S1503|golimumab/MTX|O
S1503|discontinuing|O
S1503|due|O
S1503|to|O
S1503|an|O
S1503|adverse|O
S1503|event|O
S1503|(|O
S1503|asthma|O
S1503|exacerbation|O
S1503|)|O
S1503|,|O
S1503|and|O
S1503|another|O
S1503|patient|O
S1503|on|O
S1503|placebo/MTX|O
S1503|discontinuing|O
S1503|due|O
S1503|to|O
S1503|an|O
S1503|insufficient|O
S1503|therapeutic|O
S1503|effect|O
S1503|(|O
S1503|figure|O
S1503|1|O
S1503|)|O
S1503|.|O
S5026|For|O
S5026|the|O
S5026|third|O
S5026|hypothesis|O
S5026|,|O
S5026|a|O
S5026|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S5026|margin|O
S5026|of|O
S5026|10|O
S5026|%|O
S5026|was|O
S5026|selected|O
S5026|based|O
S5026|on|O
S5026|previous|O
S5026|research|O
S5026|indicating|O
S5026|that|O
S5026|the|O
S5026|threshold|O
S5026|for|O
S5026|reproducibility|O
S5026|of|O
S5026|OCT|O
S5026|evaluation|O
S5026|of|O
S5026|retinal|O
S5026|thickness|O
S5026|is|O
S5026|10|O
S5026|%|O
S5026|and|O
S5026|that|O
S5026|a|O
S5026|20|O
S5026|%|O
S5026|change|O
S5026|is|O
S5026|associated|O
S5026|with|O
S5026|meaningful|O
S5026|changes|O
S5026|in|O
S5026|visual|O
S5026|acuity|O
S5026|.|O
S8629|The|O
S8629|study|O
S8629|was|O
S8629|undertaken|O
S8629|at|O
S8629|9|B-Settings_Multicenter
S8629|centers|I-Settings_Multicenter
S8629|in|O
S8629|Canada|B-Settings_Location
S8629|,|I-Settings_Location
S8629|the|I-Settings_Location
S8629|United|I-Settings_Location
S8629|Kingdom|I-Settings_Location
S8629|,|I-Settings_Location
S8629|the|I-Settings_Location
S8629|United|I-Settings_Location
S8629|States|I-Settings_Location
S8629|,|I-Settings_Location
S8629|Germany|I-Settings_Location
S8629|,|I-Settings_Location
S8629|and|I-Settings_Location
S8629|Israel|I-Settings_Location
S8629|,|O
S8629|in|O
S8629|compliance|O
S8629|with|O
S8629|the|O
S8629|principles|O
S8629|of|O
S8629|the|O
S8629|Declaration|O
S8629|of|O
S8629|Helsinki|O
S8629|and|O
S8629|according|O
S8629|to|O
S8629|Good|O
S8629|Clinical|O
S8629|Practice|O
S8629|guidelines|O
S8629|.|O
S3056|The|O
S3056|study|O
S3056|was|O
S3056|conducted|O
S3056|at|O
S3056|two|B-Settings_Multicenter
S3056|clinical|I-Settings_Multicenter
S3056|sites|I-Settings_Multicenter
S3056|in|O
S3056|China|B-Settings_Location
S3056|from|O
S3056|14|O
S3056|August|O
S3056|2017|O
S3056|(|O
S3056|first|O
S3056|patient|O
S3056|enrolled|O
S3056|)|O
S3056|to|O
S3056|data|O
S3056|cut-off|O
S3056|on|O
S3056|23|O
S3056|November|O
S3056|2018|O
S3056|;|O
S3056|3|O
S3056|patients|O
S3056|were|O
S3056|still|O
S3056|on|O
S3056|treatment|O
S3056|at|O
S3056|the|O
S3056|time|O
S3056|of|O
S3056|data|O
S3056|cut-off|O
S3056|.|O
S1284|Methods|O
S1284|This|O
S1284|is|O
S1284|a|O
S1284|phase|B-Design_Phase_3
S1284|III|I-Design_Phase_3
S1284|,|O
S1284|randomised|O
S1284|,|O
S1284|double-blind|B-Blinding_Double_Blind
S1284|,|O
S1284|multinational|O
S1284|,|O
S1284|multicentre|B-Settings_Multicenter
S1284|parallel|B-Design_Parallel_Group
S1284|group|I-Design_Parallel_Group
S1284|study|O
S1284|.|O
S3511|Treatment|O
S3511|randomisation|O
S3511|and|O
S3511|blinding|O
S3511|Women|O
S3511|were|O
S3511|randomised|O
S3511|in|O
S3511|a|O
S3511|1:1|B-Randomization_Ratio
S3511|ratio|O
S3511|to|O
S3511|treatment|O
S3511|with|O
S3511|either|O
S3511|follitropin|O
S3511|delta|O
S3511|(|O
S3511|Rekovelle|O
S3511|;|O
S3511|Ferring|O
S3511|Pharmaceuticals|O
S3511|,|O
S3511|Saint-Prex|O
S3511|,|O
S3511|Switzerland|O
S3511|)|O
S3511|or|O
S3511|follitropin|O
S3511|alfa|O
S3511|(|O
S3511|Gonal-f|O
S3511|;|O
S3511|Merck|O
S3511|Serono|O
S3511|,|O
S3511|Geneva|O
S3511|,|O
S3511|Switzerland|O
S3511|)|O
S3511|via|O
S3511|a|B-Randomization_Sequence_Generation_Method
S3511|central|I-Randomization_Sequence_Generation_Method
S3511|computer-generated|I-Randomization_Sequence_Generation_Method
S3511|randomisation|I-Randomization_Sequence_Generation_Method
S3511|list|I-Randomization_Sequence_Generation_Method
S3511|,|O
S3511|prepared|O
S3511|by|O
S3511|an|B-Randomization_Personnel
S3511|independent|I-Randomization_Personnel
S3511|statistician|I-Randomization_Personnel
S3511|.|O
S5448|Children|O
S5448|presenting|O
S5448|at|O
S5448|the|B-Settings_Single_Center
S5448|study|I-Settings_Single_Center
S5448|hospital|I-Settings_Single_Center
S5448|with|O
S5448|signs|O
S5448|of|O
S5448|pneumonia|O
S5448|had|O
S5448|their|O
S5448|diagnosis|O
S5448|confirmed|O
S5448|radiographically|O
S5448|.|O
S7862|Design|O
S7862|Open|B-Blinding_Open_Label
S7862|label|I-Blinding_Open_Label
S7862|randomised|O
S7862|controlled|O
S7862|trial|O
S7862|.|O
S6700|Conclusion|O
S6700|:|O
S6700|Evolocumab|O
S6700|was|O
S6700|superior|O
S6700|to|O
S6700|ezetimibe|O
S6700|in|O
S6700|reducing|O
S6700|LDL-C|O
S6700|during|O
S6700|the|O
S6700|12-week|O
S6700|double-blind|B-Blinding_Double_Blind
S6700|period|O
S6700|in|O
S6700|this|O
S6700|population|O
S6700|of|O
S6700|Japanese|O
S6700|patients|O
S6700|with|O
S6700|statin|O
S6700|intolerance|O
S6700|,|O
S6700|with|O
S6700|efficacy|O
S6700|and|O
S6700|safety|O
S6700|results|O
S6700|maintained|O
S6700|for|O
S6700|1|O
S6700|year|O
S6700|.|O
S1230|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1230|testing|O
S1230|was|O
S1230|not|O
S1230|performed|O
S1230|for|O
S1230|time|O
S1230|to|O
S1230|onset|O
S1230|of|O
S1230|action|O
S1230|on|O
S1230|Day|O
S1230|1|O
S1230|,|O
S1230|for|O
S1230|which|O
S1230|cumulative|O
S1230|incidence|O
S1230|Kaplan–Meier|O
S1230|curves|O
S1230|were|O
S1230|plotted|O
S1230|.|O
S1791|In|O
S1791|total|O
S1791|,|O
S1791|93|B-Sample_Size_Actual_at_Outcome_Analysis
S1791|%|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|of|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|participants|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|in|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|the|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|teplizumab|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|group|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|(|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|41|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|of|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|44|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|)|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|and|O
S1791|88|B-Sample_Size_Actual_at_Outcome_Analysis
S1791|%|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|of|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|participants|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|in|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|the|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|group|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|(|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|28|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|of|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|32|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|)|I-Sample_Size_Actual_at_Outcome_Analysis
S1791|completed|O
S1791|the|O
S1791|14-day|O
S1791|course|O
S1791|of|O
S1791|the|O
S1791|assigned|O
S1791|trial|O
S1791|agent|O
S1791|.|O
S6991|Results|O
S6991|Overall|O
S6991|,|O
S6991|726|B-Sample_Size_Actual_at_Enrollment
S6991|patients|O
S6991|were|O
S6991|randomized|O
S6991|(|O
S6991|tedizolid|O
S6991|,|O
S6991|n|O
S6991|=|O
S6991|366|O
S6991|;|O
S6991|linezolid|O
S6991|,|O
S6991|n|O
S6991|=|O
S6991|360|O
S6991|)|O
S6991|.|O
S4254|The|O
S4254|study|O
S4254|planned|O
S4254|to|O
S4254|enroll|O
S4254|approximately|O
S4254|440|B-Sample_Size_Target
S4254|subjects|O
S4254|(|O
S4254|220|O
S4254|per|O
S4254|group|O
S4254|)|O
S4254|to|O
S4254|provide|O
S4254|a|O
S4254|sample|O
S4254|size|O
S4254|sufficient|O
S4254|to|O
S4254|detect|O
S4254|infrequent|O
S4254|local|O
S4254|reactions|O
S4254|,|O
S4254|systemic|O
S4254|events|O
S4254|,|O
S4254|and|O
S4254|AEs|O
S4254|(|O
S4254|probability|O
S4254|of|O
S4254|0.89|O
S4254|and|O
S4254|>|O
S4254|0.999|O
S4254|of|O
S4254|detecting|O
S4254|≥1|O
S4254|event|O
S4254|with|O
S4254|a|O
S4254|true|O
S4254|rate|O
S4254|of|O
S4254|1|B-Sample_Size_Calculation_Alpha_Value
S4254|%|I-Sample_Size_Calculation_Alpha_Value
S4254|and|O
S4254|≥|B-Sample_Size_Calculation_Alpha_Value
S4254|5|I-Sample_Size_Calculation_Alpha_Value
S4254|%|I-Sample_Size_Calculation_Alpha_Value
S4254|,|O
S4254|respectively|O
S4254|,|O
S4254|in|O
S4254|a|O
S4254|group|O
S4254|of|O
S4254|200|O
S4254|subjects|O
S4254|)|O
S4254|.|O
S7126|Findings|O
S7126|We|O
S7126|randomly|O
S7126|assigned|O
S7126|162|B-Sample_Size_Actual_at_Enrollment
S7126|patients|I-Sample_Size_Actual_at_Enrollment
S7126|to|I-Sample_Size_Actual_at_Enrollment
S7126|the|I-Sample_Size_Actual_at_Enrollment
S7126|salbutamol|I-Sample_Size_Actual_at_Enrollment
S7126|group|I-Sample_Size_Actual_at_Enrollment
S7126|and|I-Sample_Size_Actual_at_Enrollment
S7126|164|I-Sample_Size_Actual_at_Enrollment
S7126|to|I-Sample_Size_Actual_at_Enrollment
S7126|the|I-Sample_Size_Actual_at_Enrollment
S7126|placebo|I-Sample_Size_Actual_at_Enrollment
S7126|group|I-Sample_Size_Actual_at_Enrollment
S7126|.|O
S3457|STUDY|O
S3457|DESIGN|O
S3457|,|O
S3457|SIZE|O
S3457|,|O
S3457|DURATION|O
S3457|Randomised|O
S3457|,|O
S3457|controlled|O
S3457|,|O
S3457|multi-centre|B-Settings_Multicenter
S3457|,|O
S3457|assessor-blind|B-Blinding_Single_Blind
S3457|trial|O
S3457|conducted|O
S3457|in|O
S3457|1009|B-Sample_Size_Actual_at_Enrollment
S3457|Asian|I-Sample_Size_Actual_at_Enrollment
S3457|patients|I-Sample_Size_Actual_at_Enrollment
S3457|from|O
S3457|mainland|B-Settings_Location
S3457|China|I-Settings_Location
S3457|,|I-Settings_Location
S3457|South|I-Settings_Location
S3457|Korea|I-Settings_Location
S3457|,|I-Settings_Location
S3457|Vietnam|I-Settings_Location
S3457|and|I-Settings_Location
S3457|Taiwan|I-Settings_Location
S3457|,|O
S3457|undergoing|O
S3457|their|O
S3457|first|O
S3457|IVF/ICSI|O
S3457|cycle|O
S3457|.|O
S7582|Participants|O
S7582|were|O
S7582|randomized|O
S7582|in|O
S7582|equal|O
S7582|proportions|O
S7582|to|O
S7582|a|O
S7582|daprodustat|B-Design_Parallel_Group
S7582|dose|I-Design_Parallel_Group
S7582|or|I-Design_Parallel_Group
S7582|placebo|I-Design_Parallel_Group
S7582|within|O
S7582|each|O
S7582|stratum|O
S7582|without|O
S7582|using|O
S7582|prior|O
S7582|rhEPO|O
S7582|dose|O
S7582|to|O
S7582|determine|O
S7582|the|O
S7582|daprodustat|O
S7582|dose|O
S7582|.|O
S1432|Methods|O
S1432|Multicentre|B-Settings_Multicenter
S1432|,|O
S1432|investigator-initiated|O
S1432|,|O
S1432|randomised|O
S1432|,|O
S1432|double-blind|B-Blinding_Double_Blind
S1432|,|O
S1432|placebo-controlled|O
S1432|,|O
S1432|parallel-design|B-Design_Parallel_Group
S1432|phase|B-Design_Phase_3
S1432|3b|I-Design_Phase_3
S1432|trial|O
S1432|in|O
S1432|11|B-Settings_Multicenter
S1432|Portuguese|B-Settings_Location
S1432|rheumatology|I-Settings_Multicenter
S1432|centres|I-Settings_Multicenter
S1432|.|O
S1902|The|O
S1902|web-based|B-Randomization_Sequence_Generation_Method
S1902|,|I-Randomization_Sequence_Generation_Method
S1902|central|I-Randomization_Sequence_Generation_Method
S1902|computer|I-Randomization_Sequence_Generation_Method
S1902|randomization|I-Randomization_Sequence_Generation_Method
S1902|system|I-Randomization_Sequence_Generation_Method
S1902|used|O
S1902|permuted|B-Randomization_Type_Block
S1902|block|I-Randomization_Type_Block
S1902|allocation|O
S1902|(|O
S1902|block|B-Randomization_Block_Size
S1902|size|I-Randomization_Block_Size
S1902|4|I-Randomization_Block_Size
S1902|)|O
S1902|with|O
S1902|stratification|B-Randomization_Type_Stratified
S1902|by|O
S1902|gestational|B-Randomization_Stratified_Criteria
S1902|age|I-Randomization_Stratified_Criteria
S1902|at|I-Randomization_Stratified_Criteria
S1902|enrollment|I-Randomization_Stratified_Criteria
S1902|(|I-Randomization_Stratified_Criteria
S1902|20|I-Randomization_Stratified_Criteria
S1902|to|I-Randomization_Stratified_Criteria
S1902|<|I-Randomization_Stratified_Criteria
S1902|28|I-Randomization_Stratified_Criteria
S1902|weeks|I-Randomization_Stratified_Criteria
S1902|;|I-Randomization_Stratified_Criteria
S1902|28|I-Randomization_Stratified_Criteria
S1902|to|I-Randomization_Stratified_Criteria
S1902|<|I-Randomization_Stratified_Criteria
S1902|31|I-Randomization_Stratified_Criteria
S1902|weeks|I-Randomization_Stratified_Criteria
S1902|;|I-Randomization_Stratified_Criteria
S1902|31|I-Randomization_Stratified_Criteria
S1902|to|I-Randomization_Stratified_Criteria
S1902|<|I-Randomization_Stratified_Criteria
S1902|34|I-Randomization_Stratified_Criteria
S1902|weeks|I-Randomization_Stratified_Criteria
S1902|;|I-Randomization_Stratified_Criteria
S1902|34|I-Randomization_Stratified_Criteria
S1902|to|I-Randomization_Stratified_Criteria
S1902|<|I-Randomization_Stratified_Criteria
S1902|37|I-Randomization_Stratified_Criteria
S1902|weeks|I-Randomization_Stratified_Criteria
S1902|)|I-Randomization_Stratified_Criteria
S1902|and|O
S1902|NRTI|B-Randomization_Stratified_Criteria
S1902|backbone|I-Randomization_Stratified_Criteria
S1902|(|I-Randomization_Stratified_Criteria
S1902|lamivudine/zidovudine|I-Randomization_Stratified_Criteria
S1902|or|I-Randomization_Stratified_Criteria
S1902|alternative|I-Randomization_Stratified_Criteria
S1902|,|I-Randomization_Stratified_Criteria
S1902|locally-supplied|I-Randomization_Stratified_Criteria
S1902|NRTI|I-Randomization_Stratified_Criteria
S1902|regimen|I-Randomization_Stratified_Criteria
S1902|)|I-Randomization_Stratified_Criteria
S1902|,|O
S1902|and|O
S1902|dynamic|B-Randomization_Stratified_Criteria
S1902|balancing|I-Randomization_Stratified_Criteria
S1902|by|I-Randomization_Stratified_Criteria
S1902|study|I-Randomization_Stratified_Criteria
S1902|site|I-Randomization_Stratified_Criteria
S1902|.|O
S7545|Long‐term|O
S7545|(|O
S7545|up|O
S7545|to|O
S7545|64|O
S7545|weeks|O
S7545|)|O
S7545|efficacy|O
S7545|and|O
S7545|safety|O
S7545|of|O
S7545|erenumab|O
S7545|in|O
S7545|patients|O
S7545|with|O
S7545|episodic|O
S7545|migraine|O
S7545|has|O
S7545|been|O
S7545|demonstrated|O
S7545|in|O
S7545|a|O
S7545|global|O
S7545|open‐label|O
S7545|extension|O
S7545|study.22|O
S7545|A|O
S7545|randomized|B-Randomization_Type_Simple
S7545|,|O
S7545|29-day|O
S7545|,|O
S7545|dose-ranging|O
S7545|,|O
S7545|efficacy|O
S7545|and|O
S7545|safety|O
S7545|study|O
S7545|of|O
S7545|daprodustat|O
S7545|,|O
S7545|administered|O
S7545|three|O
S7545|times|O
S7545|weekly|O
S7545|in|O
S7545|patients|O
S7545|with|O
S7545|anemia|O
S7545|on|O
S7545|hemodialysis|O
S3458|Randomisation|O
S3458|was|O
S3458|stratified|B-Randomization_Type_Stratified
S3458|by|O
S3458|age|B-Randomization_Stratified_Criteria
S3458|(|I-Randomization_Stratified_Criteria
S3458|<|I-Randomization_Stratified_Criteria
S3458|35|I-Randomization_Stratified_Criteria
S3458|,|I-Randomization_Stratified_Criteria
S3458|35–37|I-Randomization_Stratified_Criteria
S3458|,|I-Randomization_Stratified_Criteria
S3458|38–40|I-Randomization_Stratified_Criteria
S3458|years|I-Randomization_Stratified_Criteria
S3458|)|I-Randomization_Stratified_Criteria
S3458|.|O
S7433|The|O
S7433|study|O
S7433|comprised|O
S7433|a|O
S7433|≤3‐week|O
S7433|screening|O
S7433|phase|O
S7433|,|O
S7433|4‐week|O
S7433|baseline|O
S7433|phase|O
S7433|,|O
S7433|24‐week|O
S7433|double‐blind|B-Blinding_Double_Blind
S7433|treatment|O
S7433|phase|O
S7433|(|O
S7433|DBTP|O
S7433|)|O
S7433|,|O
S7433|76‐week|O
S7433|open‐label|O
S7433|treatment|O
S7433|phase|O
S7433|(|O
S7433|increased|O
S7433|from|O
S7433|52|O
S7433|weeks|O
S7433|after|O
S7433|a|O
S7433|protocol|O
S7433|amendment|O
S7433|)|O
S7433|,|O
S7433|and|O
S7433|12‐week|O
S7433|safety|O
S7433|follow‐up|O
S7433|phase|O
S7433|(|O
S7433|16|O
S7433|weeks|O
S7433|after|O
S7433|the|O
S7433|last|O
S7433|dose|O
S7433|of|O
S7433|investigational|O
S7433|product|O
S7433|)|O
S7433|(|O
S7433|Supporting|O
S7433|Fig|O
S7433|.|O
S5452|Findings|O
S5452|1524|B-Sample_Size_Actual_at_Enrollment
S5452|children|I-Sample_Size_Actual_at_Enrollment
S5452|were|I-Sample_Size_Actual_at_Enrollment
S5452|assigned|I-Sample_Size_Actual_at_Enrollment
S5452|to|I-Sample_Size_Actual_at_Enrollment
S5452|receive|I-Sample_Size_Actual_at_Enrollment
S5452|vitamin|I-Sample_Size_Actual_at_Enrollment
S5452|D3|I-Sample_Size_Actual_at_Enrollment
S5452|and|I-Sample_Size_Actual_at_Enrollment
S5452|1522|I-Sample_Size_Actual_at_Enrollment
S5452|placebo|I-Sample_Size_Actual_at_Enrollment
S5452|.|O
S464|This|O
S464|original|O
S464|sample|O
S464|size|O
S464|was|O
S464|chosen|O
S464|based|O
S464|on|O
S464|the|O
S464|assumption|O
S464|that|O
S464|16|O
S464|subjects|O
S464|per|O
S464|treatment|O
S464|group|O
S464|(|O
S464|32|B-Sample_Size_Required
S464|subjects|O
S464|total|O
S464|)|O
S464|,|O
S464|would|O
S464|provide|O
S464|80|B-Sample_Size_Calculation_Power_Value
S464|%|I-Sample_Size_Calculation_Power_Value
S464|power|O
S464|to|O
S464|detect|O
S464|a|O
S464|35|O
S464|%|O
S464|reduction|O
S464|from|O
S464|baseline|O
S464|in|O
S464|proteinuria|O
S464|at|O
S464|week|O
S464|16|O
S464|with|O
S464|an|O
S464|SD|O
S464|of|O
S464|50|O
S464|%|O
S464|and|O
S464|a|B-Sample_Size_Calculation_Alpha_Value
S464|two-sided|I-Sample_Size_Calculation_Alpha_Value
S464|0.05|I-Sample_Size_Calculation_Alpha_Value
S464|significance|I-Sample_Size_Calculation_Alpha_Value
S464|level|I-Sample_Size_Calculation_Alpha_Value
S464|.|O
S6628|Results|O
S6628|STAIRWAY|O
S6628|Enrollment|O
S6628|and|O
S6628|Patient|O
S6628|Disposition|O
S6628|STAIRWAY|O
S6628|enrolled|O
S6628|76|B-Sample_Size_Actual_at_Enrollment
S6628|anti-VEGF|O
S6628|treatment-naive|O
S6628|patients|O
S6628|with|O
S6628|nAMD|O
S6628|(|O
S6628|Figure|O
S6628|1|O
S6628|and|O
S6628|eFigure|O
S6628|1|O
S6628|in|O
S6628|Supplement|O
S6628|2|O
S6628|)|O
S6628|.|O
S3064|Randomization|O
S3064|Patients|O
S3064|were|O
S3064|randomized|B-Randomization_Type_Simple
S3064|1:1|B-Randomization_Ratio
S3064|to|O
S3064|receive|O
S3064|oral|B-Design_Parallel_Group
S3064|abemaciclib|I-Design_Parallel_Group
S3064|at|I-Design_Parallel_Group
S3064|150|I-Design_Parallel_Group
S3064|mg|I-Design_Parallel_Group
S3064|or|I-Design_Parallel_Group
S3064|200|I-Design_Parallel_Group
S3064|mg|I-Design_Parallel_Group
S3064|.|O
S7900|The|O
S7900|research|O
S7900|nurse|O
S7900|ascertained|O
S7900|treatment|O
S7900|allocation|O
S7900|either|O
S7900|by|O
S7900|telephone|B-Allocation_Concealment_Method
S7900|or|I-Allocation_Concealment_Method
S7900|online|I-Allocation_Concealment_Method
S7900|.|O
S598|Randomisation|O
S598|Patients|O
S598|were|O
S598|randomly|O
S598|assigned|O
S598|to|O
S598|receive|O
S598|either|O
S598|intravenous|B-Design_Parallel_Group
S598|rhEPO|I-Design_Parallel_Group
S598|40|I-Design_Parallel_Group
S598|000|I-Design_Parallel_Group
S598|IU|I-Design_Parallel_Group
S598|or|I-Design_Parallel_Group
S598|matching|I-Design_Parallel_Group
S598|placebo|I-Design_Parallel_Group
S598|(|O
S598|1:1|B-Randomization_Ratio
S598|ratio|O
S598|)|O
S598|fortnightly|O
S598|for|O
S598|12|O
S598|months|O
S598|.|O
S7758|The|O
S7758|trial|O
S7758|included|O
S7758|165|B-Settings_Multicenter
S7758|sites|I-Settings_Multicenter
S7758|across|O
S7758|17|B-Settings_Location
S7758|countries|I-Settings_Location
S7758|(|O
S7758|Supplementary|O
S7758|Data|O
S7758|)|O
S7758|.|O
S7194|Results|O
S7194|46|B-Settings_Multicenter
S7194|study|I-Settings_Multicenter
S7194|sites|I-Settings_Multicenter
S7194|participated|O
S7194|in|O
S7194|recruitment|O
S7194|;|O
S7194|a|O
S7194|further|O
S7194|25|O
S7194|sites|O
S7194|obtained|O
S7194|approval|O
S7194|to|O
S7194|start|O
S7194|the|O
S7194|trial|O
S7194|,|O
S7194|but|O
S7194|were|O
S7194|unable|O
S7194|to|O
S7194|do|O
S7194|so|O
S7194|before|O
S7194|recruitment|O
S7194|was|O
S7194|stopped|O
S7194|.|O
S3673|Each|O
S3673|participant|O
S3673|received|O
S3673|the|O
S3673|following|O
S3673|six|O
S3673|treatments|O
S3673|on|O
S3673|up|O
S3673|to|O
S3673|three|O
S3673|comparable|O
S3673|plaques|O
S3673|(|O
S3673|six|O
S3673|treatment|O
S3673|areas|O
S3673|)|O
S3673|once|O
S3673|daily|O
S3673|for|O
S3673|18|O
S3673|days|O
S3673|:|O
S3673|three|B-Design_Parallel_Group
S3673|topical|I-Design_Parallel_Group
S3673|doses|I-Design_Parallel_Group
S3673|(|I-Design_Parallel_Group
S3673|2.3|I-Design_Parallel_Group
S3673|%|I-Design_Parallel_Group
S3673|,|I-Design_Parallel_Group
S3673|0.8|I-Design_Parallel_Group
S3673|%|I-Design_Parallel_Group
S3673|and|I-Design_Parallel_Group
S3673|0.23|I-Design_Parallel_Group
S3673|%|I-Design_Parallel_Group
S3673|)|I-Design_Parallel_Group
S3673|of|I-Design_Parallel_Group
S3673|PF‐06763809|I-Design_Parallel_Group
S3673|,|I-Design_Parallel_Group
S3673|the|I-Design_Parallel_Group
S3673|PF‐06763809|I-Design_Parallel_Group
S3673|vehicle|I-Design_Parallel_Group
S3673|and|I-Design_Parallel_Group
S3673|two|I-Design_Parallel_Group
S3673|active|I-Design_Parallel_Group
S3673|comparators|I-Design_Parallel_Group
S3673|[|I-Design_Parallel_Group
S3673|0.1|I-Design_Parallel_Group
S3673|%|I-Design_Parallel_Group
S3673|betamethasone|I-Design_Parallel_Group
S3673|1|I-Design_Parallel_Group
S3673|mg/g|I-Design_Parallel_Group
S3673|and|I-Design_Parallel_Group
S3673|calcipotriol|I-Design_Parallel_Group
S3673|0.005|I-Design_Parallel_Group
S3673|%|I-Design_Parallel_Group
S3673|(|I-Design_Parallel_Group
S3673|50|I-Design_Parallel_Group
S3673|µg/mL|I-Design_Parallel_Group
S3673|)|I-Design_Parallel_Group
S3673|]|I-Design_Parallel_Group
S3673|.|O
S2888|Methods|O
S2888|:|O
S2888|MiniSTONE-2|O
S2888|(|O
S2888|Clinicaltrials.gov|O
S2888|:|O
S2888|NCT03629184|O
S2888|)|O
S2888|was|O
S2888|a|O
S2888|double-blind|B-Blinding_Double_Blind
S2888|,|O
S2888|randomized|O
S2888|,|O
S2888|active|O
S2888|controlled|O
S2888|trial|O
S2888|enrolling|O
S2888|children|O
S2888|1–|O
S2888|<|O
S2888|12|O
S2888|years|O
S2888|old|O
S2888|with|O
S2888|a|O
S2888|clinical|O
S2888|diagnosis|O
S2888|of|O
S2888|influenza|O
S2888|.|O
S6861|Patients|O
S6861|Patients|O
S6861|were|O
S6861|recruited|O
S6861|from|O
S6861|99|B-Settings_Multicenter
S6861|sites|I-Settings_Multicenter
S6861|in|O
S6861|Canada|B-Settings_Location
S6861|,|I-Settings_Location
S6861|Israel|I-Settings_Location
S6861|,|I-Settings_Location
S6861|and|I-Settings_Location
S6861|the|I-Settings_Location
S6861|United|I-Settings_Location
S6861|States|I-Settings_Location
S6861|between|O
S6861|December|O
S6861|2015|O
S6861|and|O
S6861|December|O
S6861|2016|O
S6861|.|O
S8355|Results|O
S8355|One-hundred|O
S8355|ninety-five|O
S8355|subjects|O
S8355|were|O
S8355|screened|O
S8355|,|O
S8355|and|O
S8355|23|B-Sample_Size_Actual_at_Enrollment
S8355|participants|O
S8355|were|O
S8355|included|O
S8355|in|O
S8355|the|O
S8355|study|O
S8355|.|O
S6434|We|O
S6434|used|O
S6434|a|B-Randomization_Sequence_Generation_Method
S6434|central|I-Randomization_Sequence_Generation_Method
S6434|computer|I-Randomization_Sequence_Generation_Method
S6434|generated|I-Randomization_Sequence_Generation_Method
S6434|random|I-Randomization_Sequence_Generation_Method
S6434|number|I-Randomization_Sequence_Generation_Method
S6434|list|I-Randomization_Sequence_Generation_Method
S6434|to|O
S6434|randomise|O
S6434|patients|O
S6434|to|O
S6434|treatment|O
S6434|with|O
S6434|trimethoprim-sulfamethoxazole|B-Design_Parallel_Group
S6434|or|I-Design_Parallel_Group
S6434|vancomycin|I-Design_Parallel_Group
S6434|.|O
S2561|The|O
S2561|study|O
S2561|was|O
S2561|a|O
S2561|randomised|B-Randomization_Type_Simple
S2561|,|O
S2561|double-blind|B-Blinding_Double_Blind
S2561|,|O
S2561|placebo-controlled|O
S2561|,|O
S2561|parallel-group|B-Design_Parallel_Group
S2561|study|O
S2561|.|O
S6693|This|O
S6693|phase|B-Design_Phase_3
S6693|3|I-Design_Phase_3
S6693|,|O
S6693|randomized|O
S6693|,|O
S6693|double-blind|B-Blinding_Double_Blind
S6693|trial|O
S6693|in|O
S6693|Japanese|B-Settings_Location
S6693|patients|O
S6693|with|O
S6693|statin|O
S6693|intolerance|O
S6693|aimed|O
S6693|to|O
S6693|evaluate|O
S6693|the|O
S6693|efficacy|O
S6693|and|O
S6693|safety|O
S6693|of|O
S6693|evolocumab|B-Design_Parallel_Group
S6693|vs.|I-Design_Parallel_Group
S6693|ezetimibe|I-Design_Parallel_Group
S6693|in|O
S6693|lowering|O
S6693|low-density|O
S6693|lipoprotein-cholesterol|O
S6693|(|O
S6693|LDL-C|O
S6693|)|O
S6693|.|O
S6742|Statistical|O
S6742|Analysis|O
S6742|Sample|O
S6742|Size|O
S6742|The|O
S6742|planned|O
S6742|sample|O
S6742|size|O
S6742|for|O
S6742|the|O
S6742|double-blind|O
S6742|comparison|O
S6742|was|O
S6742|60|B-Sample_Size_Target
S6742|patients|O
S6742|,|O
S6742|of|O
S6742|whom|O
S6742|40|O
S6742|were|O
S6742|for|O
S6742|evolocumab|O
S6742|(|O
S6742|n|O
S6742|=|O
S6742|20|O
S6742|at|O
S6742|Q2W|O
S6742|and|O
S6742|n|O
S6742|=|O
S6742|20|O
S6742|at|O
S6742|Q4W|O
S6742|)|O
S6742|and|O
S6742|20|O
S6742|were|O
S6742|for|O
S6742|ezetimibe|O
S6742|(|O
S6742|n|O
S6742|=|O
S6742|10|O
S6742|at|O
S6742|Q2W|O
S6742|and|O
S6742|n|O
S6742|=|O
S6742|10|O
S6742|at|O
S6742|Q4W|O
S6742|)|O
S6742|.|O
S7332|The|O
S7332|upper|O
S7332|bound|O
S7332|of|O
S7332|the|O
S7332|95|O
S7332|%|O
S7332|CI|O
S7332|was|O
S7332|greater|O
S7332|than|O
S7332|the|O
S7332|prespecified|O
S7332|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7332|margin|O
S7332|of|O
S7332|0.6|O
S7332|;|O
S7332|hence|O
S7332|,|O
S7332|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7332|of|O
S7332|tofacitinib|O
S7332|MR|O
S7332|11|O
S7332|mg|O
S7332|QD|O
S7332|relative|O
S7332|to|O
S7332|IR|O
S7332|5|O
S7332|mg|O
S7332|BID|O
S7332|was|O
S7332|not|O
S7332|met|O
S7332|(|O
S7332|Fig|O
S7332|.|O
S8070|Methods|O
S8070|Study|O
S8070|design|O
S8070|and|O
S8070|treatment|O
S8070|This|O
S8070|phase|B-Design_Phase_3
S8070|3|I-Design_Phase_3
S8070|,|O
S8070|randomized|O
S8070|,|O
S8070|double-blind|B-Blinding_Double_Blind
S8070|,|O
S8070|placebo-controlled|O
S8070|fixed-dose|O
S8070|study|O
S8070|in|O
S8070|children|O
S8070|aged|O
S8070|6–12|O
S8070|years|O
S8070|with|O
S8070|ADHD|O
S8070|was|O
S8070|conducted|O
S8070|at|O
S8070|27|B-Settings_Multicenter
S8070|sites|I-Settings_Multicenter
S8070|in|O
S8070|the|O
S8070|United|B-Settings_Location
S8070|States|I-Settings_Location
S8070|between|O
S8070|December|O
S8070|9|O
S8070|,|O
S8070|2017|O
S8070|,|O
S8070|and|O
S8070|June|O
S8070|7|O
S8070|,|O
S8070|2018|O
S8070|.|O
S1246|No|O
S1246|dose|O
S1246|of|O
S1246|GP|O
S1246|MDI|O
S1246|demonstrated|O
S1246|non-inferiority|O
S1246|to|O
S1246|open-label|B-Blinding_Open_Label
S1246|tiotropium|O
S1246|with|O
S1246|the|O
S1246|lower|O
S1246|bound|O
S1246|of|O
S1246|the|O
S1246|95|O
S1246|%|O
S1246|CI|O
S1246|exceeding|O
S1246|the|O
S1246|clinically|O
S1246|relevant|O
S1246|difference|O
S1246|of|O
S1246|−100|O
S1246|mL|O
S1246|in|O
S1246|FEV1|O
S1246|AUC0–12|O
S1246|on|O
S1246|Day|O
S1246|14|O
S1246|(|O
S1246|see|O
S1246|Additional|O
S1246|file|O
S1246|1|O
S1246|:|O
S1246|Figure|O
S1246|S2|O
S1246|)|O
S1246|.|O
S8499|Randomization|O
S8499|and|O
S8499|masking|O
S8499|Patients|O
S8499|were|O
S8499|randomly|B-Randomization_Type_Simple
S8499|assigned|I-Randomization_Type_Simple
S8499|in|O
S8499|a|O
S8499|1:1|B-Randomization_Ratio
S8499|ratio|O
S8499|to|O
S8499|receive|O
S8499|linagliptin/metformin|B-Design_Parallel_Group
S8499|2.5/850|I-Design_Parallel_Group
S8499|mg|I-Design_Parallel_Group
S8499|every|I-Design_Parallel_Group
S8499|12|I-Design_Parallel_Group
S8499|h|I-Design_Parallel_Group
S8499|+|I-Design_Parallel_Group
S8499|lifestyle|I-Design_Parallel_Group
S8499|modification|I-Design_Parallel_Group
S8499|program|I-Design_Parallel_Group
S8499|(|I-Design_Parallel_Group
S8499|LM|I-Design_Parallel_Group
S8499|group|I-Design_Parallel_Group
S8499|)|I-Design_Parallel_Group
S8499|,|I-Design_Parallel_Group
S8499|or|I-Design_Parallel_Group
S8499|to|I-Design_Parallel_Group
S8499|continue|I-Design_Parallel_Group
S8499|with|I-Design_Parallel_Group
S8499|metformin|I-Design_Parallel_Group
S8499|850|I-Design_Parallel_Group
S8499|mg|I-Design_Parallel_Group
S8499|every|I-Design_Parallel_Group
S8499|12|I-Design_Parallel_Group
S8499|h|I-Design_Parallel_Group
S8499|+|I-Design_Parallel_Group
S8499|lifestyle|I-Design_Parallel_Group
S8499|modification|I-Design_Parallel_Group
S8499|program|I-Design_Parallel_Group
S8499|(|I-Design_Parallel_Group
S8499|M|I-Design_Parallel_Group
S8499|group|I-Design_Parallel_Group
S8499|)|I-Design_Parallel_Group
S8499|.|O
S6098|The|O
S6098|study|O
S6098|was|O
S6098|conducted|O
S6098|at|O
S6098|13|B-Settings_Multicenter
S6098|investigational|I-Settings_Multicenter
S6098|sites|I-Settings_Multicenter
S6098|in|O
S6098|the|O
S6098|United|B-Settings_Location
S6098|States|I-Settings_Location
S6098|from|O
S6098|January|O
S6098|2019|O
S6098|through|O
S6098|June|O
S6098|2019|O
S6098|.|O
S3181|Setting|O
S3181|Nine|B-Settings_Multicenter
S3181|consultant|I-Settings_Multicenter
S3181|led|I-Settings_Multicenter
S3181|maternity|I-Settings_Multicenter
S3181|units|I-Settings_Multicenter
S3181|,|O
S3181|United|B-Settings_Location
S3181|Kingdom|I-Settings_Location
S3181|.|O
S702|Results|O
S702|:|O
S702|Out|O
S702|of|O
S702|113|O
S702|women|O
S702|screened|O
S702|for|O
S702|this|O
S702|study|O
S702|;|O
S702|96|B-Sample_Size_Actual_at_Enrollment
S702|women|I-Sample_Size_Actual_at_Enrollment
S702|were|O
S702|recruited|O
S702|,|O
S702|enrolled|O
S702|and|O
S702|randomized|O
S702|to|O
S702|study|O
S702|treatment|O
S702|arm|O
S702|from|O
S702|August|O
S702|2016|O
S702|to|O
S702|June|O
S702|2018|O
S702|.|O
S2454|Results|O
S2454|Subjects|O
S2454|and|O
S2454|Exposure|O
S2454|Between|O
S2454|January|O
S2454|23|O
S2454|,|O
S2454|2018|O
S2454|and|O
S2454|March|O
S2454|5|O
S2454|,|O
S2454|2019|O
S2454|,|O
S2454|804|O
S2454|subjects|O
S2454|were|O
S2454|screened|O
S2454|and|O
S2454|627|B-Sample_Size_Actual_at_Enrollment
S2454|were|O
S2454|randomized|O
S2454|in|O
S2454|a|O
S2454|1:1|O
S2454|ratio|O
S2454|(|O
S2454|ITT|O
S2454|population|O
S2454|;|O
S2454|MB02|O
S2454|:|O
S2454|315|O
S2454|subjects|O
S2454|;|O
S2454|EU-bevacizumab|O
S2454|:|O
S2454|312|O
S2454|subjects|O
S2454|)|O
S2454|.|O
S3178|Ursodeoxycholic|O
S3178|acid|O
S3178|versus|O
S3178|placebo|O
S3178|,|O
S3178|and|O
S3178|early|O
S3178|term|O
S3178|delivery|O
S3178|versus|O
S3178|expectant|O
S3178|management|O
S3178|,|O
S3178|in|O
S3178|women|O
S3178|with|O
S3178|intrahepatic|O
S3178|cholestasis|O
S3178|of|O
S3178|pregnancy|O
S3178|:|O
S3178|semifactorial|B-Design_Factorial
S3178|randomised|O
S3178|clinical|O
S3178|trial|O
S7120|Intubated|O
S7120|and|O
S7120|mechanically|O
S7120|ventilated|O
S7120|patients|O
S7120|(|O
S7120|aged|O
S7120|≥16|O
S7120|years|O
S7120|)|O
S7120|within|O
S7120|72|O
S7120|h|O
S7120|of|O
S7120|ARDS|O
S7120|onset|O
S7120|were|O
S7120|randomly|O
S7120|assigned|O
S7120|to|O
S7120|receive|O
S7120|either|O
S7120|salbutamol|B-Design_Parallel_Group
S7120|(|I-Design_Parallel_Group
S7120|15|I-Design_Parallel_Group
S7120|μg/kg|I-Design_Parallel_Group
S7120|ideal|I-Design_Parallel_Group
S7120|bodyweight|I-Design_Parallel_Group
S7120|per|I-Design_Parallel_Group
S7120|h|I-Design_Parallel_Group
S7120|)|I-Design_Parallel_Group
S7120|or|I-Design_Parallel_Group
S7120|placebo|I-Design_Parallel_Group
S7120|for|O
S7120|up|O
S7120|to|O
S7120|7|O
S7120|days|O
S7120|.|O
S7415|Results|O
S7415|Four|B-Sample_Size_Actual_at_Enrollment
S7415|hundred|I-Sample_Size_Actual_at_Enrollment
S7415|and|I-Sample_Size_Actual_at_Enrollment
S7415|seventy|I-Sample_Size_Actual_at_Enrollment
S7415|five|I-Sample_Size_Actual_at_Enrollment
S7415|patients|O
S7415|were|O
S7415|randomized|O
S7415|2:1:2:2|B-Randomization_Ratio
S7415|to|O
S7415|placebo|B-Design_Parallel_Group
S7415|and|I-Design_Parallel_Group
S7415|erenumab|I-Design_Parallel_Group
S7415|28|I-Design_Parallel_Group
S7415|,|I-Design_Parallel_Group
S7415|70|I-Design_Parallel_Group
S7415|,|I-Design_Parallel_Group
S7415|and|I-Design_Parallel_Group
S7415|140|I-Design_Parallel_Group
S7415|mg|I-Design_Parallel_Group
S7415|,|O
S7415|respectively|O
S7415|.|O
S8229|Methods|O
S8229|:|O
S8229|Twenty-three|B-Sample_Size_Actual_at_Enrollment
S8229|obese|I-Sample_Size_Actual_at_Enrollment
S8229|men|I-Sample_Size_Actual_at_Enrollment
S8229|(|O
S8229|BMI≥35|O
S8229|kg/m2|O
S8229|)|O
S8229|,|O
S8229|35–65|O
S8229|years|O
S8229|old|O
S8229|,|O
S8229|were|O
S8229|randomized|O
S8229|to|O
S8229|weight|B-Design_Parallel_Group
S8229|loss|I-Design_Parallel_Group
S8229|(|I-Design_Parallel_Group
S8229|diet|I-Design_Parallel_Group
S8229|and|I-Design_Parallel_Group
S8229|exercise|I-Design_Parallel_Group
S8229|)|I-Design_Parallel_Group
S8229|plus|I-Design_Parallel_Group
S8229|either|I-Design_Parallel_Group
S8229|anastrozole|I-Design_Parallel_Group
S8229|(|I-Design_Parallel_Group
S8229|AI+WL|I-Design_Parallel_Group
S8229|,|I-Design_Parallel_Group
S8229|n|I-Design_Parallel_Group
S8229|=|I-Design_Parallel_Group
S8229|12|I-Design_Parallel_Group
S8229|)|I-Design_Parallel_Group
S8229|at|I-Design_Parallel_Group
S8229|1|I-Design_Parallel_Group
S8229|mg|I-Design_Parallel_Group
S8229|daily|I-Design_Parallel_Group
S8229|or|I-Design_Parallel_Group
S8229|placebo|I-Design_Parallel_Group
S8229|(|I-Design_Parallel_Group
S8229|PBO+WL|I-Design_Parallel_Group
S8229|,|I-Design_Parallel_Group
S8229|n|I-Design_Parallel_Group
S8229|=|I-Design_Parallel_Group
S8229|11|I-Design_Parallel_Group
S8229|)|I-Design_Parallel_Group
S8229|for|O
S8229|6|O
S8229|months|O
S8229|.|O
S912|The|O
S912|examiner|B-Blinding_Object_Outcome_Assessors
S912|,|O
S912|study|B-Blinding_Object_Others
S912|statistician|I-Blinding_Object_Others
S912|,|O
S912|and|O
S912|sponsor|B-Blinding_Object_Others
S912|employees|I-Blinding_Object_Others
S912|were|O
S912|blinded|O
S912|to|O
S912|treatment|O
S912|allocation|O
S912|.|O
S3104|Results|O
S3104|Patients|O
S3104|A|O
S3104|total|O
S3104|of|O
S3104|26|B-Sample_Size_Actual_at_Enrollment
S3104|patients|O
S3104|were|O
S3104|enrolled|O
S3104|in|O
S3104|the|O
S3104|study|O
S3104|:|O
S3104|12|O
S3104|in|O
S3104|the|O
S3104|150|O
S3104|mg|O
S3104|cohort|O
S3104|and|O
S3104|14|O
S3104|in|O
S3104|the|O
S3104|200|O
S3104|mg|O
S3104|cohort|O
S3104|.|O
S6305|A|O
S6305|total|O
S6305|of|O
S6305|113|B-Sample_Size_Actual_at_Outcome_Analysis
S6305|patients|O
S6305|completed|O
S6305|the|O
S6305|48-week|O
S6305|study|O
S6305|,|O
S6305|while|O
S6305|11|O
S6305|patients|O
S6305|(|O
S6305|5|O
S6305|in|O
S6305|the|O
S6305|400|O
S6305|U|O
S6305|group|O
S6305|;|O
S6305|6|O
S6305|in|O
S6305|the|O
S6305|240|O
S6305|U|O
S6305|group|O
S6305|)|O
S6305|withdrew|O
S6305|from|O
S6305|the|O
S6305|trial|O
S6305|.|O
S24|MATERIALS|O
S24|AND|O
S24|METHODS|O
S24|Study|O
S24|Design|O
S24|This|O
S24|was|O
S24|a|O
S24|phase|B-Design_Phase_4
S24|IV|I-Design_Phase_4
S24|,|O
S24|randomized|B-Randomization_Type_Simple
S24|,|O
S24|observer-blinded|B-Blinding_Object_Others
S24|,|O
S24|2-arm|B-Design_Parallel_Group
S24|,|O
S24|multi-center|B-Settings_Multicenter
S24|study|O
S24|to|O
S24|evaluate|O
S24|the|O
S24|safety|O
S24|and|O
S24|immunogenicity|O
S24|of|O
S24|2|O
S24|different|O
S24|doses|O
S24|of|O
S24|IIV4|O
S24|in|O
S24|healthy|O
S24|children|O
S24|6–35|O
S24|months|O
S24|of|O
S24|age|O
S24|.|O
S66|Results|O
S66|of|O
S66|participants|O
S66|receiving|O
S66|exactly|O
S66|1|O
S66|dose|O
S66|of|O
S66|IIV4|O
S66|and|O
S66|those|O
S66|receiving|O
S66|2|O
S66|doses|O
S66|were|O
S66|combined|O
S66|in|O
S66|all|O
S66|noninferiority|B-Design_Comparative_Intent_NonInferiority
S66|assessments|O
S66|(|O
S66|ie|O
S66|,|O
S66|for|O
S66|fever|O
S66|rate|O
S66|,|O
S66|postvaccination|O
S66|HAI|O
S66|GMTs|O
S66|and|O
S66|seroconversion|O
S66|rates|O
S66|)|O
S66|.|O
S2275|Under|O
S2275|these|O
S2275|assumptions|O
S2275|,|O
S2275|a|O
S2275|total|O
S2275|of|O
S2275|702|B-Sample_Size_Required
S2275|evaluable|O
S2275|patients|O
S2275|(|O
S2275|351|O
S2275|per|O
S2275|treatment|O
S2275|group|O
S2275|)|O
S2275|were|O
S2275|required|O
S2275|.|O
S5935|Methods|O
S5935|Trial|O
S5935|population|O
S5935|Between|O
S5935|June|O
S5935|2011|O
S5935|and|O
S5935|September|O
S5935|2013|O
S5935|,|O
S5935|consecutive|O
S5935|patients|O
S5935|referred|O
S5935|for|O
S5935|elective|O
S5935|CABG|O
S5935|surgery|O
S5935|were|O
S5935|recruited|O
S5935|from|O
S5935|two|B-Settings_Multicenter
S5935|clinics|I-Settings_Multicenter
S5935|at|O
S5935|Edinburgh|B-Settings_Location
S5935|Heart|O
S5935|Centre|O
S5935|.|O
S8026|A|O
S8026|Phase|B-Design_Phase_3
S8026|3|I-Design_Phase_3
S8026|,|O
S8026|Randomized|O
S8026|Double-Blind|B-Blinding_Double_Blind
S8026|Study|O
S8026|of|O
S8026|the|O
S8026|Efficacy|O
S8026|and|O
S8026|Safety|O
S8026|of|O
S8026|Low-Dose|O
S8026|SHP465|O
S8026|Mixed|O
S8026|Amphetamine|O
S8026|Salts|O
S8026|Extended-Release|O
S8026|in|O
S8026|Children|O
S8026|with|O
S8026|Attention-Deficit/Hyperactivity|O
S8026|Disorder|O
S2358|Efficacy|O
S2358|,|O
S2358|Safety|O
S2358|and|O
S2358|Immunogenicity|O
S2358|of|O
S2358|MB02|O
S2358|(|O
S2358|Bevacizumab|O
S2358|Biosimilar|O
S2358|)|O
S2358|versus|O
S2358|Reference|O
S2358|Bevacizumab|O
S2358|in|O
S2358|Advanced|O
S2358|Non-Small|O
S2358|Cell|O
S2358|Lung|O
S2358|Cancer|O
S2358|:|O
S2358|A|O
S2358|Randomized|O
S2358|,|O
S2358|Double-Blind|B-Blinding_Double_Blind
S2358|,|O
S2358|Phase|B-Design_Phase_3
S2358|III|I-Design_Phase_3
S2358|Study|O
S2358|(|O
S2358|STELLA|O
S2358|)|O
S6273|Entry|O
S6273|criteria|O
S6273|for|O
S6273|the|O
S6273|open-label|O
S6273|phase|O
S6273|included|O
S6273|a|O
S6273|MAS|O
S6273|score|O
S6273|of|O
S6273|at|O
S6273|least|O
S6273|2|O
S6273|in|O
S6273|the|O
S6273|elbow|O
S6273|,|O
S6273|and|O
S6273|at|O
S6273|least|O
S6273|2|O
S6273|in|O
S6273|the|O
S6273|wrist|O
S6273|or|O
S6273|fingers|O
S6273|,|O
S6273|and|O
S6273|no|O
S6273|drug-related|O
S6273|SAE|O
S6273|during|O
S6273|the|O
S6273|double-blind|B-Blinding_Double_Blind
S6273|phase|O
S6273|.|O
S1640|Of|O
S1640|124|O
S1640|patients|O
S1640|who|O
S1640|completed|O
S1640|blinded|O
S1640|treatment|O
S1640|,|O
S1640|117|O
S1640|elected|O
S1640|to|O
S1640|continue|O
S1640|to|O
S1640|the|O
S1640|open-label|O
S1640|phase|O
S1640|;|O
S1640|92|B-Sample_Size_Actual_at_Outcome_Analysis
S1640|completed|O
S1640|treatment|O
S1640|for|O
S1640|96|O
S1640|weeks|O
S1640|.|O
S8597|Results|O
S8597|There|O
S8597|were|O
S8597|no|O
S8597|statistically|O
S8597|significant|O
S8597|differences|O
S8597|between|O
S8597|canakinumab|B-Design_Parallel_Group
S8597|compared|I-Design_Parallel_Group
S8597|with|I-Design_Parallel_Group
S8597|placebo|I-Design_Parallel_Group
S8597|in|O
S8597|the|O
S8597|primary|O
S8597|efficacy|O
S8597|and|O
S8597|safety|O
S8597|endpoints|O
S8597|.|O
S62|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S62|for|O
S62|seroconversion|O
S62|rates|O
S62|was|O
S62|considered|O
S62|demonstrated|O
S62|if|O
S62|the|O
S62|lower|O
S62|limit|O
S62|of|O
S62|the|O
S62|2-sided|O
S62|95|O
S62|%|O
S62|CI|O
S62|for|O
S62|the|O
S62|rate|O
S62|difference|O
S62|for|O
S62|the|O
S62|full|O
S62|dose|O
S62|minus|O
S62|the|O
S62|half|O
S62|dose|O
S62|was|O
S62|>|O
S62|−10|O
S62|%|O
S62|.|O
S2119|Overall|O
S2119|,|O
S2119|193|B-Sample_Size_Actual_at_Enrollment
S2119|subjects|O
S2119|were|O
S2119|randomised|O
S2119|(|O
S2119|CT‐P17|O
S2119|AI|O
S2119|:|O
S2119|98|O
S2119|;|O
S2119|CT‐P17|O
S2119|PFS|O
S2119|:|O
S2119|95|O
S2119|;|O
S2119|Figure|O
S2119|1|O
S2119|)|O
S2119|.|O
S1901|The|O
S1901|trial|O
S1901|was|O
S1901|open-label|B-Blinding_Open_Label
S1901|with|O
S1901|no|O
S1901|masking|O
S1901|of|O
S1901|treatment|O
S1901|assignment|O
S1901|for|O
S1901|participants|O
S1901|or|O
S1901|clinicians|O
S1901|.|O
S6064|Purpose|O
S6064|:|O
S6064|This|O
S6064|phase|B-Design_Phase_2
S6064|2|I-Design_Phase_2
S6064|,|O
S6064|randomized|O
S6064|,|O
S6064|double-masked|B-Blinding_Double_Blind
S6064|,|O
S6064|parallel-arm|B-Design_Parallel_Group
S6064|,|O
S6064|multicenter|B-Settings_Multicenter
S6064|study|O
S6064|(|O
S6064|NCT03858894|O
S6064|)|O
S6064|was|O
S6064|conducted|O
S6064|in|O
S6064|the|O
S6064|United|B-Settings_Location
S6064|States|I-Settings_Location
S6064|to|O
S6064|examine|O
S6064|whether|O
S6064|the|O
S6064|efficacy|O
S6064|and|O
S6064|safety|O
S6064|of|O
S6064|omidenepag|O
S6064|isopropyl|O
S6064|0.002|O
S6064|%|O
S6064|BID|O
S6064|dosing|O
S6064|was|O
S6064|superior|O
S6064|to|O
S6064|QD|O
S6064|dosing|O
S6064|in|O
S6064|subjects|O
S6064|with|O
S6064|primary|O
S6064|open-angle|O
S6064|glaucoma|O
S6064|or|O
S6064|ocular|O
S6064|hypertension|O
S6064|.|O
S7133|Funding|O
S7133|UK|B-Settings_Location
S7133|Medical|O
S7133|Research|O
S7133|Council|O
S7133|,|O
S7133|UK|B-Settings_Location
S7133|Department|O
S7133|of|O
S7133|Health|O
S7133|,|O
S7133|UK|B-Settings_Location
S7133|Intensive|O
S7133|Care|O
S7133|Foundation|O
S7133|.|O
S266|This|O
S266|phase|B-Design_Phase_2
S266|2b|I-Design_Phase_2
S266|,|O
S266|placebo-controlled|O
S266|,|O
S266|randomized|O
S266|clinical|O
S266|trial|O
S266|evaluates|O
S266|the|O
S266|efficacy|O
S266|and|O
S266|safety|O
S266|of|O
S266|lebrikizumab|O
S266|,|O
S266|a|O
S266|novel|O
S266|,|O
S266|high-affinity|O
S266|,|O
S266|monoclonal|O
S266|antibody|O
S266|targeting|O
S266|interleukin|O
S266|(|O
S266|IL|O
S266|)|O
S266|–13|O
S266|that|O
S266|selectively|O
S266|prevents|O
S266|formation|O
S266|of|O
S266|the|O
S266|IL-13Rα1/IL-4Rα|O
S266|heterodimer|O
S266|receptor|O
S266|signaling|O
S266|complex|O
S266|,|O
S266|in|O
S266|adults|O
S266|with|O
S266|moderate|O
S266|to|O
S266|severe|O
S266|atopic|O
S266|dermatitis|O
S266|.|O
S1074|In|O
S1074|the|O
S1074|eptifibatide|O
S1074|bolus|O
S1074|plus|O
S1074|clopidogrel|O
S1074|group|O
S1074|,|O
S1074|PCI|O
S1074|was|O
S1074|successfully|O
S1074|performed|O
S1074|in|O
S1074|all|O
S1074|patients|O
S1074|;|O
S1074|blood|O
S1074|samples|O
S1074|were|O
S1074|hemolyzed|O
S1074|in|O
S1074|2|O
S1074|patients|O
S1074|,|O
S1074|and|O
S1074|pharmacodynamic|B-Sample_Size_Actual_at_Outcome_Analysis
S1074|study|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|was|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|performed|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|in|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|48|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S1074|(|O
S1074|Figure|O
S1074|2|O
S1074|)|O
S1074|.|O
S3965|Results|O
S3965|Patients|O
S3965|Of|O
S3965|the|O
S3965|621|O
S3965|patients|O
S3965|screened|O
S3965|,|O
S3965|464|B-Sample_Size_Actual_at_Enrollment
S3965|were|O
S3965|randomised|O
S3965|between|O
S3965|October|O
S3965|2009|O
S3965|and|O
S3965|November|O
S3965|2010|O
S3965|to|O
S3965|receive|O
S3965|ponesimod|B-Design_Parallel_Group
S3965|10|I-Design_Parallel_Group
S3965|,|I-Design_Parallel_Group
S3965|20|I-Design_Parallel_Group
S3965|or|I-Design_Parallel_Group
S3965|40|I-Design_Parallel_Group
S3965|mg|I-Design_Parallel_Group
S3965|,|I-Design_Parallel_Group
S3965|or|I-Design_Parallel_Group
S3965|placebo|O
S3965|.|O
S4237|Subjects|O
S4237|were|O
S4237|randomly|O
S4237|assigned|O
S4237|in|O
S4237|a|O
S4237|1:1|B-Randomization_Ratio
S4237|ratio|O
S4237|to|O
S4237|receive|O
S4237|a|O
S4237|single|B-Design_Parallel_Group
S4237|0.5-mL|I-Design_Parallel_Group
S4237|dose|I-Design_Parallel_Group
S4237|of|I-Design_Parallel_Group
S4237|either|I-Design_Parallel_Group
S4237|PCV20|I-Design_Parallel_Group
S4237|or|I-Design_Parallel_Group
S4237|PCV13|I-Design_Parallel_Group
S4237|(|O
S4237|vaccination|O
S4237|1|O
S4237|;|O
S4237|Figure|O
S4237|1|O
S4237|)|O
S4237|.|O
S6390|Objective|O
S6390|To|O
S6390|show|O
S6390|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S6390|of|O
S6390|trimethoprim-sulfamethoxazole|O
S6390|compared|O
S6390|with|O
S6390|vancomycin|O
S6390|for|O
S6390|the|O
S6390|treatment|O
S6390|of|O
S6390|severe|O
S6390|infections|O
S6390|due|O
S6390|to|O
S6390|meticillin|O
S6390|resistant|O
S6390|Staphylococcus|O
S6390|aureus|O
S6390|(|O
S6390|MRSA|O
S6390|)|O
S6390|.|O
S6828|In|O
S6828|a|O
S6828|randomized|O
S6828|,|O
S6828|double-blind|B-Blinding_Double_Blind
S6828|,|O
S6828|parallel|B-Design_Parallel_Group
S6828|study|O
S6828|design|O
S6828|,|O
S6828|eligible|O
S6828|patients|O
S6828|with|O
S6828|a|O
S6828|sitting|O
S6828|diastolic|O
S6828|blood|O
S6828|pressure|O
S6828|(|O
S6828|BP|O
S6828|)|O
S6828|of|O
S6828|90–109|O
S6828|mm|O
S6828|Hg|O
S6828|received|O
S6828|aprocitentan|O
S6828|5|O
S6828|,|O
S6828|10|O
S6828|,|O
S6828|25|O
S6828|,|O
S6828|or|O
S6828|50|O
S6828|mg|O
S6828|,|O
S6828|placebo|O
S6828|,|O
S6828|or|O
S6828|lisinopril|O
S6828|20|O
S6828|mg|O
S6828|as|O
S6828|a|O
S6828|positive|O
S6828|control|O
S6828|once|O
S6828|daily|O
S6828|for|O
S6828|8|O
S6828|weeks|O
S6828|.|O
S7548|This|O
S7548|randomized|B-Randomization_Type_Simple
S7548|,|O
S7548|double-blind|B-Blinding_Double_Blind
S7548|,|O
S7548|placebo-controlled|O
S7548|study|O
S7548|characterized|O
S7548|the|O
S7548|initial|O
S7548|dose-hemoglobin|O
S7548|response|O
S7548|as|O
S7548|well|O
S7548|as|O
S7548|the|O
S7548|efficacy|O
S7548|and|O
S7548|safety|O
S7548|of|O
S7548|three|O
S7548|times|O
S7548|weekly|O
S7548|(|O
S7548|TIW|O
S7548|)|O
S7548|daprodustat|O
S7548|in|O
S7548|hemodialysis|O
S7548|patients|O
S7548|switched|O
S7548|from|O
S7548|stable|O
S7548|recombinant|O
S7548|human|O
S7548|erythropoietin|O
S7548|(|O
S7548|rhEPO|O
S7548|)|O
S7548|,|O
S7548|in|O
S7548|accordance|O
S7548|with|O
S7548|a|O
S7548|TIW|O
S7548|hemodialysis|O
S7548|schedule|O
S7548|.|O
S7055|RESULTS|O
S7055|Patients|O
S7055|and|O
S7055|Pathogens|O
S7055|A|O
S7055|total|O
S7055|of|O
S7055|726|B-Sample_Size_Actual_at_Enrollment
S7055|patients|O
S7055|were|O
S7055|enrolled|O
S7055|and|O
S7055|randomized|O
S7055|(|O
S7055|tedizolid|O
S7055|,|O
S7055|n|O
S7055|=|O
S7055|366|O
S7055|;|O
S7055|linezolid|O
S7055|,|O
S7055|n|O
S7055|=|O
S7055|360|O
S7055|)|O
S7055|at|O
S7055|122|O
S7055|study|O
S7055|sites|O
S7055|in|O
S7055|32|O
S7055|countries|O
S7055|.|O
S2554|Methods|O
S2554|Study|O
S2554|design|O
S2554|and|O
S2554|objectives|O
S2554|Between|O
S2554|April|O
S2554|2017|O
S2554|and|O
S2554|October|O
S2554|2018|O
S2554|,|O
S2554|we|O
S2554|conducted|O
S2554|a|O
S2554|phase|B-Design_Phase_2
S2554|II|I-Design_Phase_2
S2554|study|O
S2554|in|O
S2554|64|B-Settings_Multicenter
S2554|centers|I-Settings_Multicenter
S2554|in|O
S2554|9|B-Settings_Location
S2554|countries|I-Settings_Location
S2554|(|O
S2554|GSK|O
S2554|protocol|O
S2554|205,724|O
S2554|;|O
S2554|ClinicalTrials.gov|O
S2554|identifier|O
S2554|NCT03034967|O
S2554|)|O
S2554|.|O
S6555|Design|O
S6555|,|O
S6555|Setting|O
S6555|,|O
S6555|and|O
S6555|Participants|O
S6555|This|O
S6555|phase|B-Design_Phase_2
S6555|2|I-Design_Phase_2
S6555|randomized|O
S6555|clinical|O
S6555|trial|O
S6555|was|O
S6555|a|O
S6555|52-week|O
S6555|multicenter|B-Settings_Multicenter
S6555|,|O
S6555|active|O
S6555|comparator–controlled|O
S6555|,|O
S6555|parallel-group|B-Design_Parallel_Group
S6555|study|O
S6555|.|O
S3649|Participants|O
S3649|received|O
S3649|each|O
S3649|of|O
S3649|the|O
S3649|following|O
S3649|six|O
S3649|treatments|O
S3649|once|O
S3649|daily|O
S3649|for|O
S3649|18|O
S3649|days|O
S3649|:|O
S3649|three|B-Design_Parallel_Group
S3649|topical|I-Design_Parallel_Group
S3649|doses|I-Design_Parallel_Group
S3649|(|I-Design_Parallel_Group
S3649|2.3|I-Design_Parallel_Group
S3649|%|I-Design_Parallel_Group
S3649|,|I-Design_Parallel_Group
S3649|0.8|I-Design_Parallel_Group
S3649|%|I-Design_Parallel_Group
S3649|,|I-Design_Parallel_Group
S3649|0.23|I-Design_Parallel_Group
S3649|%|I-Design_Parallel_Group
S3649|)|I-Design_Parallel_Group
S3649|of|I-Design_Parallel_Group
S3649|PF‐06763809|I-Design_Parallel_Group
S3649|,|I-Design_Parallel_Group
S3649|a|I-Design_Parallel_Group
S3649|vehicle|I-Design_Parallel_Group
S3649|and|I-Design_Parallel_Group
S3649|two|I-Design_Parallel_Group
S3649|active|I-Design_Parallel_Group
S3649|comparators|I-Design_Parallel_Group
S3649|(|I-Design_Parallel_Group
S3649|betamethasone|I-Design_Parallel_Group
S3649|and|I-Design_Parallel_Group
S3649|calcipotriol|I-Design_Parallel_Group
S3649|)|I-Design_Parallel_Group
S3649|.|O
S3249|The|O
S3249|investigator|B-Blinding_Object_Investigators
S3249|,|O
S3249|pharmacist|B-Blinding_Object_Others
S3249|,|O
S3249|and|O
S3249|trial|B-Blinding_Object_Patients
S3249|participant|I-Blinding_Object_Patients
S3249|were|O
S3249|blind|O
S3249|to|O
S3249|group|O
S3249|allocation|O
S3249|.|O
S5665|The|O
S5665|sample|O
S5665|size|O
S5665|calculations|O
S5665|were|O
S5665|based|O
S5665|on|O
S5665|the|O
S5665|primary|O
S5665|efficacy|O
S5665|variable|O
S5665|of|O
S5665|WOMAC|O
S5665|A1|O
S5665|over|O
S5665|26|O
S5665|weeks|O
S5665|,|O
S5665|with|O
S5665|the|O
S5665|following|O
S5665|assumptions|O
S5665|:|O
S5665|0.75|O
S5665|mean|O
S5665|difference|O
S5665|in|O
S5665|treatment|O
S5665|effect|O
S5665|of|O
S5665|single|O
S5665|6|O
S5665|ml|O
S5665|Hylan|O
S5665|G-F|O
S5665|20|O
S5665|injection|O
S5665|on|O
S5665|the|O
S5665|change|O
S5665|from|O
S5665|baseline|O
S5665|in|O
S5665|WOMAC|O
S5665|A1|O
S5665|over|O
S5665|26|O
S5665|weeks|O
S5665|,|O
S5665|compared|O
S5665|to|O
S5665|placebo|O
S5665|and|O
S5665|a|O
S5665|t-test|O
S5665|at|O
S5665|a|O
S5665|2-sided|B-Sample_Size_Calculation_Alpha_Value
S5665|5|I-Sample_Size_Calculation_Alpha_Value
S5665|%|I-Sample_Size_Calculation_Alpha_Value
S5665|significance|O
S5665|level|O
S5665|with|O
S5665|90|B-Sample_Size_Calculation_Power_Value
S5665|%|I-Sample_Size_Calculation_Power_Value
S5665|power|O
S5665|.|O
S4802|Results|O
S4802|A|O
S4802|total|O
S4802|of|O
S4802|757|B-Sample_Size_Actual_at_Enrollment
S4802|adults|O
S4802|were|O
S4802|randomized|O
S4802|,|O
S4802|378|O
S4802|to|O
S4802|receive|O
S4802|aIIV3|O
S4802|and|O
S4802|379|O
S4802|to|O
S4802|receive|O
S4802|HD-IIV3|O
S4802|.|O
S300|Study|O
S300|Design|O
S300|This|O
S300|phase|B-Design_Phase_2
S300|2b|I-Design_Phase_2
S300|,|O
S300|double-blind|B-Blinding_Double_Blind
S300|,|O
S300|placebo-controlled|O
S300|,|O
S300|parallel-group|B-Design_Parallel_Group
S300|,|O
S300|dose-ranging|O
S300|randomized|O
S300|clinical|O
S300|trial|O
S300|of|O
S300|lebrikizumab|O
S300|injections|O
S300|every|O
S300|4|O
S300|weeks|O
S300|or|O
S300|every|O
S300|2|O
S300|weeks|O
S300|consisted|O
S300|of|O
S300|a|O
S300|16-week|O
S300|treatment|O
S300|period|O
S300|with|O
S300|a|O
S300|16-week|O
S300|safety|O
S300|follow-up|O
S300|(|O
S300|eFigure|O
S300|1|O
S300|in|O
S300|Supplement|O
S300|2|O
S300|)|O
S300|.|O
S1736|The|O
S1736|trial|O
S1736|was|O
S1736|conducted|O
S1736|from|O
S1736|July|O
S1736|2011|O
S1736|through|O
S1736|November|O
S1736|2018|O
S1736|at|O
S1736|sites|B-Settings_Multicenter
S1736|in|O
S1736|the|O
S1736|United|B-Settings_Location
S1736|States|I-Settings_Location
S1736|,|I-Settings_Location
S1736|Canada|I-Settings_Location
S1736|,|I-Settings_Location
S1736|Australia|I-Settings_Location
S1736|,|I-Settings_Location
S1736|and|I-Settings_Location
S1736|Germany|I-Settings_Location
S1736|(|O
S1736|Fig|O
S1736|.|O
S738|Randomization|O
S738|of|O
S738|participants|O
S738|in|O
S738|variable|O
S738|blocks|B-Randomization_Type_Block
S738|of|O
S738|eight|B-Randomization_Block_Size
S738|and|I-Randomization_Block_Size
S738|ten|I-Randomization_Block_Size
S738|was|O
S738|accomplished|O
S738|using|O
S738|computer-generated|B-Randomization_Sequence_Generation_Method
S738|random|I-Randomization_Sequence_Generation_Method
S738|numbers|I-Randomization_Sequence_Generation_Method
S738|(|O
S738|http|O
S738|:|O
S738|//www.randomization.com|O
S738|)|O
S738|.|O
S4107|The|O
S4107|study|O
S4107|was|O
S4107|designed|O
S4107|to|O
S4107|enroll|O
S4107|approximately|O
S4107|1050|B-Sample_Size_Target
S4107|participants|O
S4107|randomized|O
S4107|in|O
S4107|a|O
S4107|1:1:1|B-Randomization_Ratio
S4107|ratio|O
S4107|to|O
S4107|either|O
S4107|V114|B-Design_Parallel_Group
S4107|Lot|I-Design_Parallel_Group
S4107|1|I-Design_Parallel_Group
S4107|,|I-Design_Parallel_Group
S4107|V114|I-Design_Parallel_Group
S4107|Lot|I-Design_Parallel_Group
S4107|2|I-Design_Parallel_Group
S4107|or|I-Design_Parallel_Group
S4107|PCV13|I-Design_Parallel_Group
S4107|vaccination|I-Design_Parallel_Group
S4107|groups|I-Design_Parallel_Group
S4107|.|O
S6253|They|O
S6253|received|O
S6253|a|O
S6253|randomization|O
S6253|number|O
S6253|at|O
S6253|registration|O
S6253|based|O
S6253|on|O
S6253|a|O
S6253|computer-generated|B-Randomization_Sequence_Generation_Method
S6253|randomization|I-Randomization_Sequence_Generation_Method
S6253|allocation|I-Randomization_Sequence_Generation_Method
S6253|table|I-Randomization_Sequence_Generation_Method
S6253|.|O
S6304|Patient|O
S6304|Demographics|O
S6304|and|O
S6304|Clinical|O
S6304|Characteristics|O
S6304|Of|O
S6304|131|O
S6304|patients|O
S6304|who|O
S6304|were|O
S6304|screened|O
S6304|,|O
S6304|124|B-Sample_Size_Actual_at_Enrollment
S6304|were|O
S6304|randomized|O
S6304|(|O
S6304|61|O
S6304|in|O
S6304|the|O
S6304|400|O
S6304|U|O
S6304|group|O
S6304|;|O
S6304|63|O
S6304|in|O
S6304|the|O
S6304|240|O
S6304|U|O
S6304|group|O
S6304|)|O
S6304|and|O
S6304|received|O
S6304|the|O
S6304|first|O
S6304|administration|O
S6304|of|O
S6304|the|O
S6304|study|O
S6304|drug|O
S6304|.|O
S3672|This|O
S3672|was|O
S3672|a|O
S3672|randomized|O
S3672|,|O
S3672|double‐blind|B-Blinding_Double_Blind
S3672|,|O
S3672|vehicle‐|O
S3672|and|O
S3672|active|O
S3672|comparator‐controlled|O
S3672|,|O
S3672|multiple‐dose|O
S3672|study|O
S3672|in|O
S3672|participants|O
S3672|with|O
S3672|psoriasis|O
S3672|.|O
S2398|The|O
S2398|IWRS|O
S2398|was|O
S2398|managed|O
S2398|by|O
S2398|an|O
S2398|unblinded|B-Randomization_Personnel
S2398|third-party|I-Randomization_Personnel
S2398|provider|I-Randomization_Personnel
S2398|,|O
S2398|and|O
S2398|the|O
S2398|randomization|O
S2398|schedule|O
S2398|was|O
S2398|provided|O
S2398|by|O
S2398|a|O
S2398|separate|B-Randomization_Personnel
S2398|unblinded|I-Randomization_Personnel
S2398|statistical|I-Randomization_Personnel
S2398|team|I-Randomization_Personnel
S2398|.|O
S8627|Methods|O
S8627|Novartis|O
S8627|Pharmaceuticals|O
S8627|(|O
S8627|Cambridge|O
S8627|,|O
S8627|Massachusetts|O
S8627|)|O
S8627|initiated|O
S8627|this|O
S8627|Phase|B-Design_Phase_2
S8627|II|I-Design_Phase_2
S8627|,|O
S8627|double-blind|B-Blinding_Double_Blind
S8627|,|O
S8627|randomized|O
S8627|,|O
S8627|placebo-controlled|O
S8627|trial|O
S8627|,|O
S8627|with|O
S8627|the|O
S8627|final|O
S8627|study|O
S8627|protocol|O
S8627|designed|O
S8627|in|O
S8627|collaboration|O
S8627|with|O
S8627|the|O
S8627|investigators|O
S8627|(|O
S8627|R.P.C.|O
S8627|,|O
S8627|J.-C.T.|O
S8627|,|O
S8627|and|O
S8627|Z.A.F|O
S8627|.|O
S2940|Statistical|O
S2940|Analysis|O
S2940|A|O
S2940|sample|O
S2940|size|O
S2940|of|O
S2940|80|O
S2940|children|O
S2940|in|O
S2940|the|O
S2940|baloxavir|O
S2940|arm|O
S2940|(|O
S2940|120|O
S2940|in|O
S2940|total|O
S2940|)|O
S2940|provided|O
S2940|a|O
S2940|probability|O
S2940|of|O
S2940|≥90|B-Sample_Size_Calculation_Power_Value
S2940|%|I-Sample_Size_Calculation_Power_Value
S2940|that|O
S2940|≥1|O
S2940|child|O
S2940|would|O
S2940|experience|O
S2940|an|O
S2940|AE|O
S2940|with|O
S2940|a|O
S2940|background|O
S2940|incidence|O
S2940|rate|O
S2940|of|O
S2940|3|O
S2940|%|O
S2940|.|O
S7549|Methods|O
S7549|103|B-Sample_Size_Actual_at_Enrollment
S7549|patients|O
S7549|on|O
S7549|hemodialysis|O
S7549|with|O
S7549|baseline|O
S7549|hemoglobin|O
S7549|of|O
S7549|9.0|O
S7549|to|O
S7549|11.5|O
S7549|g/dL|O
S7549|and|O
S7549|previously|O
S7549|receiving|O
S7549|a|O
S7549|stable|O
S7549|dose|O
S7549|of|O
S7549|rhEPO|O
S7549|or|O
S7549|its|O
S7549|analogs|O
S7549|were|O
S7549|randomized|O
S7549|1:1:1:1:1|B-Randomization_Ratio
S7549|to|O
S7549|receive|O
S7549|daprodustat|B-Design_Parallel_Group
S7549|10|I-Design_Parallel_Group
S7549|,|I-Design_Parallel_Group
S7549|15|I-Design_Parallel_Group
S7549|,|I-Design_Parallel_Group
S7549|25|I-Design_Parallel_Group
S7549|,|I-Design_Parallel_Group
S7549|or|I-Design_Parallel_Group
S7549|30|I-Design_Parallel_Group
S7549|mg|I-Design_Parallel_Group
S7549|or|I-Design_Parallel_Group
S7549|placebo|I-Design_Parallel_Group
S7549|TIW|O
S7549|over|O
S7549|29|O
S7549|days|O
S7549|.|O
S7440|Randomization|O
S7440|was|O
S7440|stratified|B-Randomization_Type_Stratified
S7440|by|O
S7440|migraine|B-Randomization_Stratified_Criteria
S7440|preventive|I-Randomization_Stratified_Criteria
S7440|treatment|I-Randomization_Stratified_Criteria
S7440|status|I-Randomization_Stratified_Criteria
S7440|:|I-Randomization_Stratified_Criteria
S7440|current|I-Randomization_Stratified_Criteria
S7440|use|I-Randomization_Stratified_Criteria
S7440|,|I-Randomization_Stratified_Criteria
S7440|previous|I-Randomization_Stratified_Criteria
S7440|use|I-Randomization_Stratified_Criteria
S7440|only|I-Randomization_Stratified_Criteria
S7440|,|I-Randomization_Stratified_Criteria
S7440|and|I-Randomization_Stratified_Criteria
S7440|no|I-Randomization_Stratified_Criteria
S7440|current|I-Randomization_Stratified_Criteria
S7440|or|I-Randomization_Stratified_Criteria
S7440|previous|I-Randomization_Stratified_Criteria
S7440|use|I-Randomization_Stratified_Criteria
S7440|.|O
S6116|This|O
S6116|study|O
S6116|had|O
S6116|a|O
S6116|double-masked|O
S6116|design|O
S6116|;|O
S6116|the|O
S6116|treatment|O
S6116|was|O
S6116|masked|O
S6116|to|O
S6116|the|O
S6116|subjects|B-Blinding_Object_Patients
S6116|,|O
S6116|examiners|O
S6116|,|O
S6116|Santen|B-Blinding_Object_Others
S6116|personnel|I-Blinding_Object_Others
S6116|,|O
S6116|and|O
S6116|clinical|B-Blinding_Object_Investigators
S6116|investigators|I-Blinding_Object_Investigators
S6116|.|O
S194|The|O
S194|82|B-Sample_Size_Actual_at_Outcome_Analysis
S194|evaluable|O
S194|participants|O
S194|ranged|O
S194|from|O
S194|22–84|O
S194|years|O
S194|of|O
S194|age|O
S194|(|O
S194|Mean|O
S194|52.9|O
S194|years|O
S194|,|O
S194|standard|O
S194|deviation|O
S194|(|O
S194|SD|O
S194|)|O
S194|13.3|O
S194|)|O
S194|.|O
S330|Results|O
S330|Patient|O
S330|Disposition|O
S330|,|O
S330|Baseline|O
S330|Demographics|O
S330|,|O
S330|and|O
S330|Disease|O
S330|Characteristics|O
S330|A|O
S330|total|O
S330|of|O
S330|280|B-Sample_Size_Actual_at_Enrollment
S330|patients|O
S330|(|O
S330|mean|O
S330|[|O
S330|SD|O
S330|]|O
S330|age|O
S330|,|O
S330|39.3|O
S330|[|O
S330|17.5|O
S330|]|O
S330|years|O
S330|;|O
S330|166|O
S330|[|O
S330|59.3|O
S330|%|O
S330|]|O
S330|female|O
S330|)|O
S330|were|O
S330|randomized|O
S330|to|O
S330|placebo|O
S330|(|O
S330|n|O
S330|=|O
S330|52|O
S330|)|O
S330|or|O
S330|to|O
S330|lebrikizumab|O
S330|at|O
S330|the|O
S330|following|O
S330|doses|O
S330|:|O
S330|125|O
S330|mg|O
S330|every|O
S330|4|O
S330|weeks|O
S330|(|O
S330|n|O
S330|=|O
S330|73|O
S330|)|O
S330|,|O
S330|250|O
S330|mg|O
S330|every|O
S330|4|O
S330|weeks|O
S330|(|O
S330|n|O
S330|=|O
S330|80|O
S330|)|O
S330|,|O
S330|or|O
S330|250|O
S330|mg|O
S330|every|O
S330|2|O
S330|weeks|O
S330|(|O
S330|n|O
S330|=|O
S330|75|O
S330|)|O
S330|(|O
S330|Figure|O
S330|1|O
S330|)|O
S330|.|O
S7798|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S7798|(|O
S7798|primary|O
S7798|end|O
S7798|point|O
S7798|)|O
S7798|was|O
S7798|confirmed|O
S7798|if|O
S7798|the|O
S7798|upper|O
S7798|boundary|O
S7798|of|O
S7798|the|O
S7798|two-sided|O
S7798|95|O
S7798|%|O
S7798|CI|O
S7798|was|O
S7798|≤0.4|O
S7798|%|O
S7798|.|O
S3029|Results|O
S3029|Of|O
S3029|the|O
S3029|26|B-Sample_Size_Actual_at_Enrollment
S3029|patients|O
S3029|randomized|O
S3029|,|O
S3029|25|B-Sample_Size_Actual_at_Outcome_Analysis
S3029|received|O
S3029|abemaciclib|O
S3029|150|O
S3029|mg|O
S3029|(|O
S3029|n|O
S3029|=|O
S3029|12|O
S3029|)|O
S3029|or|O
S3029|200|O
S3029|mg|O
S3029|(|O
S3029|n|O
S3029|=|O
S3029|13|O
S3029|)|O
S3029|.|O
S4232|METHODS|O
S4232|Study|O
S4232|Design|O
S4232|and|O
S4232|Subjects|O
S4232|This|O
S4232|phase|B-Design_Phase_2
S4232|2|I-Design_Phase_2
S4232|,|O
S4232|randomized|B-Randomization_Type_Simple
S4232|,|O
S4232|active-controlled|O
S4232|,|O
S4232|double-blind|B-Blinding_Double_Blind
S4232|study|O
S4232|conducted|O
S4232|at|O
S4232|14|B-Settings_Multicenter
S4232|US|I-Settings_Multicenter
S4232|sites|I-Settings_Multicenter
S4232|evaluated|O
S4232|PCV20|O
S4232|safety|O
S4232|and|O
S4232|immunogenicity|O
S4232|in|O
S4232|healthy|O
S4232|pneumococcal|O
S4232|vaccine-naive|O
S4232|adults|O
S4232|60–64|O
S4232|years|O
S4232|of|O
S4232|age|O
S4232|.|O
S5340|Screening|O
S5340|,|O
S5340|randomization|O
S5340|and|O
S5340|enrolment|O
S5340|of|O
S5340|the|O
S5340|patients|O
S5340|were|O
S5340|performed|O
S5340|by|O
S5340|the|O
S5340|investigator|B-Randomization_Personnel
S5340|or|I-Randomization_Personnel
S5340|delegated|I-Randomization_Personnel
S5340|staff|I-Randomization_Personnel
S5340|at|I-Randomization_Personnel
S5340|each|I-Randomization_Personnel
S5340|trial|I-Randomization_Personnel
S5340|site|I-Randomization_Personnel
S5340|.|O
S7583|Participants|O
S7583|discontinued|O
S7583|their|O
S7583|current|O
S7583|rhEPO|O
S7583|therapy|O
S7583|prior|O
S7583|to|O
S7583|day|O
S7583|1|O
S7583|and|O
S7583|were|O
S7583|randomized|O
S7583|by|O
S7583|a|B-Randomization_Sequence_Generation_Method
S7583|computer-generated|I-Randomization_Sequence_Generation_Method
S7583|randomization|I-Randomization_Sequence_Generation_Method
S7583|schedule|I-Randomization_Sequence_Generation_Method
S7583|using|I-Randomization_Sequence_Generation_Method
S7583|the|I-Randomization_Sequence_Generation_Method
S7583|Prism|I-Randomization_Sequence_Generation_Method
S7583|randomization|I-Randomization_Sequence_Generation_Method
S7583|system|I-Randomization_Sequence_Generation_Method
S7583|in|O
S7583|a|O
S7583|1:1:1:1:1|B-Randomization_Ratio
S7583|ratio|O
S7583|to|O
S7583|receive|O
S7583|oral|B-Design_Parallel_Group
S7583|daprodustat|I-Design_Parallel_Group
S7583|10|I-Design_Parallel_Group
S7583|,|I-Design_Parallel_Group
S7583|15|I-Design_Parallel_Group
S7583|,|I-Design_Parallel_Group
S7583|25|I-Design_Parallel_Group
S7583|,|I-Design_Parallel_Group
S7583|or|I-Design_Parallel_Group
S7583|30|I-Design_Parallel_Group
S7583|mg|I-Design_Parallel_Group
S7583|or|I-Design_Parallel_Group
S7583|placebo|I-Design_Parallel_Group
S7583|TIW|O
S7583|on|O
S7583|a|O
S7583|dialysis|O
S7583|day|O
S7583|.|O
S7|Noninferiority|B-Design_Comparative_Intent_NonInferiority
S7|in|O
S7|the|O
S7|rate|O
S7|of|O
S7|fever|O
S7|was|O
S7|demonstrated|O
S7|for|O
S7|the|O
S7|full|O
S7|dose|O
S7|versus|O
S7|the|O
S7|half|O
S7|dose|O
S7|of|O
S7|IIV4|O
S7|(|O
S7|difference|O
S7|in|O
S7|rate|O
S7|=|O
S7|0.84|O
S7|%|O
S7|;|O
S7|95|O
S7|%|O
S7|confidence|O
S7|interval|O
S7|,|O
S7|−2.13|O
S7|%|O
S7|to|O
S7|3.80|O
S7|%|O
S7|)|O
S7|.|O
S6399|Results|O
S6399|252|B-Sample_Size_Actual_at_Enrollment
S6399|patients|O
S6399|were|O
S6399|included|O
S6399|in|O
S6399|the|O
S6399|trial|O
S6399|,|O
S6399|of|O
S6399|whom|O
S6399|91|O
S6399|(|O
S6399|36|O
S6399|%|O
S6399|)|O
S6399|had|O
S6399|bacteraemia|O
S6399|.|O
S7117|Summary|O
S7117|Background|O
S7117|In|O
S7117|a|O
S7117|previous|O
S7117|randomised|O
S7117|controlled|O
S7117|phase|B-Design_Phase_2
S7117|2|I-Design_Phase_2
S7117|trial|O
S7117|,|O
S7117|intravenous|O
S7117|infusion|O
S7117|of|O
S7117|salbutamol|O
S7117|for|O
S7117|up|O
S7117|to|O
S7117|7|O
S7117|days|O
S7117|in|O
S7117|patients|O
S7117|with|O
S7117|acute|O
S7117|respiratory|O
S7117|distress|O
S7117|syndrome|O
S7117|(|O
S7117|ARDS|O
S7117|)|O
S7117|reduced|O
S7117|extravascular|O
S7117|lung|O
S7117|water|O
S7117|and|O
S7117|plateau|O
S7117|airway|O
S7117|pressure|O
S7117|.|O
S7268|Conclusion|O
S7268|Non-inferiority|B-Design_Comparative_Intent_NonInferiority
S7268|of|O
S7268|MR|O
S7268|11|O
S7268|mg|O
S7268|QD|O
S7268|to|O
S7268|IR|O
S7268|5|O
S7268|mg|O
S7268|BID|O
S7268|was|O
S7268|not|O
S7268|met|O
S7268|in|O
S7268|this|O
S7268|study|O
S7268|.|O
S4844|Participants|O
S4844|were|O
S4844|randomized|O
S4844|(|O
S4844|1:1|B-Randomization_Ratio
S4844|)|O
S4844|to|O
S4844|receive|O
S4844|aIIV3|B-Design_Parallel_Group
S4844|or|I-Design_Parallel_Group
S4844|HD-IIV3|I-Design_Parallel_Group
S4844|using|O
S4844|a|O
S4844|permuted|B-Randomization_Type_Block
S4844|block|I-Randomization_Type_Block
S4844|randomization|O
S4844|scheme|O
S4844|stratified|B-Randomization_Type_Stratified
S4844|by|O
S4844|study|B-Randomization_Stratified_Criteria
S4844|site|I-Randomization_Stratified_Criteria
S4844|.|O
S781|RESULTS|O
S781|Ninety-six|B-Sample_Size_Actual_at_Enrollment
S781|women|I-Sample_Size_Actual_at_Enrollment
S781|were|O
S781|recruited|O
S781|,|O
S781|enrolled|O
S781|,|O
S781|and|O
S781|randomized|O
S781|in|O
S781|the|O
S781|study|O
S781|;|O
S781|48|O
S781|in|O
S781|each|O
S781|of|O
S781|the|O
S781|placebo|O
S781|and|O
S781|gabapentin|O
S781|groups|O
S781|from|O
S781|August|O
S781|2016|O
S781|to|O
S781|June|O
S781|2018|O
S781|(|O
S781|Figure|O
S781|1|O
S781|)|O
S781|.|O
S2455|Of|O
S2455|those|O
S2455|randomized|O
S2455|,|O
S2455|621|B-Sample_Size_Actual_at_Outcome_Analysis
S2455|subjects|O
S2455|were|O
S2455|treated|O
S2455|with|O
S2455|investigational|O
S2455|product|O
S2455|(|O
S2455|IP|O
S2455|)|O
S2455|.|O
S8515|In|O
S8515|order|O
S8515|to|O
S8515|be|O
S8515|able|O
S8515|to|O
S8515|detect|O
S8515|these|O
S8515|differences|O
S8515|between|O
S8515|groups|O
S8515|and|O
S8515|assuming|O
S8515|an|O
S8515|alpha|O
S8515|error|O
S8515|of|O
S8515|5|B-Sample_Size_Calculation_Alpha_Value
S8515|%|I-Sample_Size_Calculation_Alpha_Value
S8515|and|O
S8515|a|B-Sample_Size_Calculation_Power_Value
S8515|beta|I-Sample_Size_Calculation_Power_Value
S8515|error|I-Sample_Size_Calculation_Power_Value
S8515|of|I-Sample_Size_Calculation_Power_Value
S8515|20|I-Sample_Size_Calculation_Power_Value
S8515|%|I-Sample_Size_Calculation_Power_Value
S8515|,|O
S8515|we|O
S8515|required|O
S8515|a|O
S8515|minimum|O
S8515|of|O
S8515|12|B-Sample_Size_Required
S8515|patients|I-Sample_Size_Required
S8515|per|I-Sample_Size_Required
S8515|group|I-Sample_Size_Required
S8515|.|O
S273|Interventions|O
S273|Patients|O
S273|were|O
S273|randomized|B-Randomization_Type_Simple
S273|2:3:3:3|B-Randomization_Ratio
S273|to|O
S273|placebo|B-Design_Parallel_Group
S273|every|I-Design_Parallel_Group
S273|2|I-Design_Parallel_Group
S273|weeks|I-Design_Parallel_Group
S273|or|I-Design_Parallel_Group
S273|to|I-Design_Parallel_Group
S273|subcutaneous|I-Design_Parallel_Group
S273|injections|I-Design_Parallel_Group
S273|of|I-Design_Parallel_Group
S273|lebrikizumab|I-Design_Parallel_Group
S273|at|I-Design_Parallel_Group
S273|the|I-Design_Parallel_Group
S273|following|I-Design_Parallel_Group
S273|doses|I-Design_Parallel_Group
S273|:|I-Design_Parallel_Group
S273|125|I-Design_Parallel_Group
S273|mg|I-Design_Parallel_Group
S273|every|I-Design_Parallel_Group
S273|4|I-Design_Parallel_Group
S273|weeks|I-Design_Parallel_Group
S273|(|I-Design_Parallel_Group
S273|250-mg|I-Design_Parallel_Group
S273|loading|I-Design_Parallel_Group
S273|dose|I-Design_Parallel_Group
S273|[|I-Design_Parallel_Group
S273|LD|I-Design_Parallel_Group
S273|]|I-Design_Parallel_Group
S273|)|I-Design_Parallel_Group
S273|,|I-Design_Parallel_Group
S273|250|I-Design_Parallel_Group
S273|mg|I-Design_Parallel_Group
S273|every|I-Design_Parallel_Group
S273|4|I-Design_Parallel_Group
S273|weeks|I-Design_Parallel_Group
S273|(|I-Design_Parallel_Group
S273|500-mg|I-Design_Parallel_Group
S273|LD|I-Design_Parallel_Group
S273|)|I-Design_Parallel_Group
S273|,|I-Design_Parallel_Group
S273|or|I-Design_Parallel_Group
S273|250|I-Design_Parallel_Group
S273|mg|I-Design_Parallel_Group
S273|every|I-Design_Parallel_Group
S273|2|I-Design_Parallel_Group
S273|weeks|I-Design_Parallel_Group
S273|(|I-Design_Parallel_Group
S273|500-mg|I-Design_Parallel_Group
S273|LD|I-Design_Parallel_Group
S273|at|I-Design_Parallel_Group
S273|baseline|I-Design_Parallel_Group
S273|and|I-Design_Parallel_Group
S273|week|I-Design_Parallel_Group
S273|2|I-Design_Parallel_Group
S273|)|I-Design_Parallel_Group
S273|.|O
S3566|If|O
S3566|the|O
S3566|lower|O
S3566|limit|O
S3566|of|O
S3566|the|O
S3566|two-sided|B-Sample_Size_Calculation_Alpha_Value
S3566|95|I-Sample_Size_Calculation_Alpha_Value
S3566|%|I-Sample_Size_Calculation_Alpha_Value
S3566|CI|I-Sample_Size_Calculation_Alpha_Value
S3566|was|O
S3566|greater|O
S3566|than|O
S3566|the|O
S3566|non-inferiority|O
S3566|limit|O
S3566|(|O
S3566|−10.0|O
S3566|%|O
S3566|)|O
S3566|for|O
S3566|both|O
S3566|the|O
S3566|full|O
S3566|analysis|O
S3566|set|O
S3566|(|O
S3566|FAS|O
S3566|)|O
S3566|,|O
S3566|i.e|O
S3566|.|O
S2733|The|O
S2733|sites|O
S2733|conducting|O
S2733|the|O
S2733|study|O
S2733|were|O
S2733|gastroenterology|B-Settings_Multicenter
S2733|practices|I-Settings_Multicenter
S2733|(|O
S2733|n=26|O
S2733|)|O
S2733|or|O
S2733|primary|O
S2733|care|O
S2733|and|O
S2733|research|B-Settings_Multicenter
S2733|practices|I-Settings_Multicenter
S2733|(|O
S2733|n=53|O
S2733|)|O
S2733|specializing|O
S2733|in|O
S2733|internal|O
S2733|medicine|O
S2733|and/or|O
S2733|gastroenterology|O
S2733|.|O
S2941|A|O
S2941|sample|O
S2941|size|O
S2941|of|O
S2941|120|O
S2941|children|O
S2941|provided|O
S2941|a|O
S2941|probability|O
S2941|of|O
S2941|80.1|B-Sample_Size_Calculation_Power_Value
S2941|%|I-Sample_Size_Calculation_Power_Value
S2941|that|O
S2941|≥1|O
S2941|child|O
S2941|would|O
S2941|experience|O
S2941|an|O
S2941|AE|O
S2941|with|O
S2941|an|O
S2941|incidence|O
S2941|rate|O
S2941|of|O
S2941|2|O
S2941|%|O
S2941|.|O
S1887|Methods|O
S1887|Study|O
S1887|Design|O
S1887|NICHD|O
S1887|P1081|O
S1887|was|O
S1887|a|O
S1887|Phase|B-Design_Phase_4
S1887|IV|I-Design_Phase_4
S1887|multicenter|B-Settings_Multicenter
S1887|,|O
S1887|randomized|O
S1887|,|O
S1887|open-label|B-Blinding_Open_Label
S1887|trial|O
S1887|comparing|O
S1887|the|O
S1887|virologic|O
S1887|response|O
S1887|,|O
S1887|safety|O
S1887|,|O
S1887|and|O
S1887|tolerability|O
S1887|of|O
S1887|raltegravir|O
S1887|,|O
S1887|the|O
S1887|first|O
S1887|licensed|O
S1887|integrase|O
S1887|inhibitor|O
S1887|,|O
S1887|with|O
S1887|efavirenz|O
S1887|,|O
S1887|a|O
S1887|non-nucleoside|O
S1887|reverse|O
S1887|transcriptase|O
S1887|inhibitor|O
S1887|(|O
S1887|NNRTI|O
S1887|)|O
S1887|,|O
S1887|in|O
S1887|combination|O
S1887|with|O
S1887|two|O
S1887|nucleoside|O
S1887|reverse|O
S1887|transcriptase|O
S1887|inhibitors|O
S1887|(|O
S1887|NRTI|O
S1887|)|O
S1887|in|O
S1887|ART-naïve|O
S1887|pregnant|O
S1887|women|O
S1887|initiating|O
S1887|ART|O
S1887|from|O
S1887|20|O
S1887|to|O
S1887|36|O
S1887|weeks|O
S1887|gestation|O
S1887|.|O
S5660|The|O
S5660|block|B-Randomization_Block_Size
S5660|size|I-Randomization_Block_Size
S5660|was|I-Randomization_Block_Size
S5660|4|I-Randomization_Block_Size
S5660|and|O
S5660|the|O
S5660|allocation|O
S5660|ratio|O
S5660|was|O
S5660|1:1|B-Randomization_Ratio
S5660|.|O
